Sourced from ClinicalTrials.gov · NIH/NLM · Refreshed daily

1,322 APOE4 trials.
Read in plain English.

Every Alzheimer’s trial that matters for APOE4 carriers — each one translated, with our read on what it means for you. Free to browse. No login.

Curated by Dr. Kevin Tran, PharmD · APOE 4/4Last refresh: 17h ago
Already a Phoenix member?Open in your app
ClinicalTrials.gov

Every trial, in clinical language, built for researchers. Thousands of records, no read on which ones matter for your genotype.

Phoenix adds

We read the ones that matter for APOE4 carriers, translate each into plain English, and flag what it means for a 4-carrier — updated daily. Free to browse.

Free trial alerts

Want us to watch for you?

New APOE4-relevant trials open almost every week. Tell us where to send them and we’ll email you the moment one does — plus the weekly digest read by 4,100+ carriers.

Unsubscribe anytime · No spam, ever

Trials near me
Filters
APOE4-explicit only
Status
Phase
Intervention type

Showing 1,000 of 1,322 APOE4 trials

NCT03653156Recruiting

China Cognition and Aging Study

Observational only, China-based population

This is a large observational study based in China, not a drug or treatment trial. Researchers are building a national database by following thousands of people over time, tracking who develops memory problems or dementia, collecting brain scans, blood samples, and genetic data. The goal is to understand how dementia unfolds in Chinese populations. There is no Phase designation because nothing is being tested for approval — this is research groundwork.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
65 sites
NCT04575337Recruiting

Study on Biomarkers for Early Diagnosis of Alzheimer's Disease

APOE4 carriers explicitly included

This is an observational study based in China that is tracking elderly people over five years to identify early biological markers of Alzheimer's disease. Researchers are collecting blood, genetic, and brain imaging data across a range of participants — from cognitively normal to diagnosed AD — hoping to build better early-detection tools and a model that predicts five-year risk. No phase is listed because no drug or device is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07516119Recruiting

Predicting Pre-dementia

Exclusively recruits APOE4 carriers

This observational study is testing whether a multimodal prediction model — combining genetic risk scores, blood biomarkers, health record data, and wearable device readings — can accurately forecast who will progress to early MCI within two years. There is no drug or treatment involved. It is observational, meaning researchers are watching and measuring, not intervening. Think of it as a sophisticated early-warning system study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07208344Early Phase 1Recruiting

Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease

APOE4-aware design, not carrier-specific

This trial is testing whether infusing stem-like cells from donated umbilical cord blood — on top of a standard Alzheimer's drug — is safe and shows early signs of benefit in people with mild to moderate Alzheimer's. It is an Early Phase 1 trial, meaning the primary goal is safety and finding the right dose, not proving the treatment works. Thirty patients are divided into two dose groups and one placebo group, then followed for six months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07027072Phase 2Recruiting

Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Genotype-stratified, carriers likely eligible

This trial is testing KDS2010, an experimental oral drug taken once daily, in people who have early Alzheimer's-related memory problems — either mild cognitive impairment or mild dementia confirmed by amyloid PET scan. Researchers are comparing two doses against a placebo to see whether it improves cognition, daily functioning, and biomarkers over 24 weeks. This is a Phase 2a trial, meaning it is an early test of whether the drug works and is safe — not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT05649514N/ARecruiting

Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease

APOE4 carriers explicitly named

This study is observing whether poor sleep is linked to cognitive decline in people at early risk of Alzheimer's. Participants undergo sleep studies, cognitive testing, and biomarker checks — no experimental drug is involved. It is a non-interventional, observational study, meaning researchers are watching and measuring, not treating. The goal is to understand whether sleep problems predict or accelerate cognitive decline, which could eventually point toward earlier intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site

We don’t hide the trials. We hide the matching.

Free, forever
  • Every APOE4-relevant trial
  • Plain-English translation of each
  • Our APOE4 verdict on what it means
  • Refreshed daily — free, no login
Members add
  • Only the 6–12 that fit your genotype, age & history
  • The morning alert when a new one opens
  • A per-trial eligibility check on your bloodwork
  • Warm intros to sponsors when there’s a real fit
See if you’re a fit — 7-min assessment

Built by an APOE 4/4 carrier · 60-day guarantee

NCT06467253N/ARecruiting

Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI)

APOE4 genotyped, non-drug device trial

This trial is testing two types of non-invasive brain stimulation — repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) — each paired with structured cognitive exercises, in people with amnestic mild cognitive impairment. Researchers want to see which combination best supports memory and brain function. This is a Phase NA (feasibility or exploratory) trial, meaning it is designed to gather early data, not to prove a treatment works definitively.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06818409Recruiting

Is the CRP-Albumin-Lymphocyte (CALLY) Index Effective in Predicting Postoperative Delirium in Geriatric Patients Undergoing Hip Fracture Surgery

Observational only, genotype not studied

This study is testing whether a simple blood-test index called the CALLY Index, which combines three routine lab values, CRP, albumin, and lymphocyte count, can predict which elderly hip fracture patients will develop delirium after surgery. It is an observational study, not a treatment trial, meaning researchers are watching and measuring rather than giving any new therapy. Details on formal phase designation are not provided.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05245903Recruiting

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Requires at least one APOE4 allele

This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people with mild cognitive impairment or mild Alzheimer's dementia. Researchers are using a passive home sensor device to track digital biomarkers — things like sleep, movement, and breathing patterns — rather than clinic visits alone. The phase is unspecified, so the scale and stage of testing are unclear from the available information.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06601933Phase 2Recruiting

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial

Open to carriers, not 4-specific

This trial is testing whether doing crossword puzzles frequently (4 times a week) improves cognition and daily functioning better than doing them rarely (once a week) or following a health education program. Participants have mild cognitive impairment. It is a Phase 2 trial, meaning researchers are evaluating whether the approach works and is safe — it is not a proven treatment. An earlier study suggested crosswords outperformed computer-based brain training.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06122415Recruiting

The Swedish BioFINDER - Memory Clinic Study

Observational study, genotype not specified

This Swedish study is testing whether new blood tests can replace spinal fluid tests for diagnosing memory and dementia conditions. Researchers are comparing several blood biomarkers against the current gold-standard cerebrospinal fluid analysis in 1,200 memory clinic patients. The phase is unspecified — this is an observational validation study, not a drug trial, and no experimental treatment is being given.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05060614Recruiting

Analyses of Cerebrospinalfluid in Patients With Delirium

Observational only, genotype not considered

This study collects cerebrospinal fluid and blood samples from hip fracture surgery patients to look for biological markers linked to delirium. Researchers want to understand what is happening in the brain during delirium and whether it connects to dementia risk. The phase is unspecified, meaning this is likely an observational study rather than a treatment trial — no experimental drug or device is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
Save your time

Stop reading 600 trials.

Members see only the studies that actually fit their genotype, sex, age, and history, usually 6–12 trials worth a serious look, not 600.

Match me in seconds
NCT06203106Recruiting

NYSCF Scientific Discovery Biobank

Open to carriers, genotype-relevant donation

This is a biobank study, not a treatment trial. NYSCF is collecting blood, skin, or saliva samples from people with various diseases — including Alzheimer's — as well as healthy volunteers. Those samples get converted into stem cells, studied in the lab, and stored for future research. There is no phase because no drug or device is being tested. It is infrastructure for science, not a clinical intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07235111Recruiting

Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases

Open to carriers, not 4-specific

This study collects genetic, protein, and metabolic data from people with neurodegenerative diseases — including Alzheimer's, Parkinson's, ALS, FTD, and MCI — to look for biological patterns that might one day improve diagnosis or monitoring. It is an observational research study, not a treatment trial. No drug or intervention is being tested. Details on specific methods and enrollment criteria are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06608316N/ARecruiting

Intermittent Theta-burst Stimulation for Mild Cognitive Impairment

Device study, genotype not considered

This trial is testing whether a non-invasive brain stimulation technique called intermittent theta-burst stimulation (iTBS) can improve thinking skills, balance, and walking ability in people with mild cognitive impairment (MCI). Researchers will also compare stimulating one side of the brain versus both sides. Phase NA here means this is likely a feasibility or pilot study — exploratory, not a late-stage proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06201533N/ARecruiting

Low-intensity Physical-cognitive Exercise and Cognitive Function

Lifestyle study, genotype not addressed

This trial tests whether a low-intensity exercise program that combines physical movement with cognitive tasks can improve brain function in older adults with mild cognitive impairment. Participants do the combined workout three times a week for three months, and researchers measure cognitive performance and biological markers in the blood. This is a Phase NA behavioral trial — it is studying whether the approach works, not a drug being reviewed for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05661084N/ARecruiting

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

Open to carriers, genotype not assessed

This trial is testing whether a caregiver-administered brain stimulation technique called transcranial electrical stimulation (tES) can improve memory, mobility, and executive function in older adults with mild cognitive impairment or mild dementia. Caregivers apply the device at home. It is a Phase NA (feasibility and efficacy) study — meaning researchers are still working out whether the approach works and is safe enough to study further.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05020106Recruiting

The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease

Observational study, genotype not a factor

This study is not a treatment trial. Researchers are recruiting people with Alzheimer's disease, mild cognitive impairment, other dementias, and healthy controls to collect blood and cerebrospinal fluid samples. The goal is to find the most reliable cutoff values for biomarkers like amyloid and tau — the biological signals used to diagnose Alzheimer's. Think of it as calibrating the ruler before measuring. No phase is assigned because no drug or intervention is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
Never miss a fit

Get the alert before the cohort fills.

We watch ClinicalTrials.gov every morning. The minute a study lines up with your profile, you hear about it, not after recruitment closes.

Turn on my alerts
NCT06711952N/ARecruiting

German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)

Diagnostic tool study, genotype irrelevant

This study is testing whether a self-reported questionnaire called the SCD-Q accurately measures how people perceive their own memory and thinking changes — in German-speaking patients. It is not a drug trial; it is a validation study, meaning researchers are checking whether this questionnaire is a reliable tool for German clinical settings. No phase designation applies because no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06880406N/ARecruiting

Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias

Observational only, genotype not mentioned

This study is testing whether mitochondria (the energy-producing parts of cells) behave differently in people with Alzheimer's versus other forms of dementia, using a simple cognitive test and a blood draw. Researchers also want to find metabolic markers in blood that may signal those mitochondrial changes. This is a Phase NA observational study — it is collecting data, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07600996Recruiting

A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls

Observational only, genotype not addressed

This observational study is collecting leftover spinal fluid from patients already having a lumbar puncture for clinical reasons — either for ischemic stroke or Alzheimer disease — and analyzing it with a lab technique called flow cytometry to measure markers of mitochondrial health. The goal is to see whether these markers differ between the two conditions and whether they correlate with stroke severity and recovery. This is not a treatment trial; it is early-stage biological discovery work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06448975N/ARecruiting

An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a surgical procedure called deep cervical lymphovenous bypass in people who already have Alzheimer's disease. The idea is that the brain clears harmful proteins like amyloid-beta and tau through a drainage system involving lymphatic vessels in the neck — and that improving that drainage surgically might help slow or reduce cognitive decline. This is a Phase NA exploratory study, meaning it is early and investigational, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06239688N/ARecruiting

Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce

Caregiver study, not carrier-focused

This trial is testing two versions of an online dementia care training program for staff at assisted living facilities. One group gets the essentiALZ training alone; another gets that training plus Project ECHO, a mentored learning model. Researchers want to know which approach better improves staff knowledge, changes care practices, and supports wellbeing for staff, residents, and families. This is a Phase NA study — it is evaluating real-world training programs, not a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03851523Recruiting

Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.

Observational only, genotype not specified

This observational study tracks people over time to understand the very earliest signs of Alzheimer's disease — specifically, what happens when someone feels their memory is slipping but still tests normally. No treatment is given. Researchers follow participants through stages from subjective cognitive concern to mild cognitive impairment to early dementia, measuring biomarkers and cognitive tests along the way. This is a longitudinal observation study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
Help getting in

We help you actually get matched.

Finding a trial is the easy part. Phoenix supports members through screening calls and, where we can, makes warm intros to sponsors so the door actually opens.

Get me matched
NCT04902703Phase 2Recruiting

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing sargramostim, an FDA-approved bone marrow drug, to see whether it can slow cognitive decline in people who already have mild-to-moderate Alzheimer's disease. Participants receive injections over six months and are compared to a placebo group. It is a Phase 2 trial, meaning researchers are still evaluating whether it works and whether it is safe — it is not approved for Alzheimer's and is not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06274528Phase 2Recruiting

DORA and LP in Alzheimer's Disease Biomarkers

Open to carriers, not 4-specific

This Phase 2 trial is testing whether lemborexant, an FDA-approved sleep medication, can lower blood levels of amyloid-beta and tau — two proteins tied to Alzheimer's disease. Participants are cognitively normal adults 65 and older. Phase 2 means researchers are exploring whether the drug has a measurable biological effect and is safe in this group — it is not yet proven to prevent or treat Alzheimer's disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07570719Recruiting

Community-based Screening for Alzheimer's Disease

Observational only, genotype not considered

This observational study is testing whether two blood-based biomarkers, a ratio of phosphorylated tau 217 to amyloid beta 42 and a protein called GFAP, can reliably screen for Alzheimer's disease in everyday community settings among older Chinese adults. There is no drug or treatment involved. It is an observational study, meaning researchers are watching and measuring, not intervening. Details beyond the screening focus are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT05815329N/ARecruiting

MASCoD - Multidimensional Assessment of Subjective Cognitive Decline

General SCD study, genotype not considered

This trial is testing a new screening questionnaire called MASCoD, designed to detect and track subjective cognitive decline — the stage where someone feels their memory or thinking has slipped, but standard tests come back normal. Researchers want to see if MASCoD scores predict who will develop more serious cognitive decline over time. It also tests whether a tablet-based cognitive training program helps, and whether MASCoD can measure that improvement. This is a Phase NA study — essentially a validation and feasibility study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06715995N/ARecruiting

Effects of Endogenous Gamma Light Stimulation on Brain Oscillations in Cognitively-normal Older Adults

Open to carriers, not 4-specific

This trial is testing whether a special table lamp that produces gamma-frequency light (without flickering) can change brainwave patterns and cognitive performance in healthy older adults. Researchers will measure EEG brain activity before and after lamp exposure, both immediately and over time. This is a Phase NA device study, meaning it is an early exploratory investigation rather than a large-scale efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05653141Recruiting

Post-stroke Cognitive Impairment

Observational only, genotype not mentioned

This study is not testing a treatment. Instead, it is tracking how thinking and memory change over time in people who have had their first ischemic stroke. Researchers want to understand why some people recover cognitive function well while others do not. There is no intervention — it is an observational study, meaning researchers watch and measure rather than test a drug or therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07602283N/ARecruiting

Music for Pain and Dementia

Open to carriers, genotype not required

This study tests whether group drumming sessions affect pain sensitivity and brain activity in people with early Alzheimer's disease, mild dementia, or MCI who also have chronic pain. Participants attend an 8-week community drum circle alongside a caregiver partner. Researchers measure brain waves, heart rate, hormones, and pain responses before and after. Phase NA means this is a mechanistic research study, not a standard drug or device efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06411561N/ARecruiting

A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors

Lifestyle study, genotype not required

This trial tests whether combining sleep improvement strategies with cognitive training helps older adults avoid mental decline after a stay in the ICU. Researchers will compare different combinations of behavioral programs, including sleep support, cognitive exercises, and activity coaching, to see which best protects thinking skills. It is a Phase NA study, meaning this is a practical intervention trial rather than a drug study, focused on real-world feasibility and effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06010511Recruiting

WHIte MAtter Hyperintensity Shape and Glymphatics

Observational imaging, genotype not specified

This observational study is using both standard 3T and ultra-high-field 7T MRI scans to examine white matter lesions in the brains of older adults with cognitive decline or dementia. Researchers want to understand whether the shape and location of these lesions can reveal different underlying disease processes, and whether brain waste-clearance (glymphatic) system markers can help explain how dementia develops. No phase is listed — this is a research imaging study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06688968N/ARecruiting

Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease

Observational only, genotype not relevant

This observational study is mapping how people with early-stage Alzheimer's disease or Parkinson's disease engage with music in daily life, compared to healthy older adults. Researchers will use neuropsychological tests and interviews to understand how memory, executive function, and emotional response to music differ across these groups. It is a Phase NA pilot study, meaning it is exploratory and designed to generate insights, not test a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07081750N/ARecruiting

Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge

Behavioral study, genotype not considered

This trial tests whether a structured activity program — designed together with family caregivers before hospital discharge and then carried out at home for 12 weeks — can reduce behavioral and psychological symptoms in people with mild-to-moderate dementia. Think agitation, anxiety, and mood changes. It is a Phase NA randomized study, meaning it is evaluating effectiveness of a behavioral approach, not a drug. Details on the sponsoring institution are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06657274N/ARecruiting

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Non-drug study, genotype not considered

This trial is testing a home-based digital cognitive training program called RICORDO-DTx against unstructured at-home mental stimulation, in people with mild cognitive impairment, subjective cognitive complaints, or Parkinson's disease. Researchers want to know whether the structured digital program improves cognition better than casual mental activity, and whether it changes biological and brain-activity markers. This is a Phase NA randomized controlled trial — meaning it is evaluating a behavioral and digital device intervention, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06935578Recruiting

RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)

Unrelated to APOE4 risk

This Italian registry study is building a national network to improve diagnosis of rare inherited and acquired cerebrovascular diseases — conditions like CADASIL, Fabry disease, and Moyamoya — that often go unrecognized as stroke causes. It is not a drug trial. Researchers are collecting clinical, genetic, and imaging data to better understand these conditions and close the gap between specialized northern Italian centers and underserved regions. Phase is unspecified because this is an observational registry, not an intervention study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
17 sites
NCT06855368Recruiting

Biomarkers for Monitoring Dementia Progression

Open to carriers, genotype not mentioned

This study is measuring brain connectivity and other biological markers in people with mild Alzheimer's disease or mild cognitive impairment (MCI), comparing them to healthy adults. Researchers also plan to test anti-inflammatory nanoparticles in a mouse model. There is no phase listed, which typically means this is observational or early-stage research, not a treatment trial for humans yet. Details on study size and location are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT02649985Phase 1Recruiting

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Imaging study, genotype not considered

This Phase 1 study uses specialized PET brain scans to look for microglial activation — a sign of brain inflammation — in people with multiple sclerosis and Alzheimer's disease compared to healthy volunteers. It is also testing whether a newer radioactive tracer is as reliable as the current standard one. Phase 1 here means early-stage research focused on imaging accuracy and safety, not on treating any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05020626Recruiting

Modelling Tau Distribution From DTI With Generative Adversarial Network for Alzheimer's Disease Diagnosis

Imaging research, no genotype relevance

This is not a treatment trial. Researchers are training an AI model to generate synthetic tau-PET brain scans using a different, cheaper type of MRI called DTI. The goal is to see whether the AI-generated images can accurately estimate tau protein buildup in the brain without an actual PET scan. This is a diagnostic imaging research project with no specified phase — it tests a tool, not a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05072483Recruiting

Natural History Study of CADASIL

Unrelated to APOE4 genotype

This is a long-term observational study — not a treatment trial — tracking how CADASIL, a rare inherited small-vessel disease of the brain, changes blood vessels and cognition over roughly nine years. Participants have MRI scans, blood tests, cognitive assessments, and vascular measurements at four visits. There is no experimental drug or device being tested. Because no phase is assigned, this is a natural history study focused on understanding the disease, not on proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06543134Recruiting

Evaluation of The Relationship Between Perioperative Hypothermia and Emergence Agitation

No APOE4 relevance found

This study looks at whether patients who get too cold during surgery (perioperative hypothermia) are more likely to wake up confused or agitated afterward (called emergence agitation). Researchers will track body temperature and use a sedation scale to see if there is a connection. This is an observational study — no experimental drug or device is being tested, just a relationship being measured in surgical patients.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06951932N/ARecruiting

Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment

Dietary study, genotype not considered

This trial is testing whether medium-chain triglycerides (MCTs) added to a Mediterranean diet can slow cognitive decline in people recently diagnosed with mild cognitive impairment. It compares that diet against a standard Mediterranean diet using extra virgin olive oil. This is a Phase NA trial, meaning it is a practical comparison study rather than early drug safety testing. The outcome being measured is how cognition changes over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07435467Recruiting

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

Observational only, genotype not addressed

This is an observational study, not a treatment trial. Researchers are collecting blood samples from hospitalized elderly patients to test whether certain Alzheimer's and brain-injury biomarkers can predict who is likely to decline, be readmitted to the hospital, or die. No drug or intervention is involved. It is a real-world data study aimed at building a prognostic tool for clinical use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT05708001N/ARecruiting

Improvement of Memory in Mild Cognitive Impairment

Open to carriers, genotype not tracked

This trial tests whether a wearable brain stimulation device called tACS — which delivers mild electrical pulses to the brain — can improve memory in people with mild cognitive impairment when operated at home by a family caregiver. Brain activity is measured with EEG before and after sessions. This is a Phase NA feasibility study, meaning researchers are primarily checking whether the approach is practical and safe, not yet proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07040904N/ARecruiting

Mindfulness to Enhance Cognitive Health in Latinx Older Adults

Lifestyle study, genotype not required

This trial is testing whether mindfulness training can support cognitive health in Latinx adults aged 65 and older, with the goal of potentially reducing Alzheimer's risk in this community. Researchers also want to understand the mechanisms behind any benefit they observe. This is a Phase NA behavioral study — it is exploring feasibility and effect, not testing a drug, and nothing is proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05806697N/ARecruiting

Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study

Observational only, France-based cohort

This is an observational extension study, not a treatment trial. No drugs are being tested. Researchers are tracking older adults who already showed amyloid buildup in earlier brain scans, using EEG, eye-movement tests, MRI, PET scans, and blood and spinal fluid samples over 5-6 more years. The goal is to learn how preclinical Alzheimer's disease progresses naturally — specifically, who converts from no symptoms to early symptoms. This is a Phase NA observational study, meaning it is descriptive research, not an efficacy test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07220668Phase 1Recruiting

Sense4Safety Intervention

Open to MCI patients, genotype not required

Sense4Safety is a behavioral intervention using in-home sensors and machine learning to detect rising fall risk in real time, then connecting older adults with a coach to act on that risk. This Phase 1 trial enrolls people aged 65 and older who have mild cognitive impairment. Phase 1 here is about early safety and feasibility testing, not a proven or approved program.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04601038Phase 2Recruiting

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Explicitly recruits APOE4 carriers

This Phase 2 trial tests whether a drug called CORT108297 — which blocks a stress hormone receptor — can protect memory and thinking skills when the brain is under acute stress. Researchers are comparing two weeks of the drug against placebo in people with early memory problems or those at elevated risk for Alzheimer's. Phase 2 means they are gathering early evidence on whether it works and checking for side effects, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05980949Phase 3Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Late-stage AD only, genotype not relevant

This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related psychosis. It is a Phase 3 open-label extension, meaning everyone gets the active drug and the main question is long-term safety and tolerability, not whether it works better than a placebo. Only people who completed one of three specific earlier KarXT studies can join.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
426 sites
NCT06667414Recruiting

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Unrelated to APOE4 or Alzheimer's

This study is mapping specific genetic markers called SNPs in people who carry the Huntington's disease gene mutation. Participants give a blood sample and answer questions about their health history. Researchers want to understand how these genetic variants are distributed across the Huntington gene. There is no phase listed because this is an observational study, not a drug trial. It is gathering baseline genetic data, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
45 sites
NCT06372587N/ARecruiting

Next-Generation alzheImer'S Therapeutics

Lab study only, not a treatment

This trial is not testing a drug in people — it is a lab study. Researchers will take a small skin sample from people with Alzheimer's, convert those skin cells into living neurons in a dish, and then test specially engineered proteins designed to strengthen the connections between brain cells. It is classified as Phase NA, meaning it is preclinical research, not yet a human treatment trial. Details on long-term direction are still early.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04558164N/ARecruiting

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) can improve memory in people with mild cognitive impairment or significant memory complaints. A device delivers magnetic pulses to a memory-related brain region, and participants are randomly assigned to real or fake stimulation to compare results. This is a Phase NA (feasibility or pilot) study — it is exploratory, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05992831N/ARecruiting

Transcranial Magnetic Stimulation for MCI

Open to carriers, not 4-specific

This trial is testing a non-invasive brain stimulation technique called accelerated TMS (transcranial magnetic stimulation) in people who have both mild cognitive impairment and depression. Researchers want to find the right dose before moving to larger studies. It is a Phase NA device study — meaning it is dose-finding work, not yet a full efficacy test. Half the participants receive real stimulation; half receive a sham version.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03135327N/ARecruiting

Clinical Applications of Advanced Ophthalmic Imaging

Genotype-blind, not APOE4-specific

This study is testing whether advanced eye-imaging tools — including OCT scans and retinal imaging — can detect changes in the eyes of people with conditions like dementia, multiple sclerosis, and diabetes. A second phase gives participants a medical food supplement called Ocufolin for six months and tracks whether it changes what those imaging tools detect. This is a Phase NA designation, meaning it includes both observational and early interventional work, not a standard drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06399731N/ARecruiting

Non-invasive Brain Stimulation for the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Wrong condition, not APOE4-relevant

This pilot study is testing two types of non-invasive brain stimulation — repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) — in people who have both Parkinson's disease and mild cognitive impairment. The main question is simply whether participants find these approaches acceptable and feasible. It is a Phase NA pilot study, meaning it is very early and exploratory, not yet testing whether these devices definitively help cognition.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03047369Recruiting

The Myelin Disorders Biorepository Project

Unrelated to APOE4 or Alzheimer's

This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people with leukodystrophies, a group of rare genetic diseases affecting the brain's white matter. The goal is to find new genetic causes, develop biomarkers, and understand how these diseases progress over time. Details on phase are not applicable here — this is a long-term data and sample collection effort, not a drug or device study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
23 sites
NCT05196984N/ARecruiting

Gamma Frequency Stimulation in Individuals With Down Syndrome

Not relevant to APOE4 carriers

This trial tests a non-drug device called GENUS that delivers flickering light, sound, and vibration at a specific brain frequency called gamma. Researchers want to see whether this stimulation is safe and feasible in people with Down syndrome, and whether it changes brain wave patterns or cognitive performance. It is a small Phase NA exploratory study — think of it as early-stage testing to see if the approach even makes sense in this population, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06876857Recruiting

University of Central Florida CereBank

Biobank donation, genotype not specified

This is not a treatment trial. UCF is building a brain tissue and biospecimen bank called CereBank to support future research into brain diseases, including inherited ones. Donors contribute biological samples that researchers can then study. There is no experimental drug or device involved. Details on what types of samples are collected or how donation works are limited in the public record so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06854731N/ARecruiting

Preventing Falls in Older Adults With Cognitive Frailty

Open to carriers, genotype not mentioned

This trial is testing whether a home-based balance and strength exercise program, supported by health coaching, can reduce falls in older adults who have mild cognitive impairment and frailty and have already fallen at least once. Participants are compared to a group receiving health education only. This is a Phase N/A trial, meaning it is a practical clinical study rather than a drug trial — focused on real-world behavior change, not a pharmaceutical.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05509387N/ARecruiting

Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease

Device trial, genotype not considered

This trial tests whether a higher-intensity brain stimulation technique called tDCS — which delivers a mild electrical current through the scalp — improves word-finding ability in people with Alzheimer's disease when used alongside naming exercises. Researchers are comparing a standard dose of 2 milliamps against a stronger 4 milliamp dose to see which works better. This is a Phase NA study, meaning it is an exploratory trial focused on optimizing how the technique is applied, not a large-scale effectiveness study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05495087N/ARecruiting

IHT for Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing intermittent hypoxia training, or IHT, for people with mild cognitive impairment. IHT means breathing air with reduced oxygen levels for short intervals, similar to what happens at high altitude, delivered through a facemask. Researchers want to know if 12 weeks of this treatment is safe and whether it improves memory and thinking. This is a Phase NA, early-stage trial focused on safety and initial effectiveness — it is not a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07323914Phase 3Recruiting

Clinical Analgesic Management in Dementia

Open to carriers, not 4-specific

This Phase 3 trial is testing whether oxycodone combined with acetaminophen (sold as Tylex) safely and effectively manages moderate to severe chronic pain in people who already have Alzheimer's disease. It is not studying memory or disease progression — the focus is pain relief. Phase 3 means the drug itself is established, but its use specifically in this population is being formally evaluated. Only 10 participants will be enrolled, so this is a small pilot-scale study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06442852Recruiting

Study on the Relationship Between Peripheral Blood miRNA and Risk and Severity of Alzheimer's Disease

Observational only, genotype not considered

This study is looking at tiny molecules in the blood called microRNAs to see whether their levels differ between people with Alzheimer's and healthy volunteers, and whether those levels track with how severe the disease is. It is an observational study, not a treatment trial — no drug or therapy is being tested. The goal is to find possible early blood-based signals for Alzheimer's. Details on phase are not provided.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06916221N/ARecruiting

BID LTM Digital Intervention in Aging

Behavioral study, genotype not considered

This trial is testing two digital brain-training games — one focused on navigation and memory, one a word game used as a comparison — to see whether either improves long-term memory and cognitive control in older adults, including those with mild cognitive impairment. It is a Phase NA study, meaning it is a behavioral intervention trial rather than a drug trial, run entirely from home over eight weeks with a six-month follow-up. Details on the specific games are limited in the public summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05607732N/ARecruiting

Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

Detection study, genotype not considered

This trial is testing a digital screening tool called MyCog, built on the NIH Toolbox, to see whether primary care clinics can reliably catch early cognitive impairment in patients from underserved communities. It is a Phase NA pragmatic trial, meaning researchers are testing whether something works in real-world clinical settings, not a controlled lab environment. The focus is on earlier detection and better follow-up care, not on any drug or treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05331144Phase 2Recruiting

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

Open to carriers, not 4-specific

This Phase 2 trial is testing whether aggressively lowering systolic blood pressure — using two common prescription medications, losartan and amlodipine — reduces the buildup of amyloid and tau proteins in the brains of older adults who have hypertension and are at elevated risk for memory decline. Phase 2 means researchers are gathering evidence on whether the approach works and is safe, but it is not yet proven or approved as a prevention strategy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07097051Phase 2Recruiting

Multi-session Transcranial Alternating Current Stimulation to Improve Dual-task Standing and Brain Activity in Older Adults With Mild Cognitive Impairment

Open to carriers, genotype not required

This trial tests whether a non-invasive brain stimulation technique called tACS, which uses gentle electrical currents at 10 Hz to boost alpha brain waves in the frontal cortex, can improve balance while multitasking and executive function in older adults with MCI. Participants get either real or sham stimulation across multiple sessions, then are followed for up to three months. It is a Phase 2 pilot study — testing early signals of whether this works, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05552157Phase 2Recruiting

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Familial mutation only, not APOE4

This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2) that causes early-onset familial Alzheimer's disease. Researchers want to see whether the drug slows or prevents amyloid buildup in the brain, measured by PET scans and spinal fluid markers. Phase 2 means the drug is still being studied for effectiveness and safety — it is not approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
35 sites
NCT06658769N/ARecruiting

Use of Transcranial Magnetic Stimulation in the Post-Operative Cognitive Dysfunction in Elderly

Open to carriers, not 4-specific

This trial is testing whether a brain stimulation technique called Theta Burst TMS — delivered in three sessions before surgery — can help prevent memory and thinking problems that sometimes appear after major operations in older adults. Participants already have mild cognitive impairment and are 60 or older. It is a Phase NA randomized trial, meaning it is evaluating whether the approach works, but it is not yet proven or approved for this purpose.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02685969Recruiting

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

Closed cohort, APOE4 not specified

This study uses two types of PET brain scans to measure amyloid protein buildup and glucose metabolism in cognitively healthy adults who are mostly children of Alzheimer's patients. It is observational, not a treatment — no drug is being tested. Researchers want to understand what early brain changes look like before any symptoms appear. Phase is unspecified because this is a imaging and biomarker study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07064226N/ARecruiting

Validation of a Digital Intervention to Rehabilitate Cognitive Resources

Open to carriers, not 4-specific

This trial is testing RICORDO, a digital app that adapts cognitive rehabilitation exercises to each person's ability level. Researchers want to know whether it improves overall thinking and memory skills better than standard paper-and-pencil rehabilitation. It enrolls people with subjective memory complaints, mild cognitive impairment, or mild dementia. This is a Phase NA trial, meaning it is a validation or feasibility study rather than a standard efficacy phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07496918Phase 2Recruiting

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)

Open to carriers, not 4-specific

This trial tests whether flickering light and sound at 40 Hz (a specific brain-wave frequency) plus a tactile vibration device can produce measurable biological changes in the brain. Researchers at MIT will use EEG, MEG, MRI, and blood tests to look for those effects in cognitively healthy adults during a single one-day visit. It is a Phase 2 trial, meaning researchers are exploring whether the approach works and is safe, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07239869Phase 1Recruiting

A Robot-assisted Tailored Activity Programme for People With Dementia and Their Caregivers

Open to carriers, genotype irrelevant

This trial tests a robot-assisted activity programme designed to get people with dementia and their home caregivers moving more. Researchers want to know if it is feasible and whether it shows early signs of improving physical activity and wellbeing for both the person with dementia and the caregiver together. It is a Phase 1 study, meaning this is an early-stage test of safety and practicality, not a proven intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05903573N/ARecruiting

Training Response Artificial Intelligence Network (TRAIN)

Open to carriers, genotype not considered

This trial is testing whether brain MRI scans taken at the start of a study can train an AI tool to predict which people with mild memory problems will benefit most from cognitive training exercises. Participants are randomly assigned to either structured cognitive training or a comparison educational program for 12 weeks. This is a Phase N/A feasibility and tool-development study — it is not testing a drug, and no treatment effectiveness claims are being made yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06623864N/ARecruiting

Significant Activities in the Integrated Person-centered Care Model

No connection to APOE4 carriers

This trial is testing whether training care workers to lead meaningful, person-centered activities improves the quality of life for older adults living in geriatric care centers. It compares meaningful activities against standard activities. Phase NA means this is not a traditional drug trial — it is a behavioral and care-practice study. With only 10 participants, it is very small and early-stage. Details on outcomes are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05725668N/ARecruiting

A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment

Lifestyle study, genotype not mentioned

This trial is testing whether a specialized form of tai ji quan that adds mental challenges to physical movement can reduce falls in older adults with mild cognitive impairment. Participants are randomly assigned to dual-task tai ji quan, standard tai ji quan, or stretching, and researchers will track how often falls happen. This is a Phase NA behavioral trial — meaning it tests a non-drug intervention, not a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06585449Phase 1Recruiting

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing ALN-HTT02, an experimental drug designed to reduce the harmful huntingtin protein that drives Huntington's disease. Researchers are measuring safety, tolerability, and how the drug behaves in the body after single or repeated doses. It is a Phase 1 trial, meaning the primary goal is to establish that the drug is safe in humans — it is not yet proven or approved for any use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
19 sites
NCT04132362Recruiting

Benefits of Personalised Music in Dementia - a Feasibility Study

General dementia study, genotype irrelevant

This study is testing whether personalised music playlists — built around each person's own musical history — can improve the well-being of people living with mild to moderate dementia in care homes and at home. Researchers are also using brain scans to explore why music might help. This is a feasibility study, meaning the goal right now is to figure out whether the methods work before running a larger trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07457138Recruiting

Lombard Cohort of Brain Health Services

Observational only, Italy-based, not 4-specific

This Italian observational study is enrolling about 1,000 adults in the Lombardy region who have subjective memory concerns but no diagnosed cognitive impairment. Researchers will track blood-based Alzheimer's biomarkers, cognitive tests, and psychological well-being over five years. No phase applies here — this is not a drug trial but a long-term data-collection effort aimed at understanding who develops measurable Alzheimer's changes and when.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT04588285Phase 2Recruiting

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

DLB trial, collects APOE4 data

This trial is testing whether ambroxol, a drug that boosts an enzyme called GCase, can slow cognitive decline, functional loss, and behavioral symptoms in people with early or prodromal dementia with Lewy bodies. It is a Phase 2a trial, meaning researchers are examining whether the drug works and is safe in this population — it is not yet proven or approved for this purpose.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT06850597Phase 2Recruiting

Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether dimethyl fumarate, a drug already approved for multiple sclerosis, can improve memory, attention, and thinking in people with mild cognitive impairment or Alzheimer's disease. Participants take 480 mg daily or a placebo, and cognitive scores are compared at the end. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and is safe — it is not an approved Alzheimer's treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05791994N/ARecruiting

EVASION: Effect of VisuAl Stimulation on attentION

Open to carriers, not 4-specific

This trial is testing whether a visual brain-training software called Emeraude helps people with a specific type of mild cognitive impairment — the kind that affects planning and mental flexibility — process information faster. Participants either do daily visual cognitive exercises or watch TV for 30 days. Researchers also track memory, walking ability, and quality of life. This is a Phase NA trial, meaning it is more of a structured feasibility or exploratory study than a large efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06965062N/ARecruiting

Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)

Open to carriers, genotype not tracked

This trial is testing a surgical procedure that connects lymph nodes in the neck to nearby veins, with the goal of improving the brain's ability to drain waste proteins like amyloid and tau. Researchers in Singapore want to know if it is safe and whether it shows any early signs of slowing cognitive decline. This is a Phase N/A proof-of-concept study, meaning it is very early-stage — testing feasibility, not yet proving the procedure works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07445841N/ARecruiting

Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training

Stroke study, genotype not required

This trial is testing whether a structured multimodal exercise program, started early after a stroke, can protect thinking and memory and reduce the risk of future cognitive decline and dementia. Researchers will track both cognitive performance and biological markers tied to dementia risk. This is a Phase NA trial, meaning it is a controlled study comparing the exercise program against a gentler balance and stretching routine, not yet a proven or approved intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06799429N/ARecruiting

Train Your Brain Fitness SC: An Exercise Intervention for People With Cognitive Impairments

Open to carriers, not 4-specific

This trial is testing a twice-weekly exercise and coaching program for adults with mild to moderate cognitive impairment. One group meets in person, the other participates remotely. Researchers want to know whether the program is practical and enjoyable, and whether participants show changes in endurance, mobility, and cognitive function over 12 months. This is a Phase NA feasibility study, meaning the goal is to figure out if the approach works before testing it more widely.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06995573Phase 1Recruiting

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Genotyping required, not 4-specific

This trial is testing a drug called NSC001 in people who already have mild to moderate Alzheimer's disease. Researchers want to know whether it is safe and whether it has any effect on cognitive function. It is a Phase 1 trial, meaning the primary goal is safety — figuring out whether the drug causes harm — not proving it works. Participants take NSC001 or a placebo alongside their existing Alzheimer's medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
10 sites
NCT05794061Recruiting

Advances in Neuropsychological Diagnostics

Diagnostic tool study, not genotype-specific

This study is developing and refining neuropsychological tests used to diagnose cognitive impairment and dementia — tools like memory and thinking assessments given in clinics or remotely. Researchers are building and validating these instruments in both healthy Italian adults and patients with neurological or psychiatric conditions. There is no phase designation because this is not a drug or device trial — it is a diagnostic and psychometric research project.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05688618N/ARecruiting

Effect of the Administration of a Symbiotic (E. Faecium and Agave Inulin) on Mild Cognitive Impairment in Older Adults

Open to carriers, not 4-specific

This trial is testing whether a symbiotic supplement, combining a probiotic bacteria called Enterococcus faecium with agave inulin (a prebiotic fiber), can improve cognitive function in older adults with mild cognitive impairment. The idea is that a healthier gut microbiome may reduce brain inflammation. This is a Phase NA (feasibility or pilot) trial, meaning it is exploratory and early-stage, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07498426Phase 3Recruiting

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Not relevant to APOE4 carriers

This trial is testing NIO752, an experimental drug, in people diagnosed with Progressive Supranuclear Palsy Richardson Syndrome — a rare and serious brain disease distinct from Alzheimer's. Researchers want to know whether NIO752 slows the disease or reduces symptoms, and whether it is safe. It is a Phase 3 trial, meaning it is a large, late-stage test that could support future regulatory review. Participants receive either the drug or a placebo, then may continue in an open-label extension.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT04894006N/ARecruiting

Dementia Family Caregiver Study

Caregiver study, genotype irrelevant

This trial tests a 3-month home visit program delivered by community health workers to family caregivers of people with dementia. Caregivers wear a smartwatch and smart ring so researchers can track stress and sleep in real time. The program teaches mindful breathing and provides culturally appropriate support in English, Spanish, Vietnamese, or Korean. This is a Phase NA behavioral study — it is evaluating a care program, not a drug or device meant to treat disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07496021N/ARecruiting

Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

Open to carriers, genotype not tracked

This trial is testing a probiotic bacterial strain called L. lactis CKDB001 against a placebo in people with early Alzheimer's disease — meaning mild cognitive symptoms and confirmed amyloid buildup on a PET scan. Participants take the intervention for 24 weeks. This is a proof-of-concept study, which means researchers are gathering early evidence on whether it works and is safe, not confirming a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06397339N/ARecruiting

Indian Transforming Alzheimer's Care Training (INTACT)

Care system study, not carrier-focused

This trial tests a training program called INTACT, designed to help primary care clinics do a better job detecting and managing Alzheimer's and mild cognitive impairment in American Indian and Alaska Native patients. It is a Phase NA study, meaning it is evaluating real-world effectiveness of a care model, not testing a drug. Twenty-eight urban and rural clinics are being compared to see whether culturally tailored provider training improves the quality of dementia care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06999434Phase 1Recruiting

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Open to carriers, not 4-specific

This trial tests a new PET scan radiotracer called [18F]3F4AP, which is designed to image myelin — the protective coating on nerve fibers. Researchers want to see how the tracer moves through the body in healthy people and in people with conditions like MCI, Alzheimer's, MS, or spinal cord injury. This is a Phase 1 trial, meaning the focus is on basic safety and how the body handles the tracer, not on proving any treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06477484Recruiting

Blood Biomarkers for Screening of Alzheimer's Disease

Observational only, genotype not required

This observational study is testing whether certain proteins measured in a blood sample can reliably identify Alzheimer's disease early. Researchers are measuring six biomarkers including amyloid, tau, and inflammation-related proteins in people with Alzheimer's, mild cognitive impairment, and healthy individuals. No drugs or treatments are involved. The phase is unspecified, meaning this is likely early-stage research aimed at validating a screening tool rather than testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06945614Phase 1Recruiting

Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation

Healthy carriers eligible, genotype not considered

This trial is testing whether inhaling low doses of xenon gas is safe in healthy older adults. Xenon is a noble gas already used in anesthesia, and researchers think it may reduce brain inflammation linked to neurodegenerative diseases. Participants inhale xenon through an anesthesia machine across four dosing groups based on exposure time. This is a Phase 1 trial — the earliest stage, focused entirely on safety, not on proving any benefit yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06918704N/ARecruiting

BID WM Digital Intervention in Aging

Open to carriers, genotype not a factor

This trial is testing two digital brain-training apps — called Coherence and Worder — to see whether eight weeks of at-home use can improve working memory and inhibitory control in older adults, including those with mild cognitive impairment. It is a Phase NA study, meaning this is more of a feasibility and efficacy exploration than a late-stage drug trial. Participants do everything remotely, with check-ins at baseline, post-intervention, and six months later.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07306598Recruiting

[18F]NIDF PET Imaging in Tau-related Diseases

Imaging study, genotype not a factor

This study is testing a new PET brain imaging tracer called [18F]NIDF, which is designed to detect abnormal tau protein in the living brain. Tau tangles are a hallmark of Alzheimer's and related diseases. The goal is to see whether this tracer is safe and whether it produces clearer, more accurate images than existing tau-PET tracers. The phase is unspecified, so this appears to be an early-stage human safety and feasibility study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04956549N/ARecruiting

Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)

Lifestyle study, genotype not required

This trial is testing whether a structured physical activity program can reduce Alzheimer's risk factors in older African American adults who already have mild cognitive impairment, or MCI. Participants are randomly assigned to either the exercise program or an active control group called Successful Aging, and followed for 52 weeks. This is a Phase NA behavioral trial — it is studying real-world outcomes, not a drug, and no medication is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04500847Phase 1Recruiting

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Open to carriers, not 4-specific

This trial is testing emtricitabine — an HIV antiviral drug — as a possible intervention for people who already have biomarker-confirmed MCI or mild to moderate Alzheimer's-related dementia. The idea is that this class of drug may reduce a cellular stress process thought to drive brain inflammation. It is a Phase 1 trial, meaning the primary focus is on safety and tolerability in a small group of 35 people, not on proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03638583Recruiting

Alzheimer Prevention Trials (APT) Webstudy

Open registry, genotype not required

The APT Webstudy is not a treatment trial. It is an online registry that tracks cognitive health over time in people 50 and older who do not have dementia. The goal is to identify individuals who may be at higher risk for Alzheimer's and connect them with future clinical trials. There is no drug or intervention involved — just periodic online cognitive testing and possible referral for biomarker testing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06340659N/ARecruiting

Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults (The Exergames Telerehabilitation Study)

Open to carriers, not 4-specific

This trial compares two home-based, telehealth exercise programs for older adults who notice they are forgetting things more than before. One group does standard aerobic exercise via video; the other plays cognitive video games that also require physical movement, called exergames. Researchers are measuring thinking skills, fitness, and brain-related proteins in the blood. This is a Phase NA feasibility and preliminary efficacy trial, meaning they are testing whether the approach works well enough to study further.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07234942Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Open to carriers, not 4-specific

This Phase 1 trial is testing a new drug called RO7812653 in people with early Alzheimer's disease, including those with mild cognitive impairment or early dementia. Phase 1 means the primary goal is safety — researchers want to know if the drug is tolerable and how the body processes it, not yet whether it slows the disease. Details on how the drug works are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT05322343Recruiting

Biobank and Brain Health in Bordeaux.

Observational study, genotype not specified

B Cube is a large observational study in Bordeaux, France, following 2,000 adults aged 55 to 80 to understand what shapes brain aging over time. Researchers are collecting biological samples, brain scans, questionnaires, and lifestyle data — with special focus on nutrition. This is not a treatment trial; it is a data-gathering effort designed to identify risk and protective factors for cognitive decline. No phase is assigned because no intervention is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07058688Phase 2Recruiting

A Study of NTRX-07 in Participants With Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 2 trial is testing a new drug called NTRX-07 in 48 people with mild cognitive impairment or mild to moderate Alzheimer's disease. The main goal right now is safety: does the drug cause side effects, and how does the body process it? Participants take the drug or a placebo daily for 28 days. Phase 2 means researchers are still in early testing — this drug is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT03082755Phase 4Recruiting

Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 4 trial is testing whether gabapentin enacarbil (Horizant), a drug already approved for restless legs syndrome, can reduce nighttime agitation in people who have Alzheimer's dementia and also show signs of restless legs syndrome. Phase 4 means the drug is already approved for another use — researchers are now studying whether it helps this specific group. The idea is that undiagnosed restless legs may be driving some nighttime agitation, and treating it might reduce suffering and cut down on antipsychotic prescriptions.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06094192N/ARecruiting

Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

Drug-free device trial, genotype not specified

This trial is testing whether a noninvasive brain stimulation device called high-definition transcranial electrical current stimulation can improve memory in people with Alzheimer's disease or MCI due to AD. Researchers think AD disrupts the brain's natural rhythmic activity across large networks, and they want to see if this device can help correct that. This is a Phase N/A study — more exploratory and mechanistic than a standard efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05443633N/ARecruiting

Enhancing Language Function in Aphasia

Not relevant to APOE4 carriers

This trial is testing whether individualized speech-language training works better than standard language therapy for people with aphasia — a language impairment caused by stroke or a specific type of dementia called primary progressive aphasia. Researchers are also using brain imaging to understand how the brain responds to treatment. This is a Phase NA behavioral study, meaning it compares two therapy approaches rather than testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06338215N/ARecruiting

Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality

General trial, no APOE4 focus

This trial is testing whether advising moderate drinkers to follow a Mediterranean-style drinking pattern — moderate amounts, no binge drinking, preference for red wine — leads to health outcomes no worse than advising full abstention. It is tracking all-cause mortality, heart disease, cancer, diabetes, and dementia over four years. This is a Phase N/A behavioral trial, meaning it tests advice and lifestyle guidance, not a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07227961Recruiting

PROMIS and Mobility Evaluation in Sarcoma Patients

No connection to APOE4 or Alzheimer's

This study is testing whether a smartphone app can reliably track recovery in sarcoma patients after surgery. Participants complete digital questionnaires and the app passively monitors movement like step count and gait. Researchers want to see if these tools accurately capture how patients are doing over the year following surgery. The phase is unspecified, so this appears to be a validation and feasibility study rather than a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06539403Recruiting

Thinking About Memory: How Confident Are You in Your Memory, and Does it Change With Age?

Observational study, genotype not mentioned

This study looks at how people with and without memory concerns think about their own memory abilities — a concept called metacognition. Participants complete memory tasks, and researchers measure whether self-confidence in memory matches actual performance. There is no drug or device involved. The phase is unspecified, making this an observational or exploratory study designed to build understanding, not to test a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06871488Phase 4Recruiting

Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants

Unrelated to APOE4 or Alzheimer's

This trial is testing whether brainwave patterns measured by EEG can predict which children with ADHD respond well to stimulant medications for irritability and aggression. Researchers will optimize each child's stimulant dose, then run a short crossover comparing that dose to placebo while recording brain activity. It is a Phase 4 trial, meaning the medications are already approved — this study is asking who benefits most and why.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04240561N/ARecruiting

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

Device study, genotype not considered

This trial is testing two different hearing aid signal processing approaches in older adults who have Alzheimer's dementia or amnestic mild cognitive impairment and also have hearing loss. One approach heavily modifies the sound signal; the other keeps it simpler and more natural. Researchers want to know which works better for people with reduced cognitive capacity. This is a Phase NA study, meaning it is a practical comparison rather than a drug efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07604896Phase 4Recruiting

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

Drug trial, elevated ARIA risk for carriers

This Phase 4 trial is testing lecanemab, an already-approved amyloid-targeting antibody drug, in patients with early-to-moderate Alzheimer's disease over 24 months. What makes it unusual is the use of multi-omics — combining eye imaging, brain MRI, blood markers, and cognitive scores to get a fuller picture of how the drug works and who it helps or harms. Phase 4 means the drug is approved; this is post-market study to deepen understanding.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06565169N/ARecruiting

Improving PCP Advance Care Planning for People With ADRD

Dementia caregiving focus, not prevention

This trial tests a structured toolkit designed to help primary care doctors and nurses have better conversations about future care wishes with people who already have Alzheimer's or a related dementia. Researchers will compare the toolkit to usual care over 18 months, measuring how often and how well those goals-of-care conversations happen. This is a Phase NA trial, meaning it is evaluating a care process rather than a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07041450Recruiting

Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Genotype-neutral, but highly carrier-relevant

This study is testing whether a combination of digital cognitive assessments and blood-based biomarkers can quickly identify people who might qualify for newer Alzheimer's disease-modifying therapies. It is not testing a treatment — it is testing a faster screening pathway. The goal is to build an algorithm that helps clinicians triage patients more efficiently. This is an observational diagnostic study, not a drug trial, so there is no experimental treatment involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06052397Recruiting

Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium

Genotype interaction under study

This observational study is tracking sleep patterns in adults age 70 and older before and after major orthopedic surgery, like hip or knee replacement. Researchers want to know whether disrupted sleep or circadian rhythms raise the risk of postoperative delirium and cognitive decline. It is not a drug trial — no treatment is being tested. Participants wear a wrist activity monitor for two weeks before surgery and give blood samples. Details on phase are not specified.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05887674N/ARecruiting

Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease

Lifestyle study, genotype not required

This trial is testing whether a combination of three lifestyle changes — an anti-inflammatory diet, regular exercise, and cognitive training — can slow mental decline in people who already have mild cognitive impairment or early Alzheimer's disease. It is a Phase NA, meaning it is a controlled behavioral trial rather than a drug study. Researchers want to know if doing all three together makes a meaningful difference over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06850870Phase 1Recruiting

Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)

Open to carriers, genotype not relevant

This pilot trial compares two types of rideshare services for older adults with memory problems or dementia: a door-through-door service with a trained companion driver versus a standard curb-to-curb rideshare. The main question is whether the companion model reduces missed medical appointments. This is a Phase 1 pilot, meaning researchers are testing feasibility and early results, not a proven or approved intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06669182N/ARecruiting

Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）

Device trial, genotype not considered

This trial tests whether a non-invasive brain stimulation technique called intermittent theta-burst stimulation, aimed at the cerebellum, can slow cognitive decline in people with mild Alzheimer's disease. Researchers will measure changes on a standard dementia rating scale over three months. Phase NA here means this is a clinical study focused on device effectiveness and safety, not a traditional drug trial — it has not yet been proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT04363684Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

FTLD-focused, not APOE4-relevant

This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions over time. It is not testing a drug or device. Instead, it collects clinical data, biomarkers, and biological samples to better understand how these diseases progress. There is no assigned phase — this is observational research, meaning researchers watch and measure rather than intervene.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
27 sites
NCT05374278Phase 1Recruiting

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

Imaging study, genotype not a factor

This trial is testing a new PET scan tracer called [18F]RP-115, which is designed to image a protein called EAAT2 — a glutamate transporter found on brain cells called astrocytes. The goal is to see whether this tracer is safe in humans and whether it can detect early brain changes in Alzheimer's disease and frontotemporal dementia. This is a Phase 1 trial, meaning it is the very first time this imaging agent is being used in people.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07284264Recruiting

Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

Directly recruits APOE4 carriers

This study is testing a two-step early detection system for Alzheimer's disease. Step one uses a questionnaire, a digital cognitive test, and a risk prediction model to flag people who may be at risk. Step two checks blood-based biomarkers to confirm whether Alzheimer's pathology is present. This is an observational study — it is testing a detection method, not a drug or treatment, and the approach is not yet proven or in clinical use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT07294885N/ARecruiting

Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a microsurgical procedure called deep cervical lymphaticovenous anastomosis — essentially connecting small lymphatic vessels in the neck to nearby veins — to see whether it genuinely improves symptoms in people with Alzheimer's disease, or whether early improvements seen in previous patients were due to the surgery itself versus other factors like anesthesia. It uses a sham surgery comparison group to find out the true cause. This is a Phase NA controlled trial — an early-stage test of whether the procedure actually does what it appears to do.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07513844N/ARecruiting

Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing a non-invasive brain stimulation device called low-intensity focused ultrasound, or LIFU, aimed at a deep brain region called the globus pallidus. The goal is to find the right settings to safely reduce the involuntary movements, called chorea, that are a hallmark of Huntington's disease. This is a Phase NA study, meaning it is an early-stage parameter-optimization experiment, not yet a full efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06313944Recruiting

German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation

Device registry, genotype not tracked

This German registry is tracking real-world use of Transcranial Pulse Stimulation (TPS), a non-invasive brain stimulation device already approved in Europe, in people diagnosed with Alzheimer's disease. Researchers are collecting safety data, side effects, and cognitive scores across multiple clinics. This is a post-market registry, not a randomized trial, so it is documenting how the device performs in routine care rather than testing it in a controlled experiment for the first time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT04262206Phase 4Recruiting

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Open to carriers, not 4-specific

PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death, dementia, and disability in adults 75 and older who do not yet have heart disease or dementia. Phase 4 means the drug is already approved; this is studying whether it helps a new population. Researchers are also tracking mild cognitive impairment and cardiovascular events as secondary outcomes.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
103 sites
NCT06902649N/ARecruiting

Step-by-Step: Evaluation of a Stepped Care Model

Unrelated to APOE4 or Alzheimer's

This trial is testing a stepped care model for children aged 8 to 16 who have defiant or aggressive behavior problems. Families start with an internet-based parenting program, and those who need more support move on to CBT combined with virtual reality tools, either for the parent, the child, or both. This is a Phase NA study, meaning it is evaluating real-world effectiveness of a care pathway rather than a new drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06362824N/ARecruiting

Promoting Physical Activity in Older Hispanic/Latino(a) Adults

Lifestyle study, genotype not required

This trial is testing a culturally adapted, fully remote physical activity program called De Pie y a Movernos, designed specifically for older Hispanic and Latino adults. Researchers want to know whether 12 weeks of the program increases motivation, social support, and enjoyment for exercise — and whether participants end up meeting the recommended 150 minutes of moderate activity per week. This is a Phase NA behavioral trial, meaning it is evaluating a structured lifestyle program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06650969Recruiting

China Diabetes Cognitive Dysfunction Early Diagnosis and Intervention Study (China-DECODE Study)

Observational only, genotype not addressed

This is an observational study based in China tracking people with Type 2 diabetes to better understand how and why cognitive problems develop over time, from earliest warning signs through mild impairment to dementia. Researchers are building a detailed database combining brain imaging, biological samples, and cognitive testing. No new drug or device is being tested here — this is a data-gathering effort to improve future diagnosis and treatment. The phase is unspecified, consistent with a registry or cohort study rather than a clinical trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05625425N/ARecruiting

Wayfinding Intervention and Long-Term Memory

Behavioral study, genotype not addressed

This trial tests whether a VR-based navigation video game called LabyrinthVR can improve long-term memory and hippocampal function in older adults with or at risk for mild cognitive impairment. Participants play either the VR game or a placebo game and undergo brain imaging to measure changes. This is a Phase NA behavioral study, meaning it is testing a non-drug approach rather than a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05231785Phase 1Recruiting

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Open to carriers, not 4-specific

This trial is testing ALN-APP, a drug injected directly into the spinal fluid that is designed to reduce production of amyloid precursor protein in the brain. It is focused on people with early-onset Alzheimer's disease who have mild symptoms. This is a Phase 1 trial, meaning the primary goal is to understand safety and dosing in humans — it is not yet known whether the drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT03552926Recruiting

Constitution of a Clinico-radiological Database and a Biobank for Patients With Lacunar Infarcts

Observational only, genotype not relevant

This is an observational study — no drug or device is being tested. Researchers in France are building a database and tissue bank from patients who have had a recent lacunar stroke (a small, deep brain stroke) within the past 15 days. They want to track how thinking and daily function change over time. There is no assigned treatment. The phase is unspecified because this is a data-collection effort, not a clinical intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07318038N/ARecruiting

The Use of Rhythmic Light Therapy in Mild Cognitive Impairment

Open to carriers, genotype not considered

This trial tests whether flickering light at specific frequencies (10 Hz and 40 Hz) can boost brainwave activity in people with mild cognitive impairment. Researchers will use EEG to measure brain responses before, during, and after one-hour light sessions. It is a Phase NA study, meaning this is an early feasibility and measurement study, not a large test of a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03945968Recruiting

The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.

Not relevant to APOE4 carriers

This study is looking at how pre-existing conditions — including Alzheimer's disease — affect the risk of complications after abdominal surgery. Researchers want to identify which underlying health problems are the strongest predictors of post-surgical trouble. There is no assigned treatment; this is an observational study, meaning researchers are watching and recording, not intervening. Details on phase and size are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
38 sites
NCT04938349N/ARecruiting

Dual Task Perturbation Training for OAwMCI

Open to MCI; genotype not a factor

This trial tests a specialized treadmill training program for older adults with mild cognitive impairment (MCI). A motorized treadmill delivers sudden balance disruptions while participants also perform a cognitive task at the same time. Researchers want to know if this combined challenge is safe and practical, and whether it improves balance, muscle responses, and thinking. This is a Phase NA pilot study — a small early-stage test of feasibility, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05746715Recruiting

A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)

Unrelated to APOE4 or Alzheimer's

This study is observing people in Israel who carry a specific genetic mutation (E200K in the PRNP gene) that causes a rare, fatal prion disease called genetic Creutzfeldt-Jakob Disease. There is no treatment being tested. Researchers are tracking healthy at-risk relatives over four years with brain scans, spinal fluid, sleep studies, and blood work, hoping to find early biological warning signs before symptoms appear. This is a natural history study, not a clinical intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07115238Phase 3Recruiting

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

Open to carriers, genotype not required

This trial is testing a new PET imaging agent called XTR006, which is injected before a brain scan to help detect tau tangles — a hallmark of Alzheimer's damage — in people who are cognitively normal, have mild cognitive impairment, or have Alzheimer's disease. It is a Phase 3 trial, meaning researchers are evaluating how accurately this imaging tool identifies tau in the brain compared to a reference standard. It is a diagnostic tool, not a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07290387N/ARecruiting

Tele-Savvy for Latino Caregivers

Caregiver study, genotype irrelevant

This trial is testing a culturally adapted, Spanish-language version of an online caregiver education program called Tele-Savvy, designed specifically for Latino caregivers of people with Alzheimer's or related dementias. It measures whether the program reduces caregiver stress, depression, and feelings of being overwhelmed. This is a Phase NA early-stage study — researchers are checking whether the adapted program is feasible and shows early signs of helping, not a large-scale proof of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05014893N/ARecruiting

Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline

Open to carriers, genotype not required

This study looks at how and why cognitive function declines, and tests whether a combination of cognitive training, exercise, and games can improve or restore thinking ability. It enrolls people across a range of cognitive states, from healthy older adults to those with mild cognitive impairment. This is a Phase NA study, meaning it is more investigational and exploratory in nature rather than a late-stage clinical test of a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07626944N/ARecruiting

Effects of Binaural Beats and Spatialized Music on Behavioural and Psychological Symptoms of Dementia in Assisted Living Facility Residents

Non-drug option, genotype not a factor

This trial is testing whether special types of music listening — binaural beats (subtle audio tones layered into music) and spatialized music (sound engineered to feel three-dimensional) — can reduce behavioral and psychological symptoms in people living with dementia in assisted living facilities. It also looks at effects on caregiver stress and overall mood. This is a Phase NA study, meaning it is a practical, exploratory trial rather than a drug approval study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05582200Recruiting

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

Imaging research, genotype not considered

This study is testing a new brain imaging method that can separately photograph two types of inflammation cells — microglia and astrocytes — using specialized PET scans. Right now, existing scans blur those two cell types together, which makes it hard to track whether anti-inflammation treatments are working. This is not a drug treatment trial; it is a tool-building study with no specified phase, meaning researchers are still developing and validating the measurement technique itself.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04312399N/ARecruiting

Hormone Replacement Trial Against ALzheimers' Disease

Observational study, genotype not specified

This trial is studying whether hormone replacement therapy (HRT) around the time of menopause affects Alzheimer's-related proteins in the blood. Researchers will draw blood from postmenopausal women — with and without a history of breast cancer — and measure amyloid breakdown products to better understand the connection between menopause, hormones, and early Alzheimer's biology. This is a Phase NA observational-style study, meaning it is exploratory research, not a test of a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06453980N/ARecruiting

Multimodal Investigation of Neural Plasticity

Open to carriers, not 4-specific

This trial tests whether transcranial direct current stimulation (tDCS) — a gentle, non-invasive electrical brain stimulation delivered through a headset — can influence brain function and memory. Participants with mild cognitive impairment (MCI) and healthy older adults receive either real stimulation or a sham (inactive) version. This is a Phase NA study, meaning it is exploratory research focused on understanding brain effects, not a late-stage treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05655650Recruiting

Identifying Biomarkers in Alzheimer's Disease

Observational only, genotype not mentioned

This study is looking for biological markers, things measurable in blood, retinal scans, specialized MRI, and PET brain imaging, that could detect Alzheimer's disease earlier and more accurately in Chinese populations. It is an observational study with no phase designation, meaning no drug or treatment is being tested. Researchers are trying to learn whether these tools together can identify who has AD and how far along it has progressed.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05205980N/ARecruiting

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

General AD trial, genotype not mentioned

This trial tests whether perturbation training — a physical therapy technique that uses sudden, controlled surface movements to teach the body how to recover from stumbles — can reduce falls in people already diagnosed with Alzheimer's disease. Researchers want to know if people with AD can learn and retain these balance-recovery skills. This is a Phase N/A study, meaning it is a practical intervention trial rather than a drug-approval study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06375213Recruiting

Investigating Neurocognitive Disorders Epidemiology

Observational only, genotype not addressed

This observational study is tracking people in Thailand across a spectrum of cognitive health, from fully healthy to MCI to dementia, to see whether a blood biomarker called phosphorylated tau (p-tau217) can predict who will decline and how fast. Participants give blood samples and take cognitive tests, then return for follow-up visits over time. There is no drug or treatment involved. This is an epidemiology study, meaning it observes rather than intervenes.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07170150Phase 3Recruiting

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Anti-amyloid drug — carriers verify eligibility

This trial is testing trontinemab, an anti-amyloid antibody drug given by injection, against a placebo in people with early Alzheimer's — from mild cognitive impairment up to mild dementia — who have confirmed amyloid buildup in the brain. Researchers are measuring whether it slows cognitive and functional decline. This is a Phase 3 trial, meaning it is a large, late-stage test of whether the drug actually works, not a preliminary safety study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
150 sites
NCT06148051Recruiting

AusCADASIL: An Australian Cohort of CADASIL

Unrelated to APOE4 genotype

This study is building a long-term registry of Australians with CADASIL, a rare inherited condition that damages small blood vessels in the brain. Researchers will track symptoms, brain scans, blood markers, genetics, and cognitive testing over time to better understand how the disease progresses. This is an observational cohort study, not a treatment trial, so no drugs or interventions are being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT07422857Phase 3Recruiting

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Open to carriers, genotype not studied

This trial is testing a radioactive tracer called [18F]-APN-1607, used in a PET brain scan, to see how well it detects tau protein buildup in people with Alzheimer's-related memory problems versus people with normal cognition. It is a Phase 3 trial, meaning researchers are gathering the larger-scale evidence needed to confirm the tracer works accurately and safely. The goal is better diagnosis, not treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03225144Recruiting

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Unrelated conditions, not APOE4-relevant

This is a screening and natural history study at the NIH, not a treatment trial. Researchers are enrolling people already diagnosed with ALS, frontotemporal dementia, PSP, or related conditions caused by TDP-43 or Tau protein buildup. The goal is to evaluate whether participants qualify for future research studies and to better understand what these diseases have in common. No phase is assigned because no drug or device is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06867692N/ARecruiting

Effects of Aerobic Exercises on Dual-task Performance and Motor Skills in Children With Mild Cognitive Impairment

Wrong population, no APOE4 relevance

This trial is testing whether a structured aerobic exercise program improves balance, coordination, and the ability to do two things at once in children aged 7 to 12 who have mild cognitive impairment. It is a randomized controlled trial — one group does aerobic exercise three times a week for 12 weeks, the other continues normal daily activities. This phase is practical and exploratory, not a drug study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06937229Phase 3Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Symptom trial, genotype not addressed

This Phase 3 trial is testing two drug formulations — KarXT and KarX-EC, both containing the same active ingredient xanomeline — for long-term management of agitation in people with Alzheimer's disease. It is an extension study, meaning only participants who finished one of two earlier trials can enroll. Phase 3 means the drug is being evaluated at a larger scale before potential approval, but it is not yet approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
255 sites
NCT07033494Phase 2Recruiting

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Open to carriers, not 4-specific

This trial is testing MK-2214, a biological drug designed to slow the spread of tau protein in the brains of people with early Alzheimer's disease. Tau tangles are a hallmark of AD and are linked to cell damage and cognitive decline. Researchers are comparing MK-2214 against a placebo to measure tau changes and assess safety. This is a Phase 2 trial, meaning it is still in early testing — not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
78 sites
NCT07105800N/ARecruiting

Dance Intervention to Improve Executive Function and Physical Performance in Older Adults With Cognitive Impairment

Open to carriers, not 4-specific

This pilot study is testing whether a structured, music-based dance program can improve thinking skills and physical performance in older adults with mild cognitive impairment. Participants either join dance sessions built around rhythm, movement, and coordination, or serve as a comparison group. A pilot study like this is an early-stage feasibility test — the goal is to see whether the approach is practical and shows enough promise to study further. No drugs are involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05922137N/ARecruiting

Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial / Carotid Stenosis

Dietary study, genotype not considered

This trial is testing whether a specific diet — called the ORIENT diet, which appears to be an Asian-style eating pattern — can slow cognitive decline in people who have significant narrowing of arteries leading to the brain. Researchers are comparing it against standard dietary advice over six months, tracking thinking and memory tests, brain MRI scans, and blood and stool biomarkers. It is a Phase N/A trial, meaning it is a straightforward behavioral study rather than a drug safety or efficacy phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06322667Recruiting

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

Safety watch — high APOE4 ARIA risk

This is a post-marketing observational study, meaning lecanemab is already approved and in use — researchers are simply watching what happens in real clinical practice. The focus is on ARIA, a type of brain swelling or bleeding that can show up on MRI scans in patients taking lecanemab. No new drug is being given; the study tracks how often ARIA occurs and how doctors respond to it.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06984367N/ARecruiting

A Socio-Technological Intervention in Community-Based Healthcare for Individuals With Mild Cognitive Impairment (DHEAL-COM-MCI)

Open to carriers, not 4-specific

This trial is testing a socio-technical program for older adults with mild cognitive impairment. The program combines cognitive stimulation exercises, technology tools, and robotics to see whether it can slow cognitive decline and support well-being. It is a Phase NA study, meaning this is a practical intervention trial rather than a traditional drug development phase. Details on exact technology used are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04478734Phase 2Recruiting

Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing whether a combination of two B vitamins, thiamine (B1) and biotin (B7), is safe and tolerable for people with early-to-moderate Huntington's disease. Researchers are also looking at whether the vitamins affect the central nervous system by measuring changes in spinal fluid. This is a Phase 2 trial, meaning it is testing whether the approach works and is safe, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06492109N/ARecruiting

The Peripheral Blood Multi-Omics Study on Sleep Loss

General sleep study, genotype not mentioned

This study is looking at what happens in the blood when people lose sleep. Researchers will use detailed molecular analysis (multi-omics) to measure changes in genes and metabolism after sleep deprivation across different age groups and cognitive levels. The goal is to better understand the biological link between poor sleep, aging, and Alzheimer's disease. This is a Phase NA observational and behavioral study — it is gathering information, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07212699N/ARecruiting

Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App

Unrelated to APOE4 or Alzheimer's

This trial is testing a smartphone app called KneeApp that tracks movement, gait, and self-reported outcomes in people before and after knee or hip replacement surgery. The goal is to build a scoring tool — trained with machine learning — that predicts how satisfied a patient will be after joint replacement. This is a pilot study, meaning it is exploratory and data-gathering, not testing a treatment. Details beyond the app and satisfaction measurement are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05800028Recruiting

Memory and Social Interactions

No genotype focus, diagnosis required

This study is testing whether social settings help people with Alzheimer's disease or semantic dementia learn and remember new information better. Researchers compare three social learning contexts — being near someone, watching someone, and working together — to see which conditions support memory most. It is not a drug trial. The phase is unspecified, suggesting this is observational or early-stage research rather than a treatment study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06949865Recruiting

AI-Enhanced Optimization of Acute Levodopa Challenge Test

Unrelated to APOE4 or Alzheimer's

This trial is testing whether AI and video analysis can improve how doctors diagnose different types of Parkinson's-related conditions. Patients take a standard levodopa dose, and cameras plus AI software track their movement responses. The goal is to find reliable digital markers that help tell these conditions apart. The phase is unspecified, so think of it as exploratory research — building better diagnostic tools, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03799991N/ARecruiting

Vestibular Therapy in Alzheimer's Disease

Open to carriers, genotype not required

This trial is testing whether vestibular physical therapy — exercises that retrain the inner ear balance system — can reduce falls in people with mild to moderate Alzheimer's disease. Researchers are comparing it against an active control therapy. It is a Phase NA trial, meaning this is a randomized clinical study focused on feasibility and effect, not a drug approval process. Details on size and duration are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06185010N/ARecruiting

Resistance Training to Individuals for Cognitive Impairment With Dementia

Non-drug study, genotype not mentioned

This trial tests whether resistance training — weightlifting-style exercise — improves cognitive function, physical performance, blood markers, and inflammation in people with mild cognitive impairment or mild dementia. It compares doing one set versus three sets per exercise, both in a single session and across eight weeks. Phase NA here means this is a practical exercise study, not a drug trial — no regulatory approval process is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05040217Phase 1Recruiting

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether a gene therapy that delivers a brain-protective protein called BDNF directly into the brain can slow cell loss in people with early Alzheimer's disease or Mild Cognitive Impairment. A harmless virus carries the instructions for brain cells to produce BDNF continuously. This is a Phase 1 trial, meaning the primary goal is to establish safety in humans for the first time — it is not yet proven to work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06700291Recruiting

Preoperative Frailty and Postoperative Neurocognitive Disorders in Geriatric Patients in Georgia

Observational only, genotype not relevant

This study is tracking whether elderly surgery patients in Georgia (the country) who are frail before their operation are more likely to develop cognitive problems afterward — things like confusion, memory decline, or delirium. Researchers will assess patients before and after hip or knee replacement surgery, then follow up at 30 days, three months, and one year. There is no assigned phase; this appears to be an observational study, not a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06701630Recruiting

Italian Adaptation and Validation of Functional and Behavioural Scales for Subjective Cognitive Decline, Mild Cognitive Impairment and Mild Dementia.

Observational only, genotype irrelevant

This study is not a treatment trial. Researchers in Italy are translating and validating a set of questionnaires used to measure daily functioning and behavior in people with early memory concerns or mild dementia. They want to confirm these tools work accurately in Italian, and find score thresholds that can distinguish between healthy aging, subjective cognitive decline, MCI, and mild Alzheimer's. This is observational research — no phase, no intervention, no drug or device tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06747637N/ARecruiting

Demonstrating the Efficacy of a Spanish-Language Program for Latino Dementia Caregivers

Caregiver support, not APOE4-focused

This trial tests a Spanish-language skill-building program called Unidos en el Cuidado for Latino family caregivers of people with dementia. Three group sessions teach caregiving skills and coping strategies. Researchers want to know whether it reduces caregiver stress and burden compared to a wait-list group. This is a Phase NA trial — meaning it is evaluating a behavioral program, not a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07395960Phase 1Recruiting

The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment

Open to carriers, genotype not tracked

This trial is testing whether metformin, a common diabetes drug, can slow or reduce mild cognitive impairment in older adults who are overweight or obese. Researchers will compare metformin plus lifestyle changes against lifestyle changes alone, using brain scans and a standard cognitive scale over 26 weeks. This is a Phase 1 trial — focused primarily on safety, with a small group of 54 participants, so results will be early and exploratory.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06444568N/ARecruiting

Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments

Lifestyle study, genotype not required

This trial is testing whether a 12-week modified ketogenic diet improves memory and thinking in older adults with amnestic mild cognitive impairment. Participants are compared against two control groups: one following the MIND diet, one making no changes. Phase NA means this is a practical intervention study, not a drug trial moving through standard approval phases. It is small, with 36 participants total, so results will be preliminary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05145868N/ARecruiting

Just-In-Time Intervention to Reduce Alcohol-Facilitated Intimate Partner Violence Perpetration

Unrelated to APOE4 or dementia

This trial is testing whether text messages sent right before or during drinking episodes can reduce alcohol-fueled intimate partner violence in young adults. Researchers want to know if timely nudges about alcohol skills and emotion regulation actually change behavior. This is a Phase N/A trial, meaning it is a behavioral intervention study rather than a drug trial — it is testing a real-world tool, not a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02855476Recruiting

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

Unrelated to APOE4 or Alzheimer's

HDClarity is collecting cerebrospinal fluid and blood samples from people at various stages of Huntington's disease, plus healthy controls, across multiple sites. The goal is to build a biomarker library that researchers can use to develop future treatments for HD. This is not a treatment trial — no drug or intervention is being tested. It is a sample collection initiative, and the phase is unspecified because it is observational, not a clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
40 sites
NCT06534723Phase 3Recruiting

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

Open to carriers, not 4-specific

This trial is testing Wujia Yizhi granules, a traditional Chinese herbal medicine, against a placebo in people who already have mild-to-moderate Alzheimer's dementia. Researchers are measuring whether the granules are safe and whether they slow or reduce cognitive symptoms. Phase 3 means the drug has already shown early promise and is now being tested at a larger scale before any approval decision.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05826548N/ARecruiting

Financial Abilities in Neurological Diseases. Development of a Telerehabilitation Program: FINAGE

Open to MCI, not genotype-specific

This trial is testing a telerehabilitation program designed to help people with Parkinson's disease, mild cognitive impairment, or stroke maintain their ability to manage money and financial tasks independently. Researchers will compare remote digital rehabilitation to standard in-person care. This is a Phase NA behavioral study, meaning it is evaluating a structured program rather than a drug, and is still in the process of determining whether the approach works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06338904N/ARecruiting

Brief Problem-solving Intervention in Different Formats for the Prevention of Suicide in Adults Over 50

Unrelated to APOE4 or dementia

This trial is testing a brief problem-solving therapy program delivered three ways — in person, by phone call, or through a smartphone app — to see whether it reduces suicidal ideation in adults 50 and older. Researchers in Spain are comparing all three delivery formats against standard care. This is a Phase NA (real-world randomized controlled trial) — it is evaluating effectiveness, not a drug, and it is not yet proven or approved as a standard approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05594017Early Phase 1Recruiting

Pharmacological Modulation of Brain Oscillations in Memory Processing

Not relevant to APOE4 carriers

This trial is testing scopolamine, a drug that blocks certain brain signals, to understand how it changes memory-related brain activity. Researchers are recruiting epilepsy patients who already have electrodes implanted in their brains for seizure monitoring, then giving them either scopolamine or a placebo to see exactly when and where memory is disrupted. This is an Early Phase 1 study — focused on basic science questions about how the brain works, not on developing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06774443Recruiting

Hinting Task for Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This study is testing whether a cognitive assessment called the Hinting Task can reliably measure "Theory of Mind" — the ability to pick up on social cues and indirect speech — in people with Huntington's disease. It is not a treatment trial. Researchers want to validate this test as a tool for detecting social cognition problems in HD patients. Details on phase are not specified, as this is an observational study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07316413N/ARecruiting

Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration

Wrong disease, not APOE4-relevant

This trial is testing repetitive transcranial magnetic stimulation, or rTMS, in people diagnosed with frontotemporal dementia or in healthy family members who may be at risk. Using a magnetic device held near the skull, researchers deliver brief pulses to stimulate brain activity. They want to know if it is safe, feasible, and whether it changes clinical or biological markers of the disease. This is a Phase NA trial, meaning it is exploratory rather than a standard efficacy-proving phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07094516Phase 2Recruiting

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Genotype not mentioned, proceed cautiously

This trial is testing VHB937, a biological drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild AD confirmed by biomarkers. Researchers want to know if it works and is safe over 72 weeks, plus an extension period. This is a Phase 2 trial, meaning it is still in the testing stage — not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
65 sites
NCT05741853N/ARecruiting

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

Not relevant to APOE4 carriers

This trial is testing two speech-language therapy approaches — script training and word-finding practice — in bilingual people who have primary progressive aphasia, a brain disease that attacks language first. Researchers want to know whether tailoring therapy to both of a person's languages works better than standard approaches. This is a Phase NA efficacy trial, meaning it is evaluating how well the intervention works in a specific population, not yet a large-scale proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06467461N/ARecruiting

Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder

Observational study, genotype not relevant

This study is investigating whether a specific type of REM sleep behavior disorder — triggered by SSRI antidepressants rather than arising on its own — might be an early warning sign of Lewy body dementia or Parkinson's disease. Researchers will use skin biopsies, specialized 7T MRI brain scans, and speech tests to look for early signs of neurodegeneration. This is a Phase NA observational study — it is not testing a treatment, just trying to understand who is at risk and why.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05509153Phase 2Recruiting

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

Unrelated to APOE4 or Alzheimer's

This trial is testing whether N-Acetyl Cysteine, a supplement-derived antioxidant drug, can slow early brain changes in people who carry the Huntington disease gene but have not yet developed symptoms. Researchers will track clinical and MRI outcomes over three years. This is a Phase 2 trial, meaning they are gathering evidence on whether it works and is safe, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT07059871N/ARecruiting

A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease.

Late-stage AD only, genotype not relevant

This trial is testing whether silkworm pupa powder, a dietary supplement high in protein, can improve nutrition, muscle loss, frailty, and quality of life in people already diagnosed with Alzheimer's disease. It also looks at whether it affects cognitive function. It is a Phase NA trial, meaning it is a practical intervention study rather than a standard drug-approval phase, comparing the supplement against a placebo over three months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05948930N/ARecruiting

Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment

Open to carriers, genotype not required

This trial is testing whether combining aerobic exercise with computerized brain training improves memory and brain function in people with mild cognitive impairment (MCI). Participants do 12 weeks of progressive aerobic exercise, adaptive cognitive training, or both. It is a Phase NA exploratory pilot study — meaning researchers are gathering early data to design a larger trial later, not yet proving the approach works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05643144N/ARecruiting

Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes

Open to carriers, not 4-specific

This trial is testing a digital tool called CGM ASSIST, which pairs a wearable blood sugar monitor with easy-to-read interactive displays. The goal is to help people with dementia and diabetes — along with their caregivers and doctors — better understand glucose data and make decisions together. This is a feasibility study, meaning researchers are checking whether the tool is practical and useful, not yet proving it works at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07010705Recruiting

Digital Measures for Clinical Trial Endpoints in Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This study is testing whether wearable devices can reliably track movement problems like gait changes and involuntary movements in people with Huntington's disease. Participants wear sensors at home and answer surveys over roughly two years. It is not a drug trial and has no assigned phase — think of it as groundwork research to validate digital tools that could one day serve as measurement endpoints in future HD treatment trials.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05520268N/ARecruiting

Efficacy of Music Therapy and Digital Music Rehabilitation in Dementia

Behavioral study, genotype not considered

This trial is testing whether music therapy — either delivered by a therapist in person or through a digital app at home — can help people already living with dementia. Researchers are measuring how well each approach works on symptoms like mood, behavior, and cognition. This is a Phase N/A trial, meaning it sits outside the standard phase numbering — it is evaluating a behavioral approach rather than a drug, and it is being run in Finland.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07246941Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing RG6496, a new drug for Huntington's disease, in people who carry the genetic expansion that causes HD. It is a first-in-human Phase 1 study, meaning the primary goal is to check whether the drug is safe and how the body processes it, not yet to prove it works. Participants receive a single dose, then may continue into an open-label extension phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06448403Recruiting

Multimodal Assesment of Alzheimer Patients

Observational only, genotype not specified

This study is collecting brain scans, EEG recordings, sleep studies, blood samples, stool samples, and cognitive test results from people with MCI or Alzheimer's disease — plus healthy controls — to look for early warning signs of Alzheimer's. It is an observational study, not a treatment trial, so no phase applies. No intervention is being tested; researchers are building a richer picture of how the disease develops.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06608589N/ARecruiting

CONSTELLATIONS Living Lab: Improving the Care Transitions of Older Adults Living with Neurocognitive Disorders

Genotype irrelevant, Quebec region only

This project is testing a care coordination program called CoMPAS+ designed to smooth the transitions between care settings for older adults with dementia or Alzheimer's disease in Quebec's Chaudière-Appalaches region. It measures whether better communication between family doctors, specialists, and caregivers leads to improved patient and caregiver experiences. This is a Phase NA study — it is a quality improvement and evaluation project, not a drug or device trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04141878N/ARecruiting

Dementia and Diabetes Prevention Program

Lifestyle study, genotype not required

This trial is testing two lifestyle changes — aerobic exercise and a brain-healthy diet called the MIND diet — to see whether they reduce the risk of cognitive decline and dementia in older adults who are sedentary and eat poorly. It focuses on African American and non-Hispanic white adults over 60 in the San Francisco Bay Area. This is a Phase NA behavioral trial, meaning it is comparing real-world lifestyle programs, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07068620N/ARecruiting

Neurophysiological and Behavioral Study of the Cognitive Deficits Associated With Cerebral Small Vessel Disease in the SHIVA Cohort. SHIVA-CogNeurophys

Restricted cohort, genotype not relevant

This study is testing whether home-based computer cognitive training and a gentle form of non-invasive brain stimulation called tACS can improve thinking and memory in people who have cerebral small vessel disease — tiny blood vessel damage in the brain that raises stroke and dementia risk. Researchers also want to find EEG brain-wave patterns that signal cognitive trouble early. This is a Phase NA observational and intervention study, meaning it is exploratory rather than a late-stage treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06523296N/ARecruiting

Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.

Observational only, genotype not relevant

This study looks for a possible connection between a specific antibody — called anti-AChR — and cognitive decline in two groups: people with Alzheimer's disease and people with myasthenia gravis (a neuromuscular condition). Researchers will test stored spinal fluid and one new blood draw. It is an observational study, not a drug trial — no treatment is being tested, and nothing is being given to participants beyond a blood draw.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05968703N/ARecruiting

Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

Parkinson-specific, genotype not relevant

This trial is testing whether adding a second set of brain stimulation electrodes, targeting a memory-related brain region called the Nucleus Basalis of Meynert, is safe and tolerable alongside the standard deep brain stimulation surgery already used for Parkinson's motor symptoms. It is a Phase NA, meaning it is an early feasibility study focused on safety, not yet testing whether it works. Only ten participants are planned.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04863859Recruiting

Persons With Dementia and Their Extended Family Caregivers

Caregiver study, genotype not relevant

This study is not a clinical drug or device trial. Researchers are interviewing extended family caregivers of people living with dementia to learn how they manage care, what services they use, and what gets in the way. Participants do a phone interview and a short daily diary for eight days. The goal is to improve how support services are delivered to caregivers and the people they care for. No phase designation applies here.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05375513N/ARecruiting

SYNERGIC-2 Trial (SYNchronizing, Exercises and Remedies to GaIn Cognition@home)

Open to carriers, genotype not tracked

SYNERGIC-2 is testing a personalized, all-at-home program for people with mild cognitive impairment (MCI) that combines exercise, cognitive training, sleep improvement, diet changes, and heart-health management. Researchers want to know whether tackling all these lifestyle factors together can protect brain health and preserve independence. This is a Phase NA (non-drug, interventional) trial focused on whether the combined approach works, not on a single medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT05277129Recruiting

The Immune Response to Stroke

Observational only, genotype not considered

This study is tracking how the immune system responds after a stroke, specifically asking whether some patients develop an autoimmune reaction that might explain why their thinking and memory decline afterward. It is an observational study with no drug or treatment involved — researchers are collecting data to understand a mechanism, not testing a therapy. Details on scale and duration are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06493422N/ARecruiting

Online Interplay Between Deciding and Acting With Mild Cognitive Impairment

Observational only, genotype not considered

This study is watching how people with mild cognitive impairment make decisions and move their arms at the same time — specifically how quickly the brain coordinates deciding and acting. Researchers are tracking reaching movements to find early biological markers of cognitive decline. This is a Phase NA study, meaning it is observational research, not a drug or treatment trial. No intervention is being tested for effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05508841N/ARecruiting

Understanding How Alzheimer's Disease Impacts the Therapeutic Response to Transcranial Direct Current Stimulation

Open to carriers, not 4-specific

This trial is testing whether a higher dose of transcranial direct current stimulation (tDCS) — a non-invasive brain stimulation technique — combined with cognitive training improves thinking and memory in people with mild to moderate Alzheimer's. The standard dose used in most studies is 2 milliamps; this trial tests whether 4 milliamps produces stronger or more consistent results. This is a Phase NA study, meaning it is exploratory research rather than a late-stage efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04804618Recruiting

Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease

Observational only, genotype not addressed

This study collects biological samples — blood, urine, stool, saliva, and tongue coating — from people with mild cognitive impairment or Alzheimer's disease, then analyzes proteins in those samples using a laboratory technique called LC-MS/MS. The goal is to find protein patterns that might signal early disease. This is an observational study with no phase designation — no drug or treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06619613Phase 1Recruiting

A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing CM383, a biological drug, in people who have mild cognitive impairment or mild Alzheimer's disease. It is a Phase 1b study, meaning the main goals right now are safety, tolerability, and understanding how the drug behaves in the body — not yet proving it works. Participants receive either CM383 or a placebo, with doses increasing over time to find a safe range.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06014424Phase 2Recruiting

Cannabidiol Medication Intervention Trial

Open to carriers, not 4-specific

This trial is testing whether cannabidiol (CBD) capsules can safely reduce agitation in people who already have Alzheimer's disease. Agitation — restlessness, verbal outbursts, aggression — is one of the hardest symptoms for caregivers to manage. It is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and whether it is safe. Participants take either CBD or a placebo in a crossover design, so everyone tries both.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05561205N/ARecruiting

rTMS for Apathy Clinical Trial

Open to carriers, not 4-specific

This trial is testing repetitive transcranial magnetic stimulation, or rTMS, a non-invasive brain stimulation technique, as a way to reduce apathy in people with mild cognitive impairment, mild behavioural impairment, or early dementia. Some participants will also be taking methylphenidate and some will not. This is a Phase NA pilot study, meaning it is a small early-stage test focused on feasibility and initial signals, not a definitive proof of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05295615N/ARecruiting

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

Open to carriers, not 4-specific

This pilot study is testing a wearable device that delivers pulsed electromagnetic fields to the brain in people who already have mild to moderate Alzheimer's disease. Participants use the device at home, three times a day for 15 minutes, over four months. Researchers are measuring changes in memory and thinking scores. This is a Phase NA open-label pilot — a very early feasibility test, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06579378N/ARecruiting

Feasibility Study of Virtual Sail 3D in Cognitive Functions

Open to carriers, not 4-specific

This trial is testing whether a 6-week virtual reality program called CEREBRUM, built around immersive 3D sailing scenarios, can help improve memory, attention, and other cognitive skills in older adults with mild cognitive impairment. Participants are compared against a web-based health education group. This is a feasibility study, meaning researchers are checking whether the approach is practical and safe before testing it more rigorously. No drugs are involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06147999N/ARecruiting

Impact of a Biophoton Therapy on Patients With Brain Disorders

Open to carriers, genotype not considered

This trial is testing a device called a Biophotonizer, which emits biophotons (a form of light energy), to see whether it helps people with brain conditions including Alzheimer's disease, dementia, Parkinson's disease, stroke, or traumatic brain injury. It is Phase NA, meaning it is classified as an interventional study outside the standard phase framework. About 80 participants will be randomized to real or sham (placebo) device sessions at a single center in Butler, Pennsylvania.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07356817Recruiting

Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications

No APOE4 relevance found

This study is tracking about 1,800 women who had a pregnancy 3 to 6 years ago, some of whom had complications like preeclampsia. Researchers are measuring their current cardiovascular health and trying to build a risk-prediction tool, ideally a mobile app, that accounts for pregnancy history and environmental factors. The phase is unspecified, and this is an observational study, not a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04997642Recruiting

Parkinson's Disease and Movement Disorders Clinical Database

Not Alzheimer-focused, genotype irrelevant

This is not a treatment trial. It is a research database at the University of Pennsylvania that collects long-term clinical information, biological samples, and brain images from people with Parkinson's disease and related conditions like Lewy body dementia. Researchers use this data to study how these diseases progress over time. No phase is listed because no drug or therapy is being tested here.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05934188Recruiting

Exploring the Gut-Brain Axis in Ageing and Neurodegeneration

Observational only, genotype not specified

This observational study is mapping connections between gut bacteria and brain health across several conditions, including prodromal Alzheimer's disease, Parkinson's, and multiple sclerosis. Participants get an MRI, stool and blood tests, cognitive assessments, and diet questionnaires. No drugs or treatments are involved. Because no phase is listed, this is early exploratory research — the goal is to find patterns, not to test a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06126224Phase 3Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Open to carriers, not 4-specific

This Phase 3 trial is testing KarXT, a drug that targets muscarinic receptors in the brain, against a placebo in people aged 55 to 90 who have Alzheimer's disease with moderate to severe hallucinations or delusions. Phase 3 means the drug has already shown early promise and researchers are now trying to confirm whether it actually works and is safe in a larger group. The main measure is how much it reduces hallucinations and delusions.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
154 sites
NCT06983119N/ARecruiting

Case-Finding for Neurocognitive Disorders in Pavia

Observational study, genotype not considered

This Italian public health study is testing how well two early-detection programs find people with undiagnosed dementia or mild cognitive impairment in the Pavia region. Researchers are comparing three screening settings: general practitioners' offices, a dementia operations center, and community open days. They are also measuring the impact on patients, caregivers, and healthcare professionals. This is a Phase NA observational study, not a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05077618Recruiting

Nalysis of the Periodontal Microbiota in Elderly Subjects With and Without Alzheimer's Disease: a Case Control Study

Observational only, genotype not considered

This is an observational case-control study, not a treatment trial. Researchers are collecting dental plaque and blood samples from people aged 70 and older, comparing the oral bacteria of those with Alzheimer's disease to those without it. The goal is to identify whether specific mouth bacteria are linked to Alzheimer's. No phase is listed because nothing is being tested as a therapy — this is early discovery science.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06792877N/ARecruiting

Mindfulness for Cognition in Early-stage Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether a mindfulness meditation program can improve memory, thinking, brain function, and quality of life in older adults — some with mild cognitive impairment and some without. One group takes the mindfulness class right away; the other waits, then takes it. This is a Phase NA behavioral trial, meaning it is studying a non-drug intervention and gathering evidence on whether it works, not testing a drug for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07457125Phase 1Recruiting

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing CB-Exo-A600, a preparation of tiny particles called exosomes derived from umbilical cord stem cells, delivered as nasal drops to people with mild to moderate Alzheimer's disease. Researchers want to know if it is safe and what dose works. It is a Phase 1 trial, meaning the primary goal right now is safety — this is early-stage research, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06546488Recruiting

Cognitive Assessment Tools for Huntington's Disease.

Not relevant to APOE4 carriers

This study is testing whether two cognitive screening tools, the Coding Test and the SAGE (Self-Administered Gerocognitive Examination), work well for people with Huntington's Disease. Both tools have been used in Alzheimer's and Parkinson's research but have not been studied much in HD. The phase is unspecified, which typically means this is observational research rather than a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07101380N/ARecruiting

Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients

Open to carriers, not 4-specific

This trial is testing a mobile app program called SuperBrain BOOM — a personalized physical activity plan delivered by tablet or smartphone — to see whether it is safe and practical for people with mild cognitive impairment (MCI). Researchers will compare participants using the app against a usual-care group over 12 weeks, measuring cognition, physical ability, mood, and quality of life. This is a feasibility study, meaning the goal is to learn whether the program can work in practice, not yet to prove it does.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT03217396Recruiting

Biomarkers of Synaptic Damage in Multiple Sclerosis

AD comparison group, not APOE4-focused

This study is collecting blood and spinal fluid samples from people with multiple sclerosis, ALS, Alzheimer's disease, and Parkinson's disease to look for biological markers of nerve damage. It is an observational cohort study, not a drug or treatment trial, meaning no intervention is being tested. People with these conditions, along with healthy volunteers, are being followed over roughly five years. Details on current enrollment status are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07075770N/ARecruiting

Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients

Device trial, genotype not considered

This trial is testing whether combining two types of non-invasive brain stimulation — magnetic (rTMS) and electrical (tACS) — can improve brain network function in people with mild Alzheimer's disease. Researchers are targeting the Default Mode Network, a brain circuit often disrupted early in AD. They will measure cognitive test scores, brain imaging, and blood biomarkers. This is a Phase NA (non-drug device) study, meaning it is exploratory and not yet proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05765162Recruiting

Safe Brain Initiative, Operationalizing Precision Anaesthesia

General surgery study, genotype irrelevant

This initiative tests whether collecting structured patient-reported feedback about surgery-related side effects — pain, nausea, anxiety, delirium, and others — helps medical teams learn from and reduce those outcomes over time. It is a data and quality-improvement project, not a drug trial. The phase is unspecified, meaning this is more of an observational or systems-improvement effort than a traditional clinical trial testing a new treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07454824N/ARecruiting

e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most

Open to carriers, genotype not considered

This trial tests whether sending educational materials through a patient portal, followed by a pharmacist-led conversation, can help older adults with MCI or dementia safely reduce medications that may be risky for the brain. These are called CNS potentially inappropriate medications. It is a pilot study, meaning researchers are gathering early data on whether the approach is practical and promising, not yet proving it works at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06983769N/ARecruiting

CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial

Device trial, genotype not considered

This trial compares two treatments for obstructive sleep apnea in people who already have mild cognitive impairment: a CPAP machine versus a mandibular advancement device, which is a custom mouthpiece that repositions the jaw during sleep. Researchers want to know which works better for preserving or improving cognitive function over one year. This is a Phase NA randomized trial — meaning it is comparing two existing approved approaches rather than testing a new experimental drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03507257Recruiting

Longitudinal Early-onset Alzheimer's Disease Study Protocol

Open to carriers, not 4-specific

LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in people who develop cognitive symptoms before age 65. Participants get brain imaging and biomarker testing but receive no experimental drug. The goal is to understand the biology of early-onset disease. Phase is unspecified because this is a natural history study, not a drug efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
23 sites
NCT07324161N/ARecruiting

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that uses magnetic pulses to stimulate the brain — can improve symptoms in people who already have mild to moderate Alzheimer's disease. Half of participants receive real rTMS; the other half receive a sham (inactive) version as a comparison. It is a Phase NA trial, meaning it is focused on directly measuring effectiveness and safety rather than early-stage dose-finding.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07073066N/ARecruiting

Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD)

Open to carriers, genotype not studied

This trial is testing a surgical procedure called deep cervical lymphatic venous anastomosis, or DC-LVA, for people with moderate-to-severe Alzheimer's disease. The surgery aims to improve drainage of waste fluids from the brain by connecting lymphatic vessels in the neck to nearby veins. Researchers will measure cognitive decline over 12 months. This is a Phase NA randomized controlled trial — meaning it is evaluating real-world efficacy and safety in a defined patient group, not an early-stage feasibility study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
9 sites
NCT07324330N/ARecruiting

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

Not Alzheimer-focused, genotype irrelevant

This trial tests whether boosting everyday physical activity — guided by a motivational smartphone app — can slow cognitive decline in people with isolated REM sleep behavior disorder, a condition that often signals early Parkinson's or Lewy body disease before major symptoms appear. Participants wear a fitness tracker and use the app for one year. It is a Phase NA behavioral study, meaning it tests a lifestyle intervention rather than a drug, with no regulatory approval process involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06618872N/ARecruiting

Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment

Open to carriers, not 4-specific

This trial is comparing two types of brain scans in people with Mild Cognitive Impairment or mild dementia. One scan looks for amyloid plaques, the other looks for tau tangles using a radioactive tracer called RO948. Researchers want to know which scan gives doctors more useful diagnostic information. This is a Phase NA diagnostic study, meaning it is evaluating a tool, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03840083N/ARecruiting

Sleep-dependent Learning in Aging

Open to carriers, genotype ignored

This study is exploring how sleep helps the brain consolidate memories, and whether age-related memory problems are tied to changes in sleep, changes in memory itself, or both. Researchers will compare how well young and older adults learn after sleeping overnight, napping, or staying awake. This is a behavioral study, not a drug trial — no medications are involved. It is categorized as Phase NA, meaning it is basic research, not a clinical treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06629207N/ARecruiting

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Observational only, genotype not a factor

This study is tracking people who have REM sleep behavior disorder — a condition where people act out their dreams — to see if brain scans analyzed by AI can predict who will go on to develop Parkinson's disease or a related condition called Lewy body dementia. It is a non-drug observational study, not a treatment trial, so it is about building better prediction tools, not testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05928247N/ARecruiting

Manualized Assessment and Treatment Model of Challenging Behavior

No relevance to APOE4 carriers

This trial is testing a standardized behavioral treatment manual for children ages 3 to 17 who have serious challenging behaviors like aggression or self-injury. Researchers want to know whether this structured approach — using techniques like teaching communication as a replacement for problem behavior — works better than current patchwork methods. This is a Phase NA study, meaning it is a behavioral intervention trial, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06705478Phase 2Recruiting

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

HIV-specific trial, genotype not relevant

This Phase 2 trial is comparing two medications — pramipexole (a dopamine-targeting drug used in Parkinson's and restless legs) and escitalopram (a common antidepressant) — to see which works better for depression and mild cognitive problems in people living with HIV. Phase 2 means researchers are testing whether it works and whether it is safe, not that it is proven or approved for this use. Details on long-term outcomes are still limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
41 sites
NCT06803784Recruiting

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

Genotype not a stated focus

This study is collecting blood and other biofluid samples from people with Parkinson's, Alzheimer's, FTD, ALS, and healthy volunteers. The goal is to find new protein-based biomarkers — measurable signals in the blood — that could help detect these diseases earlier and track how they progress. It is an observational and discovery study, not a drug trial, so there is no treatment being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07536061Phase 1Recruiting

A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing SRP-1005, a new experimental drug, in people who have been genetically diagnosed with Huntington's disease. It is a Phase 1 study, meaning the primary goal is to learn whether the drug is safe in humans for the first time — it is not yet known whether it works. Participants receive either the drug or a placebo. Details beyond safety and early tolerability are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03836950Phase 1Recruiting

rTMS to Improve Cognition in Parkinson's

Not relevant to APOE4 carriers

This trial is testing repetitive transcranial magnetic stimulation, or rTMS, a non-invasive device that delivers magnetic pulses to the brain, to see whether it can safely improve thinking and cognition in veterans with Parkinson's disease or related conditions who already have mild cognitive impairment. It is a Phase 1 trial, meaning researchers are mainly checking that it is safe and workable at this stage, not yet proving it treats any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05592678N/ARecruiting

δ in Dementia Clinical Trials

Open to carriers, genotype irrelevant

This trial is testing whether a new mathematical measure called delta (δ) can better predict and track how well donepezil — a standard, already-approved Alzheimer's medication — works in people with cognitive impairment or MCI. Researchers want to know if blood proteins called adipokines can help identify who will respond to the drug. This is a methods-focused study, not a new treatment — it is refining how future trials are designed and measured.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05413655Phase 2Recruiting

A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing EX039, an experimental oral drug taken on top of a standard Alzheimer's medication (an acetylcholinesterase inhibitor), in people who already have mild Alzheimer's disease. Researchers are comparing it against a placebo to see if it works and is safe. It is a Phase 2 trial, meaning it is still in early testing — not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06690983Recruiting

Tau PET/CT in Various Tau-Related Disease Patients

Low relevance, cancer patients only

This trial is testing a radioactive imaging agent called 18F-S16/T807, used in a PET/CT brain scan, to see how well it detects tau protein deposits in people with tau-related neurological diseases. The phase is unspecified, and details are limited. The core question is whether this scan is a reliable diagnostic tool — not a treatment of any kind.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06352710Recruiting

Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment

No connection to APOE4 or Alzheimer's

This study is testing a free smartphone app called OP-Tracker that asks neurosurgery patients to report how they feel before and after their operation — tracking well-being and any complications over a full year. It is not a drug or device trial in the traditional sense. There is no assigned phase. The goal is to improve how surgical outcomes and side effects are measured and reported using patients' own real-time feedback.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06631742N/ARecruiting

Exergaming Revolution in Dementia

Existing dementia only, genotype irrelevant

This pilot trial is testing whether 12 weeks of exergaming — playing video games that require physical movement, using a platform called the Dividat Senso — improves outcomes for people already living with dementia in long-term care. It compares the exergaming group to usual care. Phase NA means this is a small early-stage pilot study designed to see if the approach is feasible and worth studying further, not a definitive test of whether it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07021040N/ARecruiting

Olfactory Biopsies

Open to carriers, genotype not tracked

This study is collecting small tissue samples from the nasal lining to examine how the smell system changes in Alzheimer's disease compared to healthy people. Researchers will also run smell tests and odor stimulation during the visit. It is not a treatment trial — it is observational research designed to understand whether the olfactory tissue looks or behaves differently in people who have AD biomarkers or a diagnosis. Details on scale and timeline are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07409506Recruiting

Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease

Observational only, genotype irrelevant

This study is not testing a drug or treatment. Researchers in France are using a structured questionnaire to measure how much time and effort family caregivers spend supporting people with Alzheimer's at different stages of the disease. The goal is to understand how caregiver workload shifts as the disease progresses. The phase is unspecified, and this is an observational study, not a clinical intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07216716N/ARecruiting

Evaluating the Effectiveness of the Health App Recommendation Tool

Caregiver tool, genotype not relevant

This study is testing a tool called HART that helps people with Alzheimer's-related dementia or their caregivers find smartphone apps suited to their specific needs and abilities. Researchers are recruiting 15 family caregivers to try it out and give feedback over four weeks. This is a Phase NA feasibility and acceptability study, meaning they are gathering early user feedback on the tool's design, not yet measuring health outcomes.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07392944N/ARecruiting

Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Homes (MOVE4CARE)

General study, genotype not considered

This trial is testing whether a structured multicomponent exercise program — combining strength, balance, and aerobic activity — improves physical function, thinking skills, and reduces falls in nursing home residents, compared to a basic stretching and relaxation program. It is a Phase NA trial, meaning this is a straightforward head-to-head comparison study rather than a traditional drug-approval phase. No medications are involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03987633Recruiting

EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality

Observational only, genotype not relevant

EMPOWER-1 is an observational cohort study based in the UK testing whether commonly prescribed drugs actually work as expected across different ethnic and population groups. It is not a drug trial — participants donate saliva or blood samples and allow access to their medical records. The goal is to build large datasets that could expose gaps in drug safety and effectiveness data. The phase is unspecified, meaning it is exploratory research, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05004987Phase 4Recruiting

Aβ Dynamics in LLMD

Genotype collected, not 4-specific

This Phase 4 trial is testing whether treating depression with the antidepressant escitalopram (Lexapro) changes biological markers of Alzheimer's disease in spinal fluid and blood. Researchers want to know if reducing depressive symptoms affects the same proteins — like amyloid and tau — that accumulate in Alzheimer's. Phase 4 means the drug is already FDA-approved; the question here is about its effect on Alzheimer's-related biology, not basic safety.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06746909N/ARecruiting

Identification of Neuroinflammation and Neuroimaging Biomarkers Through Data Driven Artificial Intelligence Techniques for Unraveling the Heterogeneity of Aged Subjects at Risk of Dementia and to Better Inform Prevention Strategies

Open to carriers, not 4-specific

This study is using AI and brain imaging to look for patterns in people with early memory concerns — either mild cognitive impairment (MCI) or subjective cognitive decline (SCD). Researchers will scan participants' brains, measure blood flow, and analyze immune system markers in the blood to find subgroups who may be at higher risk of progressing toward dementia. It also tests a combined cognitive and physical training program. This is a non-drug, observational and intervention study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06528964Recruiting

Proteinopathies Expression in Skin of Neurodegenerative Disorders

Observational only, genotype not considered

This observational study collects small skin biopsies from people who have been diagnosed with Alzheimer's disease, Parkinson's disease, or several related conditions, as well as from healthy volunteers. Researchers will look for abnormal protein clumps — including amyloid-beta and tau — in the skin samples and compare patterns across diagnoses. No phase is assigned because this is not a drug trial; it is a diagnostic research study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07118137Recruiting

Memory Deterioration in Alzheimer Disease

Observational only, genotype not addressed

This study is observational, not a drug trial. Researchers are using high-powered 7 Tesla MRI, EEG brain scans, blood draws, stool samples, and cognitive tests to better understand how memory breaks down in people who already have Alzheimer's disease or mild cognitive impairment. The goal is to learn more about the biology of memory loss, not to test a treatment. The phase is unspecified, consistent with a research observation study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07512362Phase 2Recruiting

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

Carriers eligible only if already on mAb

This Phase 2 trial is testing whether a single infusion of human mesenchymal stem cells, added on top of an already-approved anti-amyloid drug (lecanemab or donanemab), can slow cognitive and functional decline in people with mild cognitive impairment or early Alzheimer's. Phase 2 means researchers are still gathering evidence on whether this combination works and is safe — it is not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06516588Phase 2Recruiting

tDCS for Post-Stroke Cognitive Impairment

Open to carriers, not 4-specific

This Phase 2 trial is testing whether transcranial direct current stimulation — a mild, non-invasive electrical brain stimulation delivered through scalp electrodes — can improve memory and thinking in people who developed cognitive problems after an ischemic stroke. Phase 2 means researchers are gathering early evidence on whether it works and that it is safe, but it is not a proven or approved treatment. Details beyond the basics are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06619327N/ARecruiting

Resilient Together for Dementia (RT-D)

Open to carriers, genotype not a factor

This trial is testing a behavioral program called Resilient Together for Dementia, designed for couples in which one partner has recently been diagnosed with early-stage dementia. It measures whether the program can reduce emotional distress and prevent it from becoming chronic. This is a Phase NA feasibility study, meaning researchers are checking whether the approach is practical and shows early promise before any larger test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07262645Phase 3Recruiting

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

Open to carriers, not 4-specific

This trial is testing whether a wearable near-infrared light therapy device called NirsCure 6000 can slow cognitive decline in people who already have mild to moderate Alzheimer's disease. Participants use the device at home, compared to a sham (fake) device. With 320 people enrolled across multiple sites, this is a Phase 3 trial — a large, late-stage test meant to confirm whether the device actually works and is safe enough for broader use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
23 sites
NCT06837272Recruiting

A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease

Observational study, genotype not considered

This study tracks how the gut microbiome may influence brain health across the full Alzheimer's spectrum, from cognitively normal to full dementia. Researchers will measure gut bacteria, metabolites called short-chain fatty acids, and brain MRI scans over five years, then use machine learning to build an early detection model. There is no treatment involved — this is observational research aimed at understanding mechanisms, not testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07372066N/ARecruiting

Cognitive Stimulation Therapy Group for Residential Home Residents With Dementia and Mild Cognitive Impairment

Open to carriers, genotype not considered

This trial is testing whether a structured 14-session Cognitive Stimulation Therapy group helps older adults with dementia or mild cognitive impairment more than a calligraphy group does. Researchers are looking at changes in memory and thinking, mood, social engagement, and quality of life. This is a Phase N/A behavioral trial — meaning it is evaluating a non-drug program, not a medication, in a real-world residential care setting.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06565143N/ARecruiting

Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease

Open to carriers, genotype not required

This trial tests whether a non-invasive brain stimulation technique called transcranial alternating current stimulation, or tACS, can help people in the early stages of Alzheimer's disease. A device delivers mild electrical currents to the scalp to try to influence brain rhythms. Researchers are also using EEG to track what happens in the brain. This is a Phase N/A trial, meaning it is exploratory — not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05977088N/ARecruiting

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

Device trial, genotype not considered

This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that uses magnetic pulses to stimulate the brain — can help people already diagnosed with Alzheimer's disease. Researchers are also drawing blood before and after treatment to look for biological changes. This is a Phase NA, or exploratory, study focused on predicting who responds best to rTMS, not a large-scale effectiveness trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05762796N/ARecruiting

Neuromodulation and Neuroimaging in Older Children With Mild Traumatic Brain Injury

Unrelated to APOE4 or Alzheimer's

This trial is testing transcranial direct current stimulation (tDCS) — a mild, non-invasive electrical brain stimulation device — in children ages 10 to 15 who have lingering symptoms after a concussion. Researchers want to see whether it can help restore normal brain communication and improve motor and cognitive function. This is a Phase NA (feasibility or pilot-level) study, meaning it is exploratory and not yet proven effective.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03614962N/ARecruiting

Warmth and Transcutaneous Electrical Nerve Stimulation (TENS) in Improving Cognitive Functions in People with Dementia

Device study, genotype not considered

This trial tests whether a special hat that delivers both gentle warmth and mild electrical stimulation (TENS) to acupuncture points on the head can improve thinking and behavior in people with mild to moderate dementia. Participants are assigned to one of five versions of the hat — ranging from full warmth-plus-TENS to a control with neither. Phase NA means this is a standalone study design, not part of the standard drug-approval pipeline.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07205003Recruiting

Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders

Observational only, genotype not considered

This study uses ultrasound measurements of the carotid artery wall to see whether its stiffness and energy-dissipation properties differ between people with Alzheimer's disease, vascular dementia, and people with memory complaints but no dementia diagnosis. It is a diagnostic or observational study, not a drug trial, meaning no phase is assigned and nothing is being prescribed or treated. Details on sample size and timeline are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06254469Phase 3Recruiting

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a new PET scan tracer called F-18 Flornaptitril to see how well it can predict cognitive decline in people who already have Mild Cognitive Impairment from either Alzheimer's disease or suspected Chronic Traumatic Encephalopathy. It is also checking whether the scan can tell the two conditions apart. This is a Phase 3 trial, meaning researchers are trying to confirm how accurate and safe the imaging agent is across a larger group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06965686N/ARecruiting

Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk

Open to carriers, genotype not required

This trial is developing and pilot-testing a brief behavioral program called PERI-MIND for perimenopausal women who have a family history of Alzheimer's or dementia. The goal is to help them manage fear and anxiety about developing dementia themselves. This is a Phase NA development and feasibility study — meaning researchers are still building and refining the tool, not yet testing whether it prevents or treats any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05315895Recruiting

The Dampness Syndrome of Chinese Medicine Cohort Study

Observational only, genotype not relevant

This is an observational cohort study rooted in Traditional Chinese Medicine. Researchers are enrolling thousands of adults aged 30 to 79 to track whether a TCM concept called dampness syndrome is linked to chronic diseases including dementia and Alzheimer's. No phase is listed because this is not a drug trial — it is a long-term data-gathering study watching how people age over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07497334N/ARecruiting

A Novel Multi-Modal Approach to Promote Functional Outcomes in Cognitively Frail Older Adults

Open to carriers, genotype not considered

This trial is testing whether a combination of two types of brain stimulation (theta burst stimulation, delivered using a magnetic coil placed on the scalp) paired with aerobic exercise improves thinking and movement in older adults who have both mild cognitive impairment and physical frailty. It is a Phase NA trial, meaning it is a feasibility or mechanistic study rather than a late-stage efficacy test — researchers are still working out how this combination affects the brain.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07169630Phase 1Recruiting

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

Open to carriers, not 4-specific

This trial is testing a new PET scan radiotracer called 18F-PF974 to see if it can measure an enzyme called PDE4B in the brains of people with Alzheimer's disease or mild cognitive impairment. The idea is that PDE4B may drive brain inflammation in these conditions. This is a Phase 1 trial, meaning the main goal is basic safety and whether the imaging tool works — not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05795634N/ARecruiting

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

Likely directly relevant to APOE4 carriers

This study is testing whether stress hormones and genes linked to Alzheimer's risk predict how much a brief social stress experience affects memory and thinking in people with mild cognitive impairment. Researchers will also track whether those stress responses predict cognitive decline and changes in Alzheimer's biomarkers over two years. This is a Phase NA observational-style study — it is measuring and monitoring, not treating.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05886114N/ARecruiting

A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China

Lifestyle study, genotype not required

This trial is testing whether a structured program combining exercise, nutrition, cognitive training, social activities, and vascular risk management can slow cognitive decline in older adults already showing early warning signs. It enrolls 1,200 community residents in Zhejiang, China, over two years. This is a Phase NA randomized controlled trial, meaning it is evaluating real-world effectiveness of a behavioral program rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07486037N/ARecruiting

Caring for Caregivers of Individuals With Alzheimer's Disease

Caregiver study, genotype not relevant

The EMBRACE Study tests whether a virtual, home-based group exercise program can reduce depression and anxiety in family caregivers of people with Alzheimer's disease or related dementias. Participants use an at-home elliptical provided by the study and join weekly online sessions for three months. This is a Phase NA behavioral trial — it is evaluating whether the program is feasible and effective, not testing a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06032351N/ARecruiting

Construction and Validation of Dementia Care Management Competency

Not relevant to APOE4 carriers

This study is testing a new curriculum designed to train healthcare students in dementia care management. Researchers are comparing an innovative, competency-based teaching program against traditional classroom instruction to see which better prepares students to care for people with dementia. This is a Phase N/A study — meaning it is an educational research project, not a clinical drug or device trial, so the usual phase categories do not apply.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07497867Recruiting

Long-term Prospective Study of Korean CADASIL Patients

Unrelated genetic condition, not APOE4

This is a 10-year observational study tracking 500 Korean patients who have CADASIL, a rare inherited condition that damages blood vessels in the brain and leads to strokes and dementia. Researchers will follow symptoms, brain scans, memory tests, and genetic data over time to understand how the disease progresses. There is no drug or intervention being tested — this is a natural history study, meaning it watches and records rather than treats.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06052163Phase 2Recruiting

Bumetanide in Patients With Alzheimer's Disease

APOE4-specific science, carriers eligible

This Phase 2 trial is testing bumetanide — a common water pill already FDA-approved for fluid retention and high blood pressure — as a potential treatment for Alzheimer's disease. Researchers want to know if it is safe and tolerable for people with confirmed AD, and whether it affects cognitive or biological markers of the disease. Phase 2 means they are exploring effectiveness and safety, not yet proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06088810N/ARecruiting

The Impact of Music Intervention on Sleep

Dementia stage only, genotype-blind

This trial is testing a personalized music app called CoMPoSER, designed to play calming music at bedtime to help people living with dementia sleep better. Researchers are also measuring caregiver stress and well-being. It is a Phase NA pilot randomized controlled trial — meaning this is an early-stage test of whether the approach works and whether people find the app acceptable to use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06604520Phase 2Recruiting

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

FTD trial, not APOE4-relevant

This trial is testing whether vortioxetine, an antidepressant already approved for depression, can improve mood symptoms and thinking abilities in people with early-stage behavioral variant frontotemporal dementia (bvFTD). Participants get brain scans and cognitive tests before and after 12 weeks on the drug. It is a Phase 2 trial, meaning researchers are still exploring whether it works and is safe in this specific condition — it is not proven or approved for FTD.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06922188Recruiting

Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia

Caregiving research, genotype irrelevant

This is not a treatment trial. Researchers are building new survey tools to measure financial hardship in people living with Alzheimer's and their caregivers. They want to understand the specific costs and stresses that come with dementia — long-term care, lost caregiver income, insurance navigation — and create screening measures that are accurate across different racial, ethnic, and caregiver groups. No phase is assigned because no drug or device is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07006155N/ARecruiting

Biograph Vision 600 Versus Biograph Vision.X PET/CT

Equipment study, genotype irrelevant

This trial is comparing two PET/CT scanner models — the Biograph Vision.X and the Biograph Vision 600 — to see whether the newer machine produces better images and diagnostic accuracy. It covers both cancer and Alzheimer's disease imaging. This is a Phase NA study, meaning it is an equipment evaluation, not a drug or treatment trial. Details on the specific imaging tracers or disease focus are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06143488N/ARecruiting

Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS

Stroke trial, no APOE4 relevance

This trial is testing whether a mechanical procedure to physically remove a blood clot (endovascular thrombectomy) works better than medication alone for people who have a stroke with a blocked major brain artery but only mild symptoms. Researchers are measuring functional recovery at 90 days. This is a Phase NA trial, meaning it is a head-to-head comparison study focused on clinical effectiveness in a population previously left out of major stroke trials.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05703386Recruiting

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Vascular focus, genotype not mentioned

This study is not testing a treatment. It is an observational study that uses repeated MRI scans to watch how white matter damage in the brain develops over time in people who already have small vessel disease and vascular risk factors like high blood pressure, high cholesterol, or diabetes. The goal is to better understand how this type of brain disease progresses, not to test whether anything slows or stops it.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06595212Recruiting

Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach

Unrelated to APOE4 or Alzheimer's

This Italian study is recruiting twins where at least one twin has ALS or frontotemporal dementia (FTD). By comparing the affected twin to their unaffected co-twin, researchers hope to untangle how much genetics versus life experience drives these diseases. It is an observational study, not a drug trial, meaning no treatment is being tested. Details on phase are not specified, so this is a data-collection effort, not a clinical intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT04850053Recruiting

Detection of Alzheimer's Disease (AD)-Related Seeds for AD Diagnosis

Diagnostic study, genotype not considered

This study tests a new blood-based detection device that measures abnormal protein clumps — amyloid-beta and tau seeds — to see how accurately it can identify Alzheimer's disease. Researchers will compare results from people with AD against healthy controls and people with other dementias. It has no assigned phase, meaning it is a diagnostic accuracy study rather than a treatment trial, and no intervention is being given to participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05733520N/ARecruiting

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

Caregiver study, genotype not relevant

This trial is testing a mobile app called Brain CareNotes to see whether it reduces stress and burden in unpaid caregivers of people with Alzheimer's or related dementia. It also looks at whether the app helps manage behavioral symptoms in the person being cared for. This is a Phase NA randomized controlled trial — meaning it is evaluating a behavioral tool rather than a drug, comparing the app against a basic education-only app over 12 months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05822908Phase 1Recruiting

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Not relevant to APOE4 carriers

This trial is testing a new drug called VO659, given by injection into the spinal fluid, in people with one of three inherited neurological diseases: spinocerebellar ataxia type 1, spinocerebellar ataxia type 3, or Huntington's disease. Researchers want to know if it is safe and how the body absorbs it. This is a Phase 1 trial — the very first time it has been tested in humans, focused on safety, not effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
14 sites
NCT05460143Recruiting

Optical Neuroimaging and Cognition

Open to carriers, not 4-specific

This study is testing whether near-infrared spectroscopy, a light-based brain scan, can detect changes in brain oxygen use and metabolism in people with Alzheimer's disease, Lewy body dementia, or mild cognitive impairment. Researchers also want to see if machine learning can identify optical markers of dementia. No phase is listed because this is an observational study, not a drug trial. Details on size and timeline are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06854718N/ARecruiting

Pain With Dementia

Open to carriers, genotype not a factor

This trial is testing a behavioral program that trains family caregivers to help loved ones with mild to moderate dementia manage chronic pain at home. Researchers want to see whether teaching caregivers pain-coping techniques can reduce pain interference in daily life. It is a Phase NA study, meaning this is early-stage development work — building and refining the program, not yet a large-scale test of whether it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06992804Early Phase 1Recruiting

Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease

APOE4 4/4 carriers excluded

This early Phase 1 trial tests whether combining near-infrared light therapy with lecanemab — an FDA-approved anti-amyloid antibody drug — is safe and potentially more effective than lecanemab alone for people with mild Alzheimer's disease. Half the participants receive real light therapy plus lecanemab; the other half receive a sham device plus lecanemab. It is very early-stage, meaning the primary goal is still establishing safety and tolerability, not proving the combination works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05326451N/ARecruiting

Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease

Unrelated to APOE4 carriers

This trial is testing a brain stimulation device called tDCS — transcranial direct current stimulation — delivered at home by people with Huntington's disease in early to middle stages. Researchers want to know if it is feasible, safe, and acceptable, and whether it eases behavioral and cognitive symptoms of HD. This is a Phase NA open trial, meaning it is exploratory and not yet testing against a placebo or control group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07434479N/ARecruiting

A Virtual Reality Mindfulness Application for Aggression in Schizophrenia

Unrelated to APOE4 or dementia

This trial is testing whether a mindfulness program delivered through virtual reality headsets can reduce impulsive aggression in people diagnosed with schizophrenia or schizoaffective disorder. Researchers will use brain scans to see whether the VR sessions activate a region involved in emotional control, and whether more sessions produce stronger effects. This is a Phase NA study, meaning it is likely a feasibility or mechanistic study rather than a large efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05619263N/ARecruiting

Emergency Preparedness for Caregivers of Persons With Dementia: Disaster PrepWise

Caregiver support, no APOE4 relevance

This trial is testing a behavioral program called Disaster PrepWise, designed to help family caregivers of people with dementia build emergency plans and support networks before disasters strike. A trained volunteer works one-on-one with each caregiver to create a personalized preparedness plan. Researchers are measuring caregiver stress, resilience, and confidence. This is a Phase N/A trial — it is evaluating a practical program, not a drug or device, and has not yet been proven at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04838301Phase 2Recruiting

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing allopregnanolone — a naturally occurring brain steroid — to see whether it slows or improves cognition in people with mild Alzheimer's dementia. It is a Phase 2 trial, meaning researchers are evaluating whether it works and is safe in a controlled setting. It is not yet proven or approved. Participants receive weekly IV infusions of the drug or a placebo over several months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
10 sites
NCT06833645Recruiting

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

Imaging study, genotype not required

This study uses two specialized PET/CT brain scans to look for early signs of Alzheimer's disease. One scan detects amyloid plaques, the other detects tau tangles — the two hallmark proteins of the disease. Researchers want to map where these proteins appear first in the brain and link those patterns to standard cognitive test scores. The phase is unspecified, so this appears to be a diagnostic imaging research study rather than a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06437132Recruiting

Decoding Death and Dying in People With Dementia by Digital Thanotyping

Observational only, genotype irrelevant

This study is not testing a treatment. Researchers are using wearable sensors and clinical assessments to monitor nursing home residents with dementia, hoping to identify patterns that signal when someone is entering the final phase of life — what they call the point of no return. The goal is to build better tools for recognizing dying earlier and more accurately. This is observational research, not a drug or therapy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04855630N/ARecruiting

Combating Alzheimer's Through Sleep and Exercise

Lifestyle study, genotype not required

This trial is testing whether a combination of structured exercise and monitored sleep — tracked with a DREEM 2 headband and a Fitbit — can affect dementia risk over time. Researchers will measure biomarkers and cognitive changes in people who already report some memory or concentration problems. This is a Phase NA study, meaning it is exploratory — gathering early data rather than proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02811653N/ARecruiting

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

Observational only, genotype not relevant

This trial is studying the relationship between movement slowness and brain changes visible on MRI in people with Alzheimer's disease and related conditions. Researchers are comparing patients who have MCI or mild dementia to healthy volunteers, using brain scans, cognitive testing, and blood samples. This is not a treatment trial — it is an observational study aimed at better understanding how attention problems show up in the brain. No experimental drugs or devices are involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05556395Recruiting

Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline

Observational stroke study, genotype not required

This study is trying to understand why some stroke survivors develop cognitive decline afterward. Researchers will measure blood-brain barrier disruption — essentially leakiness in the protective lining around the brain — at the time of stroke, then track thinking and memory over the next three years to see if that early measurement predicts who declines. This is an observational study, meaning no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07002996N/ARecruiting

Spatial Memory Training and Cognitive Function

Open to carriers, genotype not tracked

This trial tests a three-month spatial memory training program called SMIP in people already diagnosed with mild cognitive impairment. Researchers will measure changes in spatial memory, hippocampal structure, and broader cognitive function before and after training, comparing participants who do the program against those who do not. Phase NA means this is a behavioral intervention study, not a drug trial — no medication is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05655403N/ARecruiting

Effects of Step Training in Older Adults with Mild Dementia

Open to carriers, genotype not considered

This trial is testing whether a step-training program — combining physical stepping with visual-spatial tasks — can improve balance, stepping speed, leg strength, and fall risk in older adults who already have mild dementia. Researchers are also looking at brain activity in the prefrontal cortex to understand why the training might help. This is a Phase N/A trial, meaning it is a structured study but not a standard drug-approval phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06417086N/ARecruiting

Clinical Evaluation of Acupuncture Treatment on Alzheimer's Disease in APOE e4 Carriers and Non-Carriers

Directly studies APOE4 carriers vs. non-carriers

This trial is testing whether acupuncture can help people with mild-to-moderate Alzheimer's disease — measuring changes in cognition, daily functioning, quality of life, and brain biomarkers. Participants get real acupuncture or sham acupuncture three times a week for 12 weeks, then are followed for about a year. This is a Phase NA interventional trial, meaning it is a formal clinical evaluation but not a standard drug-approval phase study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06539169Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Data registry, genotype not relevant

FLOWER is a virtual observational study — no treatment involved — that collects and organizes medical records from people living with rare diseases. Researchers use electronic health records, faxed documents, and lab data to build a standardized database. There is no assigned intervention. This is not a phase-numbered trial; it is a data registry designed to improve how rare disease outcomes are tracked over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06938763Phase 1Recruiting

Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults

Early safety study, not carrier-relevant

This trial is testing a new oral drug called J4 in healthy adults to see if it is safe, well-tolerated, and how the body absorbs and clears it. Researchers are giving single and multiple increasing doses to find a safe range. This is a Phase 1 trial — the very first stage in humans, focused entirely on safety and body chemistry, not yet on whether the drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07105709Phase 2Recruiting

Open-label Extension Study in Participants With Early Alzheimer's Disease

Extension only, ARIA risk relevant to carriers

This is an open-label extension study, meaning all participants receive the drug GSK4527226 — no placebo. It is only open to people who already completed the parent trial (NCT06079190). The goal is to track long-term safety and whether the drug continues to show any effect in people with early Alzheimer's disease, including MCI and mild dementia. Phase 2 means researchers are still gathering evidence on whether it works and is safe — it is not approved or proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
33 sites
NCT07609316N/ARecruiting

Effectiveness of a Culturally Adapted Online Education Program (iSupport-Korea) for Family Caregivers of People With Dementia

Caregiver study, genotype irrelevant

This trial tests iSupport-Korea, a culturally adapted online education program for family caregivers of people with dementia. It is comparing the program against a basic dementia information website to see whether caregivers report better quality of life, confidence in caregiving, and confidence in family decision-making. This is a Phase NA randomized controlled trial — it is evaluating real-world effectiveness of a behavioral program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03025334N/ARecruiting

tDCS on Parkinson's Disease Cognition

Parkinson's trial, genotype not relevant

This trial is testing whether a non-invasive brain stimulation technique called high-definition transcranial direct current stimulation (HD-tDCS) can improve thinking and memory problems in people with Parkinson's disease who have mild cognitive impairment but are not yet demented. Researchers will also use brain scans to understand how the stimulation affects brain connectivity. This is a Phase NA (likely a small, exploratory) trial — it is not yet proven or approved as a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06215274Recruiting

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

Observational only, genotype not considered

This study is examining whether staying mentally active through leisure activities — things like reading, puzzles, or learning new skills — is linked to better cognitive function and healthier brain patterns on MRI scans. Researchers are also adapting a measurement tool for cognitive leisure into Chinese. There is no drug or device involved. The phase is unspecified, meaning this is likely observational research rather than a controlled intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06005038Phase 1Recruiting

CogT pSOPT Intervention Study

Behavioral study, genotype not considered

This trial is testing a personalized computer-based brain training program called pSOPT for people with mild or subjective cognitive impairment. The program adjusts its difficulty in real time based on your heart rate and cognitive performance, aiming to keep you working at your best capacity. It is a Phase 1 pilot study — meaning researchers are still gathering early data on whether this approach works and is safe, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06460012N/ARecruiting

Support Via Technology: Living and Learning With Advancing Dementia-REVISED

Caregiver study, genotype not relevant

This trial tests an online self-directed program called STELLA-R designed to help family caregivers manage the difficult behavioral and psychological symptoms that often come with dementia. It uses a cognitive-behavioral technique to help caregivers understand and respond to upsetting behaviors. This is a Phase NA trial, meaning it is a behavioral intervention study focused on measuring real-world effectiveness rather than drug safety or dosing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07083154Phase 3Recruiting

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Open to carriers, genotype not screened

The LIGHT-COG study is testing mazdutide, a once-weekly injectable drug that activates two metabolic hormones (GLP-1 and glucagon receptors), in 420 people who have both Type 2 diabetes and early memory problems. Researchers want to see whether it slows cognitive decline over 76 weeks. This is a Phase 3 trial, meaning it is a large, late-stage test of effectiveness and safety in a real patient population.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT06734286N/ARecruiting

Working Memory Training in Patients with Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing CogMed, a computerized working memory training program, in people with mild cognitive impairment. Researchers want to know whether the training improves memory, reduces stress, and whether it changes a blood marker called p-Tau 217 that may reflect Alzheimer's-related brain changes. This is a Phase NA study, meaning it is a practical intervention trial rather than a drug study moving through standard approval phases.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04124029Recruiting

Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)

Observational study, genotype not considered

This observational study is not testing a treatment. It is using EEG brain scans, MRIs, blood draws, and spinal fluid samples to study whether Veterans who have had mild or moderate traumatic brain injuries show early signs of neurodegeneration similar to Alzheimer's disease or CTE. There is no phase because no drug or therapy is involved. Researchers are comparing TBI Veterans to people with MCI and healthy controls to look for shared biological markers.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07370311N/ARecruiting

A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisions

Caregiver support tool, not APOE4-relevant

This pilot study tests a culturally adapted decision-support tool to help Chinese American family caregivers navigate the choice between tube feeding and hand feeding for a loved one with moderate or advanced dementia. It does not test a drug or medical treatment. Phase NA means this is exploratory research focused on usability and feasibility, not on proving a clinical outcome yet. Details beyond the pilot design are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06191198Phase 2Recruiting

Communication Bridge 3 Study

Not Alzheimer's focused, genotype irrelevant

This Phase 2 trial is comparing two speech-language therapy approaches for people with mild to moderate Primary Progressive Aphasia, a condition that gradually erodes the ability to speak and communicate. One approach is the Communication Bridge program, the other is a standard impairment-focused therapy. The goal is to measure which does more to preserve communication ability. Phase 2 means researchers are testing whether it works, not that it is proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04165109Recruiting

Trial-Ready Cohort-Down Syndrome (TRC-DS)

Not relevant to APOE4 carriers

This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's clinical trials. Researchers are collecting cognitive tests, brain imaging, and biomarkers over time to figure out which measures best track Alzheimer's progression in Down syndrome. Think of it as laying the groundwork — no phase, no drug, no intervention being tested yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
22 sites
NCT03946930Recruiting

Cognitive Decline in AD

Observational only, genotype not addressed

This is an observational cohort study, not a treatment trial. Researchers are following older adults already diagnosed with Alzheimer's disease to identify which factors, including brain volume on MRI, blood biomarkers like inflammatory markers, physical activity, and insulin signaling, are most strongly linked to faster cognitive decline. The goal is to find targets for future preventive strategies. No phase is specified because no intervention is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06852352N/ARecruiting

An Exploratory Study to Confirm Efficacy of Modified Deep Cervical Lymphovenous Anastomosis (LVA) in Alzheimer's Disease/ Parkinson's Disease

Open to carriers, genotype not required

This trial is testing a surgical procedure called deep cervical lymphovenous anastomosis — a technique that connects lymphatic vessels to veins in the neck — to see if it can improve the brain's ability to clear out toxic proteins like amyloid and tau in Alzheimer's, or alpha-synuclein in Parkinson's. The idea is that aging lymphatic vessels drain poorly, letting those proteins build up. This is a Phase N/A exploratory study, meaning it is early-stage and intended to gather initial evidence, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06847321Phase 2Recruiting

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P. gingivalis — a gum bacterium linked to dementia risk. The goal is to see whether targeting this infection can slow cognitive decline, measured by standard memory tests and a blood biomarker called pTau217. Phase 2 means researchers are still building evidence on whether it works and is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
40 sites
NCT06442943N/ARecruiting

Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia

Non-drug study, genotype not considered

This trial is testing a digital, multi-domain cognitive intervention — think structured brain-training activities delivered digitally across several cognitive areas — in older adults who already show early memory or thinking concerns (SCD or MCI). Researchers want to see whether the program slows or reduces cognitive decline in this high-risk group. This is a Phase NA behavioral study, meaning it is evaluating a non-drug program, not a medication, and is not yet a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06733714N/ARecruiting

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

Non-drug trial, genotype not considered

This trial combines two non-drug approaches — a brain-stimulation device called tACS, which delivers mild electrical currents to the scalp, and a computerized brain-training program called BrainHQ. Participants do five daily 30-minute sessions of both at the same time. The goal is to see if the combination is feasible, tolerable, and shows early signs of helping cognition in older adults with memory or thinking complaints. This is a Phase NA exploratory study — it is early-stage, not yet testing proven benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06793735N/ARecruiting

Effectiveness of TeleVR App in Cognitive Decline and MCI Patients

Non-drug study, genotype not considered

This trial tests whether a virtual reality app used at home via smartphone or tablet — guided remotely by a therapist — improves cognition and social skills better than traditional paper-based exercises. Participants have Subjective Cognitive Decline or Mild Cognitive Impairment. Researchers also track brain activity, eye movements, and walking patterns. It is a Phase NA trial, meaning it is comparing two rehabilitation approaches rather than testing a new drug — no regulatory approval process is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06786676Phase 1Recruiting

A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants

Healthy volunteers only, genotype irrelevant

This trial is testing a new oral drug called AS-S603, made by Amyloid Solution Inc., which is designed to break up the amyloid-beta and tau protein clumps associated with Alzheimer's disease. Right now researchers are only checking whether it is safe and how the body processes it — this is Phase 1, the earliest human testing stage, not yet testing whether it actually works against Alzheimer's.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07615647N/ARecruiting

How Video Game Therapy Affects Thinking and Emotions in Older Adults With Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether playing commercial video games on a PlayStation can improve thinking skills and emotional wellbeing in older adults with mild to moderate cognitive impairment. Sessions run two to three times a week over two months in care settings like day centers. This is a Phase NA study, meaning it is exploratory research focused on feasibility and measurement rather than a definitive clinical test of an approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06731049N/ARecruiting

Comparison of the Effectiveness of Treadmill-Based Walking and Dual-Task Walking Training in Alzheimer's Disease

Open to carriers, not 4-specific

This trial compares two walking programs for people already diagnosed with Alzheimer's disease: standard treadmill walking versus treadmill walking combined with simultaneous cognitive challenges, like counting or naming things while moving. Researchers want to know which approach better improves walking, balance, thinking, and daily functioning. This is a Phase NA trial, meaning it is a direct comparison study rather than an early safety or efficacy phase. Details on size and location are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07284446Recruiting

Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients

No APOE4 relevance whatsoever

This observational study is tracking hospitalized chronic heart failure patients to see whether depression and mild cognitive impairment make their outcomes worse. Researchers will have participants fill out surveys measuring mood and thinking ability during their hospital stay. It is not a treatment trial — no drug or intervention is being tested. Because the phase is unspecified and no intervention is involved, this is a data-gathering study, not a test of something new.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07249918N/ARecruiting

Feasibility of Wearables in Dementia Care in Rural Taiwan

Open to carriers, genotype not considered

This study is testing two wearable devices in people with Alzheimer's or MCI and their family caregivers in rural Taiwan. One device tracks sleep and daily activity. The other is a pair of light therapy glasses meant to improve sleep and mood. Researchers want to know if these tools are practical to use at home. This is a feasibility trial — it is exploring whether a larger study is even worth doing, not proving the devices work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04800588N/ARecruiting

Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

Genotype-neutral diagnostic tool study

This trial is testing a new set of computerized cognitive assessments called the California Cognitive Assessment Battery. Researchers want to establish normal performance benchmarks across different ages, so the tests can eventually flag early signs of cognitive decline. It is not a drug trial — it is a diagnostic study, meaning it is testing a measuring tool, not a treatment. There is no experimental intervention here beyond taking the tests themselves.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05151562N/ARecruiting

Music Therapy for Patients With Alzheimer's Disease

Open to carriers, genotype not tracked

This trial is testing whether personalized virtual music therapy sessions, built around songs tied to a person's memories, can improve mood, memory, and cognition in people with mild cognitive impairment or early Alzheimer's. Participants attend two 30-minute online sessions per week for 8 weeks. Brain scans before and after measure any changes in activity. This is a Phase N/A feasibility study, meaning researchers are checking whether this approach is practical and shows early promise, not proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07212504N/ARecruiting

Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory Problems

Non-drug device trial, genotype not required

This trial is testing whether a non-invasive brain stimulation technique called deep Transcranial Magnetic Stimulation (dTMS), delivered in an accelerated schedule and combined with cognitive training, can improve memory and thinking in older adults with mild cognitive impairment (MCI) or subjective memory concerns. It is a Phase NA study — meaning it is focused on feasibility, safety, and early signals of effect rather than proving the intervention works at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05943834Recruiting

Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA)

Open to carriers, not 4-specific

PLATA is testing whether an algorithm can detect early signs of Alzheimer's disease by analyzing how people speak during a phone-based cognitive task. Researchers will compare speech patterns against established biological markers like CSF proteins and PET scans. This is a diagnostic research study, not a clinical drug trial — the goal is to see if voice analysis could one day replace invasive testing like lumbar punctures. Details on phase are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04906863Recruiting

Genetic Studies of Early-onset Dementia

Open to carriers, research only

This study collects blood samples, cognitive test results, and health questionnaires to find genetic factors linked to early-onset dementia — memory loss before age 70 — across different ethnic groups, including Alzheimer's disease and mild cognitive impairment. It is a genetic research study, not a treatment trial, so there is no drug or therapy being tested. Researchers are building a dataset to better understand who is at risk and why.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06548191Phase 1Recruiting

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

Open to carriers, genotype not tracked

This trial tests whether eating within a 10-hour daytime window — fasting for 14 hours each night — can reduce sleep problems, slow cognitive decline, and lower biological markers of Alzheimer's disease in people already diagnosed with MCI or early-to-moderate Alzheimer's. It also tests whether having a partner fast alongside you improves adherence. This is a Phase 1 trial, meaning the primary focus is safety and feasibility, not proof that it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07577440N/ARecruiting

Effectiveness of a Positive Mental Health Promotion Programme for Informal Caregivers of People With Dementia: A Randomised Controlled Trial Protocol

Caregiver support, genotype not relevant

This trial is testing a structured mental wellness program called Mentis Plus+ Caregivers, designed specifically for unpaid family caregivers of people with dementia. Researchers want to know whether it reduces depression, anxiety, stress, and caregiver burnout compared to standard primary care support. This is a Phase NA randomized controlled trial, meaning it is evaluating real-world effectiveness of a non-drug program rather than testing a new medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06444217N/ARecruiting

Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD

Unrelated to APOE4 or Alzheimer's

This trial is collecting skin biopsies from people with Huntington's disease to grow cell lines in a lab. Researchers want to test a gene therapy technique called trans-splicing, which aims to correct the faulty Huntingtin gene at the RNA level. No drug or therapy is given to participants — just a skin sample. This is a Phase NA study, meaning it is a laboratory validation effort, not a standard treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06871839Recruiting

The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

Drug trial — elevated ARIA risk for carriers

This trial is testing lecanemab, an FDA-approved anti-amyloid antibody drug, against standard dementia medications in people with early Alzheimer's disease. The focus is on understanding how lecanemab affects synaptic function and brain network activity, using brain scans, PET imaging, and fluid biomarkers. The phase is unspecified, meaning this reads more like an observational or mechanistic study than a standard efficacy trial — it is not testing a new drug, but studying how an approved one works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04632628N/ARecruiting

Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers

Caregiver study, genotype not relevant

This trial is testing a web-based version of Cognitive Behavioral Therapy for Insomnia, called NiteCAPP, designed specifically for family caregivers of people living with dementia. It measures changes in sleep quality, fatigue, mood, and cognitive functioning. This is a Phase N/A behavioral study, meaning it is evaluating a structured program rather than a drug — focused on real-world feasibility and effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05847192Recruiting

Tau Networks in Psychotic Alzheimer's Disease

Research study — carriers likely excluded

This study uses a specialized PET brain scan called PI2620 to look at tau protein buildup in people who have Alzheimer's disease with psychotic symptoms — things like hallucinations or delusions — compared to those without those symptoms and to healthy older adults. Researchers want to understand why some Alzheimer's patients develop psychosis. This is an observational study, not a treatment trial, so no experimental drug or therapy is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03860857Phase 3Recruiting

Biomarker Exploration in Aging, Cognition and Neurodegeneration

Open to carriers, genotype not required

This observational study is tracking brain changes in people 60 and older who currently have normal cognition. Researchers are using MRI, amyloid PET, tau PET, and cognitive testing to see which early brain changes best predict future memory decline. There is no drug treatment involved — this is a measurement and monitoring study. Phase 3 here means the imaging and testing methods are being validated at a larger scale, not that a therapy is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05771844N/ARecruiting

Home Sleep Therapy for Older Adults With MCI

Open to carriers, not 4-specific

This trial is testing a home-use device called SleepWISP that delivers gentle, non-invasive electrical stimulation to the brain during sleep. The goal is to see whether boosting deep sleep improves memory in people with mild cognitive impairment. It is a Phase NA study, meaning it sits outside the standard drug-approval pipeline — researchers are evaluating whether the device works and collecting data on Alzheimer's-related biomarkers through blood and nasal samples.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04330287Recruiting

HIV-HEART Aging Study

No relevance to APOE4 carriers

This is a long-running observational study, not a treatment trial. Researchers in Germany have been tracking over 1,800 HIV-positive adults since 2004 to understand how often cardiovascular diseases develop, how common they are, and how they progress over time. No drug or intervention is being tested. Because no phase is listed, this is purely a data-collection and follow-up effort, not a test of any therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT07012629Phase 3Recruiting

A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)

Open to carriers, not 4-specific

This Phase 3 trial is testing whether standard blood-thinning medications (aspirin or clopidogrel) and cholesterol-lowering statins (rosuvastatin or atorvastatin) can reduce the risk of future stroke and possibly dementia in people who have silent, symptom-free brain infarcts found incidentally on MRI. Phase 3 means the treatments themselves are well-known — the question is whether they help this specific group of people.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
14 sites
NCT04684602Phase 1Recruiting

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

Vague scope, genotype not considered

This Phase 1 trial is testing whether mesenchymal stem cell therapy — delivered as products called PrimePro and PrimeMSK — is safe and tolerable across a wide range of chronic and acute conditions, including neurological ones. Phase 1 means the primary goal is checking safety in humans, not proving the treatment works. The trial covers an unusually broad list of conditions, which makes it hard to evaluate any single use case closely.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04793776N/ARecruiting

Manage Emotions to Reduce Aggression (MERA)

No Alzheimer's or APOE4 relevance

This trial tests a 3-session behavioral therapy called MERA — Manage Emotions to Reduce Aggression — against a control therapy in veterans with PTSD who struggle with impulsive aggression. Researchers want to know whether teaching emotion regulation skills can reduce aggressive outbursts and help veterans feel ready to engage in standard PTSD treatment. This is a Phase NA study, meaning it is evaluating a behavioral approach rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07312435N/ARecruiting

B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy.

Open to carriers, genotype not tracked

This trial is testing whether a combined supplement of B-vitamins and omega-3 fatty acids can reduce a blood marker of brain cell damage called neurofilament light chain in adults over 65 with low B-vitamin levels. It is a Phase NA designation, meaning this is a straightforward randomized controlled trial focused on measuring biological effects, not a staged drug approval process. Researchers will also look at cognitive function and quality of life over three months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06956300N/ARecruiting

TMS for Cognitive Decline in Aging and Preclinical AD

Open to carriers, genotype not required

This trial is testing whether repetitive Transcranial Magnetic Stimulation — a non-invasive device that uses magnetic pulses to gently stimulate targeted brain areas — can improve motivation, memory, and brain-network function in cognitively normal older adults and people with preclinical Alzheimer's disease. Participants receive 20 sessions of either real or sham stimulation over several weeks, with MRI scans measuring what changes. This is a Phase NA designation, meaning it is a device feasibility and effects study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06507254N/ARecruiting

Polyphenols and Cognitive Decline

Open to at-risk adults, not APOE4-specific

This trial is testing whether a daily polyphenol supplement, the kind of plant compounds found in berries, cocoa, and tea, can help protect cognitive function in older adults who are at higher risk for Alzheimer's disease. Researchers will track brain changes, gut microbiome shifts, and thinking ability over 12 months. This is a Phase NA randomized controlled trial, meaning it is a well-designed study but not a standard drug-approval phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05984524N/ARecruiting

Gamma-Music Based Intervention for Mild Alzheimer's Disease

Open to carriers, genotype not tracked

This trial tests a non-drug brain stimulation tool that pairs flickering gamma-frequency lights with music a person chooses themselves. Researchers want to know whether this combination reliably changes brain activity, whether people actually stick with it and find it enjoyable, and who might benefit most. It enrolls people with mild Alzheimer's disease who have confirmed amyloid buildup. This is a Phase NA feasibility and development study — it is early-stage work, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05597124Phase 2Recruiting

Exercise to Improve Brain Health in Older African Americans

Exercise study, genotype not APOE4-specific

This trial is comparing two exercise programs in older African Americans: a cardio-dance fitness class versus a strength, flexibility, and balance program. Researchers want to see which one better supports brain health and reduces markers associated with Alzheimer's risk, measured through cognitive tests, brain scans, and blood draws. This is a Phase 2 trial, meaning it is testing whether the approach works, not a proven or approved intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07096960N/ARecruiting

Implementation of the START Intervention in Brazil: a Controlled Feasibility Trial

Caregiver study, genotype irrelevant

This trial is testing a Brazilian version of a structured program called START, which teaches coping strategies to family caregivers of people with dementia. Researchers want to know whether it is feasible and acceptable to deliver this program through community health workers across 10 Brazilian municipalities. It is a feasibility trial, meaning the goal right now is to see whether the program can be rolled out reliably, not yet to prove it works definitively.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07217912Phase 2Recruiting

Daridorexant to Prevent Post-cardiotomy Delirium

General surgery trial, genotype not considered

This Phase 2 pilot trial is testing whether daridorexant, an FDA-approved sleep medication, can reduce delirium and improve sleep in the three days after open-heart surgery. Researchers are comparing the drug against a placebo in adults 60 and older undergoing valve or bypass surgery. Phase 2 means they are gathering early evidence on whether it works and refining plans for a larger study — nothing is proven yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06933212Recruiting

Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

CAA-focused, genotype not specified

This trial is testing whether a Mediterranean diet, boosted with either extra virgin olive oil or walnuts, affects stroke risk and cognitive decline in people with two specific vascular brain conditions: CADASIL and Cerebral Amyloid Angiopathy (CAA). It first observes patients' current eating habits, then intervenes with a structured diet. The phase is unspecified, so this appears to be an early or exploratory study — not yet proven or approved as a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06935812N/ARecruiting

Comparison of the Effects of Bimanual, Finger and VR Exercises in PwMCI

Drug-free MCI study, genotype not tracked

This trial compares three types of physical exercise in people with mild cognitive impairment: coordinated two-handed movements, finger exercises, and virtual reality activities. Researchers want to see which approach does the most for thinking and memory skills. This is a Phase NA study, meaning it is a direct comparison between approaches rather than a staged drug development trial. Details on sample size and outcome measures are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06885918Recruiting

ALS Research Collaborative

Unrelated to APOE4 or Alzheimer's

This is a natural history study — not a drug trial — focused on ALS and related motor neuron diseases. Researchers are collecting biological and clinical data from people living with ALS, other motor neuron diseases, or known ALS-linked gene mutations, as well as healthy volunteers. The goal is to improve understanding of how these diseases progress, which may help guide future drug and biomarker research. No phase designation applies; this is observational only.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06584110N/ARecruiting

Buddy-Up Dyadic Physical Activity Program for Persons With Dementia and Family Caregivers

Lifestyle study, genotype not considered

This trial tests a 16-week partner exercise program called BUDPA, where a person with mild dementia and their family caregiver work out together as a pair. Researchers want to see whether exercising as a team improves the person with dementia's thinking skills and the caregiver's mood, while also strengthening the relationship between them. This is a Phase NA randomized controlled trial — it is testing whether the program works, using a real comparison group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05893524Recruiting

Uppsala-Dalarna Dementia and Gait Project

Observational study, genotype not considered

This project is testing whether a simple walking-and-talking test called the TUG dual-task can help detect early signs of cognitive decline and predict future dementia. The person walks a short distance while answering questions at the same time. Researchers want to know how accurate and reliable this test is. There is no drug or treatment involved. No phase is listed — this appears to be an observational research study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07355387N/ARecruiting

Home Based Functional Balance Intervention for Multiple Sclerosis

Unrelated to APOE4 or Alzheimer's

This trial tests a home-based balance training program for people with multiple sclerosis. Participants do either a multicomponent exercise routine — combining dual-tasking, strength, vestibular, and dynamic balance work — or a stretching program, twice a week for four months. Researchers are measuring changes in physical function, thinking skills, and daily living. This is a Phase NA feasibility trial, meaning the goal is to see whether the approach is practical and shows early promise, not to prove it works definitively.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06246929N/ARecruiting

Healthy Aging as Black Adults, In It Together: a Comparative Effectiveness Study of Chronic Pain and Cognitive Decline

Open to carriers, genotype not required

This trial compares two behavioral programs for Black older adults who have both chronic pain and early signs of cognitive decline. One program combines mindfulness-based cognitive therapy with walking (MBCT+w); the other is an active-living exercise program (ALED). Researchers want to see which works better for physical, cognitive, and emotional wellbeing over six months. This is a Phase N/A trial — a head-to-head comparison of two existing approaches, not a drug test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06679296Recruiting

Study on Aging and Cognitive Impairment in China

Observational only, genotype not addressed

This is a large observational study in China tracking how people of all ages — from children to elderly — develop or avoid cognitive decline over time. Researchers are collecting medical exams, brain scans, blood tests, and psychological assessments to build a database on aging and cognition. No phase is listed because this is not a drug trial — it is a longitudinal cohort study, meaning it follows people over time to spot patterns and risk factors.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06289569N/ARecruiting

Home Tele Rehabilitation Therapy for Vascular Dementia

Vascular focus, genotype not relevant

This trial tests whether physical rehabilitation delivered via video or remote technology at home is practical and reduces caregiver burden for stroke survivors, some of whom also have vascular dementia. It focuses on upper limb movement and arm function. This is a Phase NA feasibility study, meaning researchers are asking whether the approach is workable and safe enough to study further, not whether it is a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05395624Phase 1Recruiting

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Open to AD patients, genotype not tracked

This trial is testing a new PET scan imaging agent called 18F-OP-801. It is not a treatment — it is a radioactive tracer designed to show researchers where brain inflammation is happening by lighting up activated immune cells called microglia. The trial is enrolling people with ALS, Alzheimer's, MS, Parkinson's, and healthy volunteers to check whether the tracer is safe and behaves predictably in the body. This is a Phase 1 study — focused on safety and dosing, not effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07466394N/ARecruiting

COGSCREEN II: Early Detection of Cognitive Impairment

Open to carriers, genotype not required

COGSCREEN II is testing whether a structured screening program using digital cognitive tests and blood-based biomarkers can reliably identify early cognitive decline in people aged 60 and older through regular GP and specialist practices in Germany. This is a Phase NA behavioral study, meaning it is evaluating a detection system rather than a drug. It aims to find people with subtle memory concerns before dementia is diagnosed.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07005895Recruiting

Feasibility of Using the Gatorade Sports Science Institute (GSSI) Labs App for Hydration Related Outcomes

No relevance to APOE4 carriers

This study tests whether a Gatorade-branded smartphone app can reliably collect hydration data from everyday people at home. Participants use the app alongside a wearable fitness tracker and a bathroom scale. There is no assigned phase — this is a feasibility study, meaning researchers are simply checking whether the app works as a research tool, not testing a medical treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06112639N/ARecruiting

The DANCEREX Proof-of-Concept Study for Chronic Neurological Disorders

Open to carriers, genotype not tracked

This trial tests DANCEREX-DTx, a digital app that guides people through dance and music-based exercise sessions designed for brain and neurological health. Participants are randomly assigned to the full app experience, dance-only sessions, or an educational program. Researchers want to know whether the digital motivational layer improves how consistently people stick with the program. This is a proof-of-concept study, meaning it is an early-stage test of feasibility and initial effectiveness, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT05081596N/ARecruiting

A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD

Open to carriers, genotype not required

This trial tests a talk-therapy program called PATH-Pain, designed specifically for older adults who are dealing with three things at once: mild cognitive impairment or early Alzheimer's, chronic pain, and depression. Researchers want to know whether this structured therapy improves thinking, mood, and daily functioning better than standard care. It is a Phase NA behavioral study, meaning it is evaluating how well the approach works in practice, not testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06937541Recruiting

Family Interventions iN Dementia Mental Health Environments

Caregiver research, genotype irrelevant

This study is not a drug or treatment trial. It is UK-based research aimed at understanding what family carers go through when a loved one with dementia is admitted to a mental health ward. Researchers will survey wards, interview carers and staff, observe daily ward life, and use what they learn to design practical support strategies. There is no phase, because no intervention is being tested on patients.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06089161N/ARecruiting

Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks

Open to carriers, genotype not required

This trial tests whether a personalized coaching model called PRAISE helps Black adults with sleep apnea stick to their CPAP or PAP treatment. Researchers will then measure whether better sleep apnea treatment affects Alzheimer's disease biomarkers and cognitive performance. This is a Phase NA behavioral study, meaning it is testing a care approach rather than a drug, and results are not yet established.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06897670Recruiting

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study

Open to MCI group, genotype not specified

This study uses a noninvasive brain scanner called fNIRS — essentially a lightweight headband that tracks blood flow and oxygen in the brain — to compare brain activity patterns in people with depression, bipolar disorder, or mild cognitive impairment versus healthy controls. It is an observational study, meaning no drug or treatment is given. Researchers want to see whether these conditions produce distinct, measurable brain signatures. Details on phase are not specified.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07214727Phase 1Recruiting

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing ALN-5288, a new drug delivered directly into the spinal fluid via injection, in people who already have Alzheimer's disease at the MCI or mild-to-moderate dementia stage. The goal right now is simply to learn whether it is safe and how the body handles it. This is a Phase 1 trial — the very first stage in human testing, focused on safety, not yet on proving the drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
13 sites
NCT06338397N/ARecruiting

Social & Affective Cognition in Alzheimer's Disease & Associated Disorders

Observational only, genotype not relevant

This study is testing a tool called SCANN to measure how well people with Alzheimer's disease or frontotemporal degeneration understand social cues and emotions — things like reading a room, making decisions around others, or recognizing vulnerability. Researchers want to see whether those social and emotional abilities connect to real-world behavior problems. This is a Phase NA observational pilot study, meaning it is exploratory research, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06898476N/ARecruiting

Silkworm Pupa Powder Improves Dementia.

Open to carriers, not 4-specific

This trial is testing whether silkworm pupa powder, taken daily as a dietary supplement, can improve daily functioning, nutrition, and physical frailty in people already diagnosed with Alzheimer's disease. Participants take either the supplement or a near-identical placebo for four months. This is a Phase NA trial, meaning it sits outside the standard drug-approval pipeline — it is exploratory research into a supplement, not a regulated pharmaceutical.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06860035N/ARecruiting

Dementia Caregivers' Link to Assistance and Resources

Caregiver support, genotype not relevant

This trial tests a program called DECLARE, which pairs a caregiver self-assessment tool with increased access to licensed social workers for family members caring for someone with dementia at home. Researchers want to know whether caregivers will use it, whether clinicians find it helpful, and whether it boosts caregiver confidence and social work access. This is a Phase NA study, meaning it is evaluating a care delivery program rather than a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05372159Recruiting

Vanderbilt Memory and Aging Project

Observational study, APOE4 explicitly examined

This is an observational study — no drug or treatment is being tested. Vanderbilt researchers are tracking up to 1,000 adults age 50 and older to understand how heart and vascular health connects to early brain changes associated with Alzheimer's and cerebrovascular disease. Participants get MRI scans, cognitive tests, and biomarker measurements over time. Because it is observational, it generates knowledge, not a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06050603N/ARecruiting

MRI Guided Closed-loop TMS-EEG

Device trial, genotype not considered

This trial is testing a precision brain stimulation technique called TMS, guided in real time by fMRI brain scans and EEG brainwave recordings. The goal is to develop a personalized way to stimulate specific brain networks, with the hope of improving memory-related brain activity. It enrolls both healthy adults and people with amnestic mild cognitive impairment. This is a Phase NA feasibility study, meaning researchers are still refining how the technique works, not yet proving it prevents or treats any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05077579Recruiting

Alzheimer"s Imaging Biomarkers in Obesity

Observational study, genotype not required

This observational study is looking at whether excess body fat — especially when combined with metabolic problems like high blood sugar or insulin resistance — is linked to early Alzheimer's-related changes in the brain. Researchers are using PET and MRI brain scans to measure amyloid, tau, and signs of neuroinflammation in cognitively normal adults aged 40 to 60. This is not a drug trial — no intervention is being tested, just observation and measurement.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05877196N/ARecruiting

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

Exercise study, genotype not specified

This trial is testing four different exercise programs, ranging from gentle stretching to high-intensity interval training, in older adults aged 65 and up who already have mild cognitive impairment or early Alzheimer's disease. Researchers want to find out which type of exercise best improves cardiovascular fitness and reduces brain changes visible on MRI. This is a Phase NA adaptive trial, meaning it is designed to compare approaches and find what works best, not a standard drug approval study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05534607N/ARecruiting

Natives Engaged in Alzheimers Research - 'Ike Kupuna

Lifestyle study, genotype not considered

This trial is testing whether a traditional hula dancing program called Ola Mau i ka Hula can improve vascular risk factors — things like blood pressure, blood sugar, and cholesterol — and slow cognitive decline in Native Hawaiian and Pacific Islander adults with early memory concerns. It runs over 12 months. This is a Phase NA behavioral trial, meaning it is evaluating a cultural lifestyle program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06595511N/ARecruiting

Effects of Combined 40 Hz Audio-visual Stimulation and Cognitive Games on Alzheimer's Disease

Open to carriers, not 4-specific

This trial tests a device that combines flashing lights and sounds at 40 Hz with digital cognitive games to see whether it slows cognitive decline in Alzheimer's patients. Researchers will track changes using EEG brain recordings, neurological exams, and cognitive tests over three months. It is a Phase NA trial, meaning this is likely a feasibility or development study — not yet a large-scale test of whether it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04824144Phase 1Recruiting

Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care

No APOE4 relevance found

This trial is testing dexmedetomidine, a sedative drug, to manage severe agitated delirium in patients near the end of life receiving palliative care. Researchers want to find the right dose, confirm it is practical to give subcutaneously outside a monitored hospital setting, and get an early read on whether it works. This is a Phase 1/2 trial, meaning it is focused on safety and dosing, not yet a proven or approved approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06121544Recruiting

The Swedish BioFINDER - Preclinical AD Study

Carriers wanted, Sweden-based only

This Swedish observational study is tracking biomarkers in up to 600 cognitively healthy adults aged 50 to 80 to see whether blood tests and brain scans can detect early Alzheimer's changes before symptoms appear. Participants undergo plasma tests, amyloid and tau PET scans, and MRI over roughly four years. There is no drug or treatment involved. Because it is observational, it is about learning, not intervening.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07031687N/ARecruiting

Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease

Device trial, genotype not required

This trial is testing a non-invasive brain stimulation technique called Temporal Interference Brain Stimulation, or TIBS, in people who have early biological signs of Alzheimer's but no symptoms yet. Researchers use MRI scans and real-time brainwave monitoring to personalize the stimulation, then deliver it daily for two weeks. They want to know whether it improves memory and changes brain connectivity. This is a Phase NA trial — meaning it is exploratory research, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06416371Recruiting

Retinal Vessel Leakage in Cerebral Small Vessel Disease

Closed cohort, genotype not relevant

This observational study is testing whether blood vessels in the retina (the back of the eye) leak in people who have cerebral small vessel disease — a condition that damages tiny blood vessels in the brain and raises dementia risk. Researchers want to know if retinal leakage severity tracks with brain disease severity. There is no drug or treatment involved; participants receive an eye imaging test using an injected fluorescent dye. Details on phase are unspecified.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07224607N/ARecruiting

Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

Open to carriers, genotype not required

This trial is testing whether shining near-infrared light on the forehead, using a handheld device, can improve thinking and memory in people with Mild Cognitive Impairment or mild Alzheimer's dementia. Researchers will measure executive function and look at blood markers tied to inflammation and brain cell damage. This is a Phase NA, or feasibility-stage study, meaning the goal is early evidence and safety data, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06181513Early Phase 1Recruiting

Probiotics in Mild Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether a daily probiotic capsule can reduce brain inflammation, improve thinking and memory, and change brain activity patterns in people who already have mild Alzheimer's disease. It compares the probiotic group to a placebo group. This is an Early Phase 1 trial, meaning it is a very early-stage safety and feasibility test — far from proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03894254N/ARecruiting

Predictive Factors of Autonomy Loss in Real-life Cohort

Observational only, genotype not addressed

This French observational study is not testing a drug or treatment. It is building a long-term database of about 5,400 patients with Alzheimer's disease or related memory disorders, tracking them for up to 10 years to identify which factors predict loss of independence over time. There is no intervention — researchers are watching, measuring, and learning. This is a real-world data collection effort, not a clinical trial in the traditional sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT06718686Phase 1Recruiting

Rifaximin SSD in Dementia Trial

Open to carriers, not 4-specific

This trial is testing a new low-dose formulation of rifaximin, an antibiotic that stays in the gut rather than entering the bloodstream, to see whether it can shift gut bacteria in a more favorable direction in people who already have mild to moderate Alzheimer's or vascular dementia. It is a Phase 1 trial, meaning the primary goals are safety and tolerability, not proving the treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06164262Recruiting

Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years

Observational registry, genotype not a factor

This study is tracking people aged 30 to 60 who already show signs of cerebral small vessel disease on brain scans but do not yet have dementia. Researchers are building a registry and following participants over ten years to see who develops cognitive problems and why. It is an observational study, meaning no drug or treatment is being given — just monitoring and data collection.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07545473N/ARecruiting

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

Open to carriers, not 4-specific

This study tests whether a special eye-scanning camera can detect signs of Alzheimer's and other brain diseases by photographing the retina using multiple wavelengths of light. It is not a drug trial — it is a diagnostic imaging study. Researchers want to know if this non-invasive eye scan can pick up amyloid protein deposits and other disease markers. Phase NA means this is a feasibility and diagnostic accuracy study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06650527N/ARecruiting

Effect of Cognitive Empathy Training on Dementia Caregivers

Caregiver study, genotype not relevant

This trial is testing whether a behavioral training program called cognitive empathy training can improve mental health, reduce inflammation, and support immune function in people who care for someone with dementia. It is a Phase NA trial, meaning it is a behavioral intervention study rather than a drug trial. Researchers will use blood samples and MRI scans to look at physical changes alongside mental health outcomes. Details on session format and length are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT04946916N/ARecruiting

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

Diagnostic study, genotype not relevant

This study is testing whether a simple blood test measuring a protein called neurofilament light chain (NfL) can help doctors tell apart cognitive decline caused by psychiatric conditions like schizophrenia or bipolar disorder from cognitive decline caused by neurodegenerative diseases like Alzheimer's or FTD. It is not a drug trial — it is a diagnostic study, meaning researchers are evaluating a biomarker, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06538311Early Phase 1Recruiting

Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether repetitive Transcranial Magnetic Stimulation (rTMS) — a non-invasive device that briefly alters brain activity using magnetic pulses — can improve memory and brain-network function. Participants receive 20 sessions of either real or sham (inactive) rTMS over several weeks, with memory tests and MRI scans measuring the results. This is an Early Phase 1 study, meaning researchers are still exploring basic effects and safety in a small group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06534658Recruiting

Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia

Open to carriers, not 4-specific

This observational study is tracking people with Alzheimer's disease or mild cognitive impairment over time using brain scans, molecular imaging, blood markers, and digital tools. The goal is to better understand how these diseases progress and to find new ways to diagnose and monitor them. There is no drug or treatment being tested — researchers are collecting data only. The phase is unspecified, which is typical for observational studies.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT06095063N/ARecruiting

dTMS for Subjective Cognitive Decline

Family history required, genotype not tracked

This trial is testing whether deep transcranial magnetic stimulation (dTMS) — a non-invasive device that uses magnetic pulses to stimulate specific brain regions — combined with cognitive training can improve memory, thinking, and mood in older adults who feel their memory is slipping but score normally on tests. It is a Phase NA (feasibility or pilot) study, meaning researchers are exploring early signals, not yet proving the approach works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06058234Recruiting

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

ARIA risk — carriers discuss carefully

This is not a typical drug experiment. It is a Medicare-required data collection study tracking real-world outcomes for patients already receiving FDA-approved anti-amyloid antibody drugs such as lecanemab or donanemab. Medicare mandated this registry as a condition of coverage. Researchers are gathering clinical and claims data to see how these drugs perform outside of controlled trials. No phase applies because no experimental treatment is being tested here.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07102212N/ARecruiting

Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)

Unrelated to APOE4 or dementia

This trial is testing a smartphone and video-based program called FOCUS that uses two talk-therapy approaches, cognitive-behavioral therapy and acceptance and commitment therapy, to help people with advanced cancer manage sleep problems, anxiety, fatigue, and low mood. It is a Phase N/A trial, meaning it is evaluating how well this behavioral program works in practice rather than testing a drug. Researchers are enrolling 120 adults across five cancer types.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07413406N/ARecruiting

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

Caregiver study, genotype irrelevant

This trial tests two ways of teaching dementia caregivers practical skills. One group uses structured retrieval practice, a method where you repeatedly recall information with feedback to help it stick. The other group reads educational materials the traditional way. Researchers will track knowledge, confidence, stress levels, and how caregivers perceive behavioral symptoms over time. This is a Phase NA behavioral study, meaning it is evaluating a learning approach rather than a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06547021N/ARecruiting

Investigating Different Frequencies of Transcranial Electrical Stimulations in Dementia Population

Open to carriers, genotype not required

This trial is testing whether brain stimulation devices, specifically transcranial alternating current stimulation and transcranial direct current stimulation at different frequencies, can improve thinking and memory in people already living with dementia when paired with cognitive exercises. Researchers will also use brain scans and balance measurements to track changes. This is a Phase NA study, meaning it is an exploratory device comparison, not a late-stage efficacy trial with a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05591027Phase 1Recruiting

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing a water extract of Centella asiatica, an herbal plant, given orally for 6 weeks to people with mild cognitive impairment or early Alzheimer's dementia. Researchers want to see whether the extract produces measurable biological signals in the brain and body, and whether it is safe to take. This is a Phase 1 trial, meaning the primary goal is safety and early signal detection, not proving the treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05149742N/ARecruiting

Deafness and Cognition in Middle-aged Adults

Observational only, genotype not considered

This study is comparing cognitive test results between middle-aged adults (45 to 64) who have severe hearing loss and those with normal hearing. It is not testing a drug or treatment — researchers are simply measuring whether significant hearing loss is linked to cognitive differences at this age group. This is a Phase NA observational study, meaning it is gathering information, not evaluating a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06102486Recruiting

MCI Speech in Noise

Observational only, genotype not considered

This study is testing whether people with mild cognitive impairment (MCI) process sound differently than people with normal cognition. Researchers are measuring how the brain hears and interprets sounds, and whether those hearing-processing scores track with memory and thinking scores. There is no drug or treatment involved — it is purely a measurement and observation study. The phase is unspecified, meaning this is likely exploratory research rather than a clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06875986Recruiting

REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

General dementia drug, genotype not relevant

This study is tracking how Rexulti (brexpiprazole) performs in real-world clinical practice for people with Alzheimer's who show agitation or aggression. It is not a controlled experiment — it is a post-market surveillance survey collecting safety and effectiveness data from patients already being prescribed the drug by their doctors. The phase is unspecified, meaning this is observational, not a traditional drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06513403Recruiting

Preliminary Research Using Artificial Intelligence Technology to Identify Differences in Facial Expressions Between Healthy People, Patients With Cognitive Decline, and Patients With Dementia

Observational only, genotype not relevant

This study is testing whether artificial intelligence can detect differences in facial expressions between healthy people, those with mild cognitive decline, and those with dementia. Researchers will analyze facial cues as a potential screening tool. This is a preliminary observational study, not a treatment trial, meaning no intervention is being given and nothing is being tested for safety or effectiveness yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05231798Phase 2Recruiting

Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

DS-only study, not for carriers

This trial uses a specialized PET scan radiotracer called FEOBV to measure the health of cholinergic neurons — the brain cells most consistently damaged in Alzheimer's disease — in adults with Down syndrome. Researchers want to understand how that damage relates to aging and cognitive changes in Down syndrome. This is a Phase 2 pilot study, meaning it is gathering early data to shape future research, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06667817N/ARecruiting

Exercise From Afar: Progressing At Risk Individuals to Independent Exercise

Lifestyle study, genotype not required

This trial is testing whether a smartphone app can deliver personalized exercise programs to sedentary adults in rural Kansas and improve health markers tied to dementia risk. Researchers will measure fitness and biological indicators before and after the program. This is a Phase NA study, meaning it is a practical feasibility and efficacy investigation rather than a drug trial moving through standard approval phases. Details on duration are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05927974Recruiting

Investigating Dynamic Interactions in Distributed Cognitive Control Networks

Observational only, not APOE4 relevant

This study records brain activity in epilepsy patients who are already having brain electrodes implanted for seizure monitoring. Researchers want to understand how different brain regions coordinate during thinking, memory, and attention tasks. The goal is to learn how those networks break down in conditions like dementia and attention disorders. There is no phase designation — this is an observational research study, not a drug or device trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04801589Phase 3Recruiting

Goal-Directed Sedation in Mechanically Ventilated Infants and Children

No relevance to APOE4 carriers

This trial is testing whether dexmedetomidine, a sedative that works differently from standard benzodiazepine drugs like midazolam, reduces delirium and shortens time on a breathing machine in critically ill infants and young children. Researchers will also track recovery of thinking, behavior, and mental health after the ICU stay. This is a Phase 3 trial, meaning it is a large-scale test of effectiveness in a real patient population.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06611878N/ARecruiting

Memory for Music: Individual Intensive Musical Training in Alzheimer's Disease

Open to carriers, genotype not a factor

This trial tests whether learning new songs with a personal music teacher improves thinking and memory in people who already have Alzheimer's disease. Participants get either intensive training twice a week or minimal training once a month. It is a Phase NA study, meaning it sits outside the standard drug-trial phases — this is a behavioral intervention being tested for effectiveness and safety in a structured way across three countries.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT04715399Recruiting

UPenn Observational Research Repository on Neurodegenerative Disease

Open to carriers, not 4-specific

This is an observational study at the University of Pennsylvania — no drug or treatment involved. Researchers are building a long-term data repository by collecting cognitive tests, brain scans, and biological samples such as blood and spinal fluid from people with neurodegenerative diseases, people with a family history of these diseases, and healthy controls. The goal is to support future research. There is no experimental phase because nothing is being tested on participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07109999Recruiting

Biomarker-based Alzheimer's Disease Cohort Study (BASIC)

Observational only, not APOE4-specific

This is an observational study, not a treatment trial. Researchers in China are enrolling people who already have confirmed Alzheimer's-related biomarkers, such as amyloid detected on a PET scan or spinal fluid test, and following them over time. The goal is to track how their disease progresses, identify what risk factors speed things up, and build a prediction model. No drug or intervention is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07120347N/ARecruiting

Remote Sensing for ADRD-Specific Activities Identification in Older Adults

Open to carriers, genotype not tracked

This study puts smart-home sensors and AI into the homes of older adults, some with mild cognitive impairment or early dementia and some without, to see whether the technology can detect changes in everyday activities that signal cognitive decline. It is a Phase NA trial, meaning it is observational and feasibility-focused rather than testing a treatment. Details on exact enrollment numbers are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05574634N/ARecruiting

The Role of the Locus Coeruleus in Age-related Distractibility

General aging study, genotype not considered

This trial is studying a small brain region called the locus coeruleus and how its connections to attention networks may explain why older adults get more easily distracted. Participants will use a tablet-based cognitive training program to see whether improving those brain connections sharpens attention. This is a Phase NA study — meaning it is research-focused, exploring mechanisms rather than testing a treatment for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06058611N/ARecruiting

Effects of a Computerised Cognitive Stimulation Versus Stimulating Leisure Activities

Open to carriers, not 4-specific

This trial compares two non-drug approaches for older adults with mild or subjective cognitive impairment: a personalized computerized cognitive stimulation program delivered through primary care, versus structured leisure activities. Researchers are measuring effects on memory, thinking skills, daily functioning, and mood. It is a Phase NA trial, meaning it is comparing two active interventions rather than testing a new drug or device for safety and efficacy in the traditional sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06757569N/ARecruiting

Radialis PET Imager for the Assessment of Neuritic Amyloid Plaque Burden

Imaging tech study, genotype not relevant

This trial tests whether a smaller, portable PET scanner called the Radialis PET Imager can produce brain amyloid images that are as clear and accurate as those from a standard PET/CT or PET/MRI machine. Participants already scheduled for a routine amyloid PET scan simply stay a bit longer for a second scan on the new device. This is a device-comparison study, not a drug trial, and the intervention itself is not experimental treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05468073Phase 2Recruiting

Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD

Open to carriers, not 4-specific

This trial is testing whether very low doses of IL-2, a protein that regulates the immune system, can slow cognitive decline in people with early-stage Alzheimer's disease. It measures change on a standard dementia rating scale over 18 months compared to placebo. This is a Phase 2 trial, meaning researchers are testing whether it works and is safe in a real patient group, but it is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06640673Recruiting

Electrophysiological Signature of Mild Cognitive Impairment and Its Relationship with Parkinson's Disease: a High-density EEG Investigation

No APOE4 relevance found

This study uses high-density EEG brain scans to look for electrical patterns in the brain that might distinguish Parkinson's disease patients who have mild cognitive impairment from those who do not. Researchers will also combine the EEG data with MRI scans to study brain network connectivity. It is an observational study with no phase designation, meaning it is exploratory research rather than a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06687161N/ARecruiting

Treating Insomnia in Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether combining transcranial magnetic stimulation (a non-invasive device that uses magnetic pulses to stimulate the brain) with cognitive behavioral therapy for insomnia can improve sleep in people with mild cognitive impairment. It is a Phase NA study, meaning it is evaluating a treatment approach rather than a drug, and is still in the process of determining whether this combination works and is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05629871N/ARecruiting

Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

Observational only, genotype not addressed

This observational study is tracking sleep patterns, body temperature rhythms, and brain biomarkers in people with early-stage Alzheimer's to learn whether sleep disruption is linked to faster cognitive decline. No drug or treatment is being tested — researchers are measuring and watching. It is not a treatment trial at all, more like a detailed scientific observation to understand a connection that could shape future care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06024473N/ARecruiting

A rTMS and Virtual Reality Based Cognitive Rehabilitation Program for MCI

Non-drug trial, genotype not required

This trial is testing whether combining brain stimulation (rTMS) with immersive virtual reality cognitive training improves thinking, mood, daily functioning, and quality of life in people already diagnosed with Mild Cognitive Impairment. Participants are assigned to no treatment, rTMS alone, or rTMS plus VR training over two weeks, then followed for three months. This is a Phase NA interventional study — it is evaluating effectiveness of a combined non-drug approach, not a standard drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05820919N/ARecruiting

Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase

Late-stage dementia care, not prevention

This trial is testing a structured staff-led program called LOCK — focused on light exposure, activity, and consistent routines — to improve sleep in nursing home residents who already have Alzheimer's disease or a related dementia. Researchers are measuring whether sleep quality actually improves and whether nursing home staff can keep the program running over time. This is a Phase NA study, meaning it is a real-world implementation test, not a standard drug-safety or efficacy phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07326709Phase 3Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing votoplam, an oral drug designed to slow the progression of early-stage Huntington's disease. Researchers are comparing it against a placebo to see whether it makes a measurable difference in how quickly symptoms advance. This is a Phase 3 trial, meaning it is a large, late-stage study aimed at confirming whether the drug works well enough to support regulatory approval. Details on the full protocol are still emerging.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
13 sites
NCT06933667N/ARecruiting

Kimel Family Centre for Brain Health and Wellness

Open to carriers, not 4-specific

This trial tests whether a personalized, multi-part lifestyle program can reduce dementia risk in adults 50 and older. Participants get a detailed risk assessment across five areas: physical activity, diet, mental engagement, social connection, and mental wellbeing. Then they join programs targeting their personal weak spots. Risk and cognition are re-measured every six months. This is a Phase NA study, meaning it is evaluating a real-world wellness program rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03657732Recruiting

The Chinese Familial Alzheimer's Network

FAD gene study, not APOE4-relevant

This is a Chinese registry and research network, not a treatment trial. Researchers are enrolling families with hereditary Alzheimer's disease caused by known gene mutations to collect data on genetics, brain imaging, and biomarkers. The goal is to build a national database and better understand how familial Alzheimer's develops over time. No phase is listed because no drug or intervention is being tested — this is observational research.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
65 sites
NCT04524338N/ARecruiting

Longitudinal Study Examining At-Home tDCS

Open to carriers, genotype not tracked

This study follows people with Alzheimer's or other dementia who choose to use a tDCS device at home on their own. tDCS delivers a mild electrical current to the scalp. Researchers are not assigning the treatment — participants have already decided to use it themselves. The team advises them on setup, trains them, and collects monthly reports for at least two years. This is a Phase NA observational study, meaning it is tracking real-world use rather than running a controlled experiment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05710549N/ARecruiting

Understanding Brain Mechanisms Involved in Autobiographical Memory

Open to MCI carriers, not genotype-specific

This trial uses two non-invasive brain technologies — high-density EEG to record brain activity and gentle electrical stimulation (tACS) to nudge brain rhythms — to study how we retrieve personal memories. It enrolls healthy younger and older adults, plus people with mild cognitive impairment or early Alzheimer's. This is a Phase NA mechanistic study, meaning it is focused on understanding how the brain works, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06722352N/ARecruiting

Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)

Caregiver training, genotype irrelevant

This trial trains nurses, administrators, and dementia care coordinators at assisted living facilities on palliative and end-of-life care for residents with dementia. It measures whether that training leads to better documentation of advance care planning discussions. Phase NA means this is not a drug or device study — it is testing whether an educational program improves care quality. Details on outcomes are clear from the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06781333Phase 2Recruiting

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

Open to carriers, genotype not a factor

This trial is testing whether a single infusion of human mesenchymal stem cells, added on top of existing antipsychotic medication, can reduce behavioral symptoms in people with moderate to severe Alzheimer's disease. Behavioral symptoms here include agitation, delusions, anxiety, and sleep problems. It is a Phase 2 trial, meaning researchers are still gathering early evidence on whether the approach works and is safe — it is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06579950N/ARecruiting

Assessing the Effects of Cool Roofs on Indoor Environments and Health

Not relevant to APOE4 carriers

This trial is testing whether painting rooftops with reflective cool-roof coatings lowers indoor temperatures enough to improve the health of people living in hot, low-income housing. Researchers are measuring dozens of outcomes — heart rate, blood pressure, sleep, cognition, mood, and more — across five countries. This is a Phase NA pragmatic trial, meaning it is a real-world intervention study, not a drug trial. Details on U.S. enrollment are not available.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05458323N/ARecruiting

Cognitive Level Enhancement Through Vision Exams and Refraction

Lifestyle study, genotype not relevant

This trial is testing whether giving free prescription glasses to older adults in Hyderabad, India who have uncorrected vision problems can improve cognition, quality of life, mood, social connection, and reduce falls over three years. It is a Phase NA trial, meaning it is evaluating a practical intervention rather than a drug, and is designed to measure real-world outcomes in a community setting. Details on broader generalizability are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06507488N/ARecruiting

Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia

Open to carriers, not 4-specific

This trial is testing whether Daphnetin, a plant-derived compound, can improve thinking and memory in people who have mild cognitive problems caused by blood vessel disease in the brain — but who have not yet developed full dementia. Participants take either Daphnetin capsules or a placebo daily for six months. It is a Phase NA trial, meaning it is likely an efficacy study but outside the standard Phase 1-3 framework, and the intervention is not yet proven or approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05460468N/ARecruiting

Neuromodulation of Memory in Aging

Open to carriers, not 4-specific

This trial is testing whether a non-invasive brain stimulation technique called closed-loop TMS can improve working memory in healthy older adults and people with mild cognitive impairment. TMS uses magnetic pulses aimed at a specific brain network in the prefrontal cortex. It is a Phase NA study, meaning it is exploratory research focused on understanding how the technique works, not a late-stage test of a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06298474N/ARecruiting

The BRAIN App (Phase 2 SBIR)

Open to carriers, genotype not relevant

This trial is testing a tablet-based app called BRAIN that uses AI to deliver personalized Cognitive Stimulation Therapy to people living with dementia in long-term care. The app pulls from each person's interests and memories to suggest engaging activities, with the goal of improving quality of life and reducing difficult behaviors. This is a Phase NA behavioral study — it is testing real-world effectiveness of a digital tool, not a drug or vaccine.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04613089Recruiting

Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database

Unrelated to APOE4 or Alzheimer's

This is an observational registry study tracking how Neuronal Ceroid Lipofuscinosis (NCL), also called Batten Disease, progresses over time. Researchers collect medical records, questionnaires, and clinical exam data to understand how motor skills, language, cognition, seizures, vision, and behavior change. No new treatment is given. Because no phase is listed, this is a data-gathering effort, not a drug or device trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07404410N/ARecruiting

Robotic Technologies for APATHy in Dementia: a Randomised Controlled Trial (RAPHAel)

Non-drug study, genotype not considered

This trial is testing whether two types of home robots — one that connects people to a therapist remotely, one that holds personalized conversations — can reduce apathy (loss of motivation and engagement) in people with MCI or dementia better than standard occupational therapy. It is a Phase NA randomized controlled trial, meaning it is a head-to-head comparison study focused on effectiveness and real-world usability, not early drug safety testing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04740580Early Phase 1Recruiting

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (together called GlyNAC), can improve brain metabolism, reduce inflammation, and help cognition in people with Alzheimer's disease. Participants are compared against a placebo group taking alanine. It is an early Phase 1 trial, meaning researchers are still in the earliest stage of testing safety and early signals of effect in humans — this is not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06279325N/ARecruiting

Effects of a Computerized Cognitive Stimulation Intervention Adapted to the Level of Cognitive Reserve

Lifestyle study, genotype not considered

This trial is testing whether a computerized brain-training program, tailored to a person's level of cognitive reserve, can help preserve memory, attention, and thinking skills in older adults who do not yet have MCI. Researchers will compare people who use the adapted program against those who do not. This is a Phase NA randomized trial, meaning it is evaluating real-world effectiveness rather than early safety or drug dosing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07420426N/ARecruiting

Instant Message-delivered Personalised Acceptance and Commitment Therapy (IMPACT) for Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment

Open to MCI patients, genotype not considered

This trial is testing whether an automated therapy program delivered by instant message on a smartphone can help people with mild cognitive impairment manage neuropsychiatric symptoms like anxiety, depression, and irritability. It uses Acceptance and Commitment Therapy principles, adapted for delivery by text or voice message. This is a Phase N/A trial, meaning it is focused on testing feasibility and early effectiveness rather than being a late-stage confirmatory study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06903078Recruiting

A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.

Observational only, genotype not studied

This observational study is collecting blood samples and health data from people who have active shingles to see whether shingles raises the risk of blood vessel problems and vascular dementia. Researchers will track the shingles group for 12 months and compare them to a control group with one visit. There is no study drug or device. This is a data-collection study, not a treatment trial, so it has no phase rating.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07182396N/ARecruiting

Effects of Video Games and Ball Tossing on Eye Hand Coordination in Elderly With Mild Cognitive Impairment.

Lifestyle study, genotype not required

This trial is testing whether playing video games or doing ball-tossing exercises can improve eye-hand coordination in older adults with mild cognitive impairment (MCI). Researchers will measure coordination using a standardized visual-motor test before and after the interventions. This is a Phase N/A trial, meaning it is a practical comparison study rather than a drug test — it is exploring which activity works better, not evaluating a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06089096Recruiting

Sleep Apnea and Cognitive Function in Subjects With Subjective or Mild Cognitive Impairment

Observational only, genotype not considered

This study is testing whether people with early memory concerns — either mild cognitive impairment or subjective cognitive complaints — also have undiagnosed obstructive sleep apnea. Participants wear a home sleep monitor to check for sleep apnea. It is an observational study, not a drug trial, meaning researchers are looking for a connection rather than testing a treatment. The goal is to understand whether sleep apnea is a contributing factor in early cognitive decline.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06263920Recruiting

Neurofrailty: A Study of Late-onset Epilepsy and Its Associations

Observational only, genotype not considered

This observational study is following adults who developed their first seizure in adulthood — called late-onset epilepsy — to track their brain health over time. Researchers want to understand whether these seizures are connected to later conditions like stroke or dementia. There is no treatment being tested. This is an observational study, meaning researchers are watching and recording, not intervening.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07402356Recruiting

VR Pupillometry in Cognitive Impairment

Observational only, genotype not a factor

This study is testing whether a VR headset that tracks pupil responses can detect early signs of cognitive decline. Researchers will compare pupil behavior during memory and attention tasks across four groups: Alzheimer's disease, mild cognitive impairment, depression with cognitive symptoms, and healthy adults. Participants are followed over six months. This is an observational study, not a drug trial, so it is testing a diagnostic tool, not a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05867641N/ARecruiting

VR&R: Providing Caregiver Respite by Managing BPSDs and Improving QoL in People with Dementia Using Immersive VR-Therapy

Open to caregivers, genotype not considered

This trial is testing whether immersive virtual reality therapy used at home can help people with dementia feel calmer and better, while giving their family caregivers a genuine mental break. It compares two VR formats: solo viewing and shared viewing with a researcher. Phase NA means this is not a standard drug trial — it is a behavioral study evaluating how well the approach works in real home settings. Details on effectiveness are still being gathered.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
7 sites
NCT05109169Phase 2Recruiting

METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia

Actively recruits high-risk APOE4 carriers

MET-FINGER is testing whether combining an intensive lifestyle program (exercise, diet, brain training, and health checks) with the diabetes drug metformin can help protect cognition in older adults who have risk factors for dementia but no diagnosis yet. Cognitive performance across 14 tests is the main outcome measured over two years. This is a Phase 2 trial, meaning researchers are evaluating whether the approach works and is safe, not a proven or approved strategy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07499570N/ARecruiting

Multi-modal Large Language Model-Empowered Talk Therapy for Older Adults With ADRD

Open to carriers, genotype not mentioned

This trial is testing an AI-powered talk therapy tool called Smart Virtual Reminiscence therapy, which uses a virtual conversational agent to help older adults with MCI or mild dementia manage behavioral and psychological symptoms like anxiety, agitation, and depression. It is compared against music therapy. This is a Phase NA trial, meaning it is focused on feasibility and early effectiveness rather than a large-scale proof of efficacy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07287527N/ARecruiting

Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment

Device study, genotype not required

This trial is testing whether shining near-infrared light on the brain — a technique called transcranial photobiomodulation — can improve memory and how brain regions talk to each other in people with amnestic mild cognitive impairment. Participants also do cognitive training, and researchers use brain scans to track changes. Phase NA here means it is a controlled feasibility or pilot study — not yet at the stage of a large proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06027554Phase 2Recruiting

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Open to carriers, not 4-specific

This trial is testing MitoQ, a mitochondria-targeted antioxidant supplement, in older adults aged 65 to 80 who have slow walking speed and/or mild cognitive impairment. Researchers want to see whether MitoQ improves blood vessel function in the brain and body, physical mobility, and cognitive performance. It is a Phase 2 trial, meaning researchers are exploring whether it works and is safe — it is not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07011680N/ARecruiting

Phospholipid-rich Dairy Extract for Cognitive Function

Supplement study, no APOE4 stratification

This trial is testing whether a dairy-derived phospholipid supplement improves thinking and memory in adults aged 55 to 85 who have early, mild memory complaints. Researchers are also tracking side effects. It is a Phase NA trial, meaning it is likely a nutrition or wellness study rather than a drug trial, so it follows a different regulatory path than pharmaceutical research. Details on design length and dose are limited in this summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05939362N/ARecruiting

New Imaging Biomarkers Predictive of MA Progression

Genotype not considered in design

This trial is testing whether ultra-high-field 7 Tesla MRI, combined with a technique called magnetic resonance spectroscopy, can detect early metabolic changes in the brains of people with early-stage Alzheimer's disease. Researchers hope these scans can predict how the disease will progress over time. This is a Phase N/A observational imaging study, meaning it is not testing a drug or treatment — just gathering detailed brain measurements.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06408103N/ARecruiting

Efficacy of a Multicomponent Intervention on Cognitive Function for the Caregiver-patient Dyad

Lifestyle trial, APOE4 noted in subsample

This trial is testing a 12-week multicomponent program for people with mild cognitive impairment and their family caregivers together. The program combines physical, nutritional, and cognitive support delivered by professionals and caregivers. It measures changes in thinking, quality of life, frailty, and caregiver burden over nine months. This is a Phase NA randomized trial, meaning it is evaluating real-world effectiveness of a structured program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05446805Recruiting

Depression and Driving

Open to carriers, genotype not required

This study is examining how depression, early Alzheimer's-related brain changes, and antidepressant use affect how older adults drive. Researchers will use PET brain scans and spinal fluid tests to look for amyloid and tau proteins — the biological markers tied to Alzheimer's — and then measure real-world driving behavior. The phase is unspecified, meaning this is most likely an observational study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06104852Recruiting

Triage Survey for Neurology Research Eligibility

Screening tool, no APOE4 focus

TRIAGE-Neuro is a survey study that screens people to find out whether they might qualify for future industry-sponsored neurology trials, including Alzheimer's research. Participants answer eligibility questions and may be asked to pause certain medications temporarily. This is not a treatment trial at all — it is essentially a matching or pre-screening tool to build a pool of potential future study participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06241287N/ARecruiting

BELIDE: Better Living With Non-memory-led Dementia

Caregiver support, genotype not relevant

This trial tests an online educational programme called BELIDE for unpaid caregivers of people with rare, non-memory-led dementias — specifically primary progressive aphasia (PPA), posterior cortical atrophy (PCA), and behavioral variant frontotemporal dementia (bvFTD). It measures whether the programme improves caregivers' psychological wellbeing compared to a waiting-list control group. This is a Phase NA trial — it is evaluating a behavioral support programme, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06093126Phase 4Recruiting

Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

Single-patient study, not APOE4-specific

This trial tests lemborexant, a newer sleep medication, in a single patient with early-onset dementia and insomnia. Unlike older sleep drugs, it is designed to block wake-promoting brain signals without causing falls, cognitive fog, or rebound insomnia. An N-of-1 trial means the same patient cycles through drug and no-drug periods — it is a Phase 4 study, meaning the drug is already approved but researchers are learning how it works in this specific population.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07130565Recruiting

Pan-Amyloid PET/CT in Various Amyloid-Related Disease

Cardiac study, not APOE4 relevant

This trial is testing whether a special PET/CT imaging scan using radioactive tracers can detect amyloid deposits in patients with cardiac amyloidosis and other amyloid-related diseases. Cardiac amyloidosis is a condition where abnormal proteins build up in the heart. The phase is unspecified, so this appears to be an early feasibility or observational imaging study — not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07485387Recruiting

Global Collaborative Research on Establishing a Korean Cognitive Aging Cohort

Observational only, genotype not studied

This observational study is tracking how daily emotional stress affects memory and thinking over time in Korean adults aged 60 and older. Participants use a smartphone app for real-time mood and cognition check-ins, wear a Galaxy Watch, and give blood samples to measure inflammation markers. Researchers will follow them at 6 months and 1 year. This is a cohort study, not a clinical trial testing a treatment — it is designed to build knowledge, not test an intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07341009Recruiting

Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease

Diagnostic tool study, genotype irrelevant

This study is testing a new 10-minute brain assessment called the Chronos battery, which measures how people with Alzheimer's disease perceive and process time — things like judging the order of events, sensing how long something lasts, and mentally traveling back or forward in time. It is not a drug trial. The phase is unspecified, meaning this looks like a tool-development or validation study rather than a treatment test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07178210N/ARecruiting

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Surgical trial, genotype not required

This trial is testing a robotic surgical system to treat blockages in the lymphatic drainage pathways of the neck in people who already have mild to moderate Alzheimer's disease. The idea is that clearing those blockages might help the brain remove waste more effectively. This is a feasibility and safety study — an early phase that asks whether the procedure can be done safely, not whether it slows or stops Alzheimer's progression.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06088121N/ARecruiting

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

Device trial, genotype not addressed

This trial tests a device called ATNC MDD-V1, which combines transcranial magnetic stimulation (TMS) — a non-invasive way to stimulate the brain using magnetic pulses — with computerized cognitive training. Researchers want to know whether this combined approach affects cognitive function in people with mild Alzheimer's dementia. This is a Phase NA study, meaning it is a device trial focused on measuring real-world efficacy and safety, not yet a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
11 sites
NCT05614310Recruiting

Detecting Early Alzheimer's Using MR

Carriers likely excluded by design

This trial is testing whether a special type of MRI scan called glucoCEST can detect changes in brain glucose metabolism that show up early in Alzheimer's disease. Right now, that kind of brain imaging requires a PET scan with a radioactive tracer. The researchers want to know if MRI alone can do the same job. The phase is unspecified, suggesting this is early-stage feasibility or observational work, not a drug test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05709210N/ARecruiting

Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease

Observational only, genotype not tracked

This pilot study tracks how people with memory complaints, mild cognitive decline, or Alzheimer's disease actually use their smartphones day to day. Researchers want to know whether those usage patterns differ enough across the three groups to serve as a potential diagnostic signal. It is a Phase NA feasibility study, meaning the goal right now is simply to test whether this approach is practical and worth pursuing further, not to prove any treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06976216Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing KarXT plus KarX-EC, a combination drug approach aimed at improving cognition in people who already have mild to moderate Alzheimer's disease. Researchers are measuring whether it actually helps thinking and memory compared to a placebo. This is a Phase 3 trial, meaning it has already passed early safety testing and is now in a large, definitive study to see whether the treatment works well enough to support approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
106 sites
NCT05734378Recruiting

Prognosis of Cerebral Small Vessel Disease

CAA enrolling, genotype not stratified

This is an observational study, not a drug trial. Researchers are following people already diagnosed with cerebral small vessel disease to track what happens over time. They want to understand how the type of disease and the way it first showed up affects long-term outcomes. No treatment is being tested. Because no phase is specified, this is a natural history study meant to improve how doctors predict risk.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06168604N/ARecruiting

Evaluating the Efficacy of the Pain Identification and Communication Toolkit

Caregiver study, genotype irrelevant

This trial is testing a caregiver training program called PICT — the Pain Identification and Communication Toolkit. It teaches family caregivers how to spot signs of pain in a loved one with dementia, and how to communicate that pain clearly to medical providers. It is a behavioral study, not a drug trial, comparing PICT against a general health promotion program to see which better helps caregivers identify and report pain.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07011745Phase 3Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Open to carriers, not 4-specific

This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces agitation in people with Alzheimer's disease. Agitation is one of the most distressing symptoms for both patients and caregivers. This is a Phase 3 trial, meaning researchers are now testing whether it works well enough and is safe enough for potential approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
140 sites
NCT06948929N/ARecruiting

Synbiotic Formula (SCV09) in Alzheimer's Disease Patients

Open to carriers, not 4-specific

This pilot study is testing a synbiotic supplement called SCV09, which combines probiotics and prebiotics, in people already diagnosed with Alzheimer's disease. The goal is to see whether it improves dementia-related behaviors and is safe to use. Phase NA means this is a small exploratory study designed to gather early data before a larger, more rigorous trial. Details beyond the basics are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06922071N/ARecruiting

The REMINDER4Care Program for Older Adults Supported by Residential and Daycare Facilities

Lifestyle study, genotype not considered

This trial is testing REMINDER4Care, a lifestyle-based program designed to lower dementia risk for older adults living in or attending residential and daycare facilities. It focuses on social engagement, cognitive activities, and other modifiable lifestyle factors. Researchers will run a randomized controlled trial — one group gets the program, one does not — to see whether it improves cognitive health. Phase NA means this is not a drug trial; it is a behavioral intervention study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06597981N/ARecruiting

Dyadic Sport Stacking Program for Mild Dementia and Their Family Caregivers

Open to carriers, not 4-specific

This trial is testing sport stacking — a cup-stacking coordination activity — done together by a person with mild dementia and their family caregiver. The pair practices online and at home for 18 weeks. Researchers are measuring changes in cognition, mood, quality of life, and caregiver stress. This is a Phase NA (feasibility and early-stage) trial, meaning it is still building evidence for whether the approach works, not a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06938100Recruiting

Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASIL

Different disease, not APOE4-relevant

This study is following people with CADASIL, a rare inherited disease that damages small blood vessels in the brain and is caused by mutations in the NOTCH3 gene. Researchers want to understand how symptoms, brain imaging findings, and genetic differences relate to each other over time. There is no drug or treatment being tested here — it is an observational study, meaning researchers are watching and recording, not intervening.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06419101Recruiting

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China

China-only, genotype not addressed

This study is building a large database of Chinese patients with memory complaints, tracking them over time to find biomarkers that could help detect dementia earlier. Researchers will collect cognitive tests, brain imaging, and blood samples to watch how things change. There is no assigned treatment. This is an observational cohort study, not a clinical trial testing a drug or therapy, so there is no phase designation.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05881239Recruiting

Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

Open to carriers, not 4-specific

This study is testing a smell-based assessment tool called the AROMHA Brain Health Test to see whether changes in the sense of smell can help identify early signs of neurodegenerative disease. Participants sniff physical scratch-and-sniff cards and answer questions through a web app. It is not a drug trial and does not list a phase, meaning it is focused on validating a diagnostic tool rather than testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05336695Phase 1Recruiting

Assess Fibrin in Brains With AD/ADRD

Open to carriers, not 4-specific

This trial is testing a specialized PET/MR brain scan using a radioactive tracer called 64Cu-FBP8 to measure fibrin deposits in the brain. Fibrin is a clotting protein that some researchers believe contributes to brain inflammation and damage in Alzheimer's. The goal is to see whether fibrin levels differ across people with various stages of cognitive decline versus healthy adults. This is a Phase 1 trial, meaning it is primarily evaluating safety and basic feasibility of the imaging tool itself.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04992195Recruiting

Impact of COVID-19 Vaccines on Cerebrovascular Health

Observational study, genotype not considered

This observational study is tracking whether COVID-19 vaccines have any measurable effect on brain and vascular health over time. Participants get blood tests and cognitive screening before and after vaccination. There is no experimental drug — researchers are watching what happens naturally in a vaccinated population. The phase is unspecified, which fits an observational design: this is data-gathering, not a drug or device being tested for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07356336N/ARecruiting

Cognitive Model for Behavioral Interventions as a Non-pharmacological Intervention for Behavioral and Psychological Symptoms of Dementia

Dementia care study, genotype irrelevant

This trial tests CoMBI, a person-centered behavioral approach, to see whether training nursing home staff to use it reduces agitation, anxiety, depression, and other difficult behavioral symptoms in people already living with dementia. It also measures whether it eases caregiver burden and improves residents' quality of life. This is a Phase NA trial, meaning it is evaluating a care practice rather than a drug — no approval process is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06496945Recruiting

Assessing the Impact of DAy Programs on Individuals Living with Dementia and Their Family/friend Caregivers

General dementia study, genotype not relevant

This Canadian study is tracking older adults with dementia who attend adult day programs and comparing them over time to similar people who do not attend. Researchers want to see how day programs affect the wellbeing of both participants and their family caregivers across four provinces. It is an observational study, not a drug trial, meaning no phase applies and nothing experimental is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06649929Phase 2Recruiting

Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk

Behavioral study, genotype not required

This trial tests a couples-based coaching program called Nuestro Sueno, designed specifically for Latino couples where one partner has been diagnosed with sleep apnea and is starting CPAP therapy. Researchers want to know if involving both partners in culturally tailored support sessions improves how consistently the patient uses their CPAP machine and how well both partners sleep. This is a Phase 2 trial, meaning it is testing whether the approach works, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07504965Recruiting

Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly

Observational only, genotype not considered

This study is testing whether pharmacies can serve as early detection hubs for mild cognitive impairment. Trained pharmacy staff use a digital memory screening tool to flag people who may be experiencing cognitive changes, then refer them to specialists or support services. It is an observational cohort study, not a drug trial, so there is no experimental treatment involved. Details on phase are not specified, as this is a screening and care-pathway study rather than a traditional clinical trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05014971N/ARecruiting

Telehealth in Lewy Body Dementia

LBD trial, genotype not relevant

This trial tests whether telehealth video visits can improve access to specialized, team-based care for people with Lewy body dementia. Instead of traveling to a clinic, participants connect remotely with a coordinated care team. This is a Phase NA study, meaning it is evaluating a care delivery model rather than a drug — focused on whether this approach is practical and helpful.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06782230Recruiting

ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared Criteria

Not relevant to APOE4 carriers

This is not a clinical trial testing a drug or intervention. It is an Italian infrastructure project building a network of biobanks — repositories that store biological samples and health data from people with rare diseases. The goal is to make those samples available to researchers worldwide. There is no phase because nothing is being tested on participants; people simply donate samples and data for future research use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04610697N/ARecruiting

Cognitive Remediation in Forensic Mental Health Care

No relevance to APOE4 carriers

This trial tests whether cognitive remediation — structured brain-training exercises paired with coaching — can improve thinking skills, daily functioning, and mental health outcomes in people held in forensic psychiatric inpatient units. It is a Phase NA trial, meaning it is evaluating a behavioral intervention rather than a drug, and is designed to see whether the approach works in this specific setting. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07018726N/ARecruiting

Addressing Emotional Distress in Dyads of Persons With a Young Onset Dementia (YOD) and Their Care-partners

Open to carriers, not 4-specific

This trial is testing a six-session virtual program called Resilient Together-YOD for people recently diagnosed with young-onset dementia and their care-partners. Both attend sessions together. The goal is to reduce emotional distress and build resilience in both people — not to slow dementia itself. This is a Phase N/A trial, meaning it is evaluating whether the program works and is acceptable, not testing a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05016219N/ARecruiting

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

Open to carriers, genotype not required

This trial is testing two types of light therapy for people with mild cognitive impairment or early Alzheimer's who also have sleep problems. One light is designed to stimulate the brain's circadian clock; the other uses a 40 Hz flicker pattern thought to influence brain activity. Participants sit under their assigned light for two hours each morning for eight weeks. This is a non-drug, device-based study — essentially asking whether specific light patterns improve sleep and cognition.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06092125Recruiting

Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease

Open to carriers, not 4-specific

This trial is testing whether a combined PET/MR brain scan — a single imaging session that merges two types of scans — can improve early and accurate diagnosis across several major brain diseases, including Alzheimer's and Parkinson's. It is an observational imaging study with no phase designation, meaning it is not testing a drug or treatment but rather evaluating a diagnostic tool in real patients already receiving inpatient care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07286448N/ARecruiting

Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment

Non-drug study, genotype not mentioned

This trial tests a home-based digital brain-training app called RICORDO against a paper-and-video education program called S.A.M.B.A. in people aged 50 and older with mild cognitive impairment or subjective cognitive decline. The main goal is to see whether RICORDO better helps participants manage their own health and daily life. It is a Phase NA trial — meaning it is evaluating a device or behavioral approach rather than a drug, so it follows a different regulatory path than a pharmaceutical study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05892952Recruiting

IONA Longitudinal Cohort Study

Observational study, genotype not specified

The IONA study is a long-term observational study based in Scotland, not a drug or treatment trial. Researchers are tracking memory, thinking skills, lifestyle factors, genetics, and biological markers in people aged 50 and older over many years. The goal is to understand how dementia develops and identify who may be at higher or lower risk. This is a data-gathering effort, not a test of any therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06864000Recruiting

Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy

CAA patients only, APOE4 studied

This is an observational research study, not a treatment trial. Researchers in France are collecting genetic samples from patients already diagnosed with cerebral amyloid angiopathy, a condition where amyloid protein builds up in brain blood vessels, causing bleeds and cognitive problems. They want to understand which genetic variants, including APOE, drive the disease and its progression. There is no drug or intervention being tested. Details beyond genetic characterization are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06810960Recruiting

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

Safety watch — carriers at higher ARIA risk

This is a postmarketing surveillance study in South Korea tracking real-world safety of lecanemab (Leqembi), an already-approved anti-amyloid antibody drug for Alzheimer's disease. Researchers are watching for serious brain imaging abnormalities — swelling and microbleeds known as ARIA — and larger brain bleeds in patients already prescribed the drug by their doctors. No phase designation applies because this is observational, not an experimental trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03233646Recruiting

Retinal Imaging in Neurodegenerative Disease

Explicitly lists APOE4-positive carriers

This study uses non-invasive eye-imaging technology — optical coherence tomography (OCT) and wide-field retinal photography — to look for early signs of neurodegeneration in the retina. Researchers want to know whether changes in the tiny blood vessels and structure of the eye can serve as biomarkers for Alzheimer's, Parkinson's, and other brain diseases. There is no phase designation; this appears to be an observational imaging study, not a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05417555N/ARecruiting

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

Open to carriers, not 4-specific

This trial tests whether Low-Intensity Focused Ultrasound Pulsation (LIFUP) — a non-invasive device that delivers gentle sound waves to a specific brain region — can boost memory-related brain activity in people with Mild Cognitive Impairment or mild Alzheimer's disease. Researchers will measure brain activity, memory test scores, and network connectivity using MRI. This is a Phase NA (feasibility or pilot) study, meaning the goal is to see whether the approach shows enough promise to study further. It is not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06321588Recruiting

Autoimmune Dementia: Predictors of Neuronal Synaptic Antibodies in Patients With New-ONset Cognitive Impairment

Observational study, genotype not addressed

This observational study is looking at whether certain antibodies produced by the immune system might attack brain connections and contribute to cognitive decline. Researchers want to know how often these antibodies show up in people with new cognitive impairment, and whether they might explain some cases that do not fit a typical Alzheimer's diagnosis. This is an observational study, meaning no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT05985486N/ARecruiting

Brain Outcomes With Lifestyle Change in Down Syndrome

Not open to typical APOE4 carriers

This trial is testing whether weight loss through a reduced-calorie diet can help protect the brains of adults with Down syndrome who do not yet have dementia. Half of participants will follow a structured diet program; the other half will receive general health education. Researchers will track cognition, brain imaging, and blood markers over 12 months. This is a Phase NA behavioral study, meaning it is evaluating a lifestyle approach rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05537610N/ARecruiting

Extensions of Resurgence as Choice

Not relevant to APOE4 carriers

This trial is testing a behavioral therapy approach for children ages 3 to 17 who have persistent problem behaviors like aggression or self-injury. Researchers want to know whether alternating between sessions where a child gets what they want and sessions where they do not can reduce the tendency for problem behavior to return after treatment. This is a Phase NA study — meaning it is a behavioral intervention trial, not a drug trial, and is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06521918Recruiting

Combined Artificial Intelligence and Mobile Application for Remote Infant Motor Screening: Development and Validation

Unrelated to APOE4 or Alzheimer's

This study is developing and testing an AI-powered smartphone app called Baby Go to screen infant motor development using home videos. Parents record their babies at home, and the AI analyzes the footage for signs of motor delays. Researchers will compare what the AI detects with what parents report, and track whether early AI findings predict later outcomes. The phase is unspecified — this is a development and validation study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05858996Phase 2Recruiting

Testing the Pain Clinical Practice Guideline

Not relevant to APOE4 carriers

This trial is testing a structured pain management program for nursing home residents who have dementia. Half of the participating homes will get the full program, which includes monthly team meetings, staff training, mentoring, and ongoing tracking of resident pain. The other half gets staff education only. Researchers want to see whether the full program reduces pain intensity over 12 months. This is a Phase 2 trial, meaning it is testing effectiveness, not yet a proven standard of care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
11 sites
NCT07128186Recruiting

The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus

Observational only, genotype not considered

This observational study is testing whether an AI-powered screening tool can detect early memory and thinking problems in people who have type 2 diabetes. Researchers will follow participants for 3 to 5 years, tracking blood sugar control alongside cognitive changes. There is no drug or treatment involved — just monitoring and testing. The phase is unspecified, meaning this is likely a feasibility or validation study, not a clinical treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
21 sites
NCT06930560N/ARecruiting

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

Open to carriers, not 4-specific

This trial is testing a hearing care program for people who already have Alzheimer's disease or a related dementia and also have untreated hearing loss. The program combines a hearing device with behavioral coaching and looks at whether addressing hearing loss reduces neuropsychiatric symptoms like agitation or anxiety, and eases stress on caregivers. It is a Phase NA trial, meaning it is evaluating a practical intervention rather than a drug, not yet proven or widely adopted.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07220694N/ARecruiting

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

Open to carriers, genotype not tracked

This 8-week trial is testing a supplement called Sabroxy — a bark extract from the Oroxylum indicum plant — to see whether it reduces insulin resistance and improves cognitive performance in adults who already show signs of both. It is a Phase NA study, meaning it is classified as not a traditional drug phase trial, but rather a controlled supplement study. It uses a placebo comparison and is double-blinded, which means neither participants nor researchers know who gets the real supplement.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05711888N/ARecruiting

Semantic Recognition Task (SRT) in Alzheimer Disease

Open to carriers, not 4-specific

This study is testing a semantic recognition task, a type of memory and language exercise, in people who have already had biomarker testing for Alzheimer's disease. Researchers want to see what the task reveals and whether it could be useful in clinical settings. This is a Phase NA observational study, meaning it is watching and measuring rather than testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07012993Phase 2Recruiting

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

Imaging study, genotype not a factor

This trial is testing whether a new high-sensitivity PET scanner can produce clear brain amyloid images using 10 to 100 times less radiation than the current standard. Participants receive one of two already-approved amyloid tracers, then lie in the scanner for up to three hours. It is a Phase 2 trial, meaning researchers are still working out whether this lower-dose approach produces reliable images — it is not a treatment study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06618807N/ARecruiting

Infrared Light for Memory Loss in Mild Cognitive Impairment (MCI)

Open to carriers, not 4-specific

This trial is testing whether a wearable infrared light device called Neuro RX Gamma can help with memory and thinking in people already showing mild cognitive impairment linked to Alzheimer's disease. The device delivers near-infrared light to specific brain regions non-invasively. Researchers will compare the active device against a sham version to see if it genuinely makes a difference. This is a Phase NA trial — meaning it is evaluating a device, not a drug, and the focus is on feasibility and effect.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05511363Phase 3Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Open to carriers, not 4-specific

This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who already have Alzheimer's disease. Phase 3 means the drug is in late-stage testing: researchers are measuring whether it actually works and tracking safety in a large group before any regulatory decision. The study runs 38 weeks and compares KarXT against a placebo.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
116 sites
NCT06641726Recruiting

Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness

Observational only, genotype not targeted

This is an observational study — no drug or treatment involved. Researchers are building a large database of 50,000 people with serious mental illness or dementia, linking their genetic data, biomarkers, and health records over time. The goal is to better understand how these conditions cluster and what risk factors shape outcomes. Observational means they are watching and recording, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07218081Phase 1Recruiting

A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.

Surgical device trial, genotype not mentioned

This trial is testing whether surgically implanted electrodes that deliver brief pulses of electricity to a deep brain region called the nucleus basalis of Meynert can slow or stabilize memory loss in people with early Alzheimer's disease. Up to six people will receive the device; six others will serve as a comparison group on standard care. This is a Phase 1 trial, meaning the main focus is establishing basic safety and feasibility in a very small number of people — it is not yet proven to work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05187819N/ARecruiting

Blood-based Biomarkers for Diagnosis of Alzheimer's

Diagnostic study, genotype not required

This trial is testing whether a simple blood test can accurately diagnose Alzheimer's disease in everyday primary care settings — at the regular GP level, not just in specialist research clinics. It is not a drug trial. Researchers want to know if blood biomarkers that work well in controlled studies hold up when used on real patients whose GP suspects dementia. This is a feasibility and accuracy study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06739967Recruiting

Speech and Language Interventions for Italian People With PPA

Not APOE4-specific, Italy only

This pilot study is testing tailored speech and language therapy for people in Italy who have primary progressive aphasia, a condition that gradually erodes the ability to speak and understand language. Researchers want to see which therapy approaches help most across PPA's three variants, how long any gains last, and what brain and cognitive features predict who responds best. The phase is unspecified, meaning this is early exploratory work, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06452147N/ARecruiting

Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)

Open to carriers, not 4-specific

This trial is testing whether different anesthesia techniques — nerve blocks, IV lidocaine, or a longer-acting local anesthetic — protect elderly hip fracture patients from cognitive problems after surgery, compared to standard anesthesia care. It is a Phase NA (pragmatic real-world) platform trial, meaning it is running multiple comparisons at once across many sites to find what works best in practice, not a small early-stage experiment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07424443N/ARecruiting

Pilot Study of a Brain Health Program in Senior Centers

Lifestyle study, genotype not considered

This pilot study is testing a behavioral program called My Healthy Brain, delivered at senior centers, for older adults who notice memory slipping but do not have dementia. It is not measuring whether the program prevents Alzheimer's — it is checking whether the program is feasible, acceptable, and runs as intended. This is a Phase NA pilot, meaning it is early-stage groundwork, not a test of effectiveness yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07222280N/ARecruiting

Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

Diagnostic study, genotype not mentioned

This trial is testing a blood test called Quest AD-Detect on patients who are already hospitalized with sudden confusion or cognitive symptoms. The question is whether this blood test can spot underlying Alzheimer's disease earlier, while the patient is still in the hospital, rather than missing it during an acute illness. This is a Phase NA study, meaning it is a practical diagnostic evaluation rather than a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT06955494N/ARecruiting

ENACT Program on Auditory Perception and Function, Cognitive Function and Health-related Quality of Life

Non-drug study, genotype not considered

This trial tests a 12-week program called ENACT that combines hearing training and cognitive training for people who have both mild cognitive impairment and hearing loss. Half of participants receive the integrated program, half get usual care. Researchers are measuring changes in hearing, cognition, and quality of life. This is a Phase NA pilot study, meaning it is an early feasibility test, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06814730Phase 1Recruiting

A Study to Assess THN391 in Subjects With Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing THN391, a new drug, in people with early Alzheimer's disease who also have a condition called cerebral small vessel disease — meaning small blood vessels in the brain show signs of damage. It is a Phase 1b trial, which means the focus right now is on safety and how the drug behaves in the body, not yet on whether it actually works. Three monthly doses are given over about six months, with MRI scans and spinal taps included.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT07377331Phase 1Recruiting

Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer

Caregiver study, genotype irrelevant

This trial tests an online teaching method called Structured Retrieval Practice to help family caregivers better understand and manage the behavioral and psychological symptoms of dementia. The question is whether this educational approach helps caregivers apply what they learn to real-life situations. This is a Phase 1 trial, meaning it is an early-stage test of feasibility and approach, not a proven or approved intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03887481N/ARecruiting

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

Diagnosis-specific, genotype not a factor

This trial tests whether brain stimulation using a weak electrical current (called tDCS) delivered to specific language and memory areas of the brain, combined with a speech-language therapy program, improves communication in people diagnosed with a language-focused form of dementia called logopenic variant Primary Progressive Aphasia. It is a Phase NA trial, meaning it is a specialized research study focused on understanding how and whether this approach works, not a standard phase of drug development.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07127510Recruiting

Brain NAD in Alzheimer's Disease

Observational only, genotype not studied

This observational study is measuring NAD levels in the brains of people with and without Alzheimer's disease using a non-invasive MRI-based imaging technique called magnetic resonance spectroscopy. Participants get two brain scans eight months apart. The researchers want to know whether NAD, a molecule involved in cellular energy, is lower in Alzheimer's-affected brains. This is an observational study, meaning no drug or treatment is given — researchers are watching and measuring, not testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04916210Recruiting

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Observational only, genotype not specified

The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting cognitive tests, brain scans, and blood samples, to learn which factors predict memory and thinking decline after stroke. The goal is to identify who is at highest risk for post-stroke dementia so that future treatments can be designed. This is a research observation study, not a therapy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
31 sites
NCT05801380Recruiting

Monitoring Drug Efficacy in Patients with Alzheimer's Disease

Observational study, genotype not considered

This study is watching how well two standard Alzheimer's medications — donepezil (an AChE inhibitor) and memantine (an NMDA receptor antagonist) — work in people newly diagnosed with mild to moderate Alzheimer's. Researchers want to understand what factors predict a good or poor response to these drugs. The phase is unspecified, so this looks more like an observational study than a traditional drug trial testing a new treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06337578Recruiting

Advances in Telephone-based Cognitive Screening Procedures

Observational only, genotype not relevant

This Italian observational study is testing whether cognitive screening done by telephone works as well as standard in-person testing for people with neurological conditions like Alzheimer's, ALS, Lewy body dementia, and others. Researchers want to validate phone-based tools and create conversion formulas between telephone and paper tests. This is not a treatment trial — no phase is assigned because no drug or device is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07169578Phase 3Recruiting

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Carriers tracked, ARIA risk significant

This trial is testing trontinemab, an anti-amyloid antibody drug, against a placebo in people with early Alzheimer's disease — specifically those at the MCI or mild dementia stage who already have confirmed amyloid buildup in the brain. It is a Phase 3 trial, meaning researchers are now testing whether it actually works at scale after earlier safety phases. The main goal is to see whether it slows cognitive and functional decline.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
141 sites
NCT07172633N/ARecruiting

Effects of Dementia Scenario-Based Simulation Teaching Combined With Virtual Technology Among Nursing Students

Not relevant to APOE4 carriers

This trial tests whether using virtual reality simulation to teach nursing students about dementia is more effective than traditional case discussions. Researchers will measure changes in students knowledge, empathy, communication skills, and dementia assessment skills. This is a Phase NA study, meaning it is an educational research project, not a drug or device trial being evaluated for clinical use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04732052N/ARecruiting

The Use of Transcranial Direct Current Stimulation (tDCS) in Adults With Developmental Disabilities

Unrelated to APOE4 or Alzheimer's

This trial is testing whether a non-invasive brain stimulation technique called tDCS (which delivers a mild electrical current through the scalp) can reduce impulsivity and aggression in adults with developmental disabilities. Researchers are measuring changes in aggressive behavior and impulsivity. This is a Phase NA trial, meaning it is a standalone exploratory study rather than a standard drug-approval phase. Details on size and duration are limited in this summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06781749Recruiting

New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss

Open to carriers, genotype not required

This trial is testing whether hearing aids change how socially active and mentally sharp older adults with hearing loss are. Researchers will track social engagement using a wearable audio sensor and cognitive questionnaires before and after hearing aid use, and optionally record brainwaves via EEG. The phase is unspecified, so think of this as exploratory research — gathering real-world data rather than testing a drug or making a clinical claim.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07253038Recruiting

Evaluation of Three Tests to Assess Social Cognition in Huntington Disease

Unrelated to APOE4 or Alzheimer's

This observational study is testing whether a specific social cognition assessment tool called the DMASC-MC is useful for detecting social functioning problems in people with early Huntington disease. Researchers will compare it to two existing tests. No drugs or devices are involved — participants just meet with a doctor and psychologist for assessments. The phase is unspecified, which typically means this is a diagnostic or measurement study rather than a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06741865N/ARecruiting

The INSPIRE -Faith Study: Intervention Strategies for Preserving Intellectual Resilience and Engagement

Lifestyle study, genotype not required

The INSPIRE-Faith Study is testing whether a structured lifestyle intervention, compared to standard health education, can support cognitive health and reduce dementia risk in community members aged 55 and older. It is a Phase NA behavioral trial, meaning this is a practical intervention study rather than a drug trial testing safety and dosing. It involves 2,000 participants and is run through faith-based community partnerships in the Crenshaw, California area, with online participation also available.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07531589N/ARecruiting

BrainLive Connect: Non-professional Delivered CST for People Living With Dementia

Open to carriers, not 4-specific

This trial tests whether Cognitive Stimulation Therapy sessions, led by trained volunteers rather than clinicians, can improve thinking skills and quality of life for people already living with mild to moderate dementia. Participants receive seven weeks of structured group activities or continue with usual care. This is a Phase NA mixed-methods study, meaning it is evaluating a real-world service delivery model rather than a new drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07212894N/ARecruiting

DemensiaKITA Mobile Health App to Improve Knowledge, Attitude, Practice and Reduce Burden Among Dementia Caregivers in Malaysia

Caregiver study, genotype irrelevant

This trial is testing a Malaysian mobile app called DemensiaKITA designed to help family caregivers of people living with dementia. Researchers want to know whether using the app improves caregivers' knowledge, attitudes, and day-to-day caregiving skills, and whether it reduces their stress and burden. This is a Phase NA non-randomized study, meaning it is an early-stage evaluation rather than a full randomized trial, and results are not yet proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05234866Recruiting

Paradoxical Lucidity in Severe End-Stage Dementia

Observational only, APOE4 not relevant

This study is observational, not a drug or device trial. Researchers want to understand paradoxical lucidity — those surprising moments when someone with severe, end-stage dementia suddenly seems mentally clear. The team is building a definition, a measurement scale, and looking at brainwave patterns using video EEG during these episodes. Details on phase and design are limited, but this is early foundational research, not a treatment being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04356924N/ARecruiting

Psychological Treatment to Support the Consequences of Cognitive Impairment

Behavioral study, genotype not considered

This trial is testing a talk-therapy program — rooted in cognitive behavioral therapy — designed specifically for people in the early stages of cognitive decline. Researchers want to know whether it eases anxiety, depression, and avoidance behaviors better than cognitive training or standard care. It is a Phase NA randomized controlled trial, meaning it is evaluating a behavioral approach rather than a drug, and RCT status means it is a real head-to-head comparison, not just observational.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06130735N/ARecruiting

Impact of Intensive Computerized Cognitive Training

Not APOE4-targeted, ABI focus

This trial is testing whether intensive computerized brain training can improve attention and executive function in people with mild cognitive difficulties caused by acquired brain injury — things like stroke or traumatic brain injury. Researchers also want to know what factors predict who benefits most. This is a Phase NA behavioral study, meaning it is evaluating a non-drug training program, not a medication, and is not yet proven to work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03621839Recruiting

New CSF Biomarkers for Alzheimer's Disease

Observational only, genotype not specified

This study is collecting leftover cerebrospinal fluid (CSF) — the fluid drawn during routine lumbar punctures for dementia diagnosis — to test new biological markers that might one day help diagnose or track Alzheimer's disease. It is not testing a treatment. It is an observational biobank study, meaning researchers are gathering samples to validate future tools, not to prove a drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06413173N/ARecruiting

Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)

No Alzheimer's or APOE4 relevance

This trial tests whether a non-invasive brain stimulation technique called tDCS, delivered at home and combined with cognitive training exercises, can improve attention and concentration in Active Duty Service Members and Veterans who have had a mild traumatic brain injury. Half of participants get real stimulation, half get a placebo version. It is a Phase NA study, meaning it is a controlled clinical trial focused on measuring effectiveness and brain changes, not a standard drug approval phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06703541Recruiting

ADRC Clinical Cohort (Alzheimer's Disease)

Observational only, genotype not required

This is an observational research cohort at Duke and UNC, not a treatment trial. Researchers are enrolling people ages 25 to 80, with or without memory concerns, to track cognition over time and collect blood, urine, spinal fluid, and brain imaging. The goal is to understand how genes, lifestyle, and environment influence Alzheimer's risk as people age. There is no drug or intervention involved — just research observation and sample collection.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07140601Recruiting

Environmental Pollutants and Neurological Disorders

Observational only, genotype not relevant

This study is collecting blood, urine, hair, and tissue samples from neurosurgery patients to measure their exposure to environmental pollutants — heavy metals, plastics, PFAS, and other chemicals — and look for connections to brain tumors and cerebrovascular disease. It is an observational study with no phase designation, meaning researchers are gathering data, not testing a treatment. No intervention is being given to participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06883019Recruiting

Lecanemab for Early Onset Familial Alzheimer's Disease

Genotype-relevant, but ARIA risk is high

This observational study is giving lecanemab, an anti-amyloid antibody drug, to people under 65 who already have MCI or mild Alzheimer's and a family history of the disease. Researchers will track cognition, brain scans, and blood markers over 18 months, and do whole genome sequencing to see how genetic factors affect how well the drug works. Phase is unspecified, so this is exploratory rather than a large confirmatory trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
15 sites
NCT06224205N/ARecruiting

Digital Detection of Dementia (D Cubed) Studies: D3

Open to carriers, genotype not a factor

This trial is testing whether two digital screening tools — a Passive Digital Marker that analyzes existing health record data, and a caregiver-reported symptom questionnaire — can help primary care doctors catch Alzheimer's and related dementias earlier and more often. It is a pragmatic trial, meaning it is testing how well these tools work in real-world clinical settings, not a controlled lab environment. Details on the specific tools are somewhat limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07563777Recruiting

100-Year Human Aging Study

Observational study, genotype not required

This is a large, long-term observational study — not a drug or treatment trial. Researchers will screen participants across many health systems and follow them for the rest of their lives. The goal is to learn which measurements taken today best predict who develops serious disease, loses independence, or dies. Think of it as building a much better roadmap for what healthy aging actually looks like. The phase is unspecified — this is a data-gathering study, not a test of any treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05808153N/ARecruiting

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

Unrelated to APOE4 entirely

This trial is studying new brain imaging techniques and cognitive tests to better track Huntington's disease progression. It uses a radiotracer injection to get detailed brain scans, alongside other biological and cognitive measures. Researchers want to find more sensitive markers for the disease before and after symptoms appear. This is a Phase NA observational study — it is gathering data to improve future research tools, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04171323N/ARecruiting

The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

Open to carriers, genotype not tracked

This trial is testing different combinations of computerized brain exercises to see which combination best helps older adults with mild cognitive impairment (MCI) maintain their ability to handle everyday tasks like managing finances or medications. The comparison group does general computerized brain stimulation activities. This is a behavioral trial — no drugs involved — focused on finding the most effective cognitive training approach to delay dementia onset over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT07176286Phase 2Recruiting

18F-mFBG Cardiac Uptake With Lewy Body Dementia

Unrelated to APOE4 genotype

This trial is testing a radioactive imaging agent called 18F-mFBG to see how well it can detect nerve damage in the heart caused by Lewy body diseases like Parkinson's and Lewy body dementia. Researchers will compare heart scan results between people with Lewy body disease and those with other neurological conditions. This is a Phase 2 trial — testing whether the imaging tool works accurately, not a treatment study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05296980N/ARecruiting

Validation of the REMINDER Dementia Risk Reduction Program

Open to carriers, not 4-specific

This trial is testing a behavioral program called REMINDER against a brain health education class. REMINDER combines personal development coaching, memory aids, goal-setting, and behavior change techniques. Researchers want to know whether it improves cognitive and brain health outcomes over time compared to basic psychoeducation. This is a validation trial — not a drug study, and not yet a proven or approved intervention. Details on long-term results are still being gathered.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06326424Recruiting

Delirium Identification in Older Patients With Alzheimer's and Other Related Dementias In the Emergency Department

Open to carriers, not 4-specific

This trial is testing whether a wrist-worn biosensor called the Empatica EmbracePlus can detect delirium in older adults with dementia who come to the emergency department. The device tracks heart rate variability, movement, and skin electrical activity. Researchers want to know if these signals catch delirium better than current verbal screening tools, which miss it more than a third of the time. The phase is unspecified, suggesting this is early feasibility or observational research.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05623124Recruiting

Ruijin Neurobank of Alzheimer's Disease and Dementia

Observational only, genotype not mentioned

This is an observational study based at Ruijin Hospital in China tracking people already diagnosed with mild cognitive impairment or dementia due to Alzheimer's disease. Participants get annual MRI scans, PET scans, blood tests, and cognitive testing over time. Researchers want to map how brain blood flow and Alzheimer's biomarkers change as the disease progresses. There is no treatment involved — it is a data-gathering effort, with no specified phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06313853N/ARecruiting

Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision

Not APOE4-specific, late-stage focus

This trial is testing a communication coaching program called COACH-Cog, designed to help older adults who have both dementia and cancer make decisions about their cancer treatment. Coaches work with patients and their care partners to better support the patient's wishes and goals during oncology appointments. This is a Phase NA pilot randomized trial — an early-stage test of whether the approach works well enough to study further.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05405075Recruiting

Arizona Alzheimer's Disease Research Center (ADRC)

Observational registry, genotype not required

The Arizona ADRC is a research registry and data-collection program, not a drug or treatment trial. Participants — ranging from cognitively normal adults to those with MCI or dementia — undergo cognitive testing, brain imaging, and blood draws for genetic and biomarker research. There is no experimental intervention. This is ongoing observational science aimed at better understanding how Alzheimer's develops over time. No phase designation applies because nothing is being tested for efficacy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05999929N/ARecruiting

Memory Support System Feasibility Study

Open to carriers, genotype not tracked

This study tests whether a behavioral program called the Memory Support System can realistically be offered to people with mild cognitive impairment and their care partners at a Canadian memory clinic. Researchers want to know if patients are interested, how they prefer to receive it, what it costs to run, and whether it improves daily functioning, mood, anxiety, self-confidence around memory, and caregiver burden. This is a feasibility study, meaning it is checking whether a larger trial is even practical — not yet proving the program works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04310098Recruiting

CADASIL Registry Study

Unrelated to APOE4 genotype

This is a registry study — not a drug trial — tracking people with CADASIL, a rare inherited condition that damages small blood vessels in the brain and causes strokes and dementia. Researchers are following patients over time to understand how the disease progresses and how to manage it better. There is no experimental treatment involved. Because the phase is unspecified, this is an observational study, not a test of whether something works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05691569N/ARecruiting

Efficacy of Doll Therapy in the Dementia in Acute Geriatric Inpatients

Open to carriers, not 4-specific

This trial is testing whether giving empathy dolls to hospitalized dementia patients reduces agitation and aggression. Researchers want to see if doll therapy can lower the need for sedating medications and shorten hospital stays. This is a Phase NA trial, meaning it is a practical intervention study rather than a traditional drug trial — it is testing a non-drug approach in a real clinical setting, not yet established as standard care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07202494Recruiting

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

General brain imaging, no APOE4 focus

This study is using advanced brain scanning technology, including high-powered 7T MRI, to look at how the brain and spinal cord change in ten neurological conditions, including Alzheimer's disease, plus in healthy aging. Researchers want to understand why some people's brains hold up better than others over time. This is an observational study, meaning no drugs or treatments are given — participants just get scanned and assessed. It is based in Marseille, France.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06307574N/ARecruiting

bpMedManage: Digital Technology to Support Adherence to Hypertension Medications

Open to carriers, genotype not tracked

This trial is testing a smartphone app designed to help older adults with mild cognitive impairment stick to their blood pressure medications. One group gets the app with reminders plus education; the other gets education alone. Researchers are measuring whether the reminders improve adherence over 16 weeks. This is a Phase NA randomized controlled trial — it is evaluating effectiveness of a behavioral tool, not a drug or medical device requiring phased approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07546708N/ARecruiting

The Black Immigrant Project

Caregiver support, genotype not relevant

This trial is testing a culturally adapted caregiving support program called ACES (Active Caregiving: Enhancing Skills) with Black immigrant people living with dementia and their care partners. Researchers want to know whether the program improves caregivers' confidence, reduces unhelpful thinking patterns, and encourages positive daily activity. This is a Stage I trial, meaning it is an early feasibility and pilot study, not a definitive test of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05988385N/ARecruiting

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

Open to carriers, genotype not tracked

This trial is testing whether successfully treating moderate-to-severe obstructive sleep apnea (OSA) in older adults improves memory and changes biological markers linked to Alzheimer's disease. Participants are randomly assigned to start OSA treatment now or wait three months, then followed for two years. It is a Phase NA trial — meaning it is studying a clinical question about existing devices, not testing a new drug for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06974890N/ARecruiting

Effects of Shuttle Balance Training on Balance , Gait and Postural Control in Children With Mild Cognitive Impairment

Not relevant to APOE4 carriers

This trial is testing whether a structured balance and coordination exercise program called Shuttle Balance Training improves balance, walking, and posture in children aged 6 to 12 who have mild cognitive impairment. It is a Phase NA randomized controlled trial, meaning it is comparing the exercise program against standard care to see if it produces measurable physical benefits. Details on total enrollment numbers are not yet specified in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07153848Recruiting

An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease

Observational only, genotype not addressed

This observational study is watching people already receiving lecanemab — a drug approved for early Alzheimer's — to see whether blood-based biomarkers can accurately track how well the drug is clearing amyloid plaques from the brain, compared to PET scans. No one is being randomly assigned to treatment. It has no specified phase because it is not a drug trial — it is a real-world data collection study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06924359Recruiting

Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

Open to carriers, genotype not required

This study is testing whether eye scans and blood tests can detect Alzheimer's disease earlier than current methods. Researchers will look at specific markers in the retina and in the bloodstream across people ranging from fully healthy to already diagnosed with AD. This is an observational diagnostic study, not a treatment trial, so no experimental drug or therapy is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06889818Recruiting

Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)

Observational registry, genotype not addressed

This is a real-world registry study based in Korea, not a randomized drug trial. It is tracking how well anti-amyloid antibody therapies like lecanemab and donanemab perform in everyday clinical practice, and how diagnostic tools like amyloid PET are being used. There is no phase designation because it is an observational study, meaning researchers are watching and recording outcomes rather than testing a new intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT04896775N/ARecruiting

NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers

Caregiver study, genotype not relevant

This trial is testing two web-based behavioral programs, NiteCAPP CARES and NiteCAPP SHARES, designed to help dementia caregivers in rural areas sleep better. Researchers will track sleep quality, mood, inflammation, and cognitive function in caregivers over 12 months, and also monitor sleep in the person with dementia they care for. This is a Phase NA trial, meaning it is evaluating real-world effectiveness of an already-developed behavioral tool.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07399418Recruiting

TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics.

Open to carriers, genotype not studied

TRIAD is an observational study — no drug or treatment involved — tracking how biological, psychological, and social factors together shape the Alzheimer's disease continuum. It also examines how caregiver well-being influences the person they care for. This is a data-gathering study, not a phase-based drug trial, so it is about understanding risk profiles and early signals rather than testing any intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03926520N/ARecruiting

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Late-stage dementia care, not prevention

This trial is testing whether electroconvulsive therapy (ECT) — brief, controlled electrical stimulation of the brain — can safely reduce severe agitation in people with moderate to severe dementia, including Alzheimer's. It is a Phase NA (non-randomized feasibility or pilot) study, meaning researchers are still working out whether this approach is safe and practical enough to study further. It is not testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05452031N/ARecruiting

A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers

Open to carriers, genotype not required

This trial tests a behavioral sleep program called Care2Sleep against a sleep education control, for pairs of Alzheimer's patients and their live-in caregivers. Both in-person and telehealth versions are being compared. Researchers are measuring sleep quality, health, quality of life, and inflammation over six months. This is a Phase NA behavioral trial — it is evaluating real-world efficacy of a non-drug approach, not testing a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07511270N/ARecruiting

Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech

Open to carriers, genotype not required

This study is testing whether an AI can assess cognitive function by analyzing how people tell a story out loud. Participants describe a picture while being recorded, and the AI's estimates are compared against standard memory and attention tests given by researchers. This is a Phase NA behavioral study — it is validating a tool, not testing a drug or treatment. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06484244N/ARecruiting

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

Open to carriers, genotype not required

This study uses a split-belt treadmill — a device with two separate belt speeds — to see how people with MCI or Alzheimer's adapt their walking when the ground beneath each foot moves differently. Researchers want to understand how cognitive decline affects this ability to adjust gait. It is a non-drug study labeled Phase NA, meaning it is observational and exploratory rather than testing a treatment for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06530732Phase 3Recruiting

Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)

Open to carriers, genotype not addressed

This trial tests whether a surgical procedure called deep cervical lymphatic-venous anastomosis (dcLVA) — which aims to improve fluid drainage from the brain — can slow Alzheimer's progression when added to standard medication, including the drug lecanemab. Researchers will measure changes in a standard dementia rating scale over 12 months. It is a Phase 3 pilot study, meaning it is testing effectiveness at meaningful scale, though labeled a pilot suggesting relatively small numbers.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06090578N/ARecruiting

TabCAT Brain Health Assessment in Primary Care

Screening tool study, genotype irrelevant

This trial is testing a tablet-based brain health screening tool called TabCAT in primary care clinics. The goal is to see whether using it leads to better detection of cognitive impairment and dementia compared to usual care. It is a pragmatic trial, meaning it runs in real clinic settings rather than a controlled lab. Phase NA here means it is not a drug trial — it is evaluating a clinical workflow tool.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07353502N/ARecruiting

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

Observational only, genotype not relevant

This study is collecting blood samples, and optionally cerebrospinal fluid, from people with early Alzheimer's and healthy controls. Researchers want to know whether a specific molecular pathway (miR-342-5p/AnkG) shows up in body fluids and could serve as an early detection signal. This is not a drug trial — it is a biomarker discovery study, meaning researchers are building scientific groundwork, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07207486Recruiting

In-depth Analysis of Cholesterol Metabolism and Related Biomarkers in the Pathogenesis and Progression of the Disease in Neurodegenerative Dementias

Observational only, genotype not specified

This study is examining how cholesterol metabolism — specifically breakdown products called oxysterols and a protein called PCSK9 — may contribute to Alzheimer's and other neurodegenerative dementias. Researchers will measure these markers in brain tissue, spinal fluid, and blood to see if cholesterol disruption is a shared feature across different dementia types. This is an observational study, not a drug trial — no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03434548Recruiting

IMarkHD: in Vivo Longitudinal Imaging of HD Pathology

Unrelated to APOE4 or Alzheimer's

This trial uses PET and MRI brain scans to track how Huntington's disease changes the brain over three years, from before symptoms appear through later stages. Researchers are mapping molecular and structural brain changes to identify potential markers of disease progression. This is an observational imaging study, not a treatment trial, so it is not testing whether anything works — it is building a clearer picture of how HD unfolds.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07482800Recruiting

Dementia in Fiction and Clinical Narratives

Observational only, genotype irrelevant

This study compares the real speech and language patterns of people with early Alzheimer's or mild cognitive impairment to how dementia is portrayed in contemporary fiction. Researchers want to see whether novelists capture memory loss accurately. It is not a clinical treatment trial — no drugs or interventions are involved. The phase is unspecified, which fits an observational or humanities-based research design rather than a traditional drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05911178N/ARecruiting

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Observational only, genotype not tracked

This observational study uses four PET brain scans to map, at the same time, brain inflammation, tau protein tangles, amyloid plaques, and synapse loss in people with Alzheimer's disease versus healthy controls. No drug or treatment is given. Phase NA means this is a research imaging study, not a drug trial — it is designed to understand disease biology and help design better future trials.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06753578N/ARecruiting

Effectiveness of an ACT-Based Cognitive Intervention on Quality of Life and Cognitive Function in Elderly Residents With MCI

Behavioral study, genotype not considered

This trial tests whether a structured psychological program called Acceptance and Commitment Therapy, or ACT, can improve quality of life and slow cognitive decline in older adults with Mild Cognitive Impairment living in long-term care facilities. ACT focuses on mental flexibility, values-based living, and coping skills. It is a Phase NA study, meaning it is evaluating real-world effectiveness rather than early safety or drug dosing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06572748N/ARecruiting

Evaluation Study for the Chef Anchor 3.0 Program

Lifestyle study, genotype not considered

This trial is testing a 10-week cooking program called Chef Anchor 3.0 for older adults with mild cognitive impairment or dementia and their caregivers. Researchers want to see whether the program improves cooking confidence, independence, psychological well-being, and cognitive function — and whether those gains last. This is a Phase NA study, meaning it is a practical evaluation of an existing program rather than a traditional drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07177352Phase 3Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Gateway study, genotype not specified

This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials. Participants answer questions and complete assessments so Roche can build a pool of potentially eligible people. No drug, device, or intervention is tested here. Think of it as an intake process, not an experiment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
211 sites
NCT06808984Phase 2Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Open to carriers, not 4-specific

This trial tests BMS-986368, an experimental drug that works on the body's endocannabinoid system, to see whether it reduces agitation in people who already have Alzheimer's disease. Agitation — restlessness, aggression, emotional outbursts — is one of the hardest symptoms for caregivers to manage. This is a Phase 2 trial, meaning researchers are still gathering early evidence on whether it works and is safe. It is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
53 sites
NCT06451952N/ARecruiting

Virtual Darkness Theraphy for Agitation in Dementia

Non-drug study, genotype not relevant

This trial is testing whether blocking blue-wavelength light in the evening and overnight — called virtual darkness therapy — reduces agitation in people with dementia who are hospitalized. Patients wear amber-tinted glasses or are placed in blue-light-filtered environments from 7pm to 8am. Researchers measure agitation levels before and after 14 days. This is a Phase NA trial, meaning it is exploratory and feasibility-focused, not yet a large-scale proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05201534N/ARecruiting

Interventions in Mathematics and Cognitive Skills

No connection to APOE4 risk

This trial is studying how the brain responds to math tutoring in children ages 6 to 12, including kids with math learning disabilities. Researchers are comparing two educational approaches and using brain scans to understand what changes in the brain when children improve their number skills. This is a Phase NA study, meaning it is a behavioral and neuroscience investigation rather than a drug trial. Details on the specific interventions are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05949047N/ARecruiting

Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease

Caregiver study, genotype not relevant

This trial tests whether a one-week smartphone-based emotion regulation program can reduce stress, depression, and caregiver burden in unpaid family caregivers of people with Alzheimer's or related dementias. Participants are randomly assigned to one of two mental reframing techniques or a control group, with follow-up over three months. This is a Phase NA behavioral study — it is testing whether the approach works, not evaluating a drug or approved therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05924425Phase 4Recruiting

Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Open to carriers, not 4-specific

This trial is testing daridorexant, an FDA-approved sleep medication, in people who already have mild cognitive impairment or mild-to-moderate Alzheimer's disease and also suffer from insomnia. Researchers want to know if it improves sleep quality and whether it is safe in this population. Phase 4 means the drug is already approved for general use — this is about understanding how it works in a specific, more vulnerable group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05655325N/ARecruiting

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

Lifestyle study, genotype not considered

This trial is testing whether six months of home-based walking improves memory and brain structure and function in older adults who have both chronic kidney disease (stages 3-4) and mild cognitive impairment. Participants are compared to a group receiving health education instead of exercise. This is a Phase N/A behavioral trial, meaning it is evaluating a lifestyle intervention rather than a drug, and it is not yet proven or approved as a treatment approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04920318N/ARecruiting

Enhancing Language Function in Primary Progressive Aphasia

Not relevant to most carriers

This trial is testing whether pairing a mild electrical brain stimulation technique called tDCS with standard language therapy works better than language therapy alone for people with Primary Progressive Aphasia, a condition that progressively erodes the ability to speak and communicate. It is a Phase NA trial, meaning it sits outside the standard drug-approval pipeline — this is a device and behavioral intervention study focused on whether the combination improves language function.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06817876N/ARecruiting

Connecting Caregivers With Community Services: The Care Buddy Platform

Caregiver tool, genotype not relevant

This trial is testing Care Buddy, a mobile app designed to connect dementia caregivers with healthcare providers, community services, and peer support in one place. Researchers want to know whether the app reduces caregiver burden and improves outcomes for both caregivers and the people they care for. This is a Phase NA trial, meaning it is a practical usability and effectiveness study rather than a traditional drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07369258N/ARecruiting

Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit

Open to carriers, not 4-specific

This trial is testing whether listening to music through headphones twice a day can help prevent delirium in older adults in the ICU. It compares personalized music playlists to generic relaxing music to standard ICU care, measuring how many days patients stay free of delirium and coma over one week. This is a Phase NA trial, meaning it is evaluating a practical care intervention rather than a drug, and no prior phase testing was required.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04639622N/ARecruiting

GENetic Fronto Temporal Dementia Initiative in Lille

FTD genetics only, not APOE4

This trial is tracking people from families with a known genetic mutation linked to frontotemporal dementia (FTD) — specifically mutations in GRN, MAPT, or C9orf72 — using brain scans, biomarkers, and cognitive tests over five years. The goal is to understand how these mutations change the brain before and after symptoms appear. This is a Phase NA observational study, meaning it collects data rather than testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07456462N/ANot yet recruiting

Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance

APOE4 4/4 carriers excluded

This study is testing whether advanced MRI scans and blood tests can predict how well lecanemab or donanemab are working in people with early Alzheimer's disease or MCI — without relying on repeated PET scans. It is not a drug trial; the antibody treatments are given as standard care. Researchers will build personalized computer models to track amyloid clearance over 18 months. This is a Phase NA observational study at one site in Milan, Italy, enrolling 50 participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06474013N/ANot yet recruiting

A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease

APOE4 homozygotes explicitly excluded

This trial is testing whether repeatedly opening the blood-brain barrier using a focused ultrasound device called ExAblate 4000 is safe and shows early signs of benefit in people with Alzheimer's disease. The device uses MRI-guided sound waves to temporarily create openings in the brain's protective barrier. This is a Phase NA feasibility study — meaning researchers are gathering early safety data, not proving the approach works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06911944Phase 4Not yet recruiting

Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

Not relevant to APOE4 carriers

This trial is testing whether donanemab, an anti-amyloid antibody already approved for early Alzheimer's, can safely reduce amyloid buildup in the brains of adults with Down syndrome aged 35 to 50 who do not yet have dementia. It is a Phase 4 trial, meaning the drug is already approved for another use, but researchers are now studying it in this specific population for the first time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07222605N/AInvitation only

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

Carriers specifically sought, non-drug device

This pilot study tests a wearable head device called MemorEM in people with neurological diseases including Alzheimer's, Parkinson's, and frontotemporal dementia. Researchers are not measuring treatment effectiveness here — they are gathering feedback on comfort, ease of use, and compliance to guide future device design. It is listed as Phase NA, meaning this is a user-experience feedback study, not a clinical efficacy trial. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07399171Phase 2Not yet recruiting

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

Exclusively enrolls APOE4 carriers

This Phase 2 trial is testing an experimental drug called HT-4253 in APOE4 carriers who already show early amyloid buildup in their blood but have no dementia diagnosis. The goal is to see whether the drug can shift their amyloid risk score from high to low, and whether it affects tau and amyloid biomarkers over time. Phase 2 means researchers are testing whether it works and is safe — it is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07007208Phase 2Not yet recruiting

Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk

Actively recruits APOE4 carriers

This trial is studying a brain region called the locus coeruleus, which may show early signs of tau protein buildup before other areas affected in Alzheimer's. Researchers will use PET scans, MRI, eye-tracking, and cognitive tests to see whether changes in this region predict Alzheimer's risk and memory problems. It is a Phase 2 observational study — researchers are measuring and learning, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07204145N/ANot yet recruiting

Laser Acupuncture for Behavioral and Psychological Symptoms of Dementia

Open to carriers, genotype not relevant

This trial is testing whether laser acupuncture — a non-invasive device that uses a low-level laser pen to stimulate traditional acupuncture points — can reduce behavioral and psychological symptoms in people already living with dementia, such as agitation, anxiety, or sleep problems. It compares real laser acupuncture against a sham version. This is a Phase N/A trial, meaning it is a practical effectiveness study rather than an early drug-safety test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06495957N/ANot yet recruiting

Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether electroacupuncture can reduce agitation in people who already have Alzheimer's dementia. Researchers will also use brain scans to look at how acupuncture might affect brain activity. It is a Phase NA study, meaning it is a practical clinical trial focused on effectiveness rather than a standard drug-development phase. Details on sample size and duration are limited in the source provided.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
7 sites
NCT07569367Not yet recruiting

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

FTD-specific, not APOE4-relevant

This study is testing whether wearable sensors and digital assessments can reliably track symptoms and daily functioning in people with frontotemporal dementia and related conditions. Participants wear sensors and complete computerized tests over 24 months, with check-ins every 6 months. The goal is to develop better measurement tools for these diseases, not to test a drug or treatment. The phase is unspecified, so this is early-stage validation work.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07114224N/ANot yet recruiting

Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease

Observational scan study, genotype not mentioned

This study uses two types of PET brain scans to measure amyloid and tau protein buildup in people with Alzheimer's disease or mild cognitive impairment, compared to healthy volunteers. Researchers want to see how well these imaging patterns track disease diagnosis and progression. This is a Phase NA observational study — it collects data and images, it does not test a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06946511Phase 1Not yet recruiting

Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia

General dementia trial, no APOE4 focus

This trial is testing an experimental intravenous peptide called PMS-001 to see whether it can improve memory recall in people who already have moderate to severe dementia. Researchers are also checking safety across four dose levels. It is a Phase 1 trial, meaning the primary goal is establishing whether the drug is safe — it is very early stage and not proven or approved for anything.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06670820N/ANot yet recruiting

iTBS in MCI and Mild AD

Open to carriers, not 4-specific

This trial tests whether a non-invasive brain stimulation technique called intermittent theta burst stimulation (iTBS) — a focused pattern of magnetic pulses delivered to the forehead — can improve thinking and memory in people with mild cognitive impairment or early Alzheimer's disease. It also measures changes in BDNF, a protein tied to brain health. This is a Phase NA trial, meaning it is exploratory research rather than a late-stage efficacy study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06873750N/ANot yet recruiting

Neuromodulation and fMRI in Neurodegenerative Diseases Study

Device study, genotype not considered

This trial is testing whether a non-invasive brain stimulation technique called transcranial alternating current stimulation (tACS) can improve working memory in people with mild cognitive impairment, neurodegeneration, or traumatic brain injury. It uses fMRI and EEG brain scans to see whether the stimulation actually changes how brain networks communicate. This is a Phase NA study, meaning it is exploratory research focused on understanding how the intervention works rather than proving it as a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06828289Not yet recruiting

Rivastigmine Mini-Tablet for Alzheimer's Disease

Open to carriers, not 4-specific

This study is testing a new mini-tablet form of rivastigmine, a medication already used for Alzheimer's, to see if it works as well as or better than donepezil, another existing Alzheimer's drug. Researchers are measuring both effectiveness and safety in people with mild to moderate Alzheimer's. The phase is unspecified, so it is unclear how early or late in the development process this sits.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07545577N/ANot yet recruiting

Randomized Controlld Trial of Dementia Education Resources for Action

Not a participant trial, workers only

This trial is testing an online training program called DERA, designed to teach community health workers about Alzheimer's disease and related dementias. The goal is to see whether the training improves their knowledge, reduces stigma, and builds their confidence in connecting people to services. This is a Phase N/A trial — it is evaluating a behavioral education tool, not a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07243600N/ANot yet recruiting

Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment

Open to carriers, genotype not studied

This trial is testing two types of computerized brain training programs in older adults with mild cognitive impairment, or MCI. One program focuses on processing speed; the other targets executive function skills like planning and focus. Researchers want to see if either improves neurological and cognitive health. This is a validation study, meaning it is examining whether these tools actually work, not a standard drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07092371N/ANot yet recruiting

Smartphone Multimodal Health Intervention for Neurological Enhancement (SHINE)

Open to carriers, not 4-specific

The SHINE trial is testing a smartphone app that delivers a multimodal health program — think coordinated lifestyle guidance — to people aged 40 and older who are at high risk for stroke but do not yet have dementia. Researchers will measure cognitive scores and collect brain scans, blood, and stool samples to see whether the app slows cognitive decline. This is a Phase NA randomized controlled trial, meaning it is evaluating real-world effectiveness of a behavioral tool, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07387614N/ANot yet recruiting

WEB-BASED SUPPORT PROGRAM FOR CAREGIVERS OF VETERANS WITH DEMENTIA DISCHARGED FROM SKILLED NURSING FACILITIES TO HOME

Caregiver support, genotype irrelevant

This trial tests a web-based support program called Hospital GamePlan4Care for caregivers of Veterans with Alzheimer's or related dementia who are transitioning home after a skilled nursing facility stay. Caregivers get tailored online skills training plus phone coaching from a dementia specialist. Researchers compare this to standard health education materials. This is a Phase NA study — focused on feasibility and caregiver wellbeing outcomes, not a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07612800N/ANot yet recruiting

Tailored Brain Health Insights Through Nurturing Knowledge-based Change - Stakeholder-driven, Human-centered, AI-powered Refinement for Prevention

Lifestyle tool, genotype not required

This trial is testing BLAZE, an AI-powered brain health coaching tool delivered through WhatsApp. It gives personalized lifestyle recommendations, nudges, and goal-setting support based on each person's Brain Care Score. Researchers want to see if BLAZE improves modifiable brain health risk factors over 6 to 12 months compared to doing nothing. This is a Phase NA behavioral study — it is evaluating a digital tool, not a drug or device requiring phased approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06286293Not yet recruiting

YOD-RiSoCo: Social Cognition and Risk-taking Behaviour in Patients with Young-onset Dementia

Research only, genotype not relevant

This observational study is examining how young-onset dementia affects social judgment and risk-taking. Researchers are comparing people who developed dementia before age 65 against patients with frontal brain injury and healthy controls, using neuropsychological tests and a driving simulator. No drug or treatment is being tested. Because no phase is listed, this is a research study gathering data, not a clinical treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06534164N/ANot yet recruiting

Telerehabilitation of Balance Clinical and Economic Decision Support System

Open to MCI group, genotype not required

This trial is testing a hologram-based home balance rehabilitation system called HOLOBalance against standard care for people with balance and fall problems caused by MCI, stroke, vestibular disorders, or long COVID. A physiotherapist hologram guides exercises while sensors monitor performance in real time. This is a Phase NA feasibility and effectiveness study — it is gathering early evidence to inform a larger definitive trial, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT06706947N/ANot yet recruiting

Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a surgical procedure called lymphaticovenous anastomosis — which connects lymphatic vessels to veins — to see whether it can improve cognition, daily functioning, mood, and sleep in people already diagnosed with Alzheimer's dementia. Researchers will also track brain imaging and blood biomarkers to understand how the procedure might work. This is a Phase NA exploratory study, meaning it is early-stage investigational work, not a proven or approved approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06440447Not yet recruiting

EXploring Patterns of Use and Effects of Adult Day Programs to Improve Trajectories of Continuing CarE

Observational only, genotype not considered

This study is tracking older Canadians who attend adult day programs and comparing them to those who receive other community care. Researchers want to see whether adult day programs delay entry into long-term care homes and affect depression, physical health, and cognitive change. This is an observational study — researchers are watching what happens, not testing a new treatment. No intervention is being given; this is about understanding real-world patterns of care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06770309N/ANot yet recruiting

A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease.

General AD trial, genotype not considered

This trial is testing whether silkworm pupa powder, a protein-rich dietary supplement, can improve nutrition, muscle strength, frailty, and quality of life in people who already have Alzheimer's disease. Researchers also want to know whether it has any effect on cognition. It is Phase NA, meaning it is a practical intervention study rather than a standard drug-development phase — testing effectiveness in a defined patient group, not yet a proven or approved approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07346183N/ANot yet recruiting

CommunityRx-Dementia + Peer Navigation (CRxDpeer)

Caregiver support, genotype irrelevant

This trial tests a peer mentor program for people caring for someone with Alzheimer's or a related dementia. A trained peer navigator helps caregivers find community resources, manage social needs like food or housing insecurity, and plan for end-of-life care — with text message support over 12 months. It is a Phase NA trial, meaning it is evaluating a real-world care delivery model rather than testing a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT03899298Phase 1Not yet recruiting

Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions

Broad trial, no APOE4 relevance

This trial is testing whether injections of tissue derived from amniotic membranes and umbilical cords are safe and whether they improve quality of life across a wide range of conditions, including Alzheimer's disease. It is a Phase 1 trial, meaning the primary goal is checking for safety, not proving the treatment works. Alzheimer's is one of roughly a dozen conditions lumped together here, which makes it a very broad study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07066826Phase 2Not yet recruiting

Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Open to carriers, not 4-specific

This trial is testing whether Huperzine A controlled-release tablets improve cognitive function and daily abilities in people with mild-to-moderate Alzheimer's dementia. It compares Huperzine A against donepezil (a standard Alzheimer's medication) and a placebo. This is a Phase 2 trial, meaning researchers are still working to confirm the right dose and whether the drug works well enough to move forward. It is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06957418Phase 2Not yet recruiting

Alzheimer's Tau Platform: Master Protocol

Genotype collected, ARIA risk worth discussing

This Phase 2 platform trial is testing tau-targeting drugs, called AADvac1 and Tau2, alone or combined with the anti-amyloid drug donanemab, in people aged 50 to 80 who are in the very early or preclinical stages of Alzheimer's disease. The goal is to see whether these tau therapies reduce tau buildup and slow cognitive decline. Phase 2 means researchers are still working out whether the treatments work and are safe — nothing here is proven or approved yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06632470Phase 1Not yet recruiting

Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)

Open to carriers, not 4-specific

This trial is testing whether a secretome — a mix of proteins and signals released by stem cells from umbilical cord tissue — is safe and has any effect on inflammation and cognition in people with moderate dementia. Vitamin B12 injections are used as the comparison treatment. It is a Phase 1 trial, meaning the primary focus is on safety in humans for the first time, not proving that it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07100470N/ANot yet recruiting

Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET

Diagnostic study, genotype not considered

This study uses two specialized brain scans — a sodium MRI (which measures salt concentrations in brain cells) and an FDG-PET scan (which measures glucose metabolism) — to see whether they can better distinguish Alzheimer's disease from frontotemporal dementia earlier and more accurately. It is a diagnostic study, not a treatment trial, meaning no drug or therapy is being tested. The goal is sharper, earlier identification of which disease a person actually has.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06448442Not yet recruiting

A Pilot Study of Deep Cervical Lymphatic-venous Anastomosis in the Treatment of Alzheimer's Disease

Open to carriers, not 4-specific

This pilot study is testing a surgical procedure called deep cervical lymphatic-venous anastomosis in people already diagnosed with mild to moderate Alzheimer's. The idea is that the brain drains waste through a lymphatic pathway in the neck, and connecting lymphatic vessels to nearby veins might help that drainage work better. This is an early-stage feasibility study — researchers are checking whether the procedure is safe and practical, not whether it works as a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07448909Not yet recruiting

Cognitive-Frailty Gait Biomechanics for Early Dementia Detection

Observational only, genotype not relevant

This study is comparing how people with mild cognitive impairment walk, move, and score on a blood marker called BDNF — a protein linked to brain health — versus healthy older adults. It is an observational study, not a treatment trial, meaning no drug or therapy is being tested. Participants complete one session of physical measurements, a walking assessment, and a blood draw. Details on phase are not provided, as this is a data-collection study, not a clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06755476N/ANot yet recruiting

Psychological Counseling Program for Alzheimer's Patients' Caregivers

Caregiver study, genotype irrelevant

This trial is testing a structured psychological counseling program designed for people who care for Alzheimer's patients. Researchers want to know whether the program reduces stress and care burden, and improves psychological well-being in caregivers. It is a Phase NA randomized controlled study, meaning it is evaluating real-world effectiveness of a support program rather than a drug or device. Eighty caregivers will be split into two groups: one receives the counseling, one does not.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06587763Not yet recruiting

Late Biomarkers in Adult Survivors After Out-of-hospital Cardiac Arrest

No relevance to APOE4 carriers

This study collects blood samples from people who survived a cardiac arrest outside a hospital, about six months after the event. Researchers are banking plasma, serum, and RNA from the blood to analyze biomarkers later. It is an observational biobank study, not a treatment trial, so there is no intervention being tested on participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07348406Phase 1Not yet recruiting

Snacks and Brain Health

Open to carriers, genotype not studied

This trial is testing whether eating a daily pecan snack improves memory, mood, and brain function in people over 50 who already have some cognitive impairment — compared to eating pretzels as a control snack. Researchers will also track changes in gut bacteria, inflammation markers, and gut-brain signaling over three months. This is a Phase 1 trial, meaning it is an early-stage study focused on safety and initial signals, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06330155Not yet recruiting

A Genetic Study for Alzheimer Dementia: Case-control Study

Genetic research, no APOE4 focus

This is an observational genetic study, not a drug trial. Researchers are comparing the DNA of people who have Alzheimer's dementia against healthy adults over 60 to identify genes linked to the disease. There is no intervention or treatment involved. The phase is unspecified because this is a data-collection study, not a clinical trial testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06834893N/ANot yet recruiting

Assessing the Effects of Cool Roofs on Indoor Environments and Health in Colima, Mexico

Not APOE4-related, genotype ignored

This trial is testing whether painting rooftops with a sunlight-reflecting cool roof coating lowers indoor temperatures enough to improve health in homes in Colima, Mexico. Researchers are measuring a wide range of outcomes including heart rate, blood pressure, sleep, mood, cognition, and heat-related illness. This is a Phase NA randomized controlled trial — meaning it is a real-world intervention study, not a drug trial, and it is evaluating practical effects rather than drug safety or efficacy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07154485Phase 2Not yet recruiting

Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia

Wrong disease — carriers likely excluded

This Phase 2 trial is testing NS101, an experimental drug given by IV infusion, against a placebo in people with semantic variant frontotemporal dementia — a type of FTD that primarily affects language and word meaning. Researchers are measuring safety, how the drug behaves in the body, and early signs of whether it works. Phase 2 means the drug is still in early testing and is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07422038Not yet recruiting

BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention

Open to carriers, genotype not required

BioMIND is testing whether a nurse-led triage tool can get people with memory concerns to Alzheimer's biomarker testing faster — things like blood tests, lumbar punctures, and amyloid PET scans. The earlier pilot cut time to diagnosis from 533 days to 195 days. This next phase measures whether streamlining access to those tests at a Canadian memory clinic can be done reliably and equitably. The phase is unspecified — this reads more as a healthcare delivery study than a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07143331Phase 1Not yet recruiting

A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers

Too early, wrong age range

This trial is testing a new experimental drug called KS101 in healthy volunteers for the first time. Researchers want to know if it is safe, what side effects it causes, and how the body processes it at different doses and with or without food. It is a Phase 1 trial, which means this is the earliest stage of human testing — safety and dosing only, not yet proven to work for anything.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06993194N/ANot yet recruiting

Comparison of Haloperidol and Dexmedetomidine for Delirium and Agitation in ICU Patients With Traumatic Brain Injury

No relevance to APOE4 carriers

This trial compares two drugs — haloperidol and dexmedetomidine — for controlling delirium and agitation in ICU patients who have suffered a traumatic brain injury and are on a ventilator. It measures things like delirium severity, agitation levels, days on the ventilator, and ICU length of stay. This is a small, 40-patient study — an early-stage comparison trial, not a phase that establishes proof of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05890313N/ANot yet recruiting

Improving the Referral of Patients With Suspected Cognitive Impairment and Early Dementia

General care study, genotype not relevant

This trial is testing whether two cognitive screening tools — the paper-based MMSE and MoCA tests, and a web-based digital tool called Brain on Track — help primary care doctors in Portugal make better decisions about referring patients with suspected memory problems to neurology specialists. It is a Phase NA (not a drug trial — this is a care-process study) comparing these structured screening approaches against standard clinical practice.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06888713N/ANot yet recruiting

Telemonitoring of Activities of Daily Living in Home Care Services of Older Adults with Cognitive Deficits

Open to carriers, genotype not mentioned

This trial is testing a home sensor system called NEARS-SAPA that remotely tracks daily activities like cooking and moving around the house for older adults with cognitive decline who receive home care. The goal is to see whether this kind of monitoring helps caregivers better understand and personalize what support each person needs. This is a Phase NA feasibility and benefit study, not a drug trial, and not yet a large-scale rollout.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06059313Not yet recruiting

Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders

Observational study, genotype not relevant

This study is looking at whether a person's personality before they got sick might help explain why some people develop behavioral and cognitive symptoms from brain diseases like frontotemporal dementia or a frontal form of Alzheimer's disease. Participants and their caregivers fill out standardized personality questionnaires. There is no drug or treatment involved. This is an observational study — it is gathering information, not testing a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07230366N/ANot yet recruiting

Clinical Validation of AI-powered Smart Vehicle Assisted Gait Training in Neurodegenerative Disorders

Open to carriers, not 4-specific

This trial is testing an AI-powered electric vehicle that helps people with Parkinson's disease or dementia practice walking over a longer period. Researchers want to see whether it is safe and whether it improves gait. This is a Phase NA trial, meaning it is a clinical validation study focused on safety and early benefit signals, not a proven or approved therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06963970N/ANot yet recruiting

Using Community Health Workers to Support Rural Care Partners of Seriously Ill Older Veterans

Caregiver support, genotype not relevant

This trial is testing whether assigning a trained Community Health Worker to rural family caregivers of seriously ill Veterans reduces caregiver stress and connects them to helpful resources. The CHW works remotely to bridge gaps between the caregiver, the VA, and local community support. It is a Phase N/A study, meaning it is evaluating a care delivery approach rather than a drug or medical device. Details on outcomes and timeline are limited from the source provided.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07441122N/ANot yet recruiting

Enhancing Attention in Elderly Using a Brain-Computer-Interface

Open to carriers, not 4-specific

This trial is testing whether mindfulness meditation and gentle electrical brain stimulation (delivered through a headset while performing a memory task) can strengthen attention-related brain signals in older adults, including those with mild cognitive impairment. A computer reads brainwaves in real time and adjusts the intervention on the fly. This is a Phase NA study, meaning it is exploratory research focused on whether the approach shows measurable brain effects, not a late-stage proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07611357Phase 2Not yet recruiting

[18F]F-AraG PET Imaging in Alzheimer's Disease

Imaging study, genotype not required

This trial is testing a specialized PET scan tracer called F-AraG to see whether it can detect immune cell activity — specifically activated T cells — in the brains and bodies of people with Alzheimer's disease. Researchers want to understand whether inflammation driven by the immune system plays a measurable role in AD. This is a Phase 2 imaging study, meaning it is evaluating whether this tool works, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07214974Early Phase 1Not yet recruiting

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

Open to carriers, not 4-specific

This early-phase trial is testing three things together: a wearable brain-computer interface device, experimental stem cell therapy, and structured wellness care for adults 55 and older who have mild cognitive impairment or early cognitive decline. It aims to measure whether these interventions slow cognitive decline compared to standard care. Early Phase 1 means this is very preliminary — safety and basic feasibility are still being established, and nothing here is proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06559800N/ANot yet recruiting

Pilot Study of Cognitive Behavior Therapy With Role-plays in Virtual Reality for Children With Behavior Problems

No relevance to APOE4 carriers

This small pilot trial is testing a cognitive behavioral therapy program called YourSkills for children aged 10 to 16 who show anger or disruptive behavior. The therapy sessions include role-play practice inside virtual reality. Researchers want to know whether the program is feasible and shows early signs of helping. This is a pilot study, meaning it is a very early-stage test focused on whether the approach is workable, not a definitive proof that it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06920511N/ANot yet recruiting

Cognitive Rehabilitation With Virtual Reality in Parkinson Disease

Parkinson's study, genotype irrelevant

This pilot study is testing a robotic and virtual reality platform called PRoBio for cognitive rehabilitation in people with Parkinson's Disease who also have Mild Cognitive Impairment. Participants do three virtual cognitive training sessions per week for four weeks while sensors track their physical and physiological responses. Phase NA means this is a feasibility and usability study — the researchers are checking whether the system works and feels acceptable to patients, not yet proving clinical benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07485712N/ANot yet recruiting

Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2

Open to carriers, genotype not considered

This trial is developing and testing an adaptive software system designed to provide cognitive and social support for older adults with mild cognitive impairment (MCI). The software adjusts to each user's needs and abilities over time, and also collects speech data to study whether language changes can signal early cognitive decline. This is an early-stage development study — focused on building and refining the tool, not yet a large-scale effectiveness trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07485725N/ANot yet recruiting

Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3

Open to carriers, not 4-specific

This trial is testing an AI-powered digital assistant designed to help older adults manage everyday health tasks — things like finding support services, handling medical bills, and navigating Medicare.gov. It is a behavioral study, not a drug trial, focused on whether this kind of decision-support technology is useful and practical for people with mild cognitive impairment. Phase NA means this is not a traditional drug-development phase — it is more of a technology development and usability study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06514066Phase 2Not yet recruiting

Cannabidiol's Role in Dementia Management

General dementia trial, genotype not considered

This Phase 2 trial in Malaysia is testing whether cannabidiol (CBD) oil can improve cognitive function, daily living, mood, and quality of life in people already diagnosed with mild to severe dementia. Phase 2 means researchers are exploring whether it works and checking safety — it is not a proven or approved treatment. Details on dosing and trial size are limited in the public summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07550075N/ANot yet recruiting

Caring for Dementia Caregivers in Ethnic Immigrant Communities

Caregiver support, genotype not relevant

This trial tests K-Savvy, a six-week online caregiver support program taught in Korean, adapted from an established program called the Savvy Caregiver Program. Researchers want to know whether it reduces stress and depression in Korean American family caregivers of people with dementia and helps them feel more confident in their role. This is a behavioral study, not a drug trial, and is focused on caregiver well-being rather than the disease itself.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06976294N/ANot yet recruiting

The Effects of Cognitive Behavioral Approach-Based Psychoeducation on Caregivers of Alzheimer's Patients

Caregiver study, genotype irrelevant

This trial is testing whether a structured psychoeducation program rooted in Cognitive Behavioral Therapy can improve the mental wellbeing and resilience of people who care for someone with Alzheimer's. Researchers want to know if it reduces negative thought patterns and supports what psychologists call post-traumatic growth — finding meaning after hardship. This is a Phase NA study, meaning it is an intervention trial focused on caregivers, not patients, and not tied to a drug approval pathway.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07248345N/ANot yet recruiting

Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia

Caregiver study, genotype irrelevant

This trial tests whether a virtual reality program helps family caregivers of people living with dementia. The researchers are measuring how VR affects caregivers — likely things like stress, burnout, or wellbeing. Phase NA means this is outside the standard drug-approval pipeline, which fits a behavioral intervention like VR. Details from the source are limited, but the focus is clearly on caregiver support, not on the person with dementia directly.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06789094Not yet recruiting

Validating the Ain Shams Cognitive Assessment Tool

Diagnostic study, genotype not relevant

This study is testing a new cognitive screening tool called the Ain Shams University Cognitive Assessment, or ASCA, to see how accurately it identifies mild cognitive impairment and dementia. Researchers will compare its performance against established clinical diagnostic standards. This is a validation study, not a drug or treatment trial — it is about improving how cognitive decline gets detected, particularly in Arabic-speaking older adults.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07160959N/ANot yet recruiting

Physical Exercise to Prevent Mild-cognitive Impairment in Patients With Kidney Disfunctions

General MCI trial, genotype not considered

This trial is testing whether a home-based walking and strength training program can improve memory and thinking in people with advanced chronic kidney disease who already show early cognitive problems. Researchers will compare the exercise group to a standard-care group to measure changes in brain function. This is a Phase NA behavioral trial, meaning it is evaluating a structured lifestyle intervention rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT07414680Not yet recruiting

Integrating Systematic Data of Medicine to Explore the Solution for Healthy Aging (ISDHA) Phase 4

Observational registry, genotype not mentioned

This is an observational study based in Taiwan that is building a large health database for adults aged 40 and older. Researchers are collecting data on sleep, cognition, and aging over time — no drug or treatment is being tested. Because it is observational with no specified phase, it is essentially a long-term data-gathering effort, not a clinical intervention trial. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06559254N/ANot yet recruiting

TDCS as Augmentation Therapy to Cognitive Training in Mild Dementia

Non-drug trial, genotype not considered

This trial tests whether adding a mild brain stimulation technique called tDCS (transcranial direct current stimulation) to standard cognitive training helps people with mild dementia think more clearly. Participants get 10 sessions over two weeks, and half receive real stimulation while half receive a sham version. It is a Phase NA (feasibility or pilot-level) study — meaning researchers are still working out whether the combined approach is worth pursuing further, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07521722Not yet recruiting

DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community

Observational study, genotype not mentioned

This observational study is measuring Alzheimer's-related proteins in blood samples from cognitively healthy adults aged 50 to 75 in Barcelona. Researchers want to know whether those blood marker levels differ across ethnic groups and whether factors like income or education affect the results. There is no drug or intervention involved. The phase is unspecified, meaning this is likely a straightforward observational or feasibility study rather than a clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06989242N/ANot yet recruiting

Yoga-based, Movement Therapy Device as Noninvasive Glymphatic Clearance Augmentation in Alzheimer's Disease.

Open to carriers, not 4-specific

This trial tests a powered device that guides users through yoga-style breathing and body movements, with the goal of improving glymphatic clearance — the brain's waste-removal system — in people who already have mild cognitive impairment or early Alzheimer's. Researchers will use brain-monitoring tools and wearables to track what happens physiologically. Phase NA means this is likely a feasibility or pilot study, not yet testing a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06836180Early Phase 1Not yet recruiting

An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a device that shines near-infrared light on the head as a possible way to help people who already have mild to moderate Alzheimer's disease. Researchers are measuring both whether it does anything helpful and whether it is safe. It is an Early Phase 1 study, meaning this is very preliminary — the researchers are exploring basic questions before larger trials could ever follow.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07213284N/ANot yet recruiting

Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial

Unrelated to APOE4 or Alzheimer's

This trial is testing a mobile web app called MI MOM, designed to support pregnant women through information, videos, text messages, and optional contact with a community health worker. Researchers want to know if using the app leads to better pregnancy and postpartum outcomes compared to standard care. This is a behavioral trial — not a drug study — and it is still in the process of being evaluated for effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07206446N/ANot yet recruiting

A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

Unrelated to APOE4 or dementia

This trial is testing a smartphone app called RiSolve that delivers an eight-week behavioral therapy program for women with overactive bladder. It is a Phase NA, single-arm study — meaning all participants use the app and there is no comparison group. Researchers are measuring how usable the app is, and whether symptoms and quality of life improve. It is a post-market study of an already CE-marked device, not a first-in-human test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07409597N/ANot yet recruiting

Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease

Unrelated to APOE4 carriers

This observational study is testing whether eye-tracking technology, combined with standard memory tests, can reveal how Huntington's disease affects autobiographical memory — the ability to recall personal past events and imagine future ones. Researchers will compare HD patients to healthy controls. This is a Phase NA study, meaning it is not a drug trial — it is research designed to better understand a cognitive problem, not to test a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06392412N/ANot yet recruiting

Virtual Reality Cognitive Training for Older Adults With Mild Cognitive Impairment

Open to carriers, genotype not required

This trial tests whether virtual reality cognitive training built around everyday tasks (like cooking or shopping) works better than traditional cognitive training for older adults with mild cognitive impairment. Researchers want to know if it is feasible, effective, and how it might work. This is a Phase NA trial, meaning it is exploratory and developmental rather than a late-stage effectiveness study. Details on sample size and setting are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07244497N/ANot yet recruiting

Dementia Communication Training Program for Novice Home Care Workers

Not relevant to APOE4 carriers

This trial is testing two different training methods to help novice home care workers communicate better with people who have dementia. One method uses a real-time interactive virtual trainer; the other uses scenario-based group discussions. Researchers want to know which approach works better. This is a Phase NA study, meaning it is evaluating a training program rather than a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07376135N/ANot yet recruiting

LETHE-AT: a Personalized Multidomain Lifestyle Intervention for Individuals at Increased Risk of Memory Impairment.

Lifestyle study, genotype not required

This trial is testing whether a personalized, technology-assisted lifestyle program — covering exercise, diet, sleep, cognitive training, and social activity — can slow cognitive decline in adults aged 55 to 75 who are at higher-than-average dementia risk but still cognitively healthy. It compares a coached, app-based intervention against basic self-guided advice. This is a Phase NA feasibility and efficacy study — meaning researchers are still learning whether the approach works and can be delivered reliably.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06542458Not yet recruiting

Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog

Open to carriers, not 4-specific

This observational study is following older adults from underrepresented and under-resourced communities who have already been diagnosed with subjective cognitive decline or mild cognitive impairment through a telehealth clinic. Researchers are collecting assessments, brain imaging, and biofluid samples over time to better understand how these conditions progress. There is no experimental treatment — participants are being studied, not treated. The phase is unspecified, consistent with an observational registry study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07240805Not yet recruiting

Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

Not Alzheimer's, APOE4 irrelevant

This study is testing wearable sensor devices to track movement and physical function in people already diagnosed with Progressive Supranuclear Palsy, MCI with Lewy bodies, or Dementia with Lewy bodies. Researchers want to know whether these wearables can reliably capture how limbs are working day-to-day, at home, without clinic visits. The phase is unspecified, meaning this is likely a validation or observational study, not a drug or treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07089654N/ANot yet recruiting

Evaluation of a PMT Rehabilitation Nursing Plan for the Older Adults With MCI to Promote Cognitive Health

Open to carriers, genotype not considered

This trial is testing a structured 12-week behavioral program called Psychomotor Therapy, or PMT, against standard rehabilitation care for older adults with mild cognitive impairment. PMT combines relaxation, breathing, facial, hand, and mental exercises. Researchers will measure changes in cognition, mood, and anxiety using standard rating scales. This is a Phase NA trial, meaning it is a practical intervention study rather than a drug efficacy or safety trial in the traditional sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07114354N/ANot yet recruiting

Enhancing Utility of Neuropsychological Evaluation for Earlier and Effective Diagnosis of Dementia in Parkinson's Disease

Parkinson's focus, not APOE4-relevant

This trial is testing PDCogniCare, a digital platform designed to catch dementia earlier in people who already have Parkinson's disease. Researchers want to know whether it improves on current diagnostic tools, and what affects its adoption in clinics. This is a Phase NA study, meaning it is evaluating a diagnostic tool rather than a drug or treatment — so it is about detection, not intervention.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06235177Early Phase 1Not yet recruiting

Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues

Open to carriers, not 4-specific

This early Phase 1 trial is testing a bundle of non-drug approaches — herbal tinctures, yoga, mental imagery, relaxation techniques, and a faith-based psychological assessment — under a framework the researchers call Psychoneuromentalism Disorder. It is an extremely early stage, meaning it has not yet established basic safety or effectiveness. The source material is thin and the underlying condition being defined is not standard medical terminology.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07122856Not yet recruiting

Predictive Factors for Initial MMSE Score and Rapid Decline in Alzheimer's Disease Patients

Observational only, genotype not tracked

This is an observational study — no treatment is being tested. Researchers at a French memory clinic are reviewing medical records to identify which factors, such as age, education, nutrition, and mood, are linked to how well Alzheimer's patients score on a standard cognitive test at diagnosis and how quickly that score drops over 12 months. The goal is to understand what drives early decline, which could help doctors plan better care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06306144N/ANot yet recruiting

Early-phase Telecare Programs for Minor Stroke

Not Alzheimer's related, genotype irrelevant

This trial is testing two six-week telerehabilitation programs for people who have had a minor stroke and are experiencing cognitive difficulties afterward. One program uses psychoeducation — teaching patients about their condition and coping strategies. The other uses computerized brain exercises. Both are delivered remotely via weekly therapist-led sessions plus self-practice. This is a Phase NA feasibility and efficacy study, meaning researchers are still establishing whether these approaches work and can be delivered at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT07286812Not yet recruiting

Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study

Observational study, genotype not addressed

This study is testing whether a step-by-step screening approach using digital tools and blood markers can catch early signs of cognitive impairment more efficiently than traditional questionnaire-based methods. Researchers will analyze gait, facial expressions, and speech patterns alongside blood tests to build a predictive model for early diagnosis. The phase is unspecified, so this appears to be an observational or exploratory study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07230158N/ANot yet recruiting

Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease II (TRANSFORM-AD II)

Open to carriers, not 4-specific

This trial is testing whether transcranial alternating current stimulation (tACS) — a non-invasive device that delivers mild electrical pulses to the scalp — can help cognition in people with early Alzheimer's or amyloid-confirmed mild cognitive impairment. Half the participants receive real tACS; half receive a sham (inactive) version. It is a Phase NA trial focused on efficacy and safety, meaning the approach is still being evaluated and is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07608640Not yet recruiting

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia

Observational only, genotype not considered

This observational study is tracking more than 3,000 older adults in China to explore the link between age-related hearing loss and cognitive decline. Researchers will collect hearing tests, cognitive assessments, and blood samples, then use AI to build predictive tools — including something called a Hearing Health Clock — for earlier detection of dementia risk. No phase is listed because no drug or device is being tested; this is a data-gathering and model-building study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07212062Phase 2Not yet recruiting

The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

Open to carriers, not 4-specific

This trial is testing whether a new drug combination called X/T plus X-EC is safe and well-tolerated when added to lecanemab, an FDA-approved Alzheimer's antibody therapy. Participants must already be receiving lecanemab infusions. It is a Phase 2 trial, meaning researchers are still gathering early evidence on safety and tolerability — this is not a proven or approved treatment combination.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06705010N/ANot yet recruiting

Monitoring of Brain Metabolites Using Proton and Deuterium MR Techniques

Imaging study, genotype not a factor

This trial is developing and testing a new type of MRI scanning technique that measures brain chemistry — specifically metabolites like glucose breakdown products — using both standard proton MRI and a newer deuterium-based approach at an ultra-high-field 7 Tesla scanner. It will eventually scan healthy volunteers across age groups, plus patients with Alzheimer's, MCI, diabetes, or carotid stenosis. This is a Phase NA device development and feasibility study, meaning it is exploratory imaging research, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07061340N/ANot yet recruiting

The Effect of Therapeutic Touch on Agitation, Pain, and Cortisol Levels in Intensive Care Patients

Unrelated to APOE4 or Alzheimer's

This trial is testing whether therapeutic touch — a hands-on complementary therapy applied to energy points on the body — can reduce agitation, pain, and stress hormone (cortisol) levels in ICU patients. Researchers will compare 30 patients who receive the touch sessions to 30 who do not, measuring outcomes before and after each session. This is a Phase NA behavioral study, meaning it is evaluating a non-drug technique rather than a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07431528N/ANot yet recruiting

Dementia and Storytelling in Vietnam

No APOE4 relevance, Vietnam only

This trial is testing whether a digital storytelling program can improve awareness of Alzheimer's and related dementias among older adults and their caregivers in rural Vietnam. One group gets the storytelling intervention; the other gets basic information. It is a Phase NA study, meaning it is evaluating a behavioral approach rather than a drug, focused on education and encouraging earlier diagnosis.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07278492Phase 1Not yet recruiting

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

DS only, not for carriers

This trial is testing MIB-626, a form of a B vitamin compound called NMN, in adults with Down syndrome. Researchers want to know if different doses are safe and well-tolerated over 28 days, and how the body processes it. It is a Phase 1 trial, meaning the primary goal is safety, not proving the drug works. Twenty-four adults with Down syndrome will receive either MIB-626 or a placebo.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07115251Phase 2Not yet recruiting

Plans4Care: Personalized Dementia Care on Demand

Caregiver support, genotype not relevant

Plans4Care is testing a smartphone app designed to help family caregivers of people with dementia. The app offers personalized, non-drug strategies for over 90 common caregiving challenges, like managing anxiety or agitation in a loved one. Caregivers can also speak with a care advisor. This is a Phase 2 trial, meaning researchers are testing whether the app genuinely improves caregiver confidence and well-being, not just whether it is safe to use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07105956Not yet recruiting

Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.

Diagnostic imaging study, genotype not mentioned

This trial is testing a new PET imaging probe called 68Ga-DOTA-HK-011 that targets TSPO, a protein linked to brain inflammation. Researchers want to see how well it detects neuroinflammation in people already diagnosed with Alzheimer's disease. This is a diagnostic imaging study, not a treatment trial. The phase is unspecified, and details beyond the imaging objective are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07416734N/ANot yet recruiting

RCT of HeartBot in Women

Heart health focus, genotype not relevant

This trial is testing an AI chatbot app called HeartBot II to see whether it improves women's knowledge and awareness of heart attack symptoms. About 200 women will be randomly assigned to use the app now or wait 12 weeks before starting. It is a Phase NA study, meaning this is a behavioral and educational intervention being evaluated for effectiveness, not a drug or device requiring traditional phase classification.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06896812N/ANot yet recruiting

A Pilot Study on App-based Treatment Combining Physical Exercise, Graded Activity, and Pain Journaling for Patients with Spinal Complaints

Unrelated to APOE4 or dementia

This pilot study is testing a smartphone app that combines physical exercise, graded activity, and pain journaling for people with back or spinal complaints. Researchers want to know if patients find it useful and whether it improves pain, disability, and quality of life compared to standard options like physical therapy or watchful waiting. With only 30 participants, this is early-stage exploratory work — not yet proven effective.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07135245Phase 2Not yet recruiting

Improved Treatment and Monitoring of Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether semaglutide (Rybelsus, the oral diabetes drug now being studied for brain effects) can slow cognitive decline in people already diagnosed with early Alzheimer's disease. It also tests semaglutide combined with other interventions including candesartan, a probiotic, and vitamins. This is a Phase 2 trial, meaning researchers are still working out whether it shows enough promise to move forward — it is not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07127133N/ANot yet recruiting

An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

Open to carriers, genotype not required

This trial is testing a wearable insole and ankle device that tracks how people walk. The idea is that changes in gait, meaning the way you move when you walk, may serve as early markers of cognitive decline. Researchers want to see if this device can collect reliable walking data both in a lab and at home over one week. This is a Phase NA feasibility study, meaning it is focused on whether the device works, not on treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07152418Not yet recruiting

Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

Anti-amyloid drug, carriers face higher risk

This trial is testing lecanemab, an anti-amyloid antibody drug already approved in some countries, against standard dementia care. The focus is on using PET brain scans to track amyloid and tau protein buildup and figure out which patients benefit most from the drug. The phase is unspecified, so this appears to be an observational and comparative study rather than a standard Phase 1-3 efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05796037Not yet recruiting

An Observational Study of Patients Living With Chronic Neurological Diseases

Open to carriers, not 4-specific

TARGET-NEURO is an observational study tracking real-world health outcomes for people living with Alzheimer's disease, related dementias, mild cognitive impairment, Parkinson's disease, or multiple sclerosis. Researchers are reviewing electronic health records and collecting patient surveys over time. No new drug or treatment is being tested. Because the phase is unspecified and no intervention is involved, this is a data-gathering effort — not a clinical trial testing whether something works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06859658Not yet recruiting

Development and Validation of a Functional MRI Biomarker of Cerebral Small Vessel Dysfunction in CADASIL

Not relevant to APOE4 carriers

This study is testing whether a specific type of brain MRI scan can reliably detect early blood vessel dysfunction in people with CADASIL, a rare inherited disease that damages small blood vessels in the brain. Researchers want to know if the scan is accurate, repeatable, and sensitive enough to track disease progression over time. The phase is unspecified, meaning this is primarily a biomarker development and validation effort, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05811338N/ANot yet recruiting

Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1

Open to carriers, not 4-specific

This trial is testing a virtual reality program called CAST, designed to give older adults with mild cognitive impairment a way to stay socially connected, mentally active, and engaged through immersive VR experiences. Researchers want to know whether people find it usable and whether it actually helps. This is a Phase NA behavioral study, meaning it is in early development and testing, not a drug trial, and nothing here is proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06872658Not yet recruiting

Study to Detect Dendritic Cell Recruitment in Human Retina

Carriers with MCI may qualify

This study is developing a new imaging technique to spot immune cells called dendritic cells in the back of the eye. Researchers want to see whether these cells show up differently in people with dry macular degeneration or early Alzheimer's-related cognitive decline versus healthy older adults. It is not a treatment trial — no drug or therapy is being tested. The phase is unspecified, meaning this is early exploratory work focused on refining a detection method.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07346794N/ANot yet recruiting

The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease Population

Open to carriers, genotype ignored

This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that delivers magnetic pulses to the brain — can improve cognition in people with mild to moderate Alzheimer's by influencing the gut-brain connection. Researchers will track cognitive scores, gut bacteria, brain scans, and blood markers over one year. Phase NA means this is a mechanistic study aimed at understanding how rTMS works, not a late-stage efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06978946N/ANot yet recruiting

Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients

Open to carriers, not 4-specific

This trial is testing a surgical procedure called Deep Cervical Lymphaticovenous Anastomosis, or DLVA, in people aged 50 to 80 with moderate to severe dementia. The surgery connects lymphatic vessels in the neck to nearby veins, with the goal of improving how the brain drains waste fluid. Researchers will track cognitive scores, brain scans, and fluid samples before and after. This is a Phase NA study, meaning it is exploratory and not yet testing a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06264362N/ANot yet recruiting

Developing a Nonpharmacological Pain Intervention for Community-dwelling Older Adults With Dementia

Open to carriers, genotype not relevant

This study is building and then testing a tailored exercise program to help older adults with both knee osteoarthritis pain and mild dementia manage that pain without medication. Part 1 gathers input through interviews with patients, caregivers, and clinicians. Part 2 will test the resulting program in a small clinical trial. This is a design and feasibility study, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07444866N/ANot yet recruiting

Machine Learning Enabled Management of Behavioural and Psychological Symptoms of Dementia Intervention for Dementia Caregivers

Caregiver study, genotype irrelevant

This trial is testing a machine learning tool designed to help family caregivers manage the difficult behavioral and psychological symptoms that come with dementia — things like agitation, anxiety, and sleep problems in the person they care for. It uses a smartphone app combined with human coaching, and researchers are comparing different levels of support to see what works best. Phase NA means this is a practical, real-world intervention study rather than a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06881277N/ANot yet recruiting

Effectiveness of a Smartphone App (PRIMI) to Promote Healthy Diet and Physical Activity After Pregnancy in Migrant Women

No relevance to APOE4 carriers

This trial is testing a smartphone app called PRIMI that encourages healthy eating and physical activity in migrant women during the six months after giving birth. Researchers are comparing women who use the app against a waitlist group to see if the app improves diet quality and exercise levels. This is a Phase NA pragmatic randomized trial — it is evaluating real-world effectiveness, not a drug or device approval process.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07396298N/ANot yet recruiting

The Existential Cognitive Intervention to Enhance Positive Aspect of Caregiving (EXCITE-PAC) in a Dementia Context

Caregiver study, genotype irrelevant

This trial tests a structured psychological program called EXCITE-PAC designed to help family caregivers of people living with dementia find more meaning and positive experience in their caregiving role. It is not testing a drug — it combines cognitive behavioral tools and existential psychology delivered over 12 weeks. Researchers will measure depression, quality of life, and self-efficacy. This is a pilot randomized controlled trial, meaning it is an early-stage test of whether the approach works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06523309Not yet recruiting

Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease

Non-drug study, genotype not considered

This study is testing electroacupuncture as a way to manage the behavioral and psychological symptoms of Alzheimer's disease, such as agitation, anxiety, or mood changes. Researchers want to understand how much electroacupuncture is needed and whether it is cost-effective. The phase is unspecified, and details on study design are limited, so it is best treated as an early observational or registry-style effort rather than a definitive clinical trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
7 sites
NCT07592117N/ANot yet recruiting

Assessing the Effects of Cool Roofs on Indoor Environments and Health in Tavua, Fiji

No Alzheimer's or APOE4 relevance

This trial is testing whether painting rooftops with a heat-reflecting coating lowers indoor temperatures enough to measurably improve residents' health in Fiji. Researchers are tracking everything from blood pressure and sleep to mood and cognition. It is a Phase NA cluster-randomized trial — meaning whole neighborhoods are assigned to the intervention, not individuals — and it is designed to find out whether this low-tech housing fix actually works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07361601Not yet recruiting

Implementation of AIP Services for Older Adults With AD

Observational only, genotype not relevant

This study follows older adults with Alzheimer's disease or mild cognitive impairment — and their caregivers — over time to understand how people decide whether to stay in their own homes or move to long-term care. Researchers want to know how cognition, health literacy, chronic illness, and caregiver support shape those decisions. This is an observational study, not a drug trial — no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07196592N/ANot yet recruiting

Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI

Non-drug trial, genotype not addressed

This trial is testing a non-drug brain stimulation approach for people with mild cognitive impairment linked to early Alzheimer's. It combines transcranial alternating current stimulation (gentle electrical pulses targeting specific brain rhythms) with a multisensory virtual reality experience involving smell, sound, and vision. Researchers want to know whether this combination improves cognition and brain function. This is a Phase NA large-scale cohort study — it is exploratory and not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07182019N/ANot yet recruiting

Connecting Today to Combat Social Isolation and Loneliness

Caregiver-focused, genotype not relevant

This trial tests a structured video-call program called Connecting Today, designed to reduce loneliness and improve quality of life for nursing home residents with moderate to severe dementia and their remote family members or friends. A trained staff member helps facilitate each 60-minute weekly call. This is a Phase NA behavioral study, meaning it is evaluating a care practice, not a drug or medical device — feasibility and benefit are what is being measured.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05987007N/ANot yet recruiting

Sleep Interventions and Neurocognitive Outcomes

Open to carriers, genotype not tracked

This pilot trial is testing two non-drug sleep treatments in older adults who already have amnestic mild cognitive impairment and sleep problems. One treatment uses sound to deepen slow-wave sleep; the other is cognitive behavioral therapy for insomnia, a structured talk-based approach. Researchers are measuring whether better sleep translates into better cognitive and daily functioning over six months. This is a Phase N/A pilot — designed to gather early data, not to prove a definitive treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07431255Not yet recruiting

Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease

Technical imaging study, no recruitment

This study tests an AI model that tries to generate one type of brain scan image from another — specifically, creating a metabolic FDG PET image using only an amyloid PET scan and an MRI. No new patients are enrolled and no new procedures are done; researchers are working entirely with anonymized scan data already collected. The phase is unspecified, making this more of a technical feasibility study than a clinical trial in the traditional sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06756828N/ANot yet recruiting

Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spectrum

Open to carriers, genotype not tracked

This trial is testing whether three months of nightly melatonin can slow the progression of Alzheimer's-related changes in people who already have mild cognitive impairment and insomnia. Researchers will track blood biomarkers tied to brain injury, sleep quality, physical function, and cerebellar brain volume before and after treatment. This is a Phase NA study, meaning it is exploratory — designed to gather early data, not to prove a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07333898Not yet recruiting

Digital Measurements of Motor and Voice Functions in FTD

Not Alzheimer's focused, genotype irrelevant

This study is testing whether wearable sensors and digital assessments can accurately track how motor skills, speech, and thinking change over time in people diagnosed with frontotemporal dementia or related conditions. It is an observational study, not a drug trial — no intervention is being given. Twenty participants will be monitored over 12 months with check-ins every three months. The goal is to validate these digital tools as reliable measurement methods, not to treat anything.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07060391Phase 3Not yet recruiting

A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease

Open to carriers, genotype not considered

This trial is testing whether a surgical procedure called deep cervical lymphatic-venous anastomosis, which creates a new drainage connection in the neck to help clear waste from the brain, works better than the standard drug donepezil for people with moderate to severe Alzheimer's disease. It is a Phase 3 trial, meaning researchers are directly comparing the surgery against an existing treatment in a larger group to measure real-world effectiveness and safety over 48 weeks.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06621758Not yet recruiting

Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD

Observational only, genotype not addressed

This study uses questionnaires to learn what people with mild cognitive impairment or subjective cognitive decline want to know during diagnostic counseling — and how they want that information delivered. It is not testing a drug or treatment. The phase is unspecified, which typically means this is observational research, not a clinical intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT03454646Phase 4Not yet recruiting

Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)

Open to carriers, not 4-specific

This trial is comparing different strategies for using cholinesterase inhibitors — the standard memory drugs like donepezil, galantamine, and rivastigmine — in people with mild to moderate Alzheimer's. The main question is whether starting these drugs early delays serious cognitive and functional decline, not just temporarily improves symptoms. This is a Phase 4 trial, meaning the drugs are already approved and in use — researchers are refining how and when to use them best.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
31 sites
NCT07367815Phase 1Not yet recruiting

Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease

Open to carriers, not 4-specific

This trial is testing whether fat-tissue-derived stem cells, given by IV infusion at two different doses, are safe for people with mild to moderate Alzheimer's disease. Researchers are watching for side effects and using brain MRI and PET scans to monitor what happens. It is a Phase 1 trial, meaning the main goal right now is safety, not proving the treatment works. It is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07058129Not yet recruiting

Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)

Open to carriers, genotype not tracked

This registry is tracking real-world outcomes for Alzheimer's patients who have already undergone a surgical procedure called deep cervical lymphatic venous anastomosis, or DC-LVA. The surgery connects lymphatic vessels in the neck to nearby veins, with the idea of improving the brain's drainage of waste. Researchers are measuring whether patients' dementia rating scores improve 12 months after surgery. This is a registry, not a randomized trial, so it is collecting observational data rather than testing the procedure in a controlled way.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06495476Phase 4Not yet recruiting

Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD

Open to carriers, not 4-specific

This trial is testing whether a concentrated Ginkgo biloba extract, taken daily for 12 months, can slow or reduce cognitive decline in people who already have mild cognitive impairment caused by small vessel disease in the brain. Researchers will measure changes in standard cognitive scores at 3, 6, and 12 months. Phase 4 means the drug is already approved in its market — this is a deeper look at a specific use case.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06894953N/ANot yet recruiting

AMPER Proof of Concept Study

Device trial, genotype not considered

This trial tests a tablet-based app called AMPER that uses an animated character to help people with Alzheimer's recall personal memories through stories, photos, and videos. Half of participants get a version tailored to their own life history; the other half get a non-personalised version. Over 12 weeks, researchers measure whether the personalised approach improves memory recall and quality of life. This is a proof-of-concept study — small and exploratory, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07241598N/ANot yet recruiting

Cognitive-motor Training in Community-dwelling Older People With Mild Cognitive Impairment

Lifestyle device trial, genotype not a factor

This trial is testing a device called Smart±step — an interactive stepping platform that combines physical movement with cognitive tasks, like a video game you play with your feet. Researchers want to know if it reduces falls and improves balance, thinking, and quality of life in older adults who already have mild cognitive impairment. This is a Phase NA study, meaning it is a practical real-world effectiveness trial rather than an early safety or drug approval study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07377981Phase 4Not yet recruiting

Efficacy and Safety of Esketamine Combined With Dexmedetomidine in Non-Invasive ICU Patients With Hyperactive Delirium (ESSENTIAL Trial): Protocol of a Randomized Controlled Trial

Not relevant to APOE4 carriers

This trial is testing whether combining esketamine (a sedative and pain reliever) with dexmedetomidine works better than dexmedetomidine alone to calm ICU patients who are experiencing hyperactive delirium while on non-invasive breathing support. Researchers are measuring rates of intubation, and how long delirium and agitation last. This is a Phase 4 trial, meaning both drugs are already approved — this study is examining a new combined use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07264283Phase 2Not yet recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

PSP-only trial, not APOE4-relevant

This trial is testing LM11A-31, an experimental drug, against a placebo in people diagnosed with Progressive Supranuclear Palsy, a rare and serious brain disorder distinct from Alzheimer's disease. It is measuring whether the drug is safe and whether it slows PSP symptoms. This is a Phase 2 trial, meaning researchers are still working to establish whether it works and is safe — it is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06079216N/ANot yet recruiting

Making Connections Thru Music

Not relevant to APOE4 carriers

This trial tests whether trained volunteers can lead music and conversation sessions for people living with dementia in long-term care facilities just as effectively as paid staff can. Researchers want to see if the sessions improve residents' engagement, quality of life, and reduce agitation. This is a Phase NA trial — it is evaluating a behavioral program, not a drug, so the usual phase labels do not apply. It is an early-stage test of a practical care delivery model.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07617883N/ANot yet recruiting

Dementia Management Training Programme for Primary Health Care Providers

Not for carriers or patients

This trial is testing whether a structured 12-week training program helps primary care doctors and nurses in rural China better recognize and manage dementia. It compares that program against simple self-directed online reading. Phase NA means this is a practical implementation study, not a drug or device trial. It measures changes in knowledge, attitudes, and real clinical behaviors among healthcare workers, not patient outcomes directly.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07079787N/ANot yet recruiting

Telerehabilitation Decision Support System: Pilot Testing Protocol

MCI enrolled, genotype not a factor

This trial is testing a home-based telerehabilitation platform called HOLOBalance, which uses a holographic physiotherapist and motion sensors to guide balance and cognitive exercises remotely. Researchers want to know if the system is usable and practical before running a larger study. It enrolls people with stroke, MCI, vestibular disorders, or Long Covid who are at risk of falling. This is a pilot feasibility study — not yet testing whether the intervention works at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT06838494N/ANot yet recruiting

Using Immersive Virtual Reality for Cognitive Therapy in Elderly with Mild Cognitive Impairment

Non-drug study, genotype not considered

This trial tests whether cognitive stimulation therapy delivered inside a virtual reality headset works better than standard cognitive stimulation therapy for older adults with mild cognitive impairment. Researchers will also track eye movements during VR sessions to see if that data predicts who responds best. This is a Phase NA feasibility and efficacy study — it is exploratory, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06325527Not yet recruiting

Cognitive Impairment Cohort Study of the Elderly Population in YuGarden

Observational only, no APOE4 focus

This is an observational study, not a treatment trial. Researchers in Shanghai are following roughly 600 elderly community residents over 8 years, tracking who develops mild cognitive impairment or Alzheimer's disease and why. No drug or intervention is being tested. The goal is to build a model that might predict cognitive decline earlier. Details on enrollment size and biomarker specifics are limited in the public summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07417891N/ANot yet recruiting

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

Lifestyle study, genotype not required

This trial is testing whether a ketogenic diet can reduce joint pain and improve physical function and cognition in adults who have both osteoarthritis and mild cognitive impairment. Researchers will measure symptoms and biological markers before and after the dietary program. This is a Phase NA trial, meaning it is a practical intervention study rather than a drug trial moving through standard approval phases. Details on duration and size are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06767124N/ANot yet recruiting

Supplementing Neuro-Energy to Aid Cognition

Open to carriers, not 4-specific

This trial is testing whether a ketogenic (high-fat, low-carb) dietary supplement can support brain energy in people with Alzheimer's disease and related dementias, compared to a placebo drink. Researchers are also developing new PET-MRI brain imaging tools to measure how the brain uses energy. This is a Phase NA study, meaning it is exploratory research focused on methods and measurement rather than proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07225400N/ANot yet recruiting

Designing a Spatial Navigation Intervention Protocol Informed by Region-specific Brain Activation for Mild Cognitive Impairment

Open to carriers, genotype not tracked

This trial is testing whether people with mild cognitive impairment can use a virtual reality maze as a brain-training tool for spatial navigation. Participants walk through VR mazes while wearing EEG sensors to track brain activity changes over four months of sessions. This is a Phase NA feasibility study, meaning researchers are checking whether the approach is practical and measurable before committing to a larger test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07608510Not yet recruiting

Validation of Population Characteristics and Dosage Prescriptions for Cognitive Function Intervention Benefits of Different Doses of Tai Chi in Elderly Patients With Mild Cognitive Impairment: A Real-World Cross-Sectional Study

Lifestyle study, genotype not considered

This study is observing older adults with mild cognitive impairment who already practice Tai Chi regularly. Researchers want to test whether a machine learning model can accurately predict who benefits most from Tai Chi — and at what dose — in a real-world community setting. It is not a drug trial and has no phase designation. It is a cross-sectional observational study, meaning it captures a snapshot rather than following people over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07167966Phase 2Not yet recruiting

Alzheimer's Tau Platform: Regimen A - AADvac1

ARIA risk warrants careful discussion

This trial is testing AADvac1, a vaccine designed to target tau protein, a key driver of Alzheimer's damage. It tests AADvac1 alone and combined with donanemab, an anti-amyloid antibody. Participants are adults aged 50 to 80 with very early or preclinical Alzheimer's. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and whether it is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06840054Phase 2Not yet recruiting

The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether sodium pentaborate pentahydrate, a boron-based compound, can slow cognitive and functional decline in people already diagnosed with mild to moderate Alzheimer's disease. Participants take either the compound or a placebo alongside their existing Donepezil. Researchers will track thinking and daily living scores over six months. This is a Phase 2 trial, meaning it is exploring whether the drug works and is safe, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07397182N/ANot yet recruiting

SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment

Behavioral sleep study, genotype not required

This trial is testing a specialized form of talk therapy for sleep called SleepSMART against standard Cognitive Behavioral Therapy for Insomnia (CBT-I) in older Veterans who have both insomnia and mild cognitive impairment. SleepSMART adds extra memory and learning support to standard CBT-I to help people with cognitive difficulties follow through with treatment. This is a randomized controlled trial — the most rigorous design for comparing two active treatments, though no drug is involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06930742N/ANot yet recruiting

Mindfulness-Enhanced Dual-Task Training in PD-MCI

Not designed for APOE4 carriers

This trial is testing whether combining mindfulness training with dual-task training (doing a cognitive and physical task at the same time) improves thinking and movement in people who have both Parkinson's disease and mild cognitive impairment. Three groups are compared over four weeks. This is a Phase NA study, meaning it is an interventional trial focused on a specific therapeutic technique rather than a drug, and results are not yet established.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07507812N/ANot yet recruiting

Fall Prevention in Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing a six-week virtual rehabilitation program designed to reduce falls in older veterans who have mild cognitive impairment. Researchers will measure changes in fall risk, mobility, strength, cognition, and daily functioning. With only 28 participants, this is a small early-stage study — think of it as a first look at whether the approach shows promise, not a proven program.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06868030Not yet recruiting

Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study

Open to carriers, elevated ARIA risk

This observational study in China is tracking early Alzheimer's patients — those with MCI or mild AD confirmed by biomarkers — who are taking lecanemab (an anti-amyloid antibody) alongside standard symptomatic medications. Researchers want to see how well the combination works and how safe it is over 18 months in real-world clinical settings. This is not a randomized trial; it is observational, meaning researchers watch what happens rather than controlling treatment assignments.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06976983N/ANot yet recruiting

Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)

Unrelated to APOE4 or Alzheimer's

This trial is testing whether a wearable magnetic helmet worn at home can reduce the involuntary movements (chorea) that are a hallmark of Huntington's disease. Participants receive either a real device or a placebo version, and neither they nor the researchers know which. It is a Phase NA trial — meaning it focuses on a device, not a drug, but is still an early-stage feasibility and safety test, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07259369N/ANot yet recruiting

The Effects of an App-based Acupressure on Alleviating Fatigue, Pruritus, and Sleep Quality Among Hemodialysis Patients

Unrelated to APOE4 or Alzheimer's

This trial is testing whether a smartphone app that guides hemodialysis patients through daily acupressure sessions can reduce fatigue, skin itching, and sleep problems caused by kidney dialysis. Participants press specific body points on their own, once a day for four weeks. It is a Phase NA randomized controlled trial — meaning it is evaluating a behavioral or device-based technique rather than a drug, in a real-world test of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07516899Phase 1Not yet recruiting

Mass Balance Study of [14C] LPM3770164 in Healthy Participants

Unrelated to APOE4 or Alzheimer's

This trial is tracking how a radioactively labeled version of the drug LPM3770164 moves through the body — absorbed, broken down, and excreted — after a single dose. It is designed for Huntington disease, not Alzheimer's. Phase 1 means researchers are studying basic drug behavior and safety in healthy people, not testing whether the drug works yet. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06825663N/ANot yet recruiting

Marker of Brain Insulin Resistance in AD Prognosis

Open to carriers, genotype not required

This trial is testing whether a blood biomarker tied to brain insulin resistance can predict which people with mild cognitive impairment will go on to develop Alzheimer's disease. Researchers measure a specific protein ratio in neuron-derived particles found in plasma. It is a Phase NA study, meaning it is observational research — not testing a treatment, just evaluating whether this marker has predictive value.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07358962Not yet recruiting

Mild Cognitive Impairment and Psychopathology

Observational only, genotype not relevant

This study is observational, not a drug trial. Researchers are looking at the psychological and emotional profiles of people already diagnosed with mild cognitive impairment, examining how mental health factors like anxiety, depression, and lack of awareness of one's own deficits affect daily functioning. There is no intervention being tested. The phase is unspecified because this is a descriptive research study, not a clinical trial evaluating a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06862960Phase 2Not yet recruiting

Ozanimod in Patients With Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing ozanimod, an immune-modulating drug already approved for multiple sclerosis, in people with moderate Alzheimer's disease. Participants continue their existing Alzheimer's medications while adding ozanimod or staying on conventional treatment alone. Researchers want to see whether ozanimod provides any benefit. This is a Phase 2 trial, meaning it is exploring whether the drug works and is safe in this population, not yet proven or approved for Alzheimer's.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07473492Not yet recruiting

Assessment of Malnutrition in Hospitalized Patients: a Quasi Study

No APOE4 relevance found

This study is testing whether a structured nutritional screening and support program can improve outcomes for hospitalized patients in Iraqi hospitals. Researchers want to know if identifying and addressing malnutrition early, alongside a review of patients' medications, leads to fewer complications and shorter stays. It is an observational and interventional quasi-experimental study, meaning it is exploratory rather than a large randomized trial, and its findings are preliminary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07061470Phase 1Not yet recruiting

A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep

Not relevant to APOE4 carriers

This trial is testing whether a daily iron supplement (ferrous sulfate, available over the counter) reduces restless sleep and eases ADHD symptoms in children and teens. Researchers will compare it against a placebo over three months, tracking sleep with wrist and leg monitors and parent ratings. This is a Phase 1 trial, meaning the primary focus is on early safety and tolerability, not yet a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07459959Phase 1Not yet recruiting

LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response

Open to carriers, genotype not required

This trial is testing whether low-dose lithium orotate, a supplement form of lithium, can safely reach the brain in people who already have early, biomarker-confirmed Alzheimer's disease. Researchers want to know if the drug is tolerable and actually shows up in spinal fluid — not yet whether it helps memory. It is a Phase 1 trial, meaning the focus is on safety and basic proof-of-concept, not effectiveness. Nine weeks, placebo-controlled, with two spinal taps required.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07591727Phase 1Not yet recruiting

A Study of the Metabolic Reconstruction Oral Biologics (Gut-X-001) Medication in People With Alzheimer's Disease (ESCAPE-AD)

Open to carriers, not 4-specific

This trial is testing Gut-X-001, an oral medication that targets gut bacteria and metabolism, in people who already have a confirmed Alzheimer's diagnosis — either early-stage MCI or mild dementia. Researchers want to see whether it affects cognition, daily functioning, brain imaging markers, and blood biomarkers. This is a Phase 1 trial, meaning the primary goals are safety and feasibility. Effectiveness is not yet established or proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07547111N/ANot yet recruiting

A Comparison of the Efficacy of Different Rehabilitation Strategies in Mild Cognitive Impairment

Open to carriers, genotype not considered

This trial compares two non-drug rehabilitation approaches for older adults with mild cognitive impairment (MCI): computer-based cognitive training versus dual-task training (combining physical and mental tasks at the same time). Researchers will measure thinking, balance, fall risk, and daily functioning before and after eight weeks of twice-weekly sessions. This is a Phase NA randomized controlled trial — meaning it is comparing two active approaches rather than testing a new drug for the first time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07552896Not yet recruiting

Effect of Daily Screen Time on Postoperative Emergence Delirium in Children Aged 2-11 Years

Completely unrelated to APOE4

This observational study asks whether children who spend more time on screens before surgery wake up more agitated from anesthesia. Researchers will survey parents about daily screen habits before the procedure, then measure post-anesthesia agitation in kids aged 2 to 11 using a standard behavioral scale. No phase is listed because this is not a drug or device trial — it is a straightforward observational study looking for an association, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07297121Not yet recruiting

Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece.

Screening tool study, genotype irrelevant

This study is testing whether a newer version of the Montreal Cognitive Assessment, a widely used memory and thinking screening tool, works reliably when given in Greek. Researchers want to confirm the test measures what it is supposed to measure and gives consistent results. There is no phase designation because this is a validation study, not a drug or device trial. No intervention is being tested on participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07422311Phase 2Not yet recruiting

To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing dronabinol — a synthetic form of THC, the active compound in cannabis — as a way to reduce agitation in people who already have Alzheimer's disease. Participants receive either dronabinol or a placebo for about 12 weeks, then everyone can continue on dronabinol for six more months. It is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and is safe — it is not an approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07241156N/ANot yet recruiting

Creative Drama on Gender Role Stress, Attitudes Toward Violence Against Women, and Aggression

No Alzheimer's relevance whatsoever

This study is testing whether a creative drama program can reduce gender role stress, hostile attitudes toward women, and aggressive behavior in men who survived the 2023 earthquake in Türkiye. Participants are randomly placed into drama sessions, film-viewing sessions, or no intervention for 10 weeks. This is a Phase N/A behavioral study, meaning it is testing a structured social program rather than a drug or medical treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06665243N/ANot yet recruiting

Horticultural Activities Among the People with Dementia and Their Family Caregivers

Open to carriers, genotype not considered

This trial is testing whether indoor gardening activities — supported by a smart-growing device — can help people living with dementia feel and function better, while also easing stress and low mood in their family caregivers. Researchers will first run a small pilot, then a larger community study. Phase NA here means this is a behavioral intervention study, not a drug trial — no phase classification is required.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06992726Phase 4Not yet recruiting

Improvement of Fish Oil in Obesity With Mild Cognitive Impairment

Open to carriers, genotype not studied

This trial is testing whether daily fish oil capsules (containing omega-3 fatty acids) can improve cognitive function in people who have both obesity and mild cognitive impairment. Researchers will track memory and thinking, gut bacteria, inflammation markers, and body composition over 12 months. This is a Phase 4 trial, meaning fish oil is already approved and in use — this study is asking whether it works for this specific group.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06494956N/ANot yet recruiting

To Evaluate the Safety of DBS in Patients With Primary Parkinson's Disease

Parkinson's trial, no APOE4 relevance

This trial is testing the safety of a surgically implanted brain stimulation device — deep brain stimulation, or DBS — made by a Chinese medical technology company, for people with primary Parkinson's disease. Electrodes are placed deep in the brain to help regulate movement signals. This is a Phase NA study, meaning it is focused on evaluating safety in a defined patient group rather than proving broad effectiveness. Details beyond safety endpoints are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06821828N/ANot yet recruiting

The Efficacy of Modified Olfactory Training for MCI High-Risk Individuals

Non-drug trial, genotype not specified

This trial is testing whether a modified smell-training device can slow cognitive decline in older adults who already show early warning signs: mild olfactory loss and subjective memory concerns. Participants use the device to practice identifying scents, and researchers compare it to a standard smell-training device. This is a Phase NA trial, meaning it is likely a device feasibility or efficacy study rather than a traditional drug phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05183321N/ANot yet recruiting

Treatment of Periodontal Disease in Patients With Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether treating gum disease (periodontitis) improves outcomes in people who already have mild to moderate Alzheimer's disease. Researchers suspect a link between chronic oral infection and brain inflammation, and want to see if cleaning that up makes a measurable difference. It is a Phase NA — meaning it is a clinical study focused on feasibility and effect, not a standard drug approval pathway.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06972030N/ANot yet recruiting

Motivational Interviewing-Based Training

Completely unrelated to APOE4

This trial is testing whether motivational interviewing, a structured conversation-based technique, can reduce bullying, aggression, and social exclusion among middle schoolers aged 12 to 13. Researchers will train students who already score high on a peer bullying scale and measure whether the approach changes their behavior. This is a Phase NA study, meaning it is a behavioral intervention trial rather than a drug trial, focused on outcomes rather than safety testing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07166744N/ANot yet recruiting

Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies

Diagnostic study, genotype not targeted

This study is testing whether a specific lab measurement of abnormal alpha-synuclein protein, drawn from spinal fluid, a nasal swab, and blood, can reliably tell apart dementia with Lewy bodies from Alzheimer's disease. Right now, those two conditions are often confused, which is dangerous because common medications can severely harm Lewy body patients. This is a Phase NA diagnostic accuracy study, meaning it is evaluating a test, not a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07600320N/ANot yet recruiting

Fareon Open Label Device Clinical Trial

Device trial, genotype not considered

This trial is testing the Fareon device, a wearable at-home brain stimulation tool described as MMT (likely magnetic or electrical stimulation), in people with cognitive problems from brain injury, Long COVID, ME/CFS, or neurodegenerative conditions including Alzheimer's disease. The goal is to check whether the device is safe and practical to use at home, and to gather early data that could shape a larger future study. This is a Phase NA open-label feasibility trial — early-stage exploration, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06719297N/ANot yet recruiting

Cognitive Integrated Motor Training (CM) to Improve Gait and Balance and Reduce Falls in Older Adults With Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether a personalized virtual reality and mixed reality training program that combines movement with thinking tasks can improve walking, balance, and cognitive function in older adults with mild cognitive impairment. Researchers will also measure brain activity to understand what is changing. It is a Phase NA trial, meaning it is a direct effectiveness study rather than an early safety or dose-finding phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07612150Phase 2Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease

Open to carriers, not 4-specific

TML-6 is an experimental drug being tested against a placebo in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by blood biomarkers. The trial runs for 52 weeks and measures whether TML-6 slows cognitive and functional decline. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works and is safe. It has not been proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07097675N/ANot yet recruiting

The Change in Psychoemotional State of Individuals With Dementia Syndrome Applying Art Therapy

Open to carriers, not 4-specific

This trial is testing whether art therapy sessions can improve the emotional well-being of people already living with dementia — specifically measuring changes in anxiety, depression, and stress using a standardized art-based assessment scale called FEATS. It is a Phase NA study, meaning it is not a drug trial but a behavioral intervention study focused on whether a non-drug activity produces measurable emotional benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07158905Phase 1Not yet recruiting

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

Open to carriers, not 4-specific

This trial is testing AV-1980R, an experimental vaccine designed to trigger the immune system against tau — the protein that forms tangles in Alzheimer's-affected brains. It enrolls cognitively normal adults aged 65-80 who already show early Alzheimer's biomarkers in their blood. The goal right now is safety and immune response, not proof that it works. This is a Phase 1 trial — the earliest stage, focused on whether the vaccine is safe in humans.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06761729N/ANot yet recruiting

The Ketogenic Diet in the Treatment of Behavioral Variant Frontotemporal Dementia

Non-Alzheimer's trial, genotype not relevant

This trial is testing a specific ketogenic diet formula called JT821 in people diagnosed with behavioral variant frontotemporal dementia, a type of dementia distinct from Alzheimer's. Researchers want to see whether the diet is effective, safe, and tolerable for this condition. It is a Phase NA exploratory study, meaning it is early and investigational — not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07411365N/ANot yet recruiting

Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI

Parkinson's trial, APOE4 not relevant

This trial tests whether a home-based dual-task training program — pedaling a stationary bike while simultaneously doing digital cognitive exercises on a tablet — can protect everyday functioning and thinking skills in people who have both Parkinson's disease and mild cognitive impairment. It is a Phase NA randomized controlled trial, meaning it is a structured behavioral study comparing two exercise approaches rather than testing a drug, and results are not yet established.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06278688N/ANot yet recruiting

Precision Probiotic Supplementation in Individuals With Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether a personalized probiotic supplement — chosen based on each person's own gut bacteria profile — can slow cognitive decline in people who already have mild cognitive impairment linked to Alzheimer's biology. Participants take the probiotic or a placebo daily for 12 months, with cognitive testing at 6 and 12 months. This is a Phase NA randomized controlled trial, meaning it is a formal efficacy test but not a standard drug-approval phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07621874N/ANot yet recruiting

Intensive Care Unit Conflict Mediation Study

Unrelated to APOE4 or Alzheimer's

This trial is testing a structured conflict management program called SEM DESTINO in an adult intensive care unit. It brings together a multidisciplinary team to mediate disputes between staff and patients' families, measuring how often conflicts happen, how severe they are, and how satisfied families and staff feel afterward. This is a Phase NA behavioral study, meaning it is evaluating a process or program rather than a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06797817Phase 3Not yet recruiting

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Open to carriers, not 4-specific

This trial is testing tributyrin, a dietary supplement that the body converts to butyrate, a compound produced by gut bacteria. Researchers want to know whether it can slow cognitive decline and reduce inflammation in people with mild Alzheimer's disease. They will also track gut health and blood markers like pTau217 and NfL. It is a Phase 3 trial, meaning it is a larger, later-stage test of whether the approach actually works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06662526Phase 4Not yet recruiting

Lithium for Prevention of Cognitive Declining in Mood Illnesses

Open to carriers, genotype not tracked

This trial is testing whether a very low daily dose of lithium (50 mg, far below standard psychiatric doses) can slow or prevent the development of mild cognitive impairment in people who already have a mood disorder like depression or bipolar disorder. It is a Phase 4 trial, meaning lithium is already approved for other uses, but researchers are studying this specific low-dose, neuroprotective application in a new population.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07216950Phase 2Not yet recruiting

Knowledge and Interpersonal Skills to Develop Enhanced Relationships (KINDER)

Caregiver study, genotype not relevant

This trial tests a behavioral program called KINDER, designed to help family caregivers of people with dementia communicate better and reduce relationship strain — with the goal of preventing psychological abuse toward the person they care for. A Phase 2 trial means researchers are testing whether the program actually works, not just whether it is safe. A comparison group receives a general healthy-living program for caregivers instead.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05855863Phase 4Not yet recruiting

Clinical Study of GKT in Diabetes Related Dementia

Open to carriers, not 4-specific

This trial is testing Ginkgo Biloba Ketone Ester Tablets against a placebo in older adults who have both Type 2 diabetes and mild cognitive impairment. Researchers want to see whether this herbal extract can improve thinking and memory in a specific dementia subtype linked to diabetes-related brain changes. This is a Phase 4 trial, meaning the drug is already approved for some uses, and this study explores a new application.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07549074N/ANot yet recruiting

Multicomponent Intervention to Improve Cognitive Abilities in Older Adults With Mild Cognitive Impairment

Open to carriers, genotype not studied

This trial is testing a combination of brain-training exercises and healthy lifestyle education in older adults who already have mild cognitive impairment (MCI). Researchers want to know whether these activities, used together or separately, help maintain or improve thinking and memory skills. Phase NA means this is a practical intervention study — not testing a drug, but evaluating a structured program. It is a blinded, randomized controlled trial with 200 participants across four groups.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06628427Not yet recruiting

Unlock the Secrets of Ageing Brains Through P300 Brain-computer Interface Games

Observational only, genotype not considered

This study is testing whether EEG brainwave recordings, combined with a brain-computer interface game and a visual motion task, can help researchers better understand what is happening in the brains of people with mild cognitive impairment. It is an observational and diagnostic study, not a drug or treatment trial. There is no assigned phase, meaning this is exploratory research aimed at learning, not at proving a therapy works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06194006N/ANot yet recruiting

Long Term Follow-up Grafted Huntington's Disease Patients

Unrelated to APOE4 or Alzheimer's

This study is following Huntington's disease patients who already received experimental brain cell transplants (intrastriatal allografts) under an earlier trial called MIG-HD. Researchers want to track how those patients are doing long-term — looking at whether the transplants helped, caused side effects, or triggered immune reactions. This is a follow-up observational study, not a new treatment trial. No intervention is being given; it is purely monitoring.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07142278Phase 1Not yet recruiting

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Open to carriers, genotype not screened

DUVAX is an experimental vaccine designed to trigger the immune system to produce antibodies against amyloid-beta and tau, two proteins that build up in Alzheimer's disease. This Phase 1 trial is the earliest stage of human testing — focused on safety and immune response, not yet on whether it slows or prevents disease. Researchers are comparing two doses against a placebo in healthy adults ages 40 to 65.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07531082N/ANot yet recruiting

Effects of a Salutogenic Strength-based Social Robot-assisted Intervention on the Depressive Symptoms and Sense of Coherence of Family Caregivers of Persons With Dementia

Caregiver support, genotype not relevant

This trial tests whether a social robot with an AI chatbot can reduce depression in family caregivers of people with dementia. Caregivers use the robot at home for six weeks while researchers measure mood, stress, and coping skills. This is a Phase NA behavioral trial, meaning it is evaluating whether the approach works, not testing a drug or medical device. It is a randomized controlled trial, so results will be compared against a control group receiving reading materials.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06942728N/ANot yet recruiting

Personalized Medicine in the Elderly With Vision Impairment and Mild Cognitive Impairment

Open to carriers, genotype not considered

This trial tests a home-based computerized brain training program called nLIFE EyeFitness — a tablet or PC software that exercises attention, memory, reaction time, and executive function — in adults 60 and older who have mild cognitive impairment and some degree of vision difficulty. It is a Phase N/A study, meaning it is a feasibility or exploratory investigation, not a pivotal efficacy trial. The goal is to see whether this kind of personalized digital cognitive training can support people at this early stage.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06519643N/ANot yet recruiting

Building Your Successful Nursing Career

No relevance to APOE4 carriers

This trial is testing a mobile app designed to help male nurses plan their careers and avoid burnout. Researchers will track 120 male nurses over two years to see whether the app improves confidence, career adaptability, and intention to stay in nursing. This is a Phase NA behavioral study — it is evaluating a real-world tool, not a drug or medical treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07353359N/ANot yet recruiting

Effect of Intranasal Negative Pressure Therapy on Cognitive Function in Patients With Mild Cognitive Impairment and Obstructive Sleep Apnea

Open to carriers, not 4-specific

This trial is testing whether a device called iNAP, which uses gentle intranasal negative pressure to keep the airway open during sleep, can improve cognitive scores in people who already have both mild cognitive impairment and moderate-to-severe sleep apnea. Researchers will measure thinking ability using the MoCA test after 24 weeks of nightly use. This is a Phase NA, meaning it is a straightforward randomized controlled trial focused on feasibility and effect, not a drug approval track.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07054645N/ANot yet recruiting

Elderberry Functional Gum and Cognitive & Oral Health in Older Adults

Open to carriers, not 4-specific

This trial is testing whether chewing gum infused with elderberry anthocyanins — natural plant compounds with antioxidant properties — can support cognitive function and balance the oral microbiome in older adults with mild cognitive impairment. Participants chew either the elderberry gum or a placebo gum daily. This is a Phase NA study, meaning it is a randomized controlled trial focused on feasibility and early effect measurement, not a late-stage proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06898931N/ANot yet recruiting

Language Intervention Training for Cognitive Protection in High-risk Cardio-Cerebrovascular Elderly Population

Behavioral study, genotype not considered

This trial is testing whether a dialect-switching training program can protect cognitive function in older adults who are at high risk for stroke. Participants practice switching between dialects, similar to interpreting, over six months. Researchers will measure whether this kind of mental exercise slows early cognitive decline. This is a Phase NA behavioral study, meaning it is evaluating a structured training approach rather than a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05899764Phase 1Not yet recruiting

Epileptic Hippocampus in Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 1 trial is testing brivaracetam, an anti-seizure medication, in people with MCI or Alzheimer's disease who show abnormal electrical activity in the hippocampus — the brain's memory center. Researchers want to know whether the drug can quiet that activity and whether doing so improves cognition. Phase 1 means they are primarily checking safety and early signals, not yet proving the treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06762522N/ANot yet recruiting

Exploring Feasibility, Acceptability and Impact of Using Neurofeedback with Persons with Mild Cognitive Impairment

Open to carriers, not 4-specific

This pilot study is testing three different types of neurofeedback — a non-drug brain-training approach using real-time brainwave feedback — to see whether they are practical and acceptable for people with mild cognitive impairment, and whether five weeks of sessions might help with thinking, mood, or behavior. Phase NA means this is early exploratory work, not a test of an already-promising treatment. Details beyond the basics are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06934720Phase 1Not yet recruiting

VR-based Physical Activity and Reminiscence Therapy

Lifestyle study, genotype not mentioned

This trial is testing a combination of virtual reality and physical activity called aPAVRCT — think VR headset plus a stationary bike — to see whether it slows cognitive decline in older adults with Alzheimer's or MCI. Researchers will compare it to regular bike exercise alone over 12 to 16 weeks. This is a Phase 1 trial, meaning the focus is on safety and early signals, not yet proof that it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06559813N/ANot yet recruiting

Pilot Study of Parent Training With Role-plays in Virtual Reality for Parents of Children With Behavior Problems

Unrelated to APOE4 or dementia

This pilot study tests a parenting program that combines cognitive behavioral therapy with virtual reality role-plays. Parents of children aged 8 to 16 with defiant or aggressive behavior practice parenting skills in VR during clinic sessions. Researchers are measuring early signs of effectiveness and whether parents stick with it. This is a Phase NA pilot study, meaning it is exploratory and very early stage, not a test of a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06611202N/ANot yet recruiting

Enhancing Mobility and Mental Health in Dementia Patients

General dementia study, no genotype focus

This trial tests whether a team-based walking and activity program — led by physiotherapists, occupational therapists, and psychologists — can improve mobility, daily functioning, mood, and cognition in people already living with dementia. Clonazepam appears in the intervention list but the summary does not explain its role. Phase NA means this is not a standard drug-efficacy trial; it reads more like a structured care or feasibility study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06773741Not yet recruiting

Emotional Care Competency Scale for Dementia: Development and Correlations With Knowledge, Attitudes, and Confidence

Not relevant to APOE4 carriers

This study is not a clinical trial testing a drug, device, or health intervention. It is a research project developing and validating a measurement scale to assess how well long-term care professionals handle the emotional side of dementia care. Researchers will interview caregivers, build the scale, then survey care workers twice to test whether it holds up. The phase is unspecified because this is a tool-development study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06021704N/ANot yet recruiting

The Care for America's Aging Study

Open to carriers, not 4-specific

This trial is testing whether giving home health aides better dementia-specific training changes outcomes for people living with dementia or cognitive impairment at home. The main questions are whether the training reduces behavioral symptoms in patients and improves quality of life for both patients and their family caregivers. It is a Phase NA randomized pilot study, meaning it is an early feasibility test, not a proven or approved program.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06791720N/ANot yet recruiting

Effects of Music-with-Movement on Cognitive and Physical Performance of People With Potentially Reversible Cognitive Frailty: a Randomised Controlled Trial

Lifestyle study, genotype not considered

This trial is testing whether combining music with movement — a simultaneous mental and physical workout — improves thinking, physical ability, and wellbeing in older adults who have both mild cognitive impairment and physical frailty at the same time. Participants either join structured music-movement sessions or weekly social gatherings over 16 weeks, with follow-up at 28 weeks. This is a Phase NA behavioral trial, meaning it is evaluating a non-drug program rather than a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06761066N/ANot yet recruiting

Efficacy and Safety of NVP-NK4146 in Patients with Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing a dietary supplement called NVP-NK4146 against a placebo in adults aged 60 and older who have mild cognitive impairment (MCI) with confirmed amyloid buildup in the brain. Researchers want to see whether the supplement helps cognition and is safe. This is a Phase NA study, meaning it is exploratory in nature — early-stage evidence gathering, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07604883Not yet recruiting

Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes

Unrelated to APOE4 or Alzheimer's

This observational study is looking for molecular clues in blood, urine, and stool that could help doctors tell Parkinson's disease apart from rarer movement disorders like Multiple System Atrophy and Progressive Supranuclear Palsy. No treatments are given. Participants are followed for 12 to 18 months and donate biological samples for analysis. There is no assigned phase — this is early discovery research, not a drug test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07087951N/ANot yet recruiting

Efficacy of Gamma Auditory Stimulation for Cognitive Decline in Older Adults (Study 1)

Open to carriers, not 4-specific

This trial is testing whether listening to sound pulses at 40 Hz (a specific brainwave frequency) can improve memory and thinking in older adults who already have mild cognitive impairment or mild dementia. Researchers will compare an active sound device to a sham version to see if the stimulation affects cognition, brainwave patterns, sleep, and quality of life. This is a Phase NA trial, meaning it is evaluating effectiveness of a device rather than following a traditional drug-trial phase structure.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06351800N/ANot yet recruiting

The PredictPlusPrevent Study

General wellness trial, no APOE4 relevance

This trial is testing a smartphone app designed to prevent depression and anxiety before they start. Researchers are comparing a personalized, multi-module behavioral app against a self-help booklet program in over 9,000 adults in Spain. It is a Phase NA trial — meaning this is a direct evaluation of effectiveness, not an early safety or dosing study. The app uses risk-prediction algorithms to tailor a prevention plan for each user.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06604507Not yet recruiting

Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Injury in Ukraine (PAMELA)

No Alzheimer's or APOE4 relevance

This study is testing whether a smartphone app can help Ukrainian war amputees manage phantom limb pain without medication. Researchers will run the app in five rehabilitation centers for eight weeks, then refine it based on what they learn. The phase is unspecified, which typically means early feasibility work — the goal right now is simply to find out whether the app can be used reliably in this setting, not yet whether it definitively works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT07613957N/ANot yet recruiting

Comparison of AI-based Smartphone-derived Gait Parameters With the Gold Standard

Healthy adults only, not APOE4-related

This study is testing whether AI-powered smartphone apps can measure how people walk just as accurately as a high-tech motion-capture lab system. Researchers will ask 40 healthy adults to walk while carrying iPhones and Android phones in their pockets, while a professional Vicon camera system records the same movement simultaneously. This is a Phase NA validation study — it is not testing a treatment, just checking whether a low-cost tool matches the gold standard.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT07410052N/ANot yet recruiting

Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination

Supplement study, genotype not considered

This trial is testing whether a combination of a probiotic (Lactobacillus rhamnosus GG) and riboflavin (vitamin B2) delivered to the colon can improve memory and brain function in older adults with mild memory complaints. Participants take the supplements daily for 12 weeks. It is a Phase NA study, meaning it is a well-controlled pilot or feasibility trial rather than a late-stage efficacy study. Details on scale and funding are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05667935Not yet recruiting

Cognitive Impairment Cohort Study of the Elderly Population in SheMountain

APOE4 data collected, local enrollment only

This is an observational study, not a treatment trial. Researchers in Shanghai are following 2,000 adults aged 60 and older over two years to learn how cognitive impairment develops and progresses. They are collecting brain scans, blood samples, memory tests, speech recordings, and genetic information to build models that may better predict who develops MCI or Alzheimer's. No phase is assigned because no drug or intervention is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07047963Not yet recruiting

Neuropsychological Evaluation in Intellectual Disability (ENDI)

Not relevant to APOE4 carriers

This observational study is testing a new neuropsychological battery called ENDI, designed specifically for people with Down syndrome (Trisomy 21). Researchers want to know whether patients can comfortably complete the tests and whether the tests work as intended. There is no drug or treatment involved — just cognitive assessments. The phase is unspecified, meaning this is likely early-stage tool development and validation rather than a clinical treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07064382N/ANot yet recruiting

VR-based Multi-dimensional Intervention on Cognitive Function, With AI-agents

Open to carriers, genotype not mentioned

This trial tests a virtual reality program that combines physical activity, games, and cognitive training, guided by AI agents, to see whether it improves memory, spatial thinking, sleep, and mental health in older adults. It is a Phase NA study, meaning it is evaluating a device or behavioral approach rather than following the standard drug-trial phases. Details beyond the basic setup are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06556069N/ANot yet recruiting

Clinical Trial of Peer Support in the ED (PCORI)

Unrelated to APOE4 or dementia

This trial is testing a peer support program for people who become agitated in the emergency department. Trained peers work alongside the ER team to help calm patients without relying solely on medication or restraint. It is a feasibility study, meaning researchers are checking whether the approach is practical and acceptable before testing it more widely. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07573046Not yet recruiting

Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders

Diagnostic tool study, genotype irrelevant

This study is testing a new cognitive assessment tool called the ExéSem battery. Researchers want to know whether it can reliably tell apart two different causes of word-finding problems: one rooted in damaged semantic memory, the other in impaired executive control. It enrolls people with Alzheimer's disease, vascular cognitive impairment, a language disorder called semantic variant PPA, and healthy adults for comparison. There is no phase designation — this is a diagnostic validation study, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03887455Phase 3Active

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Open to carriers, but ARIA risk elevated

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia with confirmed amyloid in the brain. Phase 3 means the drug has already shown early promise and this is a larger confirmatory test of whether it actually slows cognitive decline, measured by a standard clinical rating scale over 18 months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
247 sites
NCT04430517Early Phase 1Active

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

Directly recruits APOE4 carriers

This early-phase trial is testing nicotinamide riboside, a form of vitamin B3, in people who already have mild cognitive impairment or mild Alzheimer's dementia. Researchers want to see whether NR affects how the brain uses energy, handles oxidative stress, and whether it influences cognitive function. Early Phase 1 means this is a preliminary safety and feasibility look, not a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04468659Phase 3Active

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

APOE4 carriers explicitly welcomed

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains — before any symptoms appear. One arm tests whether it slows cognitive decline over four years; the other tests whether it reduces amyloid accumulation. Phase 3 means this is a large-scale test of whether it actually works, not a preliminary safety study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
107 sites
NCT05386914Phase 1Active

This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults

Part II enrolls APOE4 carriers only

This trial is testing whether sirolimus, an FDA-approved drug used in transplant medicine, can improve blood flow to the brain in cognitively healthy adults. Part II also measures how the drug affects lung blood flow using a special inhaled gas MRI technique. It is a Phase 1 trial, meaning the focus is on safety and early signals, not proof that the drug works. Part I is closed; Part II is ongoing.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04055376N/AActive

Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

Device trial, carriers not excluded

This trial is testing whether daily exposure to flickering light and pulsed sound at a specific frequency (40 Hz, known as gamma stimulation) can improve brain function in people who already have mild Alzheimer's disease. Participants use a device at home and are compared to a group using a sham version that delivers no real stimulation. This is a Phase NA designation, meaning it is a device feasibility and safety study rather than a standard drug efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04792528N/AActive

REACT MCI - Repeated Advanced Cognitive Training in Mild Cognitive Impairment

Non-drug study, Norway only

This trial is testing whether computerized working memory training helps people with mild cognitive impairment (MCI) think more clearly and function better in daily life. Participants in Norway are randomly assigned to two rounds of training, one round, or an active control. Researchers will also measure brain clearance, genetics, and caregiver stress over four years. This is a Phase NA study — meaning it is evaluating a behavioral intervention rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT06605157N/AActive

A Multimodal Music Therapy Intervention for Engaging Persons With Severe Dementia

Late-stage dementia only, not carrier-focused

This pilot trial is testing whether a structured music therapy program called AMUSED, which includes live music, singing, and rhythm instruments, reduces behavioral symptoms and improves engagement in people with severe dementia living in care facilities. It compares music therapy to a group reading activity over 12 weeks. This is a feasibility pilot, meaning researchers are figuring out whether a larger, definitive trial is even practical to run.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
8 sites
NCT06705738N/AActive

The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients with Mild Cognitive Impairment

Open to carriers, genotype not tracked

This trial is testing whether combining the Mediterranean diet with a daily olive oil polyphenol supplement called SUPOL — whose main active ingredient is oleocanthal, a compound found in high-quality extra virgin olive oil — can help slow cognitive decline in people already diagnosed with mild cognitive impairment. It is a Phase NA randomized controlled trial, meaning it is an investigational study focused on whether this combined lifestyle and supplement approach shows measurable benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03016741Phase 4Active

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Cancer patients only, genotype not specified

This trial is studying whether prostate cancer hormone therapies — specifically abiraterone acetate and enzalutamide — affect brain structure and cognitive function. Researchers are using MRI scans and cognitive tests to track changes, and they are also collecting genetic data to see who may be more vulnerable to those effects. This is a Phase 4 trial, meaning the drugs are already approved but researchers are still learning about their side effects.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT06536322N/AActive

Evaluation of the Use of a Novel Oral Health Screening Instrument by Caregivers in Nursing Homes

Not APOE4-relevant, nursing home tool

This trial is testing a new oral health screening tool called OHS-interRAI, designed to be used by regular nursing home caregivers rather than dental professionals. Researchers want to know whether using this tool regularly improves the oral health of residents with dementia and other conditions over two years. This is a Phase N/A trial, meaning it is evaluating a practical care tool rather than a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05461495N/AActive

NYUCI-ES: Psychosocial Intervention to Improve Health Outcomes for Chinese and Korean ADRD Caregivers

Caregiver study, genotype not a factor

This study is testing a culturally adapted counseling and peer support program for Chinese and Korean American family caregivers of people with dementia. Caregivers are randomly assigned to receive structured counseling plus online peer support through apps like WeChat or KakaoTalk, or to a control group. Researchers measure whether the program reduces depression, stress, and physical health risks like high blood sugar and cholesterol over 12 months. This is a Phase NA behavioral trial — it tests real-world program effectiveness, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05749146N/AActive

Palliative Care for Patients With Dementia

Late-stage care, genotype not relevant

This trial is testing whether a structured in-home palliative care program improves quality of life and comfort for people with advanced dementia and their family caregivers. Participants are randomly assigned to either the home palliative care program or a standard enhanced care group. This is a Phase NA trial, meaning it is evaluating real-world effectiveness of a care delivery model, not a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06121986N/AActive

A Scalable Nutrition Adherence Intervention

Diet study, genotype not considered

This trial is testing two diets — the standard Mediterranean diet and a Modified Mediterranean-Ketogenic diet — to see how well people stick to each one and whether either diet improves gut health markers linked to Alzheimer's risk. It focuses on racially diverse rural communities in North Florida. This is a Phase N/A behavioral study, meaning it is testing a real-world program rather than a drug, and results are not yet proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05068830Phase 2Active

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 2 trial is testing whether transfusing blood plasma donated by young, fit, exercise-trained adults can be safely given to people with mild cognitive impairment or early Alzheimer's disease. Researchers will track cognitive function, brain imaging measures, and blood and spinal fluid biomarkers. Phase 2 means they are exploring whether it works and confirming safety — it is not a proven or approved treatment. The study is based in Norway.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06519357Phase 2Active

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Open to carriers, not 4-specific

This trial is testing whether lamivudine, an antiviral drug already approved for HIV and hepatitis B, can lower biological markers of cognitive decline in people with early Alzheimer's-related memory impairment. The idea is that lamivudine may quiet a type of cellular stress response linked to brain inflammation. It is a Phase 2 pilot study, meaning researchers are checking whether it shows early signs of working and is safe, not proving it as a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07503743Active

Biology-Driven Cognitive Profiling in Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is studying Huntington's disease, not Alzheimer's. Researchers are using a specialized PET brain scan with a tau-detecting tracer, MRI, and cognitive tests to build better tools for spotting early brain changes in HD gene carriers before symptoms appear. It is a small pilot study — early-stage research focused on measurement and biology, not testing a treatment. Details on long-term outcomes are limited at this stage.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03649724Phase 2Active

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Open to carriers, not 4-specific

The LUCINDA Trial is testing whether leuprolide acetate, a hormone-suppressing drug already used for other conditions, can slow cognitive decline when added to a cholinesterase inhibitor like donepezil. It enrolls post-menopausal women with MCI or early Alzheimer's and runs for 48 weeks. This is a Phase 2 trial, meaning researchers are testing whether it works and is safe — it is not proven or approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT04583215N/AActive

Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment

Open to carriers, genotype not required

This trial is testing a brain stimulation device called Paired Associative Stimulation, or PAS, which targets the prefrontal cortex to try to strengthen how brain cells connect and communicate. Researchers want to see whether stimulating this region improves cognitive function in people already diagnosed with Mild Cognitive Impairment. This is a Phase NA designation, meaning it is a device feasibility or pilot study — early-stage, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04713982Phase 2Active

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Not relevant to APOE4 carriers

This trial is testing whether deutetrabenazine, a drug already used to reduce involuntary movements in Huntington's disease, also improves how patients speak and walk. Researchers will measure changes in speech quality and gait patterns over the course of treatment. This is a Phase 2 trial, meaning scientists are still gathering evidence on whether it works and how safe it is — it is not yet proven or approved for these specific symptoms.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07364825N/AActive

Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

Open to carriers, not 4-specific

This pilot trial is testing whether patients with acute psychiatric conditions, including dementia-related behavioral symptoms, can safely receive hospital-level psychiatric care at home instead of in a traditional inpatient unit. It is measuring how many patients are eligible and willing to participate. This is a Phase NA feasibility pilot, meaning it is exploring whether the approach is practical, not yet proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT06991816Active

The Brain&Senses Study

Observational only, genotype not mentioned

This is a 5-year observational study — researchers watch what happens, they do not give any treatment. It is tracking whether losing senses like smell, hearing, or balance speeds up cognitive decline and affects quality of life in people over 60. Specialists will test all three senses at the start and follow participants over time. It is not a drug or intervention trial, so there is nothing proven or approved being tested here.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06544616Phase 2Active

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already show early tau buildup but have no memory symptoms yet — what researchers call preclinical Alzheimer's disease. This is a Phase 2 trial, meaning scientists are still determining whether it works and is safe. It has not been proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
90 sites
NCT06691256Phase 2Active

Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation

Device study, genotype not relevant

This trial is testing a smart medication dispenser called HiDO-ALZ, designed for people living with both dementia and type 2 diabetes. The device uses facial recognition and video recording to confirm the right person takes the right medications at the right time, while sharing real-time data with caregivers and doctors. It is a Phase 2 trial, meaning researchers are expanding earlier work to test whether the device actually improves medication adherence at home.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05734638N/AActive

Stress and Blood Pressure Management for Caregivers

Caregiver study, genotype not a factor

This trial tests two behavioral programs for African American women who are caregivers for someone living with dementia and who also have high blood pressure. One program teaches mindfulness and movement. The other adapts the DASH diet for Black Americans. Researchers are testing them separately and combined to see which best reduces stress and blood pressure. This is a Phase N/A trial, meaning it is a real-world behavioral study, not a drug test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05098652N/AActive

Coaching Dementia Caregivers to Master Care-Resistant Behavior

Caregiver support, genotype irrelevant

This trial is testing a behavioral coaching program called CuRB-IT, designed to help family caregivers manage moments when a person with dementia resists or refuses care — like refusing to bathe or take medications. Caregivers are coached over 12 weeks and tracked through daily diaries and surveys. This is a Phase NA trial, meaning it is evaluating how well a structured support program works in a real-world caregiving setting, not testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07224347Active

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

General aging study, genotype not addressed

ASPREE-XT is following older adults who were previously in the ASPREE aspirin trial to see what happens after they stopped taking aspirin. Researchers are watching for delayed effects on cancer, heart disease, stroke, dementia, and other outcomes. This is an observational follow-up, not a treatment study — no one is being given a drug. It is unphased, meaning it is ongoing data collection rather than a formal efficacy or safety test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
36 sites
NCT06631144N/AActive

A Spanish-language Caregiver-Enabled Care Program

Caregiver support, genotype not relevant

This trial is testing a digital support program built specifically for Spanish-speaking family caregivers of people with dementia. It delivers personalized education, one-on-one coaching, and remote check-ins through a tablet sent to the caregiver's home. The goal right now is to see whether the program is practical and usable — a feasibility study, not a final proof of effectiveness. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04289402N/AActive

Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease

Open to carriers, genotype not tracked

This pilot trial is testing whether a personalized form of transcranial direct current stimulation (tDCS) — a non-invasive technique that delivers a mild electrical current to a specific brain region — can improve thinking skills and physical mobility in people with mild Alzheimer's disease. Participants receive 10 sessions of real or sham stimulation. Phase NA means this is a small feasibility study, not a full efficacy trial. Details on longer-term outcomes are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06475534Active

The Nuestros Días ("Our Days") Study

Caregiver study, genotype not relevant

This observational study tracks the mental health and well-being of Hispanic and Latino caregivers who look after a family member with memory problems or dementia. Researchers want to understand what daily factors make depression and anxiety better or worse, and whether those patterns predict longer-term health outcomes. Participants complete online surveys at baseline, daily for three weeks, and again at six and twelve months. No phase designation — this is not a drug or device trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07386808N/AActive

Improvement of Sleep Disorders in Patients With Alzheimer's Disease After Sunlight Exposure Therapy.

General AD study, genotype not considered

This study is testing whether daily sunlight exposure helps improve sleep problems in people who already have Alzheimer's disease. Researchers will track sleep patterns over 14 days using questionnaires and recordings. It is listed as Phase NA, meaning it is an observational study rather than a controlled drug trial — it is gathering real-world data, not yet proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07093684Active

Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies

Registry study, genotype not considered

This is an observational study, not a drug trial. Researchers are analyzing over a decade of health registry data from Sweden and other countries to map the two-way relationship between kidney disease and dementia. They want to know whether each condition worsens the other, and whether drugs used for kidneys or dementia have any protective effect on the opposite organ. No phase is listed because no intervention is being tested on participants.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06870838Active

Neuroinflammation in FTLD

Not relevant to APOE4 carriers

This observational study is investigating neuroinflammation in frontotemporal lobar degeneration, a group of brain diseases distinct from Alzheimer's. Researchers are using ultra-high-field 7T MRI scans, spinal fluid, and blood samples to look for biological markers that could distinguish disease subtypes and track progression. No phase is listed because this is not a drug trial — it is a research study collecting data, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05527405N/AActive

Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes

Open to carriers, genotype not required

This trial is testing a tablet-based visual scheduling app called MapHabit, paired with a structured caregiver training program, to see whether the combination reduces caregiver burden and improves daily functioning for people with Alzheimer's or related dementias. It is a Phase NA randomized controlled trial — meaning it is evaluating a behavioral and digital tool, not a drug, in a real-world care setting. Fifty patient-caregiver pairs will be followed for six months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06721156Phase 2Active

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

Open to carriers, not 4-specific

This trial is testing MK-1167, an experimental drug given alongside a standard Alzheimer's medication called an acetylcholinesterase inhibitor. Researchers want to know if MK-1167 improves memory and thinking in people who already have mild to moderate Alzheimer's dementia. It is a Phase 2 trial, meaning they are testing whether it works and is safe — it is not approved or proven yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
72 sites
NCT05686551Phase 2Active

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Not relevant to APOE4 or Alzheimer's

This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is to see whether it is safe and whether it slows disease progression. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works — it is not approved or proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
70 sites
NCT04679441Phase 2Active

A Novel Computer-Based Functional Skills Assessment and Training Program

Open to carriers, genotype not considered

This trial is testing a computer-based program designed to help older adults practice everyday tasks like managing finances and medications. Researchers are comparing it to an existing brain-training tool called Brain HQ. It enrolls both people with Mild Cognitive Impairment and cognitively healthy older adults. This is a Phase 2 trial — meaning researchers are refining and further evaluating the program, not a final proof of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05834296Phase 1Active

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Open to carriers, not 4-specific

This trial is testing ALZN002, a personalized immune-cell therapy for people who already have mild-to-moderate Alzheimer's dementia. Researchers take a patient's own dendritic cells, load them with a modified amyloid-beta protein fragment, and inject them back — essentially trying to train the immune system to target amyloid buildup. This is a Phase 1/2a trial, meaning it is primarily focused on safety and early signals of effect. It is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04408625Phase 1Active

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Wrong condition, not APOE4-relevant

This trial is testing LY3884963, a biological therapy delivered directly into the fluid around the brain and spine, in people who have frontotemporal dementia caused by a mutation in the progranulin gene (GRN). Researchers are measuring safety, tolerability, and whether the drug raises progranulin protein levels. This is a Phase 1/2 trial — an early-stage study focused on safety and initial signs of effect, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
12 sites
NCT05507905N/AActive

Effects of Dance and Music Appreciation on Brain Health and Fitness in People at Risk for Alzheimer's Disease

Open to carriers, genotype not required

This trial is testing whether dance classes or music appreciation sessions help protect memory and cardiovascular fitness in older adults worried about memory loss. Researchers want to find the sweet spot — one, two, or three classes per week — that does the most good. It is a Phase NA study, meaning it is a behavioral intervention trial focused on finding the right dose, not a drug being evaluated for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03382223Active

Panel Study Investigating Status of Cognitively Impaired Elderly in Singapore

No APOE4 relevance found

This is an observational study in Singapore, not a clinical trial testing a drug or therapy. Researchers are surveying caregivers of people with severe dementia every few months until the patient dies, and then during bereavement. The goal is to better understand end-of-life care, costs, and caregiver burden, and to build a tool that predicts six-month mortality. No phase is listed because no intervention is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
9 sites
NCT04908358N/AActive

The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance

Open to carriers, not 4-specific

This trial is testing a non-invasive device called RAVANS, or tVNS, which delivers a gentle electrical pulse to the ear to stimulate the vagus nerve — a major nerve connecting the brain and body. Researchers want to know whether this stimulation improves thinking and memory in cognitively healthy older adults. This is a Phase NA study, meaning it is exploratory research designed to gather early evidence, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07051408Active

Predictors Of Cognitive Decline Using Digital Devices

Open to carriers, genotype not considered

This study is testing whether people with memory concerns will actually use digital devices — a smartwatch, a sleep headband, and smartphone apps — in their daily lives, and whether the data collected can be combined with clinical records to build machine learning models that might one day predict dementia risk. It is not a treatment trial. It is an observational feasibility study, meaning researchers are checking whether this kind of data collection is even practical before doing anything larger.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03909347N/AActive

PLAN: Dementia Literacy Education and Navigation for Korean Elders With Probable Dementia and Their Caregivers

Genotype irrelevant, community-specific trial

This trial is testing a community health worker program called PLAN, designed to help Korean American elders who may have undiagnosed dementia get connected to medical care, and to help their caregivers understand dementia, reduce depression, and feel more supported. It is a Phase NA behavioral study, meaning it is evaluating a real-world support and navigation program, not a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04935372Active

β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline

Observational only, genotype not specified

This observational cohort study is testing whether blood-based biomarkers can detect early Alzheimer's-related changes in people who have subjective memory concerns or mild cognitive impairment. Researchers are also evaluating a digital tool called Altoida NMI as a way to track disease progression. No drug or treatment is involved. This is not a clinical trial of a therapy — it is a data-collection study to improve how we identify and monitor early Alzheimer's pathology.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT01532739N/AActive

Making Memory Better for Seniors With Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial tests a group-based cognitive training program for people with Mild Cognitive Impairment (MCI). It focuses on everyday memory problems and pairs traditional memory exercises with a structured problem-solving approach. Phase NA here means this is a feasibility and effectiveness study — essentially asking whether the program works in a real-world clinical setting, not a standard drug trial with phased approval stages.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03846492N/AActive

Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS

Open to carriers, not 4-specific

This trial is testing whether a non-invasive brain stimulation technique called tDCS (which delivers a mild electrical current through the scalp) can reduce agitation and aggression in people living with Alzheimer's dementia. A separate brain-mapping method, TMS-EEG, is used to study why agitation happens in the first place. This is a Phase NA (exploratory) study — it is investigating mechanisms and early effectiveness, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05956834Active

A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes

Unrelated to APOE4 or Alzheimer's

This observational study is tracking motor symptoms in people diagnosed with Progressive Supranuclear Palsy (PSP) using two wearable sensor devices — PAMSys and LEGSys — that monitor movement and balance remotely over 12 months. It is not a treatment trial; no drug or therapy is being tested. The goal is to see whether these devices can reliably capture how PSP progresses from home, potentially building a monitoring toolkit for related conditions like FTD. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05368350N/AActive

Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation

Not Alzheimer-focused, genotype irrelevant

This trial is testing whether a gentle electrical current applied to specific brain regions can improve speech and language problems in people with primary progressive aphasia or progressive apraxia of speech. Researchers will measure changes using speech and language assessments and brainwave recordings. This is a Phase N/A trial, meaning it is an interventional study outside the standard phase framework — typically exploratory or feasibility-focused rather than a large-scale efficacy test.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06211374N/AActive

Communication Bridge Pilot Study

Not APOE4-focused, PPA patients only

This trial is testing a web-based communication program called Communication Bridge, designed specifically for people with primary progressive aphasia (PPA) — a brain condition that gradually erodes language ability. Researchers want to know whether the program helps maintain or improve communication, and whether it is practical to deliver. This is a feasibility pilot, meaning the goal is to see if the approach works well enough to test more broadly later. It is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07321821N/AActive

Fermented Garlic Lettuce Powder and Cognitive Function in Adults With Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether a fermented garlic lettuce powder supplement, taken daily for two months, improves cognitive function and psychological well-being in adults who already show signs of mild cognitive impairment. Participants are compared against a placebo group. This is a Phase NA trial, meaning it is a straightforward controlled study rather than a drug approval pathway, typically used for supplements and behavioral interventions.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06880510N/AActive

The Locus Coeruleus, Norepinephrine and Cognitive Aging

Open to carriers, not 4-specific

This trial is studying the locus coeruleus, a small brain region that loses health early in Alzheimer's disease. Researchers are using MRI scans, pupil-response measurements, and a mild nerve-stimulation device worn on the ear to see how this brain region functions and whether simple physical signals can reflect its condition. This is a Phase NA study, meaning it is exploratory research rather than a test of a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05738486Phase 3Active

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

ARIA-focused — carriers often restricted

This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate and severity of ARIA-E, a type of brain swelling that can occur as a side effect. Researchers also want to identify who is most at risk for ARIA. Phase 3 means the drug's basic effectiveness has been studied before; this round focuses on safety optimization across dosing strategies.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
49 sites
NCT03108846Phase 3Active

Escitalopram for Agitation in Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase 3 means the drug is well-studied generally, and researchers are now confirming whether it works for this specific problem. Agitation is one of the most distressing symptoms for both patients and caregivers, and there are few good drug options today.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
29 sites
NCT02971124Active

Dr Solitaire: Assessing Cognitive Performance Through Meaningful Play

Observational only, genotype not relevant

This study tests whether playing a digital version of Solitaire can measure cognitive performance. Researchers want to identify specific in-game behaviors — how quickly you move, how many errors you make, and so on — that might reflect how well your brain is functioning. It has no assigned phase, meaning it is an observational feasibility study, not a drug or treatment trial. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05601817N/AActive

Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure

Open to carriers, genotype not considered

This trial is testing three behavioral interventions for older adults who have both heart failure and mild cognitive impairment: a virtual reality cognitive restoration program, a computerized cognitive training program, and a combination of both. Researchers want to know which approach best supports cognitive function and overall health. This is a Phase NA trial, meaning it is a practical intervention study rather than a traditional drug trial phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05741060Phase 2Active

Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

Open to carriers, not 4-specific

This Phase 2 trial is testing whether a daily soy-derived supplement called S-equol can slow the stiffening of arteries, reduce small blood vessel damage in the brain, and help preserve memory and thinking skills. Participants aged 65 to 85 take S-equol or a placebo daily for two years, with brain MRIs and cardiovascular measurements taken over seven clinic visits. Phase 2 means researchers are still gathering evidence on whether it works and is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT06826261N/AActive

Digital Twins for Model-driven Non-invasive Electrical Brain Stimulation

Device trial, genotype not considered

This pilot trial is testing whether daily at-home electrical brain stimulation, called transcranial alternating current stimulation or tACS, can slow cognitive decline in people with mild-to-moderate Alzheimer's disease. Researchers will use personalized, computer-modeled stimulation targeting brain wave activity in the prefrontal cortex over eight weeks. This is a Phase NA feasibility study, meaning the goal right now is mainly to check whether the approach is safe and practical before running a larger trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05707663Active

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This observational study is tracking brain development in young people who have Juvenile-onset Huntington's Disease, a rare form that appears before age 21. Researchers are using MRI, cognitive tests, and neurological exams to look for biomarkers that distinguish it from adult-onset Huntington's. No treatment is being tested — this is purely a research observation study, gathering data to better understand how the disease affects developing brains differently.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05651659N/AActive

Preventing and Approaching Crises for Frail Community-dwelling Patients Through Through Innovative Care (PRACTIC)

Frailty trial, no APOE4 relevance

This trial is testing a structured care model called TIME — a bio-psychosocial, person-centered approach — to see whether it can prevent or resolve health crises in frail older adults who live at home and receive home care services. Researchers want to know if the model reduces emergency hospitalizations and improves care experiences. This is a Phase NA study, meaning it is evaluating a care process rather than a drug or device — effectiveness is still being established.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03804229Phase 3Active

Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia

Vascular dementia only, not APOE4-specific

This Phase 3 trial is testing whether Butylphthalide soft capsule — a drug already used in China for stroke-related brain injury — can improve thinking, daily functioning, and behavior in people with mild to moderate vascular dementia. Phase 3 means researchers are confirming in a larger group what earlier smaller studies suggested. Participants are compared against a placebo in a blinded, multi-center setup. Not yet proven or approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04270474N/AActive

Reducing Risk of Dementia Through Deprescribing

General prevention, genotype not considered

This trial is testing whether helping older adults stop or reduce certain common medications called anticholinergics — used for things like bladder control, allergies, and sleep — can protect cognitive health. Researchers are comparing a structured deprescribing program against usual care to see if reducing these drugs affects dementia risk. This is a Phase NA, meaning it is a pragmatic real-world trial rather than a traditional drug-development phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06721390N/AActive

Music Improvisation Training on Cognitive Function in Older Adults

Open to carriers, not 4-specific

This trial is testing whether learning to improvise on the piano helps older adults think more clearly and regulate their own mental processes. Researchers will compare people who take piano improvisation lessons against those who simply listen to music, tracking changes in brain activity and cognitive skills. It is a Phase NA behavioral study, meaning it is evaluating a non-drug training program, not a medication — the research question is whether it works and how.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06079190Phase 2Active

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia who have confirmed amyloid buildup in the brain. Phase 2 means researchers are evaluating whether it works and is safe — this drug is not proven or approved. Details on exactly how the drug works are limited in the available source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
97 sites
NCT05470816Phase 3Active

Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial

General surgery trial, genotype not considered

This trial is testing whether tranexamic acid, a drug that reduces bleeding and inflammation, can lower the chances of delirium after major gastrointestinal surgery. Delirium is a sudden state of confusion common after surgery, especially in older adults, and it is linked to longer-term cognitive decline. This is a Phase 3 trial, meaning researchers are testing whether it actually works at scale — not just whether it is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03772977N/AActive

The Brain Health Champion Study

Lifestyle study, genotype not required

This trial tests whether more frequent, personalized coaching on brain-healthy habits produces better follow-through than standard doctor advice alone. Participants receive guidance on things like exercise, diet, and sleep over six months. It is a Phase NA behavioral study, meaning it is evaluating a structured lifestyle program rather than a drug, and researchers are measuring whether the extra support actually changes what people do day to day.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07521865Active

Remote Technologies in Early Stages of Alzheimer's Disease

Non-drug study, genotype not considered

This trial is testing a tablet-based brain training app for people who already have Mild Cognitive Impairment or early Alzheimer's dementia. Researchers want to know whether the app is practical, acceptable, and easy to use — not whether it slows or stops disease. It is a small feasibility study of 36 people over two weeks, meaning it is an early-stage test of whether the concept even works logistically, not a proof of benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03113461N/AActive

MCI: CPAP Treatment of OSA (Memories2)

Open to carriers, genotype not tracked

This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild cognitive impairment (MCI). Participants get cognitive tests and optional brain MRIs at the start, six months, and one year. It is a Phase NA study, meaning it is a clinical trial focused on measuring outcomes rather than standard drug-approval phases.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT05315661Phase 1Active

The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia

Wrong disease, not APOE4-relevant

This Phase 1 trial is testing whether ET-STEM — mesenchymal stem cells treated with the drug ethionamide — is safe and tolerable when given in three repeated doses to people diagnosed with frontotemporal dementia (FTD). Phase 1 means the focus is on safety, not yet on proving the treatment works. It is a small early-stage study enrolling Korean patients between ages 40 and 85 with confirmed FTD.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04100057N/AActive

Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

Open to carriers, genotype not required

This trial tests whether treating insomnia with Cognitive Behavioral Therapy for Insomnia (CBT-I) reduces anxiety, depression, agitation, and other behavioral symptoms in people with mild cognitive impairment or early Alzheimer's. Researchers will use brain scans, sleep studies, and questionnaires to see whether better sleep calms emotional distress by improving how the brain regulates emotion. It is a Phase NA mechanistic trial — focused on understanding how sleep and brain function are connected, not on proving a drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07180147Active

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

Open to carriers, genotype not studied

ALOHA is an observational study tracking brain and body health in adults 50 and older in the Washington D.C. area over five years. Participants get a full health assessment each year — physical, cognitive, and lifestyle — and receive a personalized Health Passport with tailored wellness recommendations. There is no drug or experimental treatment involved. The study watches how health changes over time and whether those recommendations influence behavior and independence. Phase is unspecified, meaning it is not a traditional clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05625828N/AActive

Evaluation of the Effects of a Cognitive-Motor Fall Prevention Program on Fall Risk Factors

Open to carriers, genotype not required

This trial compares two exercise programs in older adults living at home to see which better reduces fall risk. One program combines physical movement with simultaneous mental tasks, like doing math while walking. The other focuses on balance, walking, and strength training alone. Both run for 10 weeks. This is a practical comparison study, not a drug trial, and no results are proven yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03556280N/AActive

Multi-Center Study of Sensory Stimulation to Improve Brain Function

Open to carriers, not 4-specific

This trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma. Researchers are measuring whether it is safe, tolerable, and effective in people with mild to moderate cognitive impairment. This is a Phase NA randomized controlled trial, meaning it is a device study being evaluated for real-world benefit but not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT07209124N/AActive

Increasing Engagement and Positive Emotional Behavior of Older Adults With Mild-Moderate Dementia With the Use of Motion-Based Technology and Meaningful Activities

Open to carriers, not 4-specific

This trial tests whether motion-based games like the Nintendo Wii and a touchscreen "Magic Table" improve mood, engagement, and positive behaviors in people with mild-to-moderate dementia attending adult day care. Participants take part in ten two-hour activity sessions over ten weeks. This is a Phase NA study, meaning it is a behavioral or feasibility study rather than a drug trial, with no formal phase designation.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06704971Active

Assessing Cognitive Decline at Home

Observational only, genotype not mentioned

This study is testing whether in-home sensors and AI software can track neuropsychiatric symptoms, things like mood changes, agitation, and daily movement patterns, in people with or at risk for memory problems. Researchers want to see if the sensor data matches clinical assessments filled out by caregivers and doctors. This is an observational study with no assigned phase, meaning no drug or treatment is being given.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06516965Phase 3Active

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Unrelated to APOE4 or dementia

This Phase 3 trial is testing povorcitinib, a JAK inhibitor pill, against a placebo in people with prurigo nodularis — a chronic skin condition causing intense itch and nodular lesions. Researchers are measuring changes in itch severity and lesion counts. Phase 3 means the drug has shown earlier promise and is now being tested in a larger group to confirm whether it works and is acceptably safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
119 sites
NCT05529277Active

Implementing Dementia Care Management Into Routine Care in the Region Siegen-Wittgenstein

Genotype irrelevant, Germany-only study

This trial is testing a structured care coordination program called Dementia Care Management, already used in some German clinical settings, to see if it can be successfully rolled out in routine everyday healthcare in one German region. Sixty people with cognitive impairment and their caregivers will receive six months of support from specially trained care managers. This is an implementation study, meaning it is evaluating how well a known program works in the real world, not a standard drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT04566900N/AActive

Neurofeedback to Improve Working Memory in Mild Cognitive Impairment

Open to carriers, genotype not required

This trial is testing whether neurofeedback — a technique that trains people to consciously shift their own brain activity using real-time visual or audio feedback — can improve working memory in people with mild cognitive impairment. Researchers are focusing on boosting gamma wave activity in the frontal brain. It is a Phase NA designation, meaning this is a smaller foundational study designed to build evidence for larger trials down the road, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05313529N/AActive

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Open to carriers, genotype not considered

This trial is testing three diabetes drugs — liraglutide, empagliflozin, and linagliptin — to see whether any of them can improve or slow mild cognitive impairment in people who already have Type 2 diabetes. Participants are followed for about 18 months total. This is a Phase NA randomized study, meaning it is exploratory — researchers are gathering evidence, not confirming a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT03278119Active

Sleep Aging and Risk for Alzheimer's 2.0

Observational only, genotype not specified

This study is tracking whether poor sleep and sleep apnea speed up amyloid buildup in the brain. Participants get two nights of sleep monitoring in a lab plus PET brain scans at the start and again two years later. It is an observational study, not a treatment trial — no drug is being tested. Researchers want to understand the sleep-to-Alzheimer's pathway in cognitively normal older adults.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04296565Phase 4Active

Water-based Activity to Enhance Recall in Veterans

Open to carriers, genotype not required

This trial tests whether combining water-based exercise with a cognitive training program improves memory in veterans who have amnestic Mild Cognitive Impairment (aMCI). Participants do an aquatic exercise phase first, then a structured brain-training program. It is a Phase 4 trial, meaning the individual approaches are already established — this is testing how well they work together in a specific population.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07347912N/AActive

Group-based Resistance Training for Adults With Down Syndrome

Unrelated to APOE4 carriers

This trial tests a group-based resistance training program called RESID in adults with Down syndrome who do not yet have memory problems. Researchers want to know whether the program is practical, enjoyable, and whether it supports brain health and physical wellbeing. This is a Phase NA feasibility study — meaning it is exploring whether the program can be delivered successfully, not proving it works yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05356702N/AActive

The Brain Health Study: A Pragmatic, Patient-Centered Trial

Detection study, genotype not relevant

This trial is testing a screening tool called eRADAR, which uses existing electronic health records to flag patients in primary care who may have undetected dementia. The goal is to see whether this low-cost approach helps doctors identify dementia earlier. This is a Phase NA pragmatic trial, meaning it is testing a real-world process rather than a drug or device, in everyday clinical settings.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT05896332Phase 1Active

rTMS in Older Adults With MCI and AUD

Open to carriers, genotype not considered

This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive brain stimulation device — can simultaneously reduce heavy drinking and improve cognitive function in older adults who have both alcohol use disorder and mild cognitive impairment. It is a Phase 1 trial, meaning the focus right now is on safety and figuring out the right approach, not yet proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06755164N/AActive

Effects of Combined Aerobic and Cognitive Training in a Simultaneous or Sequential Paradigm on Cognition and Brain Functional Activity in Patients with AMCI

Lifestyle study, genotype not considered

This trial tests two ways of combining aerobic exercise with cognitive training for people who already have amnestic mild cognitive impairment. One group does the activities back-to-back; the other does them at the same time. Researchers will measure cognitive changes and brain activity using neuropsychological tests and fMRI scans. This is a Phase NA randomized controlled trial — it is testing which method works better, not a drug, and it has not been proven superior to standard care yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07086261N/AActive

Using SRT to Improve The Drinking Problem Behavior of Elderly People With Dementia During The Care of Day Care

Behavioral study, genotype not relevant

This trial tests whether Spaced Retrieval Training (SRT) — a memory technique that practices recalling information at increasing intervals — can help elderly people with dementia drink enough water on their own. Researchers will track daily water intake, body weight, hydration levels, and caregiver stress over eight weeks. This is a Phase NA quasi-experimental study, meaning it is exploratory rather than a controlled drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07596186Active

Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices

Open to carriers, genotype not considered

This study gives a smartphone app to 100 adults aged 65 and older living in assisted living facilities. The app passively collects sensor data — movement, typing rhythm, screen use, communication patterns — without recording what you actually type or say. Researchers want to see whether those digital signals can detect early cognitive changes over three months. This is an observational study, not a drug or treatment trial — it is testing whether the technology can spot a signal, not whether anything improves cognition.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03162081Active

Medication Misuse and Dependence Among Elderly

Observational only, genotype not relevant

This study is looking at how older adults use — and sometimes misuse — prescription medications, particularly drugs that can be habit-forming. Researchers are testing and refining screening tools to detect medication dependence and misuse in elderly patients admitted to hospital geriatric or neurology units. It is an observational study, not a drug trial — no treatment is being tested, just assessment tools and patterns of use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05027789N/AActive

Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention

Lifestyle study, genotype not mentioned

This trial is testing whether teaching older adults memory strategies and healthy habits (exercise, mental activity, stress management) improves day-to-day thinking and memory. One group follows a self-guided program; the other gets structured sessions plus a digital tracking app on an iPad. It runs six months with check-ins over a year. This is a Phase NA behavioral study, meaning it is evaluating a lifestyle program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03705104N/AActive

Living Well with Chronic Pain

No APOE4 relevance at all

This trial is testing EPIO, a behavioral e-health app, to see whether it helps people manage widespread chronic pain. Participants use the app on their own smartphone, tablet, or PC. This is a Phase NA trial, meaning it is evaluating the intervention's real-world effect rather than following a traditional drug-approval phase structure. Details on what the app specifically teaches or tracks are limited in the source.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06768996N/AActive

Music, Social Attention, and Dementia

Open to carriers, not 4-specific

This study is testing whether rhythmic music activities — drumming or clapping together versus alone — can improve social connection and attention between people living with mild to moderate behavioral FTD or Alzheimer's disease and their caregivers. Researchers will also look at related brain network activity. This is an exploratory study, meaning it is early-stage and focused on gathering initial data, not proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07292233Phase 1Active

A Food Effect Study of LY03020 in Healthy Subjects

Not relevant to APOE4 carriers

This trial is testing how food affects the absorption of a drug called LY03020 in healthy volunteers. Participants take a single dose twice — once with food, once without — so researchers can compare how the body processes the drug each way. It is a Phase 1 study, meaning this is early-stage work focused on basic drug behavior in the body, not on treating any condition yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03924414Phase 4Active

Trial of Parkinson's And Zoledronic Acid

Not APOE4-related, movement disorder focus

This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in people aged 60 and older who have Parkinson's disease or a related movement disorder. It is a Phase 4 trial, meaning the drug is already approved and researchers are now studying it in this specific patient population. It is home-based and includes about 2,650 participants across the U.S.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
77 sites
NCT04437511Phase 3Active

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

High ARIA risk for carriers

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it slowed cognitive and functional decline. Phase 3 means this was a large, late-stage test of effectiveness and safety before any regulatory approval decision. An open-label safety cohort and a 3-year follow-up extension were also added after the main study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
274 sites
NCT06781541N/AActive

Physical Activity and Disability Prevention in Postmenopausal Women

Lifestyle study, genotype not considered

This trial is testing whether different physical activity programs, specifically Nordic walking, strength training, Bungy Pump exercises, and functional conditioning, can protect postmenopausal women from losing mobility, bone density, and cognitive sharpness. It is a behavioral study, not a drug trial, comparing women who do structured exercise against a control group who continue their usual routines over three months. It is exploratory in nature and not yet proven to produce specific benefits.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04042922N/AActive

High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

Open to carriers, genotype not tracked

This trial tests a device that delivers flickering light and rhythmic sound at 40 Hz to stimulate brain activity in people with mild Alzheimer's disease. Researchers want to know whether the device is safe and practical to use, and they are measuring brain waves with EEG to understand how the brain responds. This is a Phase NA feasibility study — it is exploratory and early, not a test of whether the device treats or prevents Alzheimer's.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05631236N/AActive

Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy

Open to carriers, not 4-specific

This trial is testing whether wearing light-emitting glasses in the morning — a technique called bright light therapy — can improve sleep, reduce frailty, and support cognitive function in older Veterans. Participants wear the glasses daily for a set period. This is a Phase NA feasibility pilot, meaning researchers are checking whether the study design works and estimating effect sizes before committing to a larger trial. It is not yet testing a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07480187N/AActive

Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices

Observational only, genotype not relevant

This study is testing whether biomarkers found in blood plasma and nasal tissue can accurately profile different neurodegenerative diseases, including Parkinson's and Alzheimer's. Researchers are collecting samples from 340 participants across three Italian centers to see whether these easy-to-obtain samples reflect what is happening in the brain. This is a Phase NA observational study — it collects and measures, it does not test a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT03750409N/AActive

Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia

Open to carriers, not 4-specific

This trial is testing whether a light-emitting helmet that delivers infrared and near-infrared light to the brain can support brain cell activity and self-repair in people already living with mild to moderate Alzheimer's-type dementia. It is a feasibility study, meaning the goal is simply to see whether the approach is practical and safe enough to study further. No drug is involved. Details beyond that are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06402838Phase 2Active

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

Open to carriers, not 4-specific

This Phase 2 trial is testing a drug called RO7269162 against a placebo in people who have amyloid buildup in their brain but either no symptoms yet or only mild cognitive impairment. Researchers are looking at safety and whether the drug changes biological markers linked to Alzheimer's. Phase 2 means they are still gathering evidence on whether it works and is safe — it is not approved or proven.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
46 sites
NCT04337255N/AActive

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Lifestyle study, genotype not required

This trial tests whether following the MIND diet for two to three years after a stroke slows cognitive decline compared to standard post-stroke dietary care. Researchers will also look at brain biomarkers tied to Alzheimer's and vascular disease. It enrolls 250 adults aged 55 and older who were hospitalized for an ischemic stroke and discharged home without dementia. This is a Phase NA randomized controlled trial — meaning it tests a behavioral intervention, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05399888Phase 2Active

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Open to carriers, not 4-specific

This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive impairment or mild dementia caused by Alzheimer's. The main measure is a standard dementia rating scale called the CDR-SB. Phase 2 means researchers are still working out the right dose and confirming safety — this drug is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
138 sites
NCT06602258Phase 2Active

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Anti-amyloid combo — carriers face higher ARIA risk

This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker measured in spinal fluid. Tau tangles are a key feature of Alzheimer's damage. Phase 2 means researchers are still figuring out the right dose and checking safety — this is not a proven or approved treatment combination. Details on long-term effects are limited at this stage.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
26 sites
NCT05550727N/AActive

The PorchLight Project

Community care study, genotype not relevant

The PorchLight Project is testing a training program for volunteer Senior Companions who visit and support older adults with memory loss. The goal is to see whether better-trained companions improve the experience for clients and volunteers in a real-world community setting. This is a Phase NA pragmatic trial, meaning researchers are studying how an approach works when folded into everyday community services — not a controlled lab setting.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06291909N/AActive

Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia

Lifestyle study, genotype not considered

This trial is testing a website called Small Steps that helps adults 65 and older make gradual changes to their daily routines, specifically sitting less, moving more, and sleeping better. The goal is to see whether those behavior shifts reduce known risk factors for dementia. This is a Phase NA randomized controlled trial, meaning it is evaluating how well a behavioral program works in practice rather than testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05528302N/AActive

Technology Assisted Cognitive Behavioural Therapy Intervention for Anxiety in People Living With Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether cognitive behavioural therapy, delivered remotely via a software platform, can help reduce anxiety in people who already have mild cognitive impairment or dementia. Researchers are measuring how well the tech-assisted therapy works compared to a control condition. Phase NA here means this is a practical, real-world style trial rather than a drug-approval study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
5 sites
NCT04148391Phase 2Active

NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)

Open to carriers, not 4-specific

This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's disease or Lewy body dementia. Researchers are measuring whether it improves cognition, memory, attention, and thinking. This is a Phase 2 trial, meaning scientists are still trying to determine whether it works and whether it is safe — it is not proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
26 sites
NCT06632990Phase 1Active

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Background drug study, not APOE4-relevant

This trial is testing whether BMS-984923, an experimental drug being developed for Alzheimer's disease, affects how the body processes other common medications. Participants take three well-known probe drugs before and after 18 days on BMS-984923, and blood samples track any changes in drug clearance. This is a Phase 1 trial — it is focused on safety and drug interactions in healthy volunteers, not on whether BMS-984923 works against any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06920212N/AActive

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing whether fecal microbiota transplantation (FMT) — swallowing capsules containing gut bacteria from healthy donors — can help people already living with Alzheimer's disease. Researchers want to know if it is safe and whether it improves cognition, and they will track changes in patients' gut bacteria before and after treatment. This is a Phase NA (not a standard drug phase) exploratory trial, meaning it is early and investigational, not a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05644262Phase 2Active

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Late-stage dementia care, genotype not relevant

This Phase 2 trial is testing whether a liquid oral combination of THC and CBD (the two main active compounds in cannabis) can reduce agitation in people with advanced dementia who qualify for hospice care. Researchers will compare the cannabis combination to a placebo over 12 weeks, measuring agitation using a standardized rating scale. Phase 2 means researchers are evaluating whether the treatment works and is safe — it is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
10 sites
NCT04458207N/AActive

Cognitive Changes and Neural Correlates After Rehabilitation of Masticatory Function in Elderly -an Intervention Study

Open to carriers, not 4-specific

This trial is testing whether restoring chewing ability through dental implants or fixed dental work improves memory and learning in older adults who have significant tooth loss. Researchers will use cognitive tests and brain MRI scans to look for changes before and after the dental work. This is a Phase NA interventional study — meaning it is exploring a cause-and-effect question in humans for the first time, not testing a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT07091747Phase 1Active

Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase

Closed cohort, genotype not addressed

This Phase 1 trial is testing a cannabis-based product containing CBD and THC in people already diagnosed with Alzheimer's disease. Researchers want to see how the cannabinoids affect symptoms and certain biological markers. Phase 1 means this is early-stage work focused on safety and dosing. This particular stage is open-label, meaning all participants know they are receiving the extract. Details on full outcomes are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07066137N/AActive

Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices

Open to carriers, not 4-specific

This trial is testing how various therapies, including virtual reality, brain stimulation techniques like TMS and tDCS, cryotherapy, and music therapy, affect motor learning and physical recovery across a wide range of conditions including Alzheimer's disease and other movement disorders. It is a Phase NA study, meaning it is observational and interventional in design but not testing a drug for approval. Researchers will use brain imaging tools to track how movement and brain function change over time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05601583Phase 1Active

Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial tests whether pairing a continuous glucose monitor with a mobile app — and looping in a care partner — can help older adults with both Type 2 diabetes and mild cognitive impairment manage their blood sugar better. It is a small Phase 1 study, meaning researchers are in the early stage of figuring out how the approach works in practice and what features matter most, not yet testing whether it definitively improves health outcomes.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04018092Phase 2Active

The Revitalize Study in Older Adults at Risk for Alzheimer's Disease

Family history required, genotype not specified

This trial is testing whether a light-based device — near-infrared light delivered through the scalp and nose, called photobiomodulation — can support brain health in older adults who are worried about their memory and have a parent or sibling with Alzheimer's. Researchers are measuring brain energy, brain connectivity, and cognitive performance before and after 12 weeks of treatment. This is a Phase 2 trial, meaning it is testing whether the approach shows promise, not proving it works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT03413384Phase 2Active

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

Not Alzheimer's focused, genotype irrelevant

This trial is testing whether ceftriaxone, a common antibiotic given intravenously, can improve thinking and memory in people who have dementia caused by Parkinson's disease. Researchers will compare it against a placebo in about 106 patients in Taiwan. It is a Phase 2 trial, meaning researchers are still working to establish whether it is effective and safe — it is not an approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT04220021Phase 2Active

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Unrelated to APOE4 genotype

This trial is testing whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS and frontotemporal dementia caused by a C9orf72 mutation. Researchers are also checking whether it reduces certain toxic proteins linked to that mutation. This is a Phase 2 trial, meaning it is exploring whether the drug works and is tolerable, not a proven or approved treatment for these conditions.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03452878Active

Evaluation of the Functional Results of Bilateral Amygdalotomy for Refractory Aggressive Patients

No relevance to APOE4 carriers

This trial is studying bilateral amygdalotomy — a surgical procedure that destroys a small part of the amygdala, a brain structure linked to aggression — in patients whose severe aggression has not responded to medication. Researchers will use brain imaging, clinical assessments, and hormone levels to evaluate outcomes. The phase is unspecified, and details on long-term safety and efficacy are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT05846984N/AActive

Learning Skills Together Family Caregiver Complex Intervention

Caregiver study, genotype not relevant

This trial tests a 6-week online program called Learning Skills Together, designed to help family caregivers of people with Alzheimer's or related dementias handle complex care tasks with more confidence. The goal is to see whether the program reduces caregiver depression and stress around managing behavioral symptoms. It is a Phase NA trial, meaning it is evaluating real-world effectiveness rather than testing a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04517552Active

Investigation of Inflammation Using [C-11]-CS1P1

Not Alzheimer's focused, genotype irrelevant

This trial is testing a new PET imaging tool called [11C]-CS1P1, which is designed to measure neuroinflammation in the brain. Researchers want to see if this radioactive tracer can reliably detect a protein called S1P1, which is involved in immune activity in the brain. The phase is unspecified, meaning this is likely early feasibility or imaging validation work — not a treatment trial, and not yet anywhere near proven clinical use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07034222Phase 4Active

12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

Genotype tracked, ARIA risk elevated

This trial is tracking how well and how safely lecanemab (brand name Leqemi) works in everyday clinical settings over 12 months. Lecanemab is an anti-amyloid antibody already approved for early Alzheimer's disease. Eighty people with MCI or mild AD, confirmed by amyloid PET scan, will be enrolled. This is a Phase 4 study, meaning the drug is already approved and researchers are now watching how it performs in real-world use outside a controlled research setting.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05189769N/AActive

Reducing Racism and Discrimination in Schools: Comprehensive Prevention Services

No relevance to APOE4 carriers

This trial tests two school-based behavioral programs — ReACT, a school-wide anti-racism intervention, and Coping Power+, a targeted program for at-risk 7th graders — to see whether combining them improves school climate, student behavior, and social-emotional skills. It is a Phase NA study, meaning it is evaluating real-world program effectiveness rather than testing a drug or medical treatment for safety and efficacy in the traditional clinical sense. Details beyond the school setting are limited.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05574400Phase 2Active

The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study

Open to carriers, not 4-specific

This trial is testing whether caffeine given around the time of major surgery can reduce the chances of postoperative delirium — the confusion and mental fog that often follows surgery in older adults. It is a Phase 2 trial, meaning researchers are evaluating whether the approach actually works and is safe, not a proven or approved treatment. The comparison group receives a dextrose water placebo.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05756855N/AActive

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

Unrelated to APOE4 or Alzheimer's

This trial is testing a behavioral intervention designed to reduce violent behavior in young people experiencing early psychosis, including schizophrenia and related conditions. Participants are ages 16 to 30 and are already receiving care at First Episode Psychosis clinics in New York. It is a Phase NA study, meaning it is exploratory or developmental rather than a standard drug or treatment efficacy trial. Details beyond the basic setup are limited so far.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06160908N/AActive

Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease (NIR4AD)

Open to carriers, not 4-specific

This trial is testing a wearable near-infrared light device called NirsCure in people who already have mild-to-moderate Alzheimer's disease. Participants wear the device for 30 minutes a day, six days a week, for 16 weeks, then can continue for nearly four years. Half get real light therapy, half get a sham version. Phase NA means this is a practical efficacy and safety study, not a traditional drug-approval phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06223360Phase 2Active

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Open to carriers, not 4-specific

This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's disease. The goal is to see whether it slows symptom progression and is safe to take. This is a Phase 2 trial, meaning researchers are still gathering evidence on whether it works — it is not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
47 sites
NCT06079203N/AActive

ED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care

Genotype not relevant here

This trial is testing three different care-support programs for people already living with dementia who visit an emergency department. The approaches include redesigned ER care, nurse-led phone coaching, and community paramedic follow-up after discharge. The goal is to reduce repeat ER visits and hospitalizations and improve quality of care. This is a Phase NA pragmatic care-delivery trial — it is testing how to deliver better care, not a new drug or treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05541627Phase 1Active

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Unrelated to APOE4 or Alzheimer's

This trial is testing AB-1001, a gene therapy delivered by brain surgery directly into a region called the striatum. The goal is to see whether it is safe and what dose works in adults who are in the early stages of Huntington's disease. It is a Phase 1/2 trial, meaning researchers are still establishing safety and early signs of effectiveness — this is not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06877182Active

Novel Neuroradiological Workflow for the Assisted DIAgnosis and Management of DEMentia with Artificial Intelligence

Diagnostic tool study, genotype not considered

This trial is testing whether an AI-powered MRI analysis workflow can more accurately identify and track Alzheimer's disease and other dementias. Researchers are feeding brain MRI scans into machine learning models to see if AI can standardize and improve how radiologists interpret those images. The phase is unspecified, so this appears to be a diagnostic methods study rather than a traditional drug trial testing safety or effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05983575Phase 3Active

A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease

Device trial, genotype not required

This trial is testing a wearable ultrasound device called LIPUS-Brain that delivers low-intensity sound waves through the skull. Researchers want to know whether regular use slows cognitive decline in people with early Alzheimer's disease or amyloid-confirmed MCI, measured by a standard cognitive test over 72 weeks. This is a Phase 3 trial, meaning it is a large-scale test of whether the device actually works — not a preliminary safety study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
19 sites
NCT06389032N/AActive

PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia

Not relevant to APOE4 carriers

This trial is testing a peer mentorship program for family caregivers of people with Lewy Body Dementia. Trained caregivers who have been through LBD themselves coach newer caregivers through a structured 12-week curriculum covering knowledge, coping, and practical skills. Researchers are measuring caregiver stress, confidence, and whether the person with LBD ends up needing fewer emergency visits. This is a Phase NA behavioral trial — it is evaluating a support program, not a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02959502N/AActive

Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression

Non-drug trial, genotype not considered

This trial is testing a home-based combination of cognitive rehabilitation (structured mental exercises) and transcranial direct current stimulation (tDCS, a mild electrical brain stimulation delivered via a headset) in people over 60 with mild cognitive impairment or a history of depression. The goal is to see whether this approach is feasible at home and whether it helps slow or reduce cognitive decline. Phase NA means this is a feasibility and piloting study, not yet a full efficacy trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07288736N/AActive

Aromatherapy Formulas for Sundowning and Sleep Quality in Patients With Dementia.

Dementia care study, genotype irrelevant

This trial is testing two different essential oil blends — one using rosemary and lemon in the morning paired with lavender and sweet orange in the afternoon, the other a broader calming blend — to see if aromatherapy can reduce agitation and improve sleep in people with dementia who experience sundowning. It is a Phase NA crossover study conducted in long-term care facilities in Taiwan, meaning it is exploratory in nature and not yet generating definitive proof.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04829500N/AActive

Effectiveness and Implementation of Montessori Approaches in Person-Centered Care Within VA

Not relevant to at-risk carriers

This trial is testing a staff training program called MAP-VA at eight VA long-term care facilities. The program teaches employees Montessori-based, person-centered care techniques to reduce agitation, aggression, and mood disturbances in residents with dementia or serious mental illness — without relying on extra medication. It is a Phase NA study, meaning it is evaluating a care delivery approach rather than a drug or medical device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05040321Phase 1Active

Sirtuin-NAD Activator in Alzheimer's Disease

Open to carriers, not 4-specific

This trial is testing MIB-626, an oral pill designed to boost NAD levels in the brain by activating the sirtuin-NAD pathway — a cellular energy and repair system that declines with age. Researchers want to know whether the drug actually reaches the brain and changes relevant biological markers. This is a Phase 1 trial, meaning the focus is on safety and basic biological effects, not on proving the drug helps memory or slows Alzheimer's.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05153941Active

Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures

Open to carriers, genotype not a focus

This study is not testing a drug or treatment. Researchers are testing whether smartphones, wearables, and home sensors can detect early changes in daily functioning in people with Alzheimer's or MCI more accurately than traditional clinical questionnaires. It is an observational study with no phase designation, meaning it is gathering data rather than testing whether an intervention works or is safe.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT01644591Phase 2Active

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Unrelated to APOE4 or Alzheimer's

This trial tests stereotactic radiosurgery — a precise, high-dose radiation technique aimed at individual tumors — in patients whose melanoma has spread to more than three spots in the brain. Researchers are measuring how well it works and how it affects quality of life. This is a Phase 2 trial, meaning it is testing effectiveness and safety but the approach is not yet proven or approved for this specific situation.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06298006Active

A Two Year Longitudinal Clinical Study of Neurocognitive and Psychiatric Symptoms in Post COVID-19 Patients

Observational only, genotype not considered

This study follows people who developed cognitive or psychological symptoms after a COVID-19 infection, tracking them over two years. Researchers are measuring how brain fog, mood changes, and thinking difficulties evolve over time, and looking for markers that might predict who improves or stays impaired. There is no treatment being tested here — it is purely observational, meaning researchers watch and record, they do not intervene.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05235113N/AActive

Remote Game-based Exercise Program for Cognitive and Motor Function Improvement

Non-drug study, genotype not considered

This trial tests a remote, game-based exercise platform — called a tele-exergame system — designed to improve balance and cognitive function in older adults with mild cognitive impairment or early dementia. Participants use the system at home under remote supervision rather than visiting a clinic. This is a Phase NA (non-drug, feasibility-style) study, meaning researchers are exploring whether this approach works and is practical, not testing a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05206305N/AActive

Sensory-Evoked Cortical Gamma Oscillation

Open to carriers, not 4-specific

This trial tests a device called GammaSense, which uses flickering light and sound at 40 Hz to stimulate specific brainwave patterns in people already diagnosed with Alzheimer's disease. Researchers are measuring whether this stimulation changes how the brain processes sensory information and whether it affects cognitive function, tracked with EEG brain recordings. This is a Phase NA feasibility-style study, meaning it is exploring whether the approach shows enough signal to study further.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06528951N/AActive

Impact of Resistance Training Volume on Cognitive Function and Physical Performance in Cognitively Impaired Individuals

Lifestyle study, genotype not required

This trial tests whether doing more resistance training (lifting weights at 15%, 30%, or 45% higher volumes) improves cognitive function and physical performance in people already diagnosed with cognitive impairment. Researchers will also track inflammation, blood sugar, and other health markers. This is a Phase NA trial, meaning it is a straightforward interventional study rather than a formal drug development phase — testing a structured exercise protocol, not a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03493178Early Phase 1Active

Glutathione in Mild Cognitive Impairment

Open to carriers, not 4-specific

This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (NAC), can raise glutathione levels in people with mild cognitive impairment (MCI) and whether that affects cognition. Glutathione is the body's main antioxidant, and levels tend to fall with age. It is an Early Phase 1 study, meaning this is very preliminary exploratory work — researchers are looking at mechanisms, not proving a treatment works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05891431N/AActive

Engagement and Acceptability of the Untire mHealth App

Not relevant to APOE4 carriers

This trial is testing a mobile app called Untire, designed to help adults with cancer-related fatigue. Researchers want to know whether people actually use the app, whether they find it acceptable, and whether it reduces fatigue or improves quality of life over 12 weeks. It is a Phase NA study, meaning this is more of a feasibility and early-efficacy check than a rigorous controlled trial of an already-promising treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06268886Phase 2Active

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Open to carriers, not 4-specific

This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want to know whether it slows cognitive decline, and whether it is safe and tolerable. Phase 2 means this is a mid-stage test — researchers are looking for signs it works and checking for side effects, but it is not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
176 sites
NCT05642429Phase 1Active

Study of AV-1959D, an Amyloid Beta Vaccine

Open to carriers, ARIA risk applies

This trial is testing AV-1959D, a vaccine designed to prompt the immune system to target amyloid beta — the protein that builds up in Alzheimer's disease. It enrolls people aged 60 to 85 with mild cognitive impairment or mild Alzheimer's who have confirmed amyloid on a PET scan. Phase 1 means researchers are focused on safety and dosing in humans for the first time — this is early-stage work, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT04881617N/AActive

Treatment for Speech and Language in Primary Progressive Aphasia

Not relevant to APOE4 risk

This trial is testing two speech-language therapies for people with primary progressive aphasia, a neurological condition that slowly erodes the ability to speak and communicate. One approach trains word-finding skills; the other uses scripted video conversations. Researchers want to know whether either therapy slows the decline in communication ability over time. This is a Phase NA behavioral study, meaning it is evaluating real-world therapeutic techniques rather than a drug.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT06162026N/AActive

Cognitive Screening Made Easy for PCPs - R33 Phase

Open to carriers, genotype not required

This trial is testing a tablet-based app called RACS that helps primary care doctors screen older patients for early signs of cognitive decline. The idea is that if the screening tool is easier to use, more patients will actually get screened. This is a Phase NA implementation study, meaning researchers are evaluating how well the tool works in real clinical settings rather than testing a drug or measuring disease treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06489847Active

An Objective Assessment Tool for Evaluating Functioning in Older Adults

General healthy volunteer study, not APOE4-relevant

This project is testing a mobile app that guides users through physical and cognitive assessments and scores them in real-time. Researchers are collecting video of 20 to 30 healthy adults performing a standard physical performance test so they can build and refine the app prototype. This is early-stage development work, not a clinical trial testing a treatment — think of it as building and calibrating a measurement tool.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT07037550N/AActive

Effectiveness of Strength-based Intervention for Elderly With Dementia Living in the Community

Behavioral study, genotype not considered

This trial tests a behavioral program called a strength-based intervention, designed for people with mild dementia or mild cognitive impairment and their family caregivers. Instead of focusing on what patients have lost, it builds on existing strengths and coping skills within the patient-caregiver pair. This is a Phase NA study, meaning it is evaluating real-world effectiveness rather than early safety or large-scale efficacy in a traditional pharmaceutical trial sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04098666Phase 2Active

Metformin in Alzheimer's Dementia Prevention

Open to carriers, genotype not tracked

This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing mild cognitive impairment but do not have diabetes. Over 18 months, researchers will track memory scores, brain scans, and biomarkers to see if metformin makes a measurable difference. This is a Phase 2/3 trial — an intermediate step that tests both effectiveness and safety in a larger group, but still not a proven or approved approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
22 sites
NCT04852601N/AActive

ToolBox Detect: Low Cost Detection of Cognitive Decline in Primary Care Settings

Detection tool, genotype not a factor

This trial is testing a digital screening tool called ToolboxDetect, designed to help primary care doctors spot early cognitive decline more easily during routine visits. It links to the electronic health record and is built to work in busy, everyday clinic settings. This is a non-drug, non-Phase study focused on whether the tool works well in the real world across diverse patient populations.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04305600Active

Bringing to Light the Risk Factors And Incidence of Neuropsychological Dysfunction in ICU Survivors, 2nd Study

Observational ICU study, not genotype-relevant

This study is tracking ICU survivors over time to understand why some people develop lasting cognitive problems after critical illness. Researchers are collecting brain scans, spinal fluid, and long-term cognitive test results — and eventually brain tissue donations — to map out exactly what goes wrong in the brain after a serious ICU stay. This is an observational study, not a drug trial, so there is no treatment being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT05997784Active

Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing

No relevance to APOE4 carriers

This study is tracking indoor air pollution in French primary school classrooms and measuring its effect on children's breathing and allergy symptoms. Researchers are installing sensors to monitor chemical and biological pollutants, then testing the children's lung function and collecting urine samples to look for health impacts. This is an observational study, not a drug trial, so there is no treatment being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05222386N/AActive

Community Outreach for Palliative Engagement -- Parkinson Disease

Genotype irrelevant, not APOE4-specific

This trial tests whether training community doctors in palliative care, combined with telemedicine support, improves quality of life for people with Parkinson's disease, Lewy Body Dementia, and related conditions. Palliative care focuses on managing symptoms and reducing suffering, not curing disease. This is a Phase N/A study, meaning it is evaluating a care delivery model rather than a drug or device.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04743466Active

Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes

Observational only, genotype not targeted

This study looks at existing health records and biobank data to see whether low testosterone levels are linked to higher rates of dementia, depression, and anxiety. It is not a drug trial — no one is given a treatment. Researchers are mining data already collected from large databases like the UK Biobank. The phase is unspecified because this is an observational records study, not a clinical intervention trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04120766Phase 2Active

Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging

Non-Alzheimer's focus, carriers may not qualify

This Phase 2 trial is testing nicorandil, a drug already used for heart conditions, to see whether it is safe and whether it affects a brain pathway linked to hippocampal sclerosis of aging, a form of dementia that is often mistaken for Alzheimer's. Researchers want to know if it does anything measurable in the brain, not whether it cures or treats dementia. Phase 2 means they are still in the safety and early signal-finding stage.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05345509Phase 1Active

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Healthy volunteers only, not APOE4-relevant

This trial is testing a new drug called IVL3003 — likely a new formulation of donepezil, an existing Alzheimer's medication — by comparing how the body absorbs and processes it against the brand-name version, Aricept. Researchers are measuring safety and drug levels in the blood, not whether it slows Alzheimer's. This is a Phase 1 trial, meaning it is very early — focused on basic safety in healthy people, not yet tested in patients.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06245616N/AActive

Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil

Open to carriers, not 4-specific

This trial is testing whether olive pomace oil, compared to high-oleic sunflower oil, reduces inflammation in the hours after a meal in people with early-stage Alzheimer's. Researchers will draw blood at regular intervals over six hours to track inflammatory markers. It is a Phase NA study, meaning it is a controlled dietary experiment rather than a drug trial testing efficacy or safety at scale.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06754254Active

Blood Biomarkers from Internal Jugular Vein for the Diagnosis of Alzheimer's Disease

Open to carriers, genotype not studied

This observational study is testing whether blood drawn from the internal jugular vein in the neck gives more accurate Alzheimer's biomarker readings than blood drawn from the standard arm vein. Researchers think brain-draining blood may carry stronger signals of disease. No phase is specified because this is not a drug or treatment trial — it is a diagnostic accuracy study, meaning no intervention is being given.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05361382Phase 1Active

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

Imaging study, genotype not required

This trial is comparing two different PET scan tracers — Flortaucipir and MK-6240 — that are used to measure tau tangles in the brain, a hallmark of Alzheimer's. The goal is to figure out how well the two tracers agree with each other so researchers can combine or compare data from studies that used different tracers. This is a Phase 1 imaging study, meaning it is focused on measurement and safety, not on testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
9 sites
NCT04474379N/AActive

Everyday Memory Impairment in PD-related Cognitive Decline

PD-focused, genotype not considered

This trial is testing a behavioral strategy-training program designed to help people with Parkinson's disease manage everyday memory problems. Participants are randomly assigned to either strategy training or a process-training comparison. Researchers then track memory performance over 12 months. This is a Phase N/A trial, meaning it is a behavioral intervention study rather than a drug trial — it is not testing whether a treatment is safe or effective in the pharmaceutical sense.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03881579N/AActive

Supportive Care for Cognitively Impaired Patients and Families

Open to carriers, not 4-specific

This trial tests whether a year-long nurse-led palliative care program improves quality of life and reduces healthcare use for people living with dementia or mild cognitive impairment and their caregivers. It is a behavioral intervention study — meaning no drugs, just structured supportive care. The goal is to see if getting this kind of support early makes a real difference for patients and families managing cognitive decline at home.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05209035Phase 4Active

Evaluation of Trazodone in OSA-MCI

Open to carriers, not 4-specific

This trial is testing whether trazodone, a medication commonly used for sleep, can lower certain protein markers linked to neurodegeneration in people who have both mild cognitive impairment and obstructive sleep apnea. Researchers will track those markers and cognitive performance over one year. This is a Phase 4 trial, meaning trazodone is already approved for other uses, but its effect in this specific population is still being studied.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06182085Phase 2Active

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

Open to carriers, not 4-specific

This Phase 2 trial is testing a drug called PRI-002 in people who already have mild cognitive impairment or mild dementia linked to Alzheimer's disease. PRI-002 is designed to break apart the clumped amyloid proteins thought to drive AD. Phase 2 means researchers are checking whether it actually works and is safe — it is not proven or approved. The trial uses a placebo comparison to measure the difference.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
38 sites
NCT06626412N/AActive

Longitudinal SV2A PET and MRI in Premanifest HD

Unrelated to APOE4 or Alzheimer's

This trial is testing whether a specialized PET scan (using a tracer called 18F-SynVesT-1 that measures synaptic density) is better than standard volumetric MRI at detecting early brain changes in people who carry the Huntington's disease gene mutation but don't yet have symptoms. Participants get both scans at the start and again two years later. This is a Phase NA diagnostic imaging study — it is not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03098459Active

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

Observational only, genotype not relevant

This is an observational study — no drug or treatment is being tested. Researchers are tracking cognitive function over time in adults who were hospitalized in a trauma ICU for serious injuries. The goal is to understand how often long-term cognitive problems develop after traumatic injury, and what inflammation in the body might have to do with it. There is no phase, because no intervention is being tried.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04693520Phase 2Completed

Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease

Exclusively recruits APOE4 carriers

This trial is testing ALZ-801, a daily oral pill, in people who already carry one or two copies of the APOE4 gene and have early Alzheimer's disease. Researchers are measuring whether the drug changes key biological markers of Alzheimer's in the brain and body, and whether it is safe. This is a Phase 2 trial, meaning it is designed to test whether the drug actually does something useful, not yet a final proof of effectiveness.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
6 sites
NCT03887741Phase 1Completed

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Exclusively enrolls APOE4 homozygotes

This trial is testing whether it is safe to give plasma from young APOE3 carriers to people who are APOE4 homozygous and already showing mild cognitive impairment, or to remove and replace their plasma through plasmapheresis. It is a Phase 1 trial, meaning the primary goal is safety, not effectiveness. Researchers want to know if the procedure causes harm before studying whether it might help.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02565511Phase 2Terminated

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Built exclusively for APOE 4/4 carriers

This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid production), each against placebo, in cognitively healthy older adults at high genetic risk for Alzheimer's. The goal was to see whether either drug could slow or delay the appearance of cognitive symptoms. This was a Phase 2 trial, meaning researchers were evaluating whether it worked and was safe, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
129 sites
NCT01625195N/ACompleted

Causal Relationships Between LC-omega-3-enriched Diet and Cognition

Supplement study, APOE4 explicitly noted

This trial is testing whether a diet enriched with long-chain omega-3 fatty acids improves cognition in adults aged 20 to 80. Researchers are measuring effects on memory, verbal fluency, and visuospatial skills in a randomized, double-blind, placebo-controlled design — meaning neither participants nor researchers know who gets the real supplement. This is a Phase NA study, meaning it is a nutritional investigation rather than a standard drug trial phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05880849Phase 1Completed

Choline Effects - Pre-symptomatic AD

Directly recruits APOE4 carriers

This Phase 1 trial is testing whether choline — a common dietary supplement — is safe and tolerable in people who carry the APOE4 gene and show no symptoms of Alzheimer's yet. Phase 1 means the focus is on safety and dosing, not proving it works. Researchers are also watching for any early signals of effect on Alzheimer's progression. It is a small, early-stage study.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT01211782Phase 2Withdrawn

AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

Stratified by APOE4 genotype specifically

This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that ketones may provide an alternative fuel source for a brain struggling to use glucose. Researchers measured memory, cognition, daily functioning, and quality of life over six months. This is a Phase 2 trial — testing whether it works and is safe, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06402266Completed

Simultaneous tDCS and Computerised Gamified Short-term Memory Task Feasibility

Exclusively recruits healthy APOE4 carriers

This small feasibility study is testing whether a non-invasive brain stimulation device called tDCS, worn as a headset, can be used comfortably by healthy APOE4 carriers while they play a computerised memory game on an app. Researchers want to know if stimulating one side of the brain works better than the other, or better than fake stimulation, for short-term memory performance. This is an early feasibility study, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03978052N/ACompleted

Prevention of Cognitive Decline in ApoE4 Carriers With Subjective Cognitive Decline After EGCG and a Multimodal Intervention

Directly recruits APOE4 carriers only

This trial is testing whether a green tea compound called EGCG, combined with a personalized lifestyle program covering diet, exercise, and cognitive training, can slow cognitive decline in people who feel their memory is slipping but still test normally. It is a Phase NA trial — meaning it focuses on feasibility and effect size rather than a late-stage definitive proof. The primary outcomes include cognitive performance and brain connectivity measured by MRI.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT04770220Phase 3Completed

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Built exclusively for APOE4/4 carriers

This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's disease. Phase 3 means it is a large, late-stage study focused on whether the drug actually works and confirming its safety profile. Participants are randomly assigned to ALZ-801 or placebo, and neither they nor researchers know which they receive.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
95 sites
NCT04009629N/ACompleted

Dementia Risk and Dynamic Response to Exercise

Directly recruits APOE4 carriers

This trial is testing how a single session of moderate aerobic exercise changes brain blood flow and blood biomarkers in older adults who carry the APOE4 gene. Researchers will measure these biological responses right after exercise to learn what exercise does in the brain of someone at higher Alzheimer's risk. This is a Phase NA study, meaning it is an observational or measurement-focused investigation, not a drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT01767311Phase 2Completed

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Carriers enrolled, but higher ARIA risk

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia with confirmed amyloid in the brain. Researchers compared five different doses against placebo over 18 months, measuring cognitive and functional decline. Phase 2 means the drug was being evaluated for whether it works and at what dose — it was not yet approved at the time.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
169 sites
NCT05687201Completed

Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage

APOE4 carriers actively studied, not Alzheimer-focused

This observational study is comparing what happens to patients who have a brain bleed (intracerebral hemorrhage) depending on whether they carry the APOE4 gene or not. Researchers are using CT and MRI scans to measure swelling around the bleed and track short-term recovery. There is no experimental treatment being tested — this is a study watching and recording outcomes, not a clinical intervention trial. The phase is unspecified because it is observational research, not a drug or device trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05161715Phase 2Completed

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Exclusively recruits APOE4 carriers

This trial is testing obicetrapib — a cholesterol-modifying drug — in people with early Alzheimer's disease. Researchers want to see how the drug moves through the body, what it does to biological markers, and whether it is safe. It is a Phase 2a study, meaning it is an early proof-of-concept test in a small group of patients, not a large-scale effectiveness trial. Details beyond that are limited in the public summary.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03876314N/ACompleted

Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype

APOE4 genotype central to study

This trial is testing whether a structured physical activity program improves cognitive performance in middle-aged adults (40-65) who have a family history of Alzheimer's but no current cognitive impairment. Researchers are specifically examining whether APOE4 status changes how much someone benefits from exercise. It is a Phase NA behavioral trial — meaning it tests a lifestyle intervention, not a drug, and is focused on learning whether the approach works and for whom.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03634007Phase 1Completed

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

Built exclusively for APOE4 homozygotes

This Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have Alzheimer's-related cognitive symptoms ranging from mild cognitive impairment to moderate dementia. Phase 1 means the primary goal is safety and finding the right dose — not yet proving it works. The therapy is designed to introduce a different APOE version into the brain.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
4 sites
NCT05965414Early Phase 1Completed

Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers

Actively recruits APOE4 carriers

This trial is testing CS6253, an injected drug, in healthy volunteers to see if it is safe and how the body processes it. It is an Early Phase 1 trial, meaning researchers are just beginning to establish basic safety in humans — this is the earliest possible stage, far from any proven benefit. Doses are given by IV or under the skin. Spinal fluid samples are collected in some cohorts to track how the drug moves through the body.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03794141N/ACompleted

Genetic Information as a Life Style Change Motivator

Directly tests APOE4 carrier awareness

This trial tests whether telling people they carry the APOE4 gene motivates them to make healthier lifestyle changes. Researchers also look at how learning your genetic risk affects sensory preferences and explore the ethics of sharing that kind of information. It is a behavioral study — Phase NA means it is not testing a drug or device, just whether knowledge itself changes behavior.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT02292238Phase 2Completed

Benfotiamine in Alzheimer's Disease: A Pilot Study

APOE4 response explicitly analyzed

This trial is testing benfotiamine, a fat-soluble form of vitamin B1, in people with early memory problems or mild Alzheimer's. The idea is that boosting thiamine in the brain may help it use glucose more efficiently and slow cognitive decline. Researchers are measuring thinking scores and brain glucose metabolism with PET scans over one year. This is a Phase 2 pilot study — testing early signals of whether it works and is safe, not a proven therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03131453Phase 2Terminated

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Built specifically for APOE4 carriers

This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for Alzheimer's symptoms. Researchers measured effects on cognition, clinical status, and brain amyloid levels. This was a Phase 2 trial, meaning it was evaluating whether the drug worked and was safe — it was not a proven or approved treatment. Note: this trial has since been stopped early due to unexpected cognitive side effects.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
194 sites
NCT06275243N/ACompleted

Polymorphism of ApoE in Alzheimer's Disease: Genetic Study in Castile and Leon (Spain)

Genetic study, APOE4 is the focus

This study is collecting cheek swabs from people in the Castile and Leon region of Spain to map how common the APOE4 gene variant is among people with and without Alzheimer's. Researchers also want to know whether APOE4 carriers in this region have different cholesterol levels. This is a genetic observational study, not a drug trial — no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02977819N/ACompleted

Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training

Open to carriers, not 4-specific

This trial is testing whether regular meditation practice can support healthy cognitive aging in adults 65 and older who currently have no memory problems. It compares meditators to a control group learning English as a foreign language, tracking brain and cognitive changes over 24 months. This is a Phase NA study — meaning it is a structured research trial but not a drug trial, so there is no drug approval process involved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03613844Phase 2Completed

DHA Brain Delivery Trial

Designed specifically around APOE4 carriers

This trial is testing whether APOE4 carriers absorb less DHA (an omega-3 fatty acid) into the brain compared to non-carriers, and whether DHA supplements can close that gap. Researchers are measuring actual DHA levels in the brain, not just in the blood. It is a Phase 2 trial, meaning it is exploring whether the approach works and is safe, not a proven treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04117178Phase 4Completed

Monitoring Anti-Dementia Drugs by Serum Levels

Genotype collected, not carrier-specific

This Phase 4 trial is testing whether measuring the actual blood levels of two common dementia drugs, donepezil and memantine, helps doctors fine-tune the dose for better results and fewer side effects. Phase 4 means the drugs are already approved — this is about using them more precisely. Researchers will compare patients whose dosing is guided by blood level measurements against patients receiving standard care, tracking cognition and daily functioning over 12 months.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06263010Phase 1Completed

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Parkinson's trial, not APOE4-relevant

This trial is testing allopregnanolone, a naturally occurring brain steroid, as a possible regenerative treatment for Parkinson's disease. Participants receive weekly intravenous infusions for 12 weeks, with no placebo group. It is a Phase 1 pilot study — the primary goals are to check safety and tolerability, and to see whether a larger trial would even be practical. It is not yet testing whether the drug works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT00710684Phase 2Completed

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

Open to carriers, not 4-specific

This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's disease. Researchers measured whether the combination was safer and more effective than donepezil plus a placebo. Phase 2 means they were evaluating whether it works and is safe — not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
102 sites
NCT07251985Phase 2Withdrawn

Cognitive Effects of Bioavailable Curcumin

Open to carriers, not 4-specific

This trial is testing whether a bioavailable form of curcumin, taken twice daily as a supplement, improves memory and attention in non-demented adults aged 50 to 85 who have noticed memory changes. It is a Phase 2 trial, meaning researchers are evaluating whether it actually works, not just whether it is safe. It builds on a smaller earlier study that showed promising but preliminary results. The study runs 6 to 12 months depending on an interim analysis.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT03654911Completed

Sustainable Method for Alzheimer's Prediction

APOE4 genotype central to study

This observational study is testing whether a combination of brainwave recordings (EEG), neuropsychological testing, and APOE genotyping can reliably predict which people with mild memory problems will go on to develop Alzheimer's. No phase is listed because no drug or treatment is being given — researchers are watching and measuring, not intervening. The goal is to find a simpler, lower-cost early screening approach.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04864938UNKNOWN

Recovery After Critical Covid-19 Infection

Observational only, genotype irrelevant

This study is tracking how people recover from COVID-19 across three settings: intensive care, hospital wards, and home treatment. Researchers are measuring respiratory, cardiovascular, and neurological outcomes over time and comparing them to people who never had COVID-19. The phase is unspecified, meaning this is an observational study — researchers are watching and measuring, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT06213766N/AUNKNOWN

Spatial and Ocular Trajectories for the Early Diagnosis of Alzheimer's Disease.

Genotype data collected, carriers eligible

This study is testing whether tracking how people navigate through a video game environment — combined with eye-movement data — can help detect Alzheimer's disease earlier. Researchers will compare spatial navigation patterns and eye tracking between healthy adults and people already diagnosed with Alzheimer's. It is a diagnostic study, not a drug trial, meaning no treatment is given and researchers are evaluating a potential early detection tool, not a therapy.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT03971123Phase 1Completed

Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body Production

Healthy volunteers only, not APOE4-specific

This trial tests whether different formulations of tricaprilin — a compound derived from a type of fat called medium-chain triglycerides — produce different levels of ketones in the blood. Ketones are an alternative fuel source the brain can use. This is a Phase 1 trial, meaning it is focused on how the drug behaves in the body, not whether it helps Alzheimer's. It enrolled only healthy young men to measure absorption and metabolism across formulations.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT00428090Phase 3Completed

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

APOE4 stratified, suggests less benefit

This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's disease. The idea was that if brain cells struggle to use glucose in AD, a drug that improves glucose processing might help. Phase 3 means this was a large, late-stage test of whether it actually works — not yet approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
138 sites
NCT02008357Phase 3Completed

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

Amyloid-focused, drug did not succeed

This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their brains detected by PET scan. The goal was to see whether the drug could slow early memory decline before symptoms fully appear. Phase 3 means the intervention had already passed earlier safety testing and was being evaluated at large scale for effectiveness. The trial has since completed and solanezumab did not meet its primary endpoint.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
68 sites
NCT06114914UNKNOWN

TapTalkTest Project:Development of a Non-invasive Screening Test to Detect Risk of Alzheimer's Disease Pathology

General risk screening, genotype not mentioned

This project is developing a smartphone-based screening test called TapTalk that analyzes hand movements and speech patterns to detect early signs of Alzheimer's-related brain changes. Participants tap and talk into their phone, and machine-learning algorithms look for patterns linked to Alzheimer's pathology. This is a diagnostic tool development study, not a treatment trial — the goal is to see whether this test can flag risk early, before symptoms appear.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04187547Phase 3Withdrawn

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

APOE4 carriers explicitly excluded

This Phase 3 trial is testing tricaprilin, a synthetic medium-chain triglyceride (a type of fat-derived compound), in people already diagnosed with mild to moderate Alzheimer's disease. The idea is that it may provide an alternative fuel source for brain cells that struggle to use glucose. Phase 3 means this is a large, rigorous test of whether it actually works — not a small early-stage safety study. Results here could support or sink a path toward approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT06377332UNKNOWN

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders

Observational study, genotype not required

This observational study is testing whether people with chronic breathing and sleep disorders — COPD, sleep apnea, or both — show early blood and brain markers linked to dementia risk. Researchers will use brain scans, sleep studies, blood tests, and cognitive assessments to look for those signals. There is no drug or treatment being given. Because no phase is listed, this is a research observation study, not a clinical drug trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT00348309N/ACompleted

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

Enrolled carriers, prior data unfavorable

This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to moderate Alzheimer's disease. Researchers also wanted to know whether APOE4 status affected how well the drug worked. This was a Phase NA trial, meaning it was a larger confirmatory study rather than early-stage safety testing. Participants were randomized to receive low-dose rosiglitazone, high-dose rosiglitazone, or placebo alongside their existing donepezil.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
249 sites
NCT03393130UNKNOWN

Perioperative Research Into Memory, Genomics in the Intensive Therapy Unit: Alzheimer's

APOE4 is the core research question

This is an observational study, not a drug or treatment trial. Researchers are collecting DNA from people who survived a major burn injury requiring intensive care, then comparing cognitive outcomes between those who carry the APOE4 gene variant and those who do not. The idea is to explore whether APOE4 carriers suffer worse long-term cognitive impairment after the severe inflammation caused by critical illness. No phase is assigned because no treatment is being tested.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
NCT03954210N/ACompleted

SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid

Lifestyle study, no drug needed

This trial is testing whether Cognitive Behavioral Therapy for Insomnia (CBT-I) — a structured, talk-based sleep program — can improve memory and thinking skills in older adults with chronic insomnia, and whether it can slow the buildup of amyloid protein in the brain. Some participants will get a brain PET scan to measure that amyloid change. This is a Phase NA (non-drug) trial, meaning it is evaluating a behavioral program, not a medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04279743N/AUNKNOWN

Fatty Acid Metabolism in Carriers of Apolipoprotein E Epsilon 4 Allele: Determining the Blood-to-brain Link

Directly targets APOE4 carrier biology

This trial is testing whether two different forms of omega-3 supplements — one packaged as phospholipids, one as triglycerides — deliver DHA (the brain-healthy fat in fish) to the brain differently, and whether APOE4 carriers absorb and transport DHA less efficiently than non-carriers. It is a mechanistic study, not a treatment trial — meaning researchers are trying to understand a biological process, not prove a therapy works.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03461861Phase 2Completed

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

Directly targets APOE4 carriers

This trial is testing AGB101, a low-dose extended-release form of levetiracetam (an existing seizure medication), to see whether it can calm overactive hippocampal activity in healthy older adults. The hippocampus is the brain's memory hub, and abnormal hyperactivity there is thought to be an early sign of Alzheimer's risk. Brain scans measure whether the drug changes that activity. This is a Phase 2 trial — testing whether it works and is safe, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04134806UNKNOWN

Gait Analysis by Induced Disorientation in a VR Environment

Observational only, genotype not relevant

This study uses a virtual reality headset to deliberately disorient participants and then measures how that disorientation affects the way they walk. Researchers want to know whether a VR lab setup can reliably capture gait changes in people with mild cognitive impairment or mild dementia. The phase is unspecified, meaning this looks like early observational or feasibility research rather than a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02884206Phase 3Completed

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Heart trial, genotype not relevant

This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a specific type of heart failure called HFpEF. Researchers measured thinking and memory using a standardized computer test. Phase 3 means the drug was already known to work for heart failure — this study asked whether it also had a meaningful effect on the brain.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
135 sites
NCT03698747Terminated

Myelin Imaging in Concussed High School Football Players

No relevance to APOE4 carriers

This study uses a specialized MRI technique called McDESPOT to look at myelin — the protective coating around nerve fibers in the brain — in high school football players who have had a concussion. Researchers want to see whether a concussion changes myelin structure compared to teens who don't play contact sports. The phase is unspecified, so this appears to be observational research, not a treatment trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03186846N/ACompleted

Volume Optimisation and Cognitive Function in Major Abdominal Surgery

Open to carriers, not 4-specific

This trial tests whether using multiple monitors at once during major abdominal surgery — tracking blood flow, brain oxygen levels, and depth of anesthesia together — reduces cognitive decline after the operation. It is a Phase NA study, meaning it is a practical clinical protocol test rather than a standard drug-efficacy phase. Researchers want to know if this combined monitoring approach leads to better brain outcomes than standard care.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04162990N/ACompleted

Lifestyle Remodeling in Subjective Memory Complaint (SMC): Brain Imaging and Blood Biochemistry Study

Lifestyle study, genotype not required

This trial is testing whether a structured lifestyle change program can improve memory and thinking in people who feel their memory is slipping but have not yet been diagnosed with MCI or dementia. Researchers are using brain imaging and blood tests to measure any changes. This is a Phase N/A behavioral study, meaning it is evaluating a non-drug intervention rather than a new medication.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02972658Phase 3Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Discontinued trial, not APOE4-specific

This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It was an extension of a larger study called AMARANTH. Phase 3 means the drug was being evaluated for real-world effectiveness in a large group — but note that lanabecestat's development program was halted in 2018 after trials failed to show benefit.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
133 sites
NCT02525198N/ACompleted

The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial

Open to carriers, genotype not considered

This trial is testing a dietary supplement that combines fatty acids (like omega-3s) and flavonoids (plant-based compounds) to see whether the combination improves cognition in older adults with mild cognitive impairment or subjective memory complaints. It is a Phase NA trial, meaning it is a straightforward intervention study rather than a staged drug approval process. Researchers want to know if these two compound types work better together than either would alone.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
3 sites
NCT04871074Phase 2Completed

The Synapse Project

Observational study, genotype not specified

This trial uses a specialized PET scan tracer called C-11 UCB-J to measure synapse loss in the brain across different stages of Alzheimer's disease — from people with no symptoms all the way to mild dementia. Researchers will track amyloid, tau, and synapse levels over time using repeat scans. This is a Phase 2 study, meaning it is investigational and aimed at better understanding disease progression, not testing a treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT02747784N/ATerminated

Evaluation to Assess Cognitive Training for the Prevention of Post-operative Cognitive Decline

Behavioral study, genotype not considered

This trial tested whether a computer-based cognitive training program called RehaCom could reduce the risk of post-operative cognitive decline in women having urogynecological or breast cancer surgery. Researchers compared it against another computer training program and tracked thinking and memory changes over three months. This is a Phase NA trial, meaning it is a practical pilot study rather than a standard drug-efficacy phase — early-stage and exploratory.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT00550420Phase 3Terminated

Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers

Closed trial, APOE4 stratified

This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning everyone received the drug after completing an earlier trial, and the main goal was to assess long-term safety and tolerability over about a year. Phase 3 means the drug was being evaluated at scale, but this trial is now completed and rosiglitazone was never approved for Alzheimer's.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
70 sites
NCT03744156N/ACompleted

Sleep and Pain Interventions in Women With Fibromyalgia

Unrelated to APOE4 or Alzheimer's

This trial is testing whether Cognitive Behavioral Therapy for Insomnia works better than basic sleep hygiene education for women who have both fibromyalgia and insomnia. Researchers are also studying how sleep and brain function relate to chronic pain. This is a Phase NA randomized controlled trial, meaning it is a direct head-to-head comparison study rather than a traditional drug-development phase.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05364307Completed

Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)

Screening registry, genotype not targeted

This is not a treatment trial. APHELEIA is a prescreening registry designed to find and evaluate people who might qualify for future Alzheimer's therapeutic trials. It uses brief cognitive tests, medical history, and blood-based biomarkers to sort out who is a good candidate for referral elsewhere. There is no experimental drug or device involved — just assessment and data collection.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
19 sites
NCT00348140Phase 3Completed

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

APOE4 enrolled, response may differ

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate Alzheimer's disease. Phase 3 means it was a large, late-stage test of whether the drug actually works. Researchers specifically wanted to know whether having or not having the APOE4 gene changed how well the drug performed.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
194 sites
NCT03136679Completed

Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease

Observational only, genotype not required

This study is collecting blood and urine samples from people with varying degrees of cognitive impairment to search for new biological markers that might detect Alzheimer's earlier. Researchers are also looking at B-vitamin levels to see if they connect to those markers. This is an observational study, not a drug trial — no treatment is being tested, and nothing here is proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT05591313N/ACompleted

Acute Exercise on Neurocognitive Function Among Adults With/Without Generic Risk of AD

Directly compares APOE4 carriers vs. non-carriers

This trial tests whether a single bout of exercise at different intensities affects brain function in adults aged 50 to 70. The three conditions compare low-intensity exercise for 40 minutes, moderate-intensity for 30 minutes, and high-intensity for 16 minutes. Researchers also want to know whether APOE4 carrier status changes the response. This is a Phase NA behavioral study — it is exploratory research, not a drug or device being evaluated for approval.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03679533N/ACompleted

The Impact of Cranberries On the Microbiome and the Brain in Healthy Ageing sTudy (COMBAT)

Open to carriers, not 4-specific

This trial is testing whether eating freeze-dried cranberry powder twice daily for 12 weeks improves memory and brain health in people aged 50 to 80 with no memory complaints. Researchers will also look at whether cranberries change gut bacteria, and whether those changes connect to brain function measured by cognitive tests and MRI scans. This is a Phase NA dietary supplement study — exploratory work, not a drug trial, and not yet proven to prevent any disease.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03715244Completed

Rate of Postoperative Delirium and Postoperative Cognitive Dysfunction After Spinal Anesthesia

General study, genotype not considered

This trial compares two types of anesthesia for short elective surgeries: standard general anesthesia versus spinal anesthesia using short-acting local drugs. Researchers are tracking rates of post-surgery delirium and longer-term cognitive changes up to one year out. It is not a drug being tested for a disease — it is a procedural comparison. The phase is unspecified, making it likely an observational or early comparative study rather than a late-stage trial.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT00265148Phase 2Completed

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

General AD trial, no APOE4 focus

This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's disease. Researchers used brain scans and cognitive tests to see whether the drug changed brain activity or thinking ability. Phase 2 means the trial was exploring whether it works and is safe, not that it was proven or approved for this use.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
15 sites
NCT05984446N/ACompleted

Targeting Default Mode Network Dysfunction in Persons At Risk of Alzheimer's Disease with Non-invasive Techniques

Directly recruits APOE4 carriers

This trial is testing repetitive transcranial magnetic stimulation, or rTMS, a non-invasive brain stimulation technique, to see whether it can improve the function of the default mode network — a brain circuit known to break down early in Alzheimer's disease. Participants get either real rTMS or a sham version. Researchers will measure brain and cognitive changes using neuroimaging. This is a Phase NA (exploratory) study — early-stage, not yet proven or approved.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT03676738Completed

Cohort Study of Risk Factors for Postoperative Cognitive Decline

Genetic risk study, APOE4 plausible focus

This observational cohort study is tracking patients who undergo elective spine surgery under general anesthesia to see who develops cognitive decline afterward — a condition called postoperative cognitive dysfunction, or POCD. Researchers want to know whether genetic factors (including possibly APOE4) and biological sex predict who is most at risk. No phase is listed because this is not a drug trial — it is a data-gathering study watching what naturally happens.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
1 site
NCT04049643N/ACompleted

Hearing Aid and Individuals With Cognitive Disorders

Explicitly targets APOE4-related condition

This pilot study is testing whether different ways of fitting hearing aids — by an audiologist, through a support service, or as a standalone device — can help older adults with mild or moderate cognitive impairment who also have hearing loss. It measures how hearing aids affect daily life and caregiver burden at six weeks. A Phase NA pilot means it is a feasibility run to see if a larger trial is worth doing, not a test of effectiveness yet.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
2 sites
NCT02814526N/ACompleted

Exercise in Adults With Mild Memory Problems

Open to carriers, not 4-specific

This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild memory problems. Researchers are measuring cognitive test scores, brain shrinkage, blood flow, and spinal fluid markers linked to Alzheimer's. It is a Phase NA designating a behavioral trial — not a drug study, so there is no approval process involved, but the science is still being established.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
14 sites
NCT02245737Phase 2Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Open to carriers, not 4-specific

This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia. It measured cognitive change using a standard memory and thinking scale. This was a Phase 2 trial, meaning it was evaluating whether the drug works and is safe, not a proven or approved treatment.

Eligibility, Phoenix members see ✓ likely eligible / ✗ excluded based on their profile
254 sites
Free trial alerts

Want the next one in your inbox?

We add new APOE4 trials as they open. Turn on alerts and we’ll send the ones worth your attention — nothing else.

Unsubscribe anytime · No spam, ever

APOE4 trial pipeline

Where the trials sit in the development pipeline. Higher bars = more research underway.

12
Early P1
Safety in healthy volunteers
69
Phase 1
Safety + dose-finding
96
Phase 2
Efficacy signal
41
Phase 3
Pivotal, FDA-grade evidence
20
Phase 4
Post-market surveillance
Live · 625 active · APOE4 carriers
7 min · 60-day guaranteeStart free assessment
625+
Active members
27
Biomarkers with APOE4 optimal ranges
89%
See improvements in APOE4 biomarkers in 3 months
4.9
Satisfaction rating
Phoenix

Precision health for APOE4 carriers. Founded by Dr. Kevin Tran, Doctor of Pharmacy, APOE 4/4.

4,100+ APOE4 carriers · weekly

The product
Community
Members
The Phoenix app, iOS & Android

Phoenix provides health optimization guidance and community support. It does not diagnose, treat, cure, or prevent any disease, including Alzheimer's, and is not a substitute for professional medical advice. Consult your physician before starting any new health program. Member outcomes and biomarker changes shown on this site are individual, self-reported, and observational; they are not typical and do not establish that Phoenix causes any result. Any founder results are a single individual's experience (n=1).

© 2026 The Phoenix Community · HIPAA compliant · 32% of members are healthcare professionalsPrivacyTermsAboutContact

We use cookies to enhance your experience.

Privacy policy